FN Clarivate Analytics Web of Science
VR 1.0
PT J
AU Rizzacasa, B
   Morini, E
   Mango, R
   Vancheri, C
   Budassi, S
   Massaro, G
   Maletta, S
   Macrini, M
   D'Annibale, S
   Romeo, F
   Novelli, G
   Amati, F
AF Rizzacasa, Barbara
   Morini, Elena
   Mango, Ruggiero
   Vancheri, Chiara
   Budassi, Simone
   Massaro, Gianluca
   Maletta, Sara
   Macrini, Massimiliano
   D'Annibale, Silvio
   Romeo, Francesco
   Novelli, Giuseppe
   Amati, Francesca
TI MiR-423 is differentially expressed in patients with stable and unstable
   coronary artery disease: A pilot study
SO PLOS ONE
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; O-GLCNAC TRANSFERASE; PLASMA MICRORNA;
   PROTEIN EBP1; PROLIFERATION; EPIGENETICS; MECHANISM; DIAGNOSIS;
   BIOMARKER; SERUM
AB Coronary artery disease (CAD) and acute myocardial infarction (AMI) are the leading causes of death worldwide. Since only a subset of CAD patients develops myocardial infarction, it is likely that unique factors predispose to AMI. Circulating microRNAs represent diagnostic powerful biomarkers for detection of heart injuries and patients' risk stratification. Using an array-based approach, the expression of 84 circulating miRNAs was analyzed in plasma of pooled stable CAD patients (CAD; n = 5) and unstable CAD patients (AMI_T0; n = 5) enrolled within 24 hours from an AMI event. The array experiments showed 27 miRNAs differentially expressed with a two-fold up- or down-regulation (10 up- and 17 down-regulated miRNAs). Among them, miR-423-5p dis-regulation was confirmed in a larger case study (n = 99). Circulating miR-423-5p resulted to be significantly down-regulated within 24 hours from the AMI event (FC = -2, p <= 0.05). Interestingly, miR-423-5p expression resulted to be increased (FC = +2; p <= 0.005) in a subgroup of the same AMI patients (AMI_T1; n = 11) analyzed after 6 months from the acute event. We extended miR-423-5p expression study on PBMCs (peripheral blood mononuclear cells), confirming also in this tissue its up regulation at 6 months post-AMI. Receiver operating characteristic analyses (ROC) were performed to detect the power of miR-423-5p to discriminate stable and unstable CAD. In plasma, miR-423-5p expression accurately distinguishes stable and unstable CAD patients (AUC = 0.7143, p <= 0.005). Interestingly, the highest discriminatory value (AUC = 0.8529 p <= 0.0005) was identified in blood cells, where miR-423-5p expression is able to differentiate unstable CAD patients during an acute event (AMI_T0) from those at six months post-AMI (AMI_T1). Furthermore, cellular miR-423-5p may discriminate also stable CAD patients from unstable CAD patients after six months post-AMI (AUC = 0.7355 p <= 0.05). The results of this pilot-study suggest that miR-423-5p expression level both in plasma and blood cells, could represent a new promising biomarker for risk stratification of CAD patients.
C1 [Rizzacasa, Barbara; Morini, Elena; Vancheri, Chiara; Maletta, Sara; Novelli, Giuseppe; Amati, Francesca] Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy.
   [Mango, Ruggiero; Budassi, Simone; Massaro, Gianluca; Macrini, Massimiliano; Romeo, Francesco] PTV Fdn, Policlin Tor Vergata, Complex Operat Unit Cardiol, Rome, Italy.
   [D'Annibale, Silvio; Romeo, Francesco] Univ Roma Tor Vergata, Dept Syst Med, Rome, Italy.
   [Novelli, Giuseppe] PTV Fdn, Policlin Tor Vergata, Complex Operat Unit Med Genet, Rome, Italy.
   [Amati, Francesca] Univ San Raffaele, Dept Human Sci & Qual Life Promot, Rome, Italy.
RP Amati, F (reprint author), Univ Roma Tor Vergata, Dept Biomed & Prevent, Rome, Italy.; Amati, F (reprint author), Univ San Raffaele, Dept Human Sci & Qual Life Promot, Rome, Italy.
EM amati@med.uniroma2.it
FU Fondazione Roma [NCDS-2013-00000333]; Bandi Ateneo "Consolidate
   Foundations" [AmiRNA E82F16000570005]
FX This study was funded by Fondazione Roma (Sn. NCDS-2013-00000333 to GN
   and FR) and Bandi Ateneo "Consolidate Foundations" (AmiRNA
   E82F16000570005 to FA). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ai J, 2010, BIOCHEM BIOPH RES CO, V391, P73, DOI 10.1016/j.bbrc.2009.11.005
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Camici GG, 2015, EUR HEART J, V36, P3392, DOI 10.1093/eurheartj/ehv587
   Chen X, 2008, CELL RES, V18, P997, DOI 10.1038/cr.2008.282
   Cheng YH, 2010, J CARDIOVASC TRANSL, V3, P251, DOI 10.1007/s12265-010-9169-7
   Cheng YH, 2010, CLIN SCI, V119, P87, DOI 10.1042/CS20090645
   Condorelli G, 2014, J AM COLL CARDIOL, V63, P2177, DOI 10.1016/j.jacc.2014.01.050
   Costantino S, 2018, INT J CARDIOL, V250, P207, DOI 10.1016/j.ijcard.2017.09.188
   D'Alessandra Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080345
   Feinberg MW, 2016, CIRC RES, V118, P703, DOI 10.1161/CIRCRESAHA.115.306300
   Figeac N, 2014, DEV BIOL, V386, P135, DOI 10.1016/j.ydbio.2013.11.017
   Gidlof O, 2011, CARDIOLOGY, V118, P217, DOI 10.1159/000328869
   Gilad S, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003148
   Goldraich LA, 2014, BIOMARKERS, V19, P135, DOI 10.3109/1354750X.2013.870605
   Goren Y, 2012, EUR J HEART FAIL, V14, P147, DOI 10.1093/eurjhf/hfr155
   Grimaldi V, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-014-0476-3
   Khera AV, 2017, CIRCULATION, V135, P1005, DOI 10.1161/CIRCULATIONAHA.116.026479
   Li CJ, 2013, BMC MED GENOMICS, V6, DOI 10.1186/1755-8794-6-16
   Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liu N, 2010, DEV CELL, V18, P510, DOI 10.1016/j.devcel.2010.03.010
   Luo P, 2015, MOL MED REP, V12, P1163, DOI 10.3892/mmr.2015.3491
   Miyamoto S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0142904
   Nabel EG, 2012, NEW ENGL J MED, V366, P54, DOI 10.1056/NEJMra1112570
   Nabialek E, 2013, MINERVA CARDIOANGIOL, V61, P627
   Paneni F, 2017, J AM COLL CARDIOL, V69, P1952, DOI 10.1016/j.jacc.2017.01.064
   Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI [10.1093/eurheartj/ehw106, 10.1016/j.rec.2016.09.009]
   Romeo F, 2016, J CARDIOVASC MED, V17, P851, DOI 10.2459/JCM.0000000000000405
   Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73
   Shafi R, 2000, P NATL ACAD SCI USA, V97, P5735, DOI 10.1073/pnas.100471497
   Su X, 2015, REPRODUCTION, V150, P65, DOI 10.1530/REP-15-0007
   Thygesen K, 2012, J AM COLL CARDIOL, V60, P1581, DOI 10.1016/j.jacc.2012.08.001
   Tijsen AJ, 2010, CIRC RES, V106, P1035, DOI 10.1161/CIRCRESAHA.110.218297
   Townsend N, 2016, EUR HEART J, V37, P3232, DOI 10.1093/eurheartj/ehw334
   van der Harst P, 2017, J AM COLL CARDIOL, V70, P590, DOI 10.1016/j.jacc.2017.05.067
   Wang GK, 2010, EUR HEART J, V31, P659, DOI 10.1093/eurheartj/ehq013
   Wang WS, 2017, AM J TRANSL RES, V9, P3796
   World Med Assoc, 2013, JAMA-J AM MED ASSOC, V310, P2191, DOI 10.1001/jama.2013.281053
   Yao CC, 2016, ONCOTARGET, V7, P2201, DOI 10.18632/oncotarget.6876
   Zhang YX, 2005, NUCLEIC ACIDS RES, V33, P6024, DOI 10.1093/nar/gki903
   Zhang YX, 2004, J BIOL CHEM, V279, P26126, DOI 10.1074/jbc.M314305200
   Zile MR, 2011, CIRC-CARDIOVASC GENE, V4, P614, DOI 10.1161/CIRCGENETICS.111.959841
   2010, P NATL ACAD SCI USA, V107, P1779, DOI DOI 10.1073/PNAS.1001907107
NR 43
TC 0
Z9 0
U1 1
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 6
PY 2019
VL 14
IS 5
AR UNSP e0216363
DI 10.1371/journal.pone.0216363
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HW7RE
UT WOS:000466886300041
PM 31059534
DA 2019-06-18
ER

PT J
AU Lee, SG
   Lee, SJ
   Thuy, NVP
   Kim, JS
   Lee, JJ
   Lee, OH
   Kim, CK
   Oh, J
   Park, S
   Lee, OH
   Kim, SH
   Park, S
   Lee, SH
   Hong, SJ
   Ahn, CM
   Kim, BK
   Ko, YG
   Choi, D
   Hong, MK
   Jang, Y
AF Lee, Seul-Gee
   Lee, Seung-Jun
   Nguyen Viet Phuong Thuy
   Kim, Jung-Sun
   Lee, Jung-Jae
   Lee, Oh-Hyun
   Kim, Choong-Ki
   Oh, Jaewon
   Park, Seil
   Lee, Ok-Hee
   Kim, Se Hoon
   Park, Sungha
   Lee, Sang-Hak
   Hong, Sung-Jin
   Ahn, Chul-Min
   Kim, Byeong-Keuk
   Ko, Young-Guk
   Choi, Donghoon
   Hong, Myeong-Ki
   Jang, Yangsoo
TI Synergistic protective effects of a statin and an angiotensin receptor
   blocker for initiation and progression of atherosclerosis
SO PLOS ONE
LA English
DT Article
ID OLMESARTAN; MACROPHAGES; HETEROGENEITY; ROSUVASTATIN; INFLAMMATION;
   INHIBITOR; DISEASE; CELLS
AB Aim
   Although the atheroprotective effects of statins and angiotensin II receptor blockers (ARBs) are well-established, little is known about their additive effects, especially during the early period of atherosclerosis. The aim of this study was to investigate whether combination of a statin and an ARB exerts synergistic anti-atherosclerotic effects, and to elucidate the mechanisms of combined effects.
   Methods
   Atherosclerotic plaques were developed in arteries of 23 rabbits using a high-cholesterol diet (HCD) and intra-arterial balloon inflation. Rabbits received one of five different treatment strategies for 4 weeks: positive control [n = 5, HCD]; negative control [n = 3, regular chow diet]; statin [n = 5, HCD and rosuvastatin 10 mg]; ARB [n = 5, HCD and olmesartan 20 mg]; and combination [n = 5, HCD and statin+ARB].
   Results
   Histological analysis demonstrated that development of atherosclerotic plaques was inhibited more in combination group than in statin group (P = 0.001). Although macrophage infiltration identified by RAM11 staining was not significantly different between combination and individual treatment groups (31.76 +/- 4.84% [combination] vs. 38.11 +/- 6.53% [statin; P = 0.35] or 35.14 +/- 2.87% [ARB; P = 0.62]), the relative proportion of pro-inflammatory M1-macrophages was significantly lower in combination group than in ARB group (3.20 +/- 0.47% vs. 5.20 +/- 0.78%, P = 0.02). Furthermore, M2-macrophage polarization was higher in combination group than in statin group (17.70 +/- 3.04% vs. 7.86 +/- 0.68%, P = 0.001).
   Conclusion
   Combination treatment with a statin and an ARB produced synergistic protective effects for atherosclerosis initiation and progression, which may be attributed to modulation of macrophage characteristics in the early period of atherosclerosis.
C1 [Lee, Seul-Gee; Kim, Jung-Sun] Yonsei Univ, Coll Med, Cardiovasc Res Inst, Seoul, South Korea.
   [Lee, Seul-Gee; Kim, Jung-Sun] Yonsei Univ Hlth Syst, Severance Integrat Res Inst Cerebral & Cardiovasc, Seoul, South Korea.
   [Lee, Seung-Jun; Kim, Jung-Sun; Lee, Oh-Hyun; Kim, Choong-Ki; Oh, Jaewon; Park, Sungha; Lee, Sang-Hak; Hong, Sung-Jin; Ahn, Chul-Min; Kim, Byeong-Keuk; Ko, Young-Guk; Choi, Donghoon; Hong, Myeong-Ki; Jang, Yangsoo] Yonsei Univ, Severance Cardiovasc Hosp, Coll Med, Cardiol Div, Seoul, South Korea.
   [Nguyen Viet Phuong Thuy] Cho Ray Hosp, HCMC, Ho Chi Minh, Vietnam.
   [Kim, Jung-Sun; Park, Seil; Lee, Ok-Hee; Hong, Myeong-Ki; Jang, Yangsoo] Yonsei Univ, Coll Med, Cardiovasc Prod Evaluat Ctr, Seoul, South Korea.
   [Lee, Jung-Jae] Yonsei Univ, Grad Program Sci Aging, Seoul, South Korea.
   [Kim, Se Hoon] Yonsei Univ, Coll Med, Dept Pathol, Seoul, South Korea.
RP Kim, JS (reprint author), Yonsei Univ, Coll Med, Cardiovasc Res Inst, Seoul, South Korea.; Kim, JS (reprint author), Yonsei Univ Hlth Syst, Severance Integrat Res Inst Cerebral & Cardiovasc, Seoul, South Korea.; Kim, JS (reprint author), Yonsei Univ, Severance Cardiovasc Hosp, Coll Med, Cardiol Div, Seoul, South Korea.; Kim, JS (reprint author), Yonsei Univ, Coll Med, Cardiovasc Prod Evaluat Ctr, Seoul, South Korea.
EM KJS1218@yuhs.ac
OI Hong, Myeong-Ki/0000-0002-2090-2031; Hong, Sung-Jin/0000-0003-4893-039X;
   Lee, Oh Hyun/0000-0001-7070-7720; Jang, Yangsoo/0000-0002-2169-3112;
   Kim, Jung-Sun/0000-0003-2263-3274; Choi, Donghoon/0000-0002-2009-9760
FU National Research Foundation of Korea (NRF) - Korean government (MSIT)
   [2017R1A2B2003191]; Ministry of Science and ICT [2017M3A9E9073585];
   Daewoong Pharmaceutical Company; Cardiovascular Research Center (Seoul,
   Korea)
FX This study was supported by grants from the National Research Foundation
   of Korea (NRF) grant funded by the Korean government (MSIT) (No.
   2017R1A2B2003191), the Ministry of Science and ICT (2017M3A9E9073585),
   the Daewoong Pharmaceutical Company and the Cardiovascular Research
   Center (Seoul, Korea) to JSK. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Agata J, 2006, HYPERTENS RES, V29, P865, DOI 10.1291/hypres.29.865
   Branen L, 2004, ARTERIOSCL THROM VAS, V24, P2137, DOI 10.1161/01.ATV.0000143933.20616.1b
   Briasoulis Alexandros, 2012, Recent Pat Cardiovasc Drug Discov, V7, P21
   Chinetti-Gbaguidi G, 2015, NAT REV CARDIOL, V12, P10, DOI 10.1038/nrcardio.2014.173
   Crisby M, 2001, CIRCULATION, V103, P926
   Egner B, 2015, HANDB EXP PHARMACOL, V229, P243, DOI 10.1007/978-3-662-46943-9_10
   Fan JL, 2015, PHARMACOL THERAPEUT, V146, P104, DOI 10.1016/j.pharmthera.2014.09.009
   Guo HY, 2012, CARDIOVASC DRUG THER, V26, P375, DOI 10.1007/s10557-012-6406-0
   Hirohata A, 2010, J AM COLL CARDIOL, V55, P976, DOI 10.1016/j.jacc.2009.09.062
   Hotchi J, 2013, J ATHEROSCLER THROMB, V20, P257, DOI 10.5551/jat.14266
   Ijas P, 2007, ARTERIOSCL THROM VAS, V27, P154, DOI 10.1161/01.ATV.0000251991.64617.e7
   Jin Y, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064434
   Johnson JL, 2009, CURR OPIN LIPIDOL, V20, P370, DOI 10.1097/MOL.0b013e3283309848
   Kato M, 2005, J CARDIOVASC PHARM, V46, P556, DOI 10.1097/01.fjc.0000179434.18750.28
   Kim JS, 2016, YONSEI MED J, V57, P1095, DOI 10.3349/ymj.2016.57.5.1095
   Kogai J, 2008, HYPERTENS RES, V31, P1791, DOI 10.1291/hypres.31.1791
   Laslett LJ, 2012, J AM COLL CARDIOL, V60, pS1, DOI 10.1016/j.jacc.2012.11.002
   Li ZH, 2016, ATHEROSCLEROSIS, V248, P27, DOI 10.1016/j.atherosclerosis.2016.02.028
   Libby P, 2002, CIRCULATION, V105, P1135, DOI 10.1161/hc0902.104353
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Miyoshi T, 2014, HEART VESSELS, V29, P178, DOI 10.1007/s00380-013-0343-0
   Moore KJ, 2013, NAT REV IMMUNOL, V13, P709, DOI 10.1038/nri3520
   Otani H, 2011, ANTIOXID REDOX SIGN, V15, P1911, DOI 10.1089/ars.2010.3739
   Remppis A, 2010, MEDIAT INFLAMM, DOI 10.1155/2010/194896
   Roh H, 2014, CLIN THER, V36, P1159, DOI 10.1016/j.clinthera.2014.06.022
   Sakai K, 2018, ARTERIOSCL THROM VAS, V38, P2590, DOI 10.1161/ATVBAHA.118.311664
   Siragy H, 1999, AM J CARDIOL, V84, p3S
   Sperlagh B, 1998, NEUROCHEM INT, V33, P209, DOI 10.1016/S0197-0186(98)00025-4
   Stancu C, 2001, J CELL MOL MED, V5, P378, DOI 10.1111/j.1582-4934.2001.tb00172.x
   Tahara N, 2014, NAT MED, V20, P215, DOI 10.1038/nm.3437
   Thomas AC, 2007, ARTERIOSCL THROM VAS, V27, P571, DOI 10.1161/01.ATV.0000256470.23842.94
   Wilson HM, 2010, J CELL MOL MED, V14, P2055, DOI 10.1111/j.1582-4934.2010.01121.x
   Zhang H, 2012, INT J MOL SCI, V13, P1512, DOI 10.3390/ijms13021512
NR 33
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 3
PY 2019
VL 14
IS 5
AR e0215604
DI 10.1371/journal.pone.0215604
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HW5AX
UT WOS:000466702600007
PM 31050669
DA 2019-06-18
ER

PT J
AU Zietzer, A
   Niepmann, ST
   Camara, B
   Lenart, MA
   Jansen, F
   Becher, MU
   Andrie, R
   Nickenig, G
   Tiyerili, V
AF Zietzer, Andreas
   Niepmann, Sven Thomas
   Camara, Bakary
   Lenart, Monika Anna
   Jansen, Felix
   Becher, Marc Ulrich
   Andrie, Rene
   Nickenig, Georg
   Tiyerili, Vedat
TI Sodium thiocyanate treatment attenuates atherosclerotic plaque formation
   and improves endothelial regeneration in mice
SO PLOS ONE
LA English
DT Article
ID HYPOTHIOCYANOUS ACID HOSCN; HIGH-DENSITY-LIPOPROTEIN; C-REACTIVE
   PROTEIN; NEOINTIMA FORMATION; CLASS-B; MYELOPEROXIDASE; INFLAMMATION;
   OXIDATION; SMOKING; PLASMA
AB Introduction
   Atherosclerotic plaque formation is an inflammatory process that involves the recruitment of neutrophil granulocytes and the generation of reactive oxygen species (ROS). ROS formation by myeloperoxidase, a key enzyme in H2O2 degradation, can be modulated by addition of sodium thiocyanate (NaSCN). However, the therapeutic use of NaSCN to counteract atherogenesis has been controversial, because MPO oxidizes NaSCN to hypothiocyanous acid, which is a reactive oxygen species itself. Therefore, this study aimed to investigate the effect of NaSCN treatment on atherogenesis in vivo.
   Methods
   Apolipoprotein E knockout (ApoE(-/-)) mice on western-diet were treated with NaSCN for 8 weeks. Blood levels of total cholesterol, IL-10, and IL-6 were measured. Aortic roots from these mice were analyzed histologically to quantify plaque formation, monocyte, and neutrophil granulocyte infiltration. Oxidative damage was evaluated via an L-012 chemiluminescence assay and staining for chlorotyrosine in the aortic walls. Endothelial function was assessed by use of endothelium-dependent vasodilation in isolated aortic rings. Neointima formation was evaluated in wild-type mice following wire injury of the carotid artery.
   Results
   NaSCN treatment of ApoE(-/-) mice lead to a reduction of atherosclerotic plaque size in the aortic roots but had no effect on monocyte or granulocyte infiltration. Serum levels of the pro-inflammatory cytokine IL-6 decreased whereas anti-inflammatory IL-10 increased upon NaSCN treatment. In our experiments, we found oxidative damage to be reduced and the endothelial function to be improved in the NaSCN-treated group. Additionally, NaSCN inhibited neointima formation.
   Conclusion
   NaSCN has beneficial effects on various stages of atherosclerotic plaque development in mice.
C1 [Zietzer, Andreas; Niepmann, Sven Thomas; Camara, Bakary; Lenart, Monika Anna; Jansen, Felix; Becher, Marc Ulrich; Andrie, Rene; Nickenig, Georg; Tiyerili, Vedat] Univ Hosp Bonn, Med Dept 2, Bonn, Germany.
RP Tiyerili, V (reprint author), Univ Hosp Bonn, Med Dept 2, Bonn, Germany.
EM vedat.tiyerili@ukbonn.de
FU German Society of Cardiology [DGK16/2018]; Medical Faculty of the
   Rheinische Friedrich-Wilhelms-University Bonn (BONFOR Gerok-grant);
   Else-Kroner-Fresenius-Foundation through the Medical Faculty of the
   University of Bonn; German Heart Foundation (Kaltenbach Stipendium)
FX AZ was supported by the German Society of Cardiology (DGK16/2018) and by
   the Medical Faculty of the Rheinische Friedrich-Wilhelms-University Bonn
   (BONFOR Gerok-grant). STN was supported by the
   Else-Kroner-Fresenius-Foundation through the Medical Faculty of the
   University of Bonn. MAL was supported by the German Heart Foundation
   (Kaltenbach Stipendium). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abdo AI, 2017, REDOX BIOL, V13, P623, DOI 10.1016/j.redox.2017.08.004
   Chandler JD, 2013, J BIOL CHEM, V288, P18421, DOI 10.1074/jbc.M113.468090
   Daiber A, 2017, REDOX BIOL, V12, P35, DOI 10.1016/j.redox.2017.02.001
   DEGIAMPIETRO P, 1987, J CLIN CHEM CLIN BIO, V25, P711
   Exner M, 2004, FREE RADICAL BIO MED, V37, P146, DOI 10.1016/j.freeradbiomed.2004.04.039
   Hadfield KA, 2013, BIOCHEM J, V449, P531, DOI 10.1042/BJ20121210
   Heslop CL, 2010, J AM COLL CARDIOL, V55, P1102, DOI 10.1016/j.jacc.2009.11.050
   Ismael FO, 2015, ARCH BIOCHEM BIOPHYS, V573, P40, DOI 10.1016/j.abb.2015.03.008
   Kettle AJ, 1997, BIOCHEM J, V321, P503, DOI 10.1042/bj3210503
   Lau D, 2006, PHARMACOL THERAPEUT, V111, P16, DOI 10.1016/j.pharmthera.2005.06.023
   Laufs U, 2004, CIRCULATION, V109, P220, DOI 10.1161/01.CIR.0000109141.48980.37
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liu CQ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050767
   Love DT, 2016, FREE RADICAL BIO MED, V94, P88, DOI 10.1016/j.freeradbiomed.2016.02.016
   Marsche G, 2004, ARTERIOSCL THROM VAS, V24, P2302, DOI 10.1161/01.ATV.0000148703.43429.25
   Marsche G, 2003, J BIOL CHEM, V278, P47562, DOI 10.1074/jbc.M308428200
   Marsche G, 2002, J BIOL CHEM, V277, P32172, DOI 10.1074/jbc.M200503200
   Morgan PE, 2015, FREE RADICAL RES, V49, P743, DOI 10.3109/10715762.2015.1019347
   Nedoboy PE, 2014, FREE RADICAL RES, V48, P1256, DOI 10.3109/10715762.2014.947286
   Pasceri V, 2001, CIRCULATION, V103, P2531
   Ronald JA, 2009, CIRCULATION, V120, P592, DOI 10.1161/CIRCULATIONAHA.108.813998
   Sokolov AV, 2014, CHEM PHYS LIPIDS, V180, P72, DOI 10.1016/j.chemphyslip.2014.02.006
   Teng N, 2017, REDOX REP, V22, P51, DOI 10.1080/13510002.2016.1256119
   Tiyerili V, 2016, INT J CARDIOL, V204, P29, DOI 10.1016/j.ijcard.2015.11.128
   vanDalen CJ, 1997, BIOCHEM J, V327, P487
   Vita JA, 2004, CIRCULATION, V110, P1134, DOI 10.1161/01.CIR.0000140262.20831.8F
   Wang Z, 2007, NAT MED, V13, P1176, DOI 10.1038/nm1637
   WATKINSON G, 1947, BRIT MED J, V1, P595, DOI 10.1136/bmj.1.4504.595
   World Health Organisation, 2018, GLOB HLTH EST 2016 D
   Zielonka J, 2013, FREE RADICAL BIO MED, V65, P1310, DOI 10.1016/j.freeradbiomed.2013.09.017
NR 30
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 2
PY 2019
VL 14
IS 4
AR e0214476
DI 10.1371/journal.pone.0214476
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HR2UW
UT WOS:000462993900026
PM 30939159
OA DOAJ Gold
DA 2019-06-18
ER

PT J
AU Infante, T
   Forte, E
   Schiano, C
   Punzo, B
   Cademartiri, F
   Cavaliere, C
   Salvatore, M
   Napoli, C
AF Infante, Teresa
   Forte, Ernesto
   Schiano, Concetta
   Punzo, Bruna
   Cademartiri, Filippo
   Cavaliere, Carlo
   Salvatore, Marco
   Napoli, Claudio
TI Evidence of association of circulating epigenetic-sensitive biomarkers
   with suspected coronary heart disease evaluated by Cardiac Computed
   Tomography
SO PLOS ONE
LA English
DT Article
ID BINDING PROTEIN (SREBP)-2; BLOOD MONONUCLEAR-CELLS; GENE-EXPRESSION;
   ARTERY-DISEASE; CT-ANGIOGRAPHY; ATHEROSCLEROSIS; PLAQUE; EXTENT;
   CHALLENGES; PREVENTION
AB Circulating biomarkers available in clinical practice do not allow to stratify patients with coronary heart disease (CHD) prior the onset of a clinically relevant event. We evaluated the methylation status of specific genomic segments and gene expression in peripheral blood of patients undergoing Cardiac Computed Tomography (CCT) for CHD (n = 95).
   We choose to investigate cholesterol metabolism. Methylation and gene expression of low density lipoprotein receptor (LDLR), sterol regulatory element-binding factor 2 (SREBF2) and ATP-binding cassette transporter 1 (ABCA1) were evaluated by qRT-PCR. Calcium score (CACS), stenosis degree, total plaque volume (TPV), calcified plaque volume (CPV), non-calcified plaque volume (NCPV) and plaque burden (PB) were assessed in all CHD patients (n = 65). The percentage of methylation at the specific analyzed segment of LDLR promoter was higher in CHD patients vs healthy subjects (HS) (n = 30) (p = 0.001). LDLR, SREBF2 and ABCA1 mRNAs were up-regulated in CHD patients vs HS (p = 0.02; p = 0.019; p = 0.008). SREBF2 was overexpressed in patients with coronary stenosis >50% vs subjects with stenosis <50% (p = 0.036). After adjustment for risk factors and clinical features, ABCA1 (p = 0.005) and SREBF2 (p = 0.010) gene expression were identified as independent predictors of CHD and severity. ROC curve analysis revealed a good performance of ABCA1 on predicting CHD (AUC = 0.768; p<0.001) and of SREBF2 for the prediction of disease severity (AUC = 0.815; p<0.001). Moreover, adjusted multivariate analysis demonstrated SREBF2 as independent predictor of CPV, NCPV and TPV (p = 0.022; p = 0.002 and p = 0.006) and ABCA1 as independent predictor of NCPV and TPV (p = 0.002 and p = 0.013).
   CHD presence and characteristics are related to selected circulating transcriptional and epigenetic-sensitive biomarkers linked to cholesterol pathway. More extensive analysis of CHD phenotypes and circulating biomarkers might improve and personalize cardiovascular risk stratification in the clinical settings.
C1 [Infante, Teresa; Forte, Ernesto; Schiano, Concetta; Punzo, Bruna; Cademartiri, Filippo; Cavaliere, Carlo; Salvatore, Marco; Napoli, Claudio] IRCCS SDN, Naples, Italy.
   [Napoli, Claudio] Univ Campania Luigi Vanvitelli, Dept Med Surg Neurol Metab & Geriatr Sci, Naples, Italy.
RP Infante, T (reprint author), IRCCS SDN, Naples, Italy.
EM tinfante@sdn-napoli.it
RI Cademartiri, Filippo/H-7336-2015; Infante, Teresa/K-8735-2016
OI Cademartiri, Filippo/0000-0002-0579-3279; Infante,
   Teresa/0000-0002-1764-9610
FU Italian Ministry of Health [GR-2011-02349436]
FX This study was supported by Italian Ministry of Health grants "Giovani
   Ricercatori 2011-12", project code GR-2011-02349436 (TI) and "Ricerca
   Corrente 2013-15" (CN). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Bamberg F, 2012, INT J CARDIOVAS IMAG, V28, P183, DOI 10.1007/s10554-010-9773-2
   Bobryshev YV, 2016, BIOMED RES INT, DOI 10.1155/2016/9582430
   Cademartiri F, 2017, HEART, V103, P975, DOI 10.1136/heartjnl-2016-310473
   Canpolat U, 2013, INT J CARDIOVAS IMAG, V29, P1371, DOI 10.1007/s10554-013-0209-7
   Chen HH, 2016, CURR ATHEROSCLER REP, V18, DOI 10.1007/s11883-016-0634-x
   Clee SM, 2000, J CLIN INVEST, V106, P1263, DOI 10.1172/JCI10727
   Dalen JE, 2014, AM J MED, V127, P807, DOI 10.1016/j.amjmed.2014.04.015
   De Castro-Oros I, 2014, BMC MED GENOMICS, V7, DOI 10.1186/1755-8794-7-17
   de Nigris F, 2018, JAMA CARDIOL, V3, P1184, DOI 10.1001/jamacardio.2018.3546
   Demina EP, 2011, MOL BIOL+, V45, P258, DOI 10.1134/S0026893310061019
   Duan L, 2018, GENE, V646, P91, DOI 10.1016/j.gene.2017.12.033
   Eberle D, 2004, BIOCHIMIE, V86, P839, DOI 10.1016/j.biochi.2004.09.018
   Fan YM, 2008, THROMB J, V6, DOI 10.1186/1477-9560-6-17
   Forte E, 2017, EUR HEART J-CARD IMG, V18, P1229, DOI 10.1093/ehjci/jew218
   Forte E, 2016, SURG RADIOL ANAT, V38, P987, DOI 10.1007/s00276-016-1634-9
   Friedlander Y, 2008, ATHEROSCLEROSIS, V196, P896, DOI 10.1016/j.atherosclerosis.2007.02.006
   Goldstein JL, 2009, ARTERIOSCL THROM VAS, V29, P431, DOI 10.1161/ATVBAHA.108.179564
   Grimaldi V, 2015, CURR ATHEROSCLER REP, V17, DOI 10.1007/s11883-014-0476-3
   Guaricci AI, 2017, EUR HEART J-CARD IMG, V18, P1049, DOI 10.1093/ehjci/jew173
   Harada K, 2013, INT J CARDIOVAS IMAG, V29, P1149, DOI 10.1007/s10554-013-0181-2
   Heo SH, 2018, J STROKE, V20, P80, DOI 10.5853/jos.2017.02390
   Infante T, 2017, FRONT ENDOCRINOL, V8, DOI 10.3389/fendo.2017.00209
   Infante T, 2017, AM J TRANSL RES, V9, P3148
   Kontaraki JE, 2014, HELL J CARDIOL, V55, P119
   Kunita E, 2012, CIRC J, V76, P1687, DOI 10.1253/circj.CJ-11-1442
   Leipsic J, 2014, J CARDIOVASC COMPUT, V8, P342, DOI 10.1016/j.jcct.2014.07.003
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liu C, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032060
   Liu HF, 2012, EXP THER MED, V4, P297, DOI 10.3892/etm.2012.576
   Maiwald S, 2013, CURR OPIN CLIN NUTR, V16, P411, DOI 10.1097/MCO.0b013e32836236f9
   Mega JL, 2015, LANCET, V385, P2264, DOI 10.1016/S0140-6736(14)61730-X
   Mirabelli P, 2017, OPEN J BIORESOURCES, V4, P2, DOI [10.5334/ojb.26, DOI 10.5334/OJB.26]
   Miserez AR, 2002, ATHEROSCLEROSIS, V164, P15, DOI 10.1016/S0021-9150(01)00762-6
   Mozzini C, 2014, FREE RADICAL BIO MED, V68, P178, DOI 10.1016/j.freeradbiomed.2013.12.017
   Muller PY, 2002, J MED GENET, V39, P271, DOI 10.1136/jmg.39.4.271
   Napoli C, 2016, WORLD J CARDIOL, V8, P211, DOI 10.4330/wjc.v8.i2.211
   Napoli C, 2012, CIRCULATION, V125, P2363, DOI 10.1161/CIRCULATIONAHA.111.085787
   Rienzo M, 2013, CLIN TRANSL ONCOL, V15, P211, DOI 10.1007/s12094-012-0904-1
   Rizvi A, 2017, ATHEROSCLEROSIS, V258, P145, DOI 10.1016/j.atherosclerosis.2017.01.018
   Romano M, 2010, ATHEROSCLEROSIS, V210, P493, DOI 10.1016/j.atherosclerosis.2009.11.051
   Sato R, 2010, ARCH BIOCHEM BIOPHYS, V501, P177, DOI 10.1016/j.abb.2010.06.004
   Schiano C, 2015, TRENDS PHARMACOL SCI, V36, P226, DOI 10.1016/j.tips.2015.02.005
   Shchelkunova TA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0063374
   Sinnaeve PR, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007037
   Song Q, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0081148
   Strang AC, 2009, AM J CARDIOL, V104, p22E, DOI 10.1016/j.amjcard.2009.09.016
   Tabas I, 2017, IMMUNITY, V47, P621, DOI 10.1016/j.immuni.2017.09.008
   ten Kate GJR, 2013, ATHEROSCLEROSIS, V227, P334, DOI 10.1016/j.atherosclerosis.2012.12.016
   Voros S, 2014, ATHEROSCLEROSIS, V233, P284, DOI 10.1016/j.atherosclerosis.2013.12.045
   Weber C, 2011, NAT MED, V17, P1410, DOI 10.1038/nm.2538
   Westerterp M, 2014, CIRC RES, V114, P157, DOI 10.1161/CIRCRESAHA.114.300738
   Wingrove JA, 2008, CIRC-CARDIOVASC GENE, V1, P31, DOI 10.1161/CIRCGENETICS.108.782730
NR 52
TC 0
Z9 0
U1 0
U2 0
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 23
PY 2019
VL 14
IS 1
AR e0210909
DI 10.1371/journal.pone.0210909
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA HI4TC
UT WOS:000456442800057
PM 30673762
OA Other Gold
DA 2019-06-18
ER

PT J
AU Lee, M
   Baek, H
   Park, JS
   Kim, S
   Kyung, C
   Baik, SJ
   Lee, BK
   Kim, JH
   Ahn, CW
   Kim, KR
   Kang, S
AF Lee, Minyoung
   Baek, Haeri
   Park, Jong Suk
   Kim, Sohee
   Kyung, Chanhee
   Baik, Su Jung
   Lee, Byoung Kwon
   Kim, Jie-Hyun
   Ahn, Chul Woo
   Kim, Kyung Rae
   Kang, Shinae
TI Current Helicobacter pylori infection is significantly associated with
   subclinical coronary atherosclerosis in healthy subjects: A
   cross-sectional study
SO PLOS ONE
LA English
DT Article
ID ARTERY-DISEASE; CARDIOVASCULAR-DISEASE; HEART-DISEASE; RISK-FACTORS;
   MYOCARDIAL-INFARCTION; CHLAMYDIA-PNEUMONIAE; ERADICATION THERAPY;
   STRAINS; SEROPOSITIVITY; INFLAMMATION
AB Helicobacter pylori is a gastrointestinal pathogen known to be associated with cardiovascular disease (CVD). However, most analyses about the effect of H. pylori infection have been done in patients with a history of CVD but not in healthy subjects. We evaluated the association between H. pylori infection and subclinical atherosclerosis by using cardiac multidetector computed tomography (MDCT) in healthy subjects without previous CVD. From December 2007 to February 2014, 463 subjects who underwent the rapid urease test (CLO test), pulse-wave velocity (PWV) measurement, and MDCT for a self-referred health checkup were enrolled to this study. Helicobacter pylori infection was defined on the basis of CLO test positivity on endoscopic gastric biopsy. Significant coronary artery stenosis was defined as >= 50% stenosis in any of the major epicardial coronary vessel on MDCT. The CLO-positive subjects had a lower high-density lipoprotein-cholesterol (HDL-cholesterol) level compared to the CLO-negative subjects. The incidence of significant coronary stenosis was higher in the CLO-positive group (7.6% vs. 2.9%, P = 0.01). Furthermore, the number of subjects with coronary artery calcium score > 0 and log{(number of segments with plaque)+ 1} were also significantly higher in the CLO-positive group. However, there was no statistical difference in the number of subjects with coronary artery calcium score > 100, the prevalence of any plaque nor the plaque characteristics (calcified, mixed, or soft). Pulse-wave velocity (PWV) was neither associated with CLO test positivity. The CLO-positive group was 3-fold more likely to have significant coronary artery stenosis even after adjusting for confounding factors (adjusted odds ratio 2.813, 95% confidence interval 1.051-7.528, P = 0.04). In a healthy population, current H. pylori infection was associated with subclinical but significant coronary artery stenosis. The causal relationship between H. pylori infection and subclinical atherosclerosis in a "healthy" population remains to be investigated in the future.
C1 [Lee, Minyoung; Baek, Haeri; Park, Jong Suk; Kyung, Chanhee; Ahn, Chul Woo; Kim, Kyung Rae; Kang, Shinae] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Div Endocrinol,Dept Internal Med, Seoul, South Korea.
   [Baek, Haeri] HPlus Yangji Gen Hosp, Dept Internal Med, Seoul, South Korea.
   [Park, Jong Suk; Ahn, Chul Woo; Kang, Shinae] Yonsei Univ, Coll Med, Severance Inst Vasc & Metab Res, Seoul, South Korea.
   [Kim, Sohee] Aswell Convalescent Hosp, Gwangju, South Korea.
   [Kyung, Chanhee] Rhin Hosp, Gyeonggi Do, South Korea.
   [Baik, Su Jung] Gangnam Severance Hosp, Hlth Promot Ctr, Healthcare Res Team, Seoul, South Korea.
   [Lee, Byoung Kwon] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Div Cardiol,Dept Internal Med, Seoul, South Korea.
   [Kim, Jie-Hyun] Yonsei Univ, Gangnam Severance Hosp, Coll Med, Div Gastroenterol,Dept Internal Med, Seoul, South Korea.
RP Kang, S (reprint author), Yonsei Univ, Gangnam Severance Hosp, Coll Med, Div Endocrinol,Dept Internal Med, Seoul, South Korea.; Kang, S (reprint author), Yonsei Univ, Coll Med, Severance Inst Vasc & Metab Res, Seoul, South Korea.
EM shinae95@yuhs.ac
RI Kim, Jie-Hyun/Q-9061-2019
OI Kim, Jie-Hyun/0000-0002-9198-3326; Lee, Byoung Kwon/0000-0001-9259-2776;
   Baik, Su Jung/0000-0002-3790-7701; Lee, Minyoung/0000-0002-9333-7512;
   Ahn, Chul Woo/0000-0003-3733-7486; Park, Jong Suk/0000-0002-5385-1373;
   Kang, Shinae/0000-0002-9719-4774
FU National Research Foundation of Korea (NRF) - Korea government Ministry
   of Science (MSIP) [2014R1A1A3051221]
FX This work was supported by the National Research Foundation of Korea
   (NRF, http://www.nrf.re.kr) grant funded by the Korea government
   Ministry of Science (MSIP) (No. 2014R1A1A3051221). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Adachi K, 2003, J GASTROEN HEPATOL, V18, P771, DOI 10.1046/j.1440-1746.2003.03059.x
   Adiloglu AK, 2005, ACTA CARDIOL, V60, P599, DOI 10.2143/AC.60.6.2004930
   Al-Nozha MM, 2003, SAUDI MED J, V24, P1370
   Atkinson NSS, 2016, DIGEST DIS SCI, V61, P19, DOI 10.1007/s10620-015-3877-4
   Ayada K, 2007, ANN NY ACAD SCI, V1108, P594, DOI 10.1196/annals.1422.062
   Blankenberg S, 2001, HERZ, V26, P9
   Budoff MJ, 1996, CIRCULATION, V93, P898, DOI 10.1161/01.CIR.93.5.898
   Budzynski J, 2016, INT J ANGIOL, V25, P3, DOI 10.1055/s-0035-1547385
   Chen LW, 2016, MEDICINE, V95, DOI 10.1097/MD.0000000000003616
   Chey WD, 2007, AM J GASTROENTEROL, V102, P1808, DOI 10.1111/j.1572-0241.2007.01393.x
   Chmiela M, 2003, FEMS IMMUNOL MED MIC, V36, P187, DOI 10.1016/S0928-8244(03)00030-0
   Chmiela M, 2015, WORLD J CARDIOL, V7, P187, DOI 10.4330/wjc.v7.i4.187
   Chon Seung Joo, 2016, J Menopausal Med, V22, P146, DOI 10.6118/jmm.2016.22.3.146
   Coskun S, 2008, PEDIATR INT, V50, P150, DOI 10.1111/j.1442-200X.2008.02542.x
   Crabtree JE, 1999, J CLIN PATHOL, V52, P653, DOI 10.1136/jcp.52.9.653
   de Ferranti S, 2002, CLIN CHIM ACTA, V317, P1, DOI 10.1016/S0009-8981(01)00797-5
   Diomedi M, 2008, HELICOBACTER, V13, P525, DOI 10.1111/j.1523-5378.2008.00627.x
   Duntas LH, 2007, THYROID, V17, P1075, DOI 10.1089/thy.2007.0116
   Epstein SE, 1999, CIRCULATION, V100, pE20, DOI 10.1161/01.CIR.100.4.e20
   Farsak B, 2000, J CLIN MICROBIOL, V38, P4408
   Franceschi F, 2009, ATHEROSCLEROSIS, V202, P535, DOI 10.1016/j.atherosclerosis.2008.04.051
   Haberl R, 2001, J AM COLL CARDIOL, V37, P451, DOI 10.1016/S0735-1097(00)01119-0
   Huang BS, 2011, DIGEST DIS SCI, V56, P109, DOI 10.1007/s10620-010-1274-6
   Ikeda A, 2013, ATHEROSCLEROSIS, V230, P67, DOI 10.1016/j.atherosclerosis.2013.06.013
   Jin Seung-Won, 2007, Korean Journal of Internal Medicine, V22, P152
   Kanbay M, 2005, DIGEST DIS SCI, V50, P2071, DOI 10.1007/s10620-005-3009-7
   Kim DW, 2014, ORAL DIS, V20, P551, DOI 10.1111/odi.12168
   Kim SK, 2014, ANN OCCUP ENVIRON ME, V26, DOI 10.1186/2052-4374-26-1
   Kountouras J, 2017, INT J CARDIOL, V229, P17, DOI 10.1016/j.ijcard.2016.11.265
   Kowalski M, 2002, DIGEST LIVER DIS, V34, P398, DOI 10.1016/S1590-8658(02)80036-6
   Kowalski M, 2001, DIGEST LIVER DIS, V33, P222, DOI 10.1016/S1590-8658(01)80711-8
   KULLER L, 1994, AM J EPIDEMIOL, V139, P1164, DOI 10.1093/oxfordjournals.aje.a116963
   Kuller LH, 2006, ARCH INTERN MED, V166, P71, DOI 10.1001/archinte.166.1.71
   Laurila A, 1999, ATHEROSCLEROSIS, V142, P207, DOI 10.1016/S0021-9150(98)00194-4
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liu M, 2014, EUR REV MED PHARMACO, V18, P2918
   Makoveichuk E, 2017, BBA-MOL CELL BIOL L, V1862, P533, DOI 10.1016/j.bbalip.2017.02.005
   Manolakis A, 2007, HELICOBACTER, V12, P287, DOI 10.1111/j.1523-5378.2007.00511.x
   Mason JC, 2015, EUR HEART J, V36, P482, DOI 10.1093/eurheartj/ehu403
   Mayr M, 2003, STROKE, V34, P610, DOI 10.1161/01.STR.0000058481.82639.EF
   MENDALL MA, 1994, BRIT HEART J, V71, P437
   Mentis A, 2015, HELICOBACTER, V20, P1, DOI 10.1111/hel.12250
   Mete R, 2013, EUR REV MED PHARMACO, V17, P2884
   Nakagawa H, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/142358
   Nazligul Y, 2011, CLIN BIOCHEM, V44, P647, DOI 10.1016/j.clinbiochem.2011.03.001
   Niemela S, 1996, HEART, V75, P573, DOI 10.1136/hrt.75.6.573
   Ohnishi M, 2008, METABOLISM, V57, P1760, DOI 10.1016/j.metabol.2008.08.001
   Okada T, 2007, J AUTOIMMUN, V29, P106, DOI 10.1016/j.jaut.2007.05.004
   Park MJ, 2011, GUT LIVER, V5, P321, DOI 10.5009/gnl.2011.5.3.321
   Pohjanen VM, 2016, BMJ OPEN, V6, DOI 10.1136/bmjopen-2015-009987
   Qu BG, 2017, SCI REP-UK, V7, P1, DOI 10.1038/srep43059
   Quinn MJ, 1999, AM J CARDIOL, V83, P1664, DOI 10.1016/S0002-9149(99)00175-7
   Rezaee-Zavareh MS, 2016, ARYA ATHEROSCLER, V12, P41
   Rogha M, 2012, ARYA ATHEROSCLER, V8, P5
   Schottker B, 2012, ATHEROSCLEROSIS, V220, P569, DOI 10.1016/j.atherosclerosis.2011.11.029
   Sheu WHH, 2000, CLIN EXP HYPERTENS, V22, P595, DOI 10.1081/CEH-100100094
   Silverman MG, 2014, JACC-CARDIOVASC IMAG, V7, P476, DOI 10.1016/j.jcmg.2014.03.005
   Sun J, 2016, HELICOBACTER, V21, P11, DOI 10.1111/hel.12234
   Tabata N, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0166240
   Tobin NP, 2008, AM J PHYSIOL-HEART C, V295, pH1403, DOI 10.1152/ajpheart.00240.2008
   Tsai CJ, 2000, DIGEST DIS SCI, V45, P1227, DOI 10.1023/A:1005522624004
   Wang F, 2013, PLOS ONE, V8, DOI [10.1371/journal.pone.0061792, 10.1371/journal.pone.0069284, 10.1371/journal.pone.0064373, 10.1371/journal.pone.0080480]
   Yamaoka Y, 2014, FUTURE ONCOL, V10, P1487, DOI [10.2217/fon.14.29, 10.2217/FON.14.29]
   Yu XJ, 2017, EXP THER MED, V13, P787, DOI 10.3892/etm.2017.4028
   Zuin M, 2016, INT J CARDIOL, V223, P711, DOI 10.1016/j.ijcard.2016.08.320
NR 65
TC 5
Z9 5
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 2
PY 2018
VL 13
IS 3
AR e0193646
DI 10.1371/journal.pone.0193646
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FY0AM
UT WOS:000426472300018
PM 29499055
OA Other Gold
DA 2019-06-18
ER

PT J
AU Bras, JP
   Silva, AM
   Calin, GA
   Barbosa, MA
   Santos, SG
   Almeida, MI
AF Bras, Joao Paulo
   Silva, Andreia Machado
   Calin, George A.
   Barbosa, Mario Adolfo
   Santos, Susana Gomes
   Almeida, Maria Ines
TI miR-195 inhibits macrophages pro-inflammatory profile and impacts the
   crosstalk with smooth muscle cells
SO PLOS ONE
LA English
DT Article
ID TOLL-LIKE RECEPTORS; EXPRESSION; POLARIZATION; TLR2; ATHEROSCLEROSIS;
   ACTIVATION; PROLIFERATION; INVOLVEMENT; MODULATION; PHENOTYPE
AB Macrophages are a main component of atherosclerotic plaques. Recent studies suggest that pro-inflammatory M1 macrophages are pro-atherogenic while M2 macrophages promote plaque stability. Moreover, toll-like receptor signalling pathways are implicated in atherosclerotic plaque formation, evolution and regression. We propose microRNAs as key regulators of these processes. In this context, our goal is to promote inflammation resolution using miR-195 to reduce M1-like macrophage polarization and to evaluate the molecular mechanisms underlying such effect, as well as to explore the functional consequences for smooth muscle cell recruitment. Human primary macrophages were differentiated from peripheral blood monocytes and stimulated with LPS or IL-10 to promote M1 or M2c polarization, respectively. miR-195 levels were upregulated in M2c macrophages compared with M1 macrophages. In THP-1 macrophages stimulated with LPS and IFN-gamma, results show that TLR2 levels were reduced by miR-195 overexpression compared with scrambled control. In addition, phosphorylated forms of p54 JNK, p46 JNK and p38 MAPK were decreased by miR-195 in macrophages following M1 stimulation. Moreover, miR-195 significantly decreased levels of IL-1 beta, IL-6 and TNF-alpha pro-inflammatory cytokines in the supernatants of M1-stimulated macrophage cultures. At the functional level, results from smooth muscle cell recruitment and migration models showed that miR-195 impairs the capacity of M1 macrophages to promote smooth muscle cells migration. In conclusion, miR-195 is involved in macrophage polarization and inhibits TLR2 inflammatory pathway mediators. Moreover, miR-195 impairs the effect of macrophages on smooth muscle cells recruitment capacity and migration profile. Thus, miR-195 might be used as a new potential tool to promote inflammation resolution in cardiovascular research.
C1 [Bras, Joao Paulo; Silva, Andreia Machado; Barbosa, Mario Adolfo; Santos, Susana Gomes; Almeida, Maria Ines] Univ Porto, Inst Invest & Inovacao Saude, Oporto, Portugal.
   [Bras, Joao Paulo; Silva, Andreia Machado; Barbosa, Mario Adolfo; Santos, Susana Gomes; Almeida, Maria Ines] Univ Porto, Inst Engn Biomed, Oporto, Portugal.
   [Bras, Joao Paulo] Univ Porto, Fac Engn, Oporto, Portugal.
   [Bras, Joao Paulo; Silva, Andreia Machado; Barbosa, Mario Adolfo] Univ Porto, Inst Ciencias Biomed Abel Salazar, Oporto, Portugal.
   [Calin, George A.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RP Almeida, MI (reprint author), Univ Porto, Inst Invest & Inovacao Saude, Oporto, Portugal.; Almeida, MI (reprint author), Univ Porto, Inst Engn Biomed, Oporto, Portugal.
EM ines.almeida@ineb.up.pt
RI Calin, George/E-9390-2011; Santos, Susana G/L-9351-2013; Almeida, Maria
   Ines/N-3196-2013
OI Santos, Susana G/0000-0002-8604-2978; Bras, Joao/0000-0003-1867-0486;
   Almeida, Maria Ines/0000-0003-2072-8587; Barbosa,
   Mario/0000-0003-3568-7482
FU Norte Portugal Regional Operational Programme (NORTE) under the PORTUGAL
   through the European Regional Development Fund (ERDF)
   [NORTE-01-0145-FEDER-000012]; FCT Fundacao para a Ciencia e a Tecnologia
   [PD/BI/128356/2017, SFRH/BD/85968/2012, SFRH/BPD/91011/2012]
FX This work was funded by the project (NORTE-01-0145-FEDER-000012),
   supported by Norte Portugal Regional Operational Programme (NORTE 2020),
   under the PORTUGAL 2020 Partnership Agreement, through the European
   Regional Development Fund (ERDF). JPB, AMS and MIA were supported by FCT
   Fundacao para a Ciencia e a Tecnologia, through fellowships
   PD/BI/128356/2017, SFRH/BD/85968/2012 and SFRH/BPD/91011/2012,
   respectively. JPB would like to thank to BiotechHealth PhD Programme and
   MIA to L'Oreal-UNESCO-FCT for the Medal of Honor for Women in Science.
CR Almeida MI, 2011, MUTAT RES-FUND MOL M, V717, P1, DOI 10.1016/j.mrfmmm.2011.03.009
   Almeida MI, 2016, ONCOTARGET, V7, P7, DOI 10.18632/oncotarget.6589
   Averill MM, 2012, ARTERIOSCL THROM VAS, V32, P223, DOI 10.1161/ATVBAHA.111.236927
   Banerjee S, 2012, J IMMUNOL, V29, P997
   Banerjee S, 2013, J BIOL CHEM, V288, P35428, DOI 10.1074/jbc.M112.426866
   Benakanakere MR, 2009, J BIOL CHEM, V284, P23107, DOI 10.1074/jbc.M109.013862
   Bosisio D, 2002, BLOOD, V99, P3427, DOI 10.1182/blood.V99.9.3427
   Burdon KP, 2010, MEDIAT INFLAMM, DOI 10.1155/2010/170153
   Bustin SA, 2009, CLIN CHEM, V55, P611, DOI 10.1373/clinchem.2008.112797
   Chavez-Sanchez L, 2014, HUM IMMUNOL, V75, P322, DOI 10.1016/j.humimm.2014.01.012
   Chen T, 2009, CARDIOVASC RES, V83, P131, DOI 10.1093/cvr/cvp121
   Chinetti-Gbaguidi G, 2015, NAT REV CARDIOL, V12, P10, DOI 10.1038/nrcardio.2014.173
   Cole JE, 2013, TRENDS PHARMACOL SCI, V34, P629, DOI 10.1016/j.tips.2013.09.008
   Colin S, 2014, IMMUNOL REV, V262, P153, DOI 10.1111/imr.12218
   Fernandez-Velasco M, 2014, BIOCHEM J, V458, P187, DOI 10.1042/BJ20131501
   Frink RJ, 2002, INFLAMMATORY ATHEROS, P1
   Gomez D, 2012, CARDIOVASC RES, V95, P156, DOI 10.1093/cvr/cvs115
   Islam K, 2016, SM J BIOMED ENG, V2, P1008
   Jimenez VC, 2014, PHYSIOL GENOMICS, V46, P91, DOI 10.1152/physiolgenomics.00140.2013
   Koga J, 2012, VASC PHARMACOL, V57, P24, DOI 10.1016/j.vph.2012.02.011
   Leitinger N, 2013, ARTERIOSCL THROM VAS, V33, P1120, DOI 10.1161/ATVBAHA.112.300173
   Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liu Y, 2001, INFECT IMMUN, V69, P2788, DOI 10.1128/IAI.69.5.2788-2796.2001
   Maiolino G, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/714653
   Matsuguchi T, 2000, J IMMUNOL, V165, P5767, DOI 10.4049/jimmunol.165.10.5767
   Mazza G, 2016, CYTOTECHNOLOGY, V68, P701, DOI 10.1007/s10616-014-9822-0
   Moore KJ, 2013, NAT REV IMMUNOL, V13, P709, DOI 10.1038/nri3520
   Mullick AE, 2005, J CLIN INVEST, V115, P3149, DOI 10.1172/JCI25482
   O'Connell RM, 2007, P NATL ACAD SCI USA, V104, P1604, DOI 10.1073/pnas.0610731104
   O'Neill LAJ, 2013, NAT REV IMMUNOL, V13, P453, DOI 10.1038/nri3446
   Oliveira MI, 2017, ACTA BIOMATER, V49, P296, DOI 10.1016/j.actbio.2016.11.034
   Oliveira MI, 2012, EUR CELLS MATER, V24, P136, DOI 10.22203/eCM.v024a10
   Philippe L, 2012, J IMMUNOL, V188, P454, DOI 10.4049/jimmunol.1102348
   Qu Q, 2017, CELL BIOL INT, V41, P287, DOI 10.1002/cbin.10723
   Randolph GJ, 2014, CIRC RES, V114, P1757, DOI 10.1161/CIRCRESAHA.114.301174
   Seneviratne AN, 2012, CLIN CHIM ACTA, V413, P3, DOI 10.1016/j.cca.2011.08.021
   Shoenfelt J, 2009, J LEUKOCYTE BIOL, V86, P303, DOI 10.1189/jlb.1008587
   Stoger JL, 2012, ATHEROSCLEROSIS, V225, P461, DOI 10.1016/j.atherosclerosis.2012.09.013
   Tabas I, 2016, CIRC RES, V118, P653, DOI 10.1161/CIRCRESAHA.115.306256
   Taganov KD, 2006, P NATL ACAD SCI USA, V103, P12481, DOI 10.1073/pnas.0605298103
   Thulin P, 2013, INT J MOL MED, V31, P1003, DOI 10.3892/ijmm.2013.1311
   TSUCHIYA S, 1980, INT J CANCER, V26, P171, DOI 10.1002/ijc.2910260208
   Wang Q, 2001, INFECT IMMUN, V69, P2
   Wang YS, 2012, CARDIOVASC RES, V95, P517, DOI 10.1093/cvr/cvs223
   Willerson JT, 2004, CIRCULATION, V109, P2, DOI 10.1161/01.CIR.0000129535.04194.38
   Ying HJ, 2015, J IMMUNOL, V194, P1239, DOI 10.4049/jimmunol.1402088
   Zanoni I, 2011, CELL, V147, P868, DOI 10.1016/j.cell.2011.09.051
   Zhang ZG, 2017, CANCER LETT, V393, P1, DOI 10.1016/j.canlet.2017.02.008
NR 49
TC 8
Z9 8
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 22
PY 2017
VL 12
IS 11
AR e0188530
DI 10.1371/journal.pone.0188530
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FN5GQ
UT WOS:000416035300046
PM 29166412
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Jayachandran, M
   Garovic, VD
   Mielke, MM
   Bailey, KR
   Lahr, BD
   Miller, VM
AF Jayachandran, Muthuvel
   Garovic, Vesna D.
   Mielke, Michelle M.
   Bailey, Kent R.
   Lahr, Brian D.
   Miller, Virginia M.
TI Characterization of intravascular cellular activation in relationship to
   subclinical atherosclerosis in postmenopausal women
SO PLOS ONE
LA English
DT Article
ID BLOOD-BORNE MICROVESICLES; CIRCULATING MICROPARTICLES; CARDIOVASCULAR
   RISK; NORMAL-PREGNANCY; HISTORY; PREECLAMPSIA; ESTROGEN
AB Objective
   Mechanisms and interactions among intravascular cells contributing to development of subclinical atherosclerosis are poorly understood. In women, both menopausal status and pregnancy history influence progression of atherosclerosis. This study examined activation and interactions among blood elements with subclinical atherosclerosis in menopausal women with known pregnancy histories.
   Methods
   Carotid intima-media thickness (CIMT), as a marker of subclinical atherosclerosis, was measured using B-mode ultrasound in age-and parity-matched women [40 with and 40 without a history of preeclampsia] 35 years after the index pregnancy. Interactions among intravascular cells (38 parameters) were measured by flow cytometry in venous blood. Data analysis was by principal component which retained 7 independent dimensions accounting for 63% of the variability among 38 parameters.
   Results
   CIMT was significantly greater in women with a history of preeclampsia (P = 0.004). Platelet aggregation and platelet interactions with granulocytes and monocytes positively associated with CIMT in postmenopausal women independent of their pregnancy history (rho = 0.258, P<0.05). However, the association of the number of platelets, platelet activation and mono-cyteplatelet interactions with CIMT differed significantly depending upon pregnancy history (test for interaction, P<0.001).
   Conclusion
   Interactions among actived intravascular cells and their association with subclinical atherosclerosis differ in women depending upon their pregnancy histories.
C1 [Jayachandran, Muthuvel; Miller, Virginia M.] Mayo Clin, Dept Surg, Rochester, MN 55905 USA.
   [Jayachandran, Muthuvel; Miller, Virginia M.] Mayo Clin, Physiol & Biomed Engn, Rochester, MN 55905 USA.
   [Garovic, Vesna D.] Mayo Clin, Div Nephrol & Hypertens, Gen Internal Med, Rochester, MN USA.
   [Mielke, Michelle M.; Bailey, Kent R.; Lahr, Brian D.] Mayo Clin, Div Epidemiol, Hlth Sci Res, Rochester, MN USA.
   [Mielke, Michelle M.] Mayo Clin, Neurol, Rochester, MN USA.
   [Bailey, Kent R.; Lahr, Brian D.] Mayo Clin, Div Biostat, Hlth Sci Res, Rochester, MN USA.
RP Miller, VM (reprint author), Mayo Clin, Dept Surg, Rochester, MN 55905 USA.; Miller, VM (reprint author), Mayo Clin, Physiol & Biomed Engn, Rochester, MN 55905 USA.
EM miller.virginia@mayo.edu
OI Mielke, Michelle/0000-0001-7177-1185
FU National Institutes of Health (NIH) [P50 AG044170, R01 AG034676, UL1
   TR000135]; Department of Surgery; Mayo Foundation; American Heart
   Association [12GRNT12050147]; National Center for Advancing
   Translational Sciences, a component of the National Institutes of Health
FX This study was supported by the National Institutes of Health (NIH) P50
   AG044170, R01 AG034676, UL1 TR000135 (a Mayo Clinic Clinical and
   Translational Science Award), the Department of Surgery, the Mayo
   Foundation, and the American Heart Association grant 12GRNT12050147. The
   Mayo Clinic Clinical and Translational Science Award is from the
   National Center for Advancing Translational Sciences, a component of the
   National Institutes of Health. The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Berckmans RJ, 2001, THROMB HAEMOSTASIS, V85, P639
   Borzychowski AM, 2006, SEMIN FETAL NEONAT M, V11, P309, DOI 10.1016/j.siny.2006.04.001
   Bretelle F, 2003, THROMB HAEMOSTASIS, V89, P486
   Campello E, 2015, THROMB RES, V136, P427, DOI 10.1016/j.thromres.2015.05.029
   Cronqvist T, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090020
   Garcia M, 2016, MAYO CLIN PROC, V91, P226, DOI 10.1016/j.mayocp.2015.11.001
   Garovic VD, 2013, CURR HYPERTENS REP, V15, P114, DOI 10.1007/s11906-013-0329-4
   Gilani SI, 2016, CURR HYPERTENS REP, V18, DOI 10.1007/s11906-016-0678-x
   Goynumer G, 2013, J CLIN ULTRASOUND, V41, P145, DOI 10.1002/jcu.21962
   Gustafson CM, 2015, BIOL SEX DIFFER, V6, DOI 10.1186/s13293-015-0028-8
   Hamad RR, 2009, THROMB RES, V123, P580, DOI 10.1016/j.thromres.2008.03.022
   Harman SM, 2014, ANN INTERN MED, V161, P249, DOI 10.7326/M14-0353
   Harman SM, 2005, CLIMACTERIC, V8, P3, DOI 10.1080/13697130500042417
   Holthe MR, 2005, PLATELETS, V16, P91, DOI 10.1080/09537100400004355
   Jayachandran M, 2012, J IMMUNOL METHODS, V375, P207, DOI 10.1016/j.jim.2011.10.012
   Jayachandran M, 2011, J CARDIOVASC TRANSL, V4, P811, DOI 10.1007/s12265-011-9296-9
   Kim DK, 2015, BIOINFORMATICS, V31, P933, DOI 10.1093/bioinformatics/btu741
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lok CAR, 2009, AM J REPROD IMMUNOL, V61, P346, DOI 10.1111/j.1600-0897.2009.00701.x
   Luppi P, 2006, CLIN IMMUNOL, V118, P268, DOI 10.1016/j.clim.2005.11.001
   Martin S, 2004, CIRCULATION, V109, P1653, DOI 10.1161/01.CIR.0000124065.31211.6E
   McDonald SD, 2013, ATHEROSCLEROSIS, V229, P234, DOI 10.1016/j.atherosclerosis.2013.04.020
   Mellembakken JR, 2001, OBSTET GYNECOL, V97, P371, DOI 10.1016/S0029-7844(00)01179-0
   Milic NM, 2017, ULTRASOUND OBST GYN, V49, P110, DOI 10.1002/uog.17367
   Miller VM, 2007, CLIN EXP PHARMACOL P, V34, P814, DOI 10.1111/j.1440-1681.2007.04685.x
   Miller VM, 2016, ATHEROSCLEROSIS, V253, P150, DOI 10.1016/j.atherosclerosis.2016.09.006
   Miller VM, 2015, PLATELETS, V9, P1
   Morel O, 2011, SEMIN IMMUNOPATHOL, V33, P469, DOI 10.1007/s00281-010-0239-3
   Mosca, 2011, CIRCULATION, V123, pE624, DOI 10.1161/CIR.0b013e318222b330
   Rainger GE, 2015, PLATELETS, V26, P507, DOI 10.3109/09537104.2015.1064881
   Redman CWG, 2015, AM J OBSTET GYNECOL, V213, DOI 10.1016/j.ajog.2015.08.003
   Redman CWG, 2003, PLACENTA, V24, pS21, DOI 10.1053/plac.2002.0930
   Tatsumi K, 2015, J ATHEROSCLER THROMB, V22, P543, DOI 10.5551/jat.30940
   Toldi G, 2015, AM J REPROD IMMUNOL, V74, P110, DOI 10.1111/aji.12380
   White W. M., 2016, AM J OBSTET GYNECOL, V214, pe1, DOI DOI 10.HTTPS://D0I.0RG/10.1016/J.AJ0G.2016.02.003
   Xiong J, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0025504
   Xiong J, 2012, J CARDIOVASC PHARM, V59, P124, DOI 10.1097/FJC.0b013e31820c6254
   Zoet GA, 2015, MATURITAS, V82, P153, DOI 10.1016/j.maturitas.2015.07.004
NR 38
TC 3
Z9 3
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 14
PY 2017
VL 12
IS 9
AR e0183159
DI 10.1371/journal.pone.0183159
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FH0VR
UT WOS:000410859200007
PM 28910282
OA DOAJ Gold, Green Published
DA 2019-06-18
ER

PT J
AU Christiansen, MK
   Larsen, SB
   Nyegaard, M
   Neergaard-Petersen, S
   Ajjan, R
   Wurtz, M
   Grove, EL
   Hvas, AM
   Jensen, HK
   Kristensen, SD
AF Christiansen, Morten Krogh
   Larsen, Sanne Bojet
   Nyegaard, Mette
   Neergaard-Petersen, Sos
   Ajjan, Ramzi
   Wurtz, Morten
   Grove, Erik Lerkevang
   Hvas, Anne-Mette
   Jensen, Henrik Kjaerulf
   Kristensen, Steen Dalby
TI Coronary artery disease-associated genetic variants and biomarkers of
   inflammation
SO PLOS ONE
LA English
DT Article
ID C-REACTIVE PROTEIN; GENOME-WIDE ASSOCIATION; MYELOID-RELATED PROTEIN-14;
   HEART-DISEASE; MYOCARDIAL-INFARCTION; LDL-CHOLESTEROL; RISK SCORES;
   LOCI; APOE; MYELOID-RELATED-PROTEIN-8/14
AB Introduction Genetic constitution and inflammation both contribute to development of coronary artery disease (CAD). Several CAD-associated single-nucleotide polymorphisms (SNPs) have recently been identified, but their functions are largely unknown. We investigated the associations between CAD-associated SNPs and five CAD-related inflammatory biomarkers.
   Methods We genotyped 45 CAD-associated SNPs in 701 stable CAD patients in whom levels of highsensitivity C-reactive protein (hsRCP), interleukin-6, calprotectin, fibrinogen and complement component 3 levels had previously been measured. A genetic risk score was calculated to assess the combined risk associated with all the genetic variants. A multiple linear regression model was used to assess associations between the genetic risk score, single SNPs, and the five inflammatory biomarkers.
   Results The minor allele (G) (CAD risk allele) of rs2075650 (TOMM40/APOE) was associated with lower levels of high-sensitivity C-reactive protein (effect per risk allele: -0.37 mg/l [95% CI -0.56 to -0.18 mg/l]). The inflammatory markers tested showed no association with the remaining 44 SNPs or with the genetic risk score.
   Conclusions In stable CAD patients, the risk allele of a common CAD-associated marker at the TOMM40/APOE locus was associated with lower hsCRP levels. No other genetic variants or the combined effect of all variants were associated with the five inflammatory biomarkers.
C1 [Christiansen, Morten Krogh; Larsen, Sanne Bojet; Neergaard-Petersen, Sos; Wurtz, Morten; Grove, Erik Lerkevang; Jensen, Henrik Kjaerulf; Kristensen, Steen Dalby] Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark.
   [Christiansen, Morten Krogh; Larsen, Sanne Bojet; Grove, Erik Lerkevang; Hvas, Anne-Mette; Jensen, Henrik Kjaerulf; Kristensen, Steen Dalby] Aarhus Univ, Inst Clin Med, Fac Hlth, Aarhus, Denmark.
   [Nyegaard, Mette] Aarhus Univ, Dept Biomed, Aarhus, Denmark.
   [Ajjan, Ramzi] Univ Leeds, Leeds Inst Cardiovasc & Metab Med LICAMM, Leeds, W Yorkshire, England.
   [Hvas, Anne-Mette] Aarhus Univ Hosp, Dept Clin Biochem, Aarhus, Denmark.
RP Christiansen, MK (reprint author), Aarhus Univ Hosp, Dept Cardiol, Aarhus, Denmark.; Christiansen, MK (reprint author), Aarhus Univ, Inst Clin Med, Fac Hlth, Aarhus, Denmark.
EM mkc@dadlnet.dk
RI Jensen, Henrik/A-7980-2018; Nyegaard, Mette/M-3379-2019
OI Jensen, Henrik/0000-0003-1802-4302; Nyegaard, Mette/0000-0003-4973-8543;
   Christiansen, Morten Krogh/0000-0002-3894-888X
FU Novo Nordic Foundation [NNF14OC0008817]; Pfizer [WS2632086]
FX Funding was received from the Novo Nordic Foundation (grant no.
   NNF14OC0008817 to SDK) and Pfizer (unrestricted research grant no.
   WS2632086 to HKJ). The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abraham G, 2016, EUR HEART J, V37, P3267, DOI 10.1093/eurheartj/ehw450
   Altwegg LA, 2007, EUR HEART J, V28, P941, DOI 10.1093/eurheartj/ehm078
   Bekris LM, 2012, J HUM GENET, V57, P18, DOI 10.1038/jhg.2011.123
   Chaineau M, 2009, FEBS LETT, V583, P3817, DOI 10.1016/j.febslet.2009.10.026
   Chasman DI, 2006, GENES IMMUN, V7, P211, DOI 10.1038/sj.gene.6364289
   Christiansen MK, 2017, INT J CARDIOL, P1
   Christiansen MK, 2017, ATHEROSCLEROSIS, V257, P172, DOI 10.1016/j.atherosclerosis.2017.01.010
   CORDER EH, 1993, SCIENCE, V261, P921, DOI 10.1126/science.8346443
   de Vries PS, 2016, HUM MOL GENET, V25, P358, DOI 10.1093/hmg/ddv454
   Deelen J, 2011, AGING CELL, V10, P686, DOI 10.1111/j.1474-9726.2011.00705.x
   Dehghan A, 2011, CIRCULATION, V123, P731, DOI 10.1161/CIRCULATIONAHA.110.948570
   Deloukas P, 2013, NAT GENET, V45, P25, DOI 10.1038/ng.2480
   Denny JC, 2013, NAT BIOTECHNOL, V31, P1102, DOI 10.1038/nbt.2749
   Dorajoo R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067650
   Ganna A, 2013, ARTERIOSCL THROM VAS, V33, P2267, DOI 10.1161/ATVBAHA.113.301218
   Guo YR, 2013, HUM MOL GENET, V22, P184, DOI 10.1093/hmg/dds396
   Healy AM, 2006, CIRCULATION, V113, P2278, DOI 10.1161/CIRCULATIONAHA.105.607333
   Ionita MG, 2009, ARTERIOSCL THROM VAS, V29, P1220, DOI 10.1161/ATVBAHA.109.190314
   Jensen LJN, 2010, J INTERV CARDIOL, V23, P123, DOI 10.1111/j.1540-8183.2010.00532.x
   Johnson AD, 2008, BIOINFORMATICS, V24, P2938, DOI 10.1093/bioinformatics/btn564
   Kaptoge S, 2014, EUR HEART J, V35, P578, DOI 10.1093/eurheartj/eht367
   Kaptoge S, 2010, LANCET, V375, P132, DOI 10.1016/S0140-6736(09)61717-7
   Kocarnik JM, 2014, CIRC-CARDIOVASC GENE, V7, P178, DOI 10.1161/CIRCGENETICS.113.000173
   Larsen SB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126767
   Larsen SB, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125992
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   McPherson Ruth, 2014, CURR GENET MED REP, V2, P1, DOI DOI 10.1007/S40142-014-0033-Y
   Middelberg RPS, 2011, BMC MED GENET, V12, DOI 10.1186/1471-2350-12-123
   Morrow DA, 2008, AM HEART J, V155, P49, DOI 10.1016/j.ahj.2007.08.018
   MUSCARI A, 1995, AM J MED, V98, P357, DOI 10.1016/S0002-9343(99)80314-3
   Musunuru K, 2010, NATURE, V466, P714, DOI 10.1038/nature09266
   Naitza S, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002480
   Neergaard-Petersen S, 2014, THROMB HAEMOSTASIS, V112, P1142, DOI 10.1160/TH14-05-0468
   Neergaard-Petersen S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071150
   Ridker PM, 2008, AM J HUM GENET, V82, P1185, DOI 10.1016/j.ajhg.2008.03.015
   Ripatti S, 2010, LANCET, V376, P1393, DOI 10.1016/S0140-6736(10)61267-6
   Sabater-Lleal M, 2013, CIRCULATION, V128, P1310, DOI 10.1161/CIRCULATIONAHA.113.002251
   Sandhu MS, 2008, LANCET, V371, P483, DOI 10.1016/S0140-6736(08)60208-1
   Schunkert H, 2011, NAT GENET, V43, P333, DOI [10.1038/ng.784, 10.1161/CIRCGENETICS.111.960443]
   Shah T, 2013, CIRC-CARDIOVASC GENE, V6, P163, DOI 10.1161/CIRCGENETICS.112.964254
   Vaara S, 2016, CIRC-CARDIOVASC GENE, V9, P172, DOI 10.1161/CIRCGENETICS.115.001271
   Wensley F, 2011, BRIT MED J, V342, DOI 10.1136/bmj.d548
   Yang XB, 2012, PLOS GENET, V8, DOI 10.1371/journal.pgen.1002916
NR 43
TC 5
Z9 5
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 7
PY 2017
VL 12
IS 7
AR e0180365
DI 10.1371/journal.pone.0180365
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA FA5DZ
UT WOS:000405464100054
PM 28686695
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Frostegard, J
   Su, J
   Sing, S
   Hua, X
   Vikstrom, M
   Leander, K
   Gigante, B
   de Faire, U
   Frostegard, AG
AF Frostegard, Johan
   Su, Jun
   Sing, Sudhir
   Hua, Xiang
   Vikstrom, Max
   Leander, Karin
   Gigante, Bruna
   de Faire, Ulf
   Frostegard, Anna G.
TI IgM antibodies to oxidized phosphatidylserine as protection markers in
   cardiovascular disease among 60-year olds
SO PLOS ONE
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; ATHEROSCLEROTIC PLAQUES; RISK-FACTORS;
   CELLS; EXTERNALIZATION; CLEARANCE; APOPTOSIS; PHOSPHORYLCHOLINE;
   CARDIOLIPIN; PREVALENCE
AB Objective
   Phosphatidylserine is exposed on apoptotic cells and is prone to oxidation (OxPS). Here we analyze the association of IgM antibodies against OxPS (anti-OxPS) with the risk of cardiovascular disease (CVD).
   Methods
   Among sixty-year olds from Stockholm County in Sweden, previously screened for cardiovascular risk factors (2039 men, 2193 women), there were 210 incident CVD-cases identified during a 5-year follow-up. Using a nested case-control design, 622 age-and sex-matched controls were selected. Odds ratios (OR) with 95% intervals (CI) were calculated by conditional logistic regression. IgM anti-OxPS was measured by ELISA. Phagocytosis of apoptotic Jurkat-cells by macrophages was studied by flow cytometry.
   Results
   Anti-OxPS levels were lower among cases (median (interquartile range): 80.7 (60.9-101.0 vs. 84.6 (65.8-109.6); p = 0.047); among men (76.6 (55.8-99.2) vs. 82.0 (63.1-105.1); p = 0.022) and among women 89.6 (72.3-110.1) vs. 89.8 (69.9-114.4); p = 0.79).
   After adjustment for smoking, BMI, diabetes mellitus type II, hypercholesterolaemia and hypertension, and dividing into quartiles, using the highest quartile (quartile 4) as reference, quartile 3 was associated with a OR of 1.74 (CI 1.08-2.81). Quartiles 2 and 1 had similar associations, the later reaching statistical significance. Among men associations were stronger whereas no significant associations were observed in women. The OR of MI/angina comparing quartile 3 with quartile 4 was 2.31 (CI 1.30-4.11). The OR for quartile 2 and 1, respectively, were similar as for quartile 3.
   Total IgM increased uptake of apoptotic cells, which was reversed if incubated with OxPS.
   Conclusions
   IgM anti-OxPS is a novel potential protection marker for CVD, in particular in men. Increased phagocytosis of dying/dead cells could be one potential underlying mechanism.
C1 [Frostegard, Johan; Su, Jun; Sing, Sudhir; Hua, Xiang; Frostegard, Anna G.] Karolinska Inst, Unit Immunol & Chron Dis, Inst Environm Med, Stockholm, Sweden.
   [Frostegard, Johan] Karolinska Univ Hosp, Dept Emergency Med, Stockholm, Sweden.
   [Vikstrom, Max; Leander, Karin; Gigante, Bruna; de Faire, Ulf] Karolinska Inst, Unit Cardiovasc Epidemiol, Inst Environm Med, Stockholm, Sweden.
   [Gigante, Bruna] Danderyd Hosp, Dept Cardiovasc Clin Sci, Stockholm, Sweden.
   [de Faire, Ulf] Karolinska Univ Hosp, Dept Cardiol, Solna, Sweden.
RP Frostegard, J (reprint author), Karolinska Inst, Unit Immunol & Chron Dis, Inst Environm Med, Stockholm, Sweden.; Frostegard, J (reprint author), Karolinska Univ Hosp, Dept Emergency Med, Stockholm, Sweden.
EM johan.frostegard@ki.se
OI Gigante, Bruna/0000-0003-4508-7990
FU HjaErt-Lungfonden [20150622]; Reumatikerforbundet [66081]; Swedish Heart
   Lung Foundation [20150622]; Swedish Association against Rheumatism
   [66081]
FX This study was funded by grant number 20150622 from Hjart-Lungfonden and
   grant number 66081 from Reumatikerforbundet to Prof. Johan Frostegard.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.; This study was
   supported by by grants to JF: the Swedish Heart Lung Foundation grant
   number 20150622; https://www.hjart-lungfonden.se), Swedish Association
   against Rheumatism grant number 66081;
   https://www.reumatikerforbundet.org). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Anania C, 2010, ARTHRITIS RES THER, V12, DOI 10.1186/ar3193
   Arroyo A, 2002, J BIOL CHEM, V277, P49965, DOI 10.1074/jbc.M204513200
   Carlsson AC, 2008, AM J HYPERTENS, V21, P771, DOI 10.1038/ajh.2008.167
   de Faire U, 2010, J AUTOIMMUN, V34, P73, DOI 10.1016/j.jaut.2009.05.003
   Fabisiak J. P., 2005, METHOD MOL BIOL, V291
   Fiskesund R, 2010, STROKE, V41, P607, DOI 10.1161/STROKEAHA.109.558742
   Frostegard AG, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111764
   Frostegard J, 1999, ATHEROSCLEROSIS, V145, P33, DOI 10.1016/S0021-9150(99)00011-8
   Frostegard J, 2013, BMC MED, V11, DOI 10.1186/1741-7015-11-117
   Frostegard J, 2010, CLIN IMMUNOL, V134, P47, DOI 10.1016/j.clim.2009.08.013
   Greenberg ME, 2006, J EXP MED, V203, P2613, DOI 10.1084/jem.20060370
   Halldin M, 2007, NUTR METAB CARDIOVAS, V17, P349, DOI 10.1016/j.numecd.2006.01.002
   Jiang JF, 2004, LIPIDS, V39, P1133, DOI 10.1007/s11745-004-1340-1
   Jitkaew S, 2009, J LEUKOCYTE BIOL, V85, P427, DOI 10.1189/jlb.0408232
   Kagan VE, 2002, J IMMUNOL, V169, P487, DOI 10.4049/jimmunol.169.1.487
   Kaptoge S, 2014, EUR HEART J, V35, P578, DOI 10.1093/eurheartj/eht367
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Nagata S, 2010, CELL, V140, P619, DOI 10.1016/j.cell.2010.02.014
   Ridker PM, 2001, JAMA-J AM MED ASSOC, V285, P2481, DOI 10.1001/jama.285.19.2481
   Silvestre-Roig C, 2014, CIRC RES, V114, P214, DOI 10.1161/CIRCRESAHA.114.302355
   Sjoberg BG, 2009, ATHEROSCLEROSIS, V203, P528, DOI 10.1016/j.atherosclerosis.2008.07.009
   Su J, 2008, RHEUMATOLOGY, V47, P1144, DOI 10.1093/rheumatology/ken120
   Su J, 2013, J RHEUMATOL
   Su J, 2013, J RHEUMATOL, V40, P1856, DOI 10.3899/jrheum.121173
   Su J, 2013, BMC CARDIOVASC DISOR, V13, DOI 10.1186/1471-2261-13-1
   Tyurin VA, 2012, BIOCHEMISTRY-US, V51, P9736, DOI 10.1021/bi301024e
   Zalewski A, 2006, CLIN CHEM, V52, P1645, DOI 10.1373/clinchem.2006.070672
NR 27
TC 2
Z9 2
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 21
PY 2017
VL 12
IS 4
AR e0171195
DI 10.1371/journal.pone.0171195
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ES9KN
UT WOS:000399876100002
PM 28430795
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Simonetto, C
   Azizova, TV
   Barjaktarovic, Z
   Bauersachs, J
   Jacob, P
   Kaiser, JC
   Meckbach, R
   Schollnberger, H
   Eidemuller, M
AF Simonetto, Cristoforo
   Azizova, Tamara V.
   Barjaktarovic, Zarko
   Bauersachs, Johann
   Jacob, Peter
   Kaiser, Jan Christian
   Meckbach, Reinhard
   Schollnberger, Helmut
   Eidemuller, Markus
TI A mechanistic model for atherosclerosis and its application to the
   cohort of Mayak workers
SO PLOS ONE
LA English
DT Article
ID CARDIOVASCULAR-DISEASE; PRODUCTION-ASSOCIATION; INFLAMMATORY RESPONSE;
   IONIZING-RADIATION; CARCINOGENESIS; MACROPHAGE; RISK; CANCER;
   ATHEROGENESIS; INSTABILITY
AB We propose a stochastic model for use in epidemiological analysis, describing the age-dependent development of atherosclerosis with adequate simplification. The model features the uptake of monocytes into the arterial wall, their proliferation and transition into foam cells. The number of foam cells is assumed to determine the health risk for clinically relevant events such as stroke. In a simulation study, the model was checked against the age-dependent prevalence of atherosclerotic lesions. Next, the model was applied to incidence of atherosclerotic stroke in the cohort of male workers from the Mayak nuclear facility in the Southern Urals. It describes the data as well as standard epidemiological models. Based on goodness-of-fit criteria the risk factors smoking, hypertension and radiation exposure were tested for their effect on disease development. Hypertension was identified to affect disease progression mainly in the late stage of atherosclerosis. Fitting mechanistic models to incidence data allows to integrate biological evidence on disease progression into epidemiological studies. The mechanistic approach adds to an understanding of pathogenic processes, whereas standard epidemiological methods mainly explore the statistical association between risk factors and disease outcome. Due to a more comprehensive scientific foundation, risk estimates from mechanistic models can be deemed more reliable. To the best of our knowledge, such models are applied to epidemiological data on cardiovascular diseases for the first time.
C1 [Simonetto, Cristoforo; Barjaktarovic, Zarko; Jacob, Peter; Kaiser, Jan Christian; Meckbach, Reinhard; Schollnberger, Helmut; Eidemuller, Markus] Helmholtz Zentrum Munchen, Dept Radiat Sci, Neuherberg, Germany.
   [Azizova, Tamara V.] Southern Urals Biophys Inst, Ozyorsk, Chelyabinsk Reg, Russia.
   [Bauersachs, Johann] Hannover Med Sch, Dept Cardiol & Angiol, Hannover, Germany.
   [Jacob, Peter] RADRISK, Schliersee, Germany.
RP Simonetto, C (reprint author), Helmholtz Zentrum Munchen, Dept Radiat Sci, Neuherberg, Germany.
EM cristoforo.simonetto@helmholtz-muenchen.de
RI Azizova, Tamara/R-5295-2019
OI Azizova, Tamara/0000-0001-6954-2674
FU Federal Ministry of Education and Research (BMBF) [02NUK026]; Federal
   Ministry for the Environment, Nature Conservation, Building and Nuclear
   Safety; Federal Office for Radiation Protection (BfS) [3611S30022]; EU
   [295823]
FX This work was supported by the Federal Ministry of Education and
   Research (BMBF, www.bmbf.de) with contract number 02NUK026 (PASSOS).
   Furthermore, it was supported by the Federal Ministry for the
   Environment, Nature Conservation, Building and Nuclear Safety and the
   Federal Office for Radiation Protection (BfS, www.bfs.de, contract
   3611S30022) and by the EU Seventh Framework (ec.europa.eu/research/fp7)
   project ProCardio (contract number 295823). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Adams MJ, 2003, CRIT REV ONCOL HEMAT, V45, P55, DOI 10.1016/S1040-8428(01)00227-X
   ALEXANDER RW, 1995, HYPERTENSION, V25, P155, DOI 10.1161/01.HYP.25.2.155
   Alwan A, 2011, GLOBAL STATUS REPORT ON NONCOMMUNICABLE DISEASES 2010, pVII
   Ambrose JA, 2004, J AM COLL CARDIOL, V43, P1731, DOI 10.1016/j.jacc.2003.12.047
   Anspaugh LR, 2002, RADIAT ENVIRON BIOPH, V41, P19, DOI 10.1007/s00411-002-0148-5
   ARMITAGE P, 1954, BRIT J CANCER, V8, P1, DOI 10.1038/bjc.1954.1
   Azizova TV, 2010, RADIAT RES, V174, P851, DOI 10.1667/RR1928.1
   Azizova TV, 2008, HEALTH PHYS, V94, P449, DOI 10.1097/01.HP.0000300757.00912.a2
   Bentzon JF, 2014, CIRC RES, V114, P1852, DOI 10.1161/CIRCRESAHA.114.302721
   Borghini A, 2013, ATHEROSCLEROSIS, V230, P40, DOI 10.1016/j.atherosclerosis.2013.06.010
   Bulelzai MAK, 2012, J THEOR BIOL, V297, P1, DOI 10.1016/j.jtbi.2011.11.023
   Chien A, 2011, AM J NEURORADIOL, V32, P1249, DOI 10.3174/ajnr.A2483
   Cilia M, 2013, J R SOC INTERFACE, V11
   Cohen A, 2014, B MATH BIOL, V76, P1117, DOI 10.1007/s11538-014-9948-4
   DAVIES MJ, 1993, BRIT HEART J, V69, P377
   DAVIES RB, 1977, BIOMETRIKA, V64, P247, DOI 10.2307/2335690
   Deanfield JE, 2007, CIRCULATION, V115, P1285, DOI 10.1161/CIRCULATIONAHA.106.652859
   Eidemuller M, 2015, MUTAT RES-FUND MOL M, V775, P1, DOI 10.1016/j.mrfmmm.2015.03.002
   FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Hegyi L, 1996, J PATHOL, V180, P423, DOI 10.1002/(SICI)1096-9896(199612)180:4<423::AID-PATH677>3.0.CO;2-1
   Heidenreich WF, 2007, RADIAT RES, V168, P750, DOI 10.1667/RR0919.1
   Heidenreich WF, 1997, RISK ANAL, V17, P391, DOI 10.1111/j.1539-6924.1997.tb00878.x
   Hinkle Janice L, 2007, J Neurosci Nurs, V39, P285
   Ibragimov AI, 2005, MATH MED BIOL, V22, P305, DOI 10.1093/imammb/dqi011
   James F., 2004, MINUIT USERS GUIDE
   Jeon J, 2008, MATH BIOSCI, V213, P56, DOI 10.1016/j.mbs.2008.02.006
   Julius S, 2004, LANCET, V363, P2022, DOI 10.1016/S0140-6736(04)16451-9
   Kaiser JC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0111024
   Kreuzer M, 2015, MUTAT RES-REV MUTAT, V764, P90, DOI 10.1016/j.mrrev.2015.03.002
   Krombach F, 1997, ENVIRON HEALTH PERSP, V105, P1261, DOI 10.2307/3433544
   Kruglov A, 2002, HIST SOVIET ATOMIC I
   Le Gallic C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128539
   Ley K, 2011, ARTERIOSCL THROM VAS, V31, P1506, DOI 10.1161/ATVBAHA.110.221127
   Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Little M.P., 2015, CARDIOONCOLOGY, V1, P1, DOI DOI 10.1186/S40959-015-0007-6
   Little MP, 2009, PLOS COMPUT BIOL, V5, DOI 10.1371/journal.pcbi.1000539
   Luebeck EG, 2002, P NATL ACAD SCI USA, V99, P15095, DOI 10.1073/pnas.222118199
   Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
   Mendis S, 2011, GLOBAL ATLAS CARDIOV
   Meza R, 2008, P NATL ACAD SCI USA, V105, P16284, DOI 10.1073/pnas.0801151105
   Mitchel REJ, 2011, RADIAT RES, V175, P665, DOI 10.1667/RR2176.1
   MOOLGAVKAR SH, 1981, J NATL CANCER I, V66, P1037, DOI 10.1093/jnci/66.6.1037
   MOOLGAVKAR SH, 1979, MATH BIOSCI, V47, P55, DOI 10.1016/0025-5564(79)90005-1
   Nielsen LB, 1996, ATHEROSCLEROSIS, V123, P1, DOI 10.1016/0021-9150(96)05802-9
   Nowak MA, 2002, P NATL ACAD SCI USA, V99, P16226, DOI 10.1073/pnas.202617399
   Ougrinovskaia A, 2010, B MATH BIOL, V72, P1534, DOI 10.1007/s11538-010-9509-4
   Parton A, 2015, BRIEF BIOINFORMATICS
   Robbins CS, 2013, NAT MED, V19, P1166, DOI 10.1038/nm.3258
   ROSS R, 1977, AM J PATHOL, V86, P675
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Santoro F, 2014, CLIN RES CARDIOL, V103, P955, DOI 10.1007/s00392-014-0718-y
   Shimizu Y, 2010, BMJ-BRIT MED J, V340, DOI 10.1136/bmj.b5349
   Shuryak I, 2010, RADIAT RES, V174, P357, DOI 10.1667/RR2143.1
   Simonetto C, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125904
   STARY HC, 1994, ARTERIOSCLER THROMB, V14, P840, DOI 10.1161/01.ATV.14.5.840
   Stary HC, 2000, AM J CLIN NUTR, V72, p1297S, DOI 10.1093/ajcn/72.5.1297s
   Stewart FA, 2013, CLIN ONCOL-UK, V25, P617, DOI 10.1016/j.clon.2013.06.012
   Tabas I, 2016, CIRC RES, V118, P653, DOI 10.1161/CIRCRESAHA.115.306256
   Tabas I, 2010, NAT REV IMMUNOL, V10, P36, DOI 10.1038/nri2675
   Takahashi I, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000654
   Takahashi Kiyoshi, 2002, Medical Electron Microscopy, V35, P179, DOI 10.1007/s007950200023
   Tan WY, 2010, BIOL DIRECT, V5, DOI 10.1186/1745-6150-5-26
   van der Wal AC, 1999, CARDIOVASC RES, V41, P334, DOI 10.1016/S0008-6363(98)00276-4
   Vasilenko EK, 2010, AAHP SPEC SESS HLTH
   Xu JP, 2013, INTERV NEUROL, V2, P183, DOI 10.1159/000363068
   ZHANG S, 2013, DISCRETE CONT S NOV, P825
   Zollner S, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0126238
NR 69
TC 2
Z9 2
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD APR 6
PY 2017
VL 12
IS 4
AR e0175386
DI 10.1371/journal.pone.0175386
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA ES2QB
UT WOS:000399371900167
PM 28384359
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Wu, Y
   Liu, F
   Adi, D
   Yang, YN
   Xie, X
   Li, XM
   Ma, X
   Fu, ZY
   Huang, Y
   Chen, BD
   Shan, CF
   Ma, YT
AF Wu, Yun
   Liu, Fen
   Adi, Dilare
   Yang, Yi-Ning
   Xie, Xiang
   Li, Xiao-Mei
   Ma, Xiang
   Fu, Zhen-Yan
   Huang, Ying
   Chen, Bang-Dang
   Shan, Chun-Fang
   Ma, Yi-Tong
TI Association between carotid atherosclerosis and different subtypes of
   hypertension in adult populations: A multiethnic study in Xinjiang,
   China
SO PLOS ONE
LA English
DT Article
ID INTIMA-MEDIA THICKNESS; CARDIOVASCULAR-DISEASE; BLOOD-PRESSURE; RISK;
   CORONARY; PLAQUE; PROGRESSION; PREVALENCE; PREDICTION; IMPACT
AB Background Ethnic differences in non-invasive measurements of carotid atherosclerosis are being increasingly reported, but the association between carotid atherosclerosis and different subtypes of hypertension in adult populations is not fully understood in different ethnicities. We aimed to investigate the association of carotid atherosclerosis with different subtypes of hypertension in different ethnicities in Xinjiang, a northwestern province in China.
   Methods A total of 14,618 participants (5,757 Hans, 4,767 Uygurs, and 4,094 Kazakhs) from 26 villages of seven cities in Xinjiang were randomly selected from the Cardiovascular Risk Survey conducted during 2007 and 2010. A standard questionnaire, a physical examination and biochemical tests were employed.
   Results The mean common carotid intima-media thickness (CIMT) for the 14,618 participants was 0.86 +/- 0.003 mm. The CIMT gradually increased with age. Men (0.92 +/- 0.005 mm) had a higher CIMT than women (0.81 +/- 0.004 mm). The Uygur participants (0.82 +/- 0.006 mm) had a lower CIMT than the Han (0.88 +/- 0.005 mm) and Kazakh participants (0.88 +/- 0.005 mm). The overall prevalences of carotid intimal thickening and carotid plaques were 12.4% and 9.7%, respectively. The prevalence of CIMT varied for the different subtypes of hypertension. Multivariate logistic regression analysis showed different risk factors for abnormal CIMT in different ethnicities. The associations between abnormal CIMT and the different subtypes of hypertension within different ethnic backgrounds were also different. The risk factors for abnormal CIMT included systolic- diastolic hypertension (SDH) in Han participants (OR: 1.323, 95% CI: 1.100 -1.590), SDH ( OR: 1.426, 95% CI: 1.160 - 1.753) and isolated-systolic hypertension (ISH) (OR: 1.844, 95% CI: 1.470 - 2.313) in Uygur participants, and isolateddiastolic hypertension (IDH) (OR: 1.536, 95% CI: 1.170 - 2.016) in Kazakh participants.
   Conclusion There was an ethnic difference in the prevalence of abnormal CIMT in Xinjiang, a northwestern province in China. The associations between abnormal CIMT and the subtypes of hypertension varied among the different ethnic groups. Among the studied populations, Han participants with SDH, Uygur participants with SDH and ISH, and Kazakh with IDH were more likely to suffer carotid atherosclerosis than those with other subtypes of hypertension. Participants with different ethnic backgrounds had different sets of risk factors for abnormal CIMT.
C1 [Wu, Yun; Adi, Dilare; Yang, Yi-Ning; Xie, Xiang; Li, Xiao-Mei; Ma, Xiang; Fu, Zhen-Yan; Huang, Ying; Shan, Chun-Fang; Ma, Yi-Tong] Xinjiang Med Univ, Dept Cardiol, Affiliated Hosp 1, Urumqi, Peoples R China.
   [Wu, Yun] Xinjiang Med Univ, Dept Gen Practice, Affiliated Hosp 1, Urumqi, Peoples R China.
   [Liu, Fen; Adi, Dilare; Yang, Yi-Ning; Xie, Xiang; Li, Xiao-Mei; Ma, Xiang; Fu, Zhen-Yan; Huang, Ying; Chen, Bang-Dang; Shan, Chun-Fang; Ma, Yi-Tong] Xinjiang Med Univ, Xinjiang Key Lab Cardiovasc Dis Res, Affiliated Hosp 1, Urumqi, Peoples R China.
RP Ma, YT (reprint author), Xinjiang Med Univ, Dept Cardiol, Affiliated Hosp 1, Urumqi, Peoples R China.; Ma, YT (reprint author), Xinjiang Med Univ, Xinjiang Key Lab Cardiovasc Dis Res, Affiliated Hosp 1, Urumqi, Peoples R China.
EM myt_xj@sina.com
FU Key Laboratory of Xinjiang Uygur Autonomous Region [2014KL011]
FX This work was funded by the special funded project, Key Laboratory of
   Xinjiang Uygur Autonomous Region (grant#2014KL011).
CR Arima H, 2012, HYPERTENSION, V59, P1118, DOI 10.1161/HYPERTENSIONAHA.111.187252
   Baber U, 2015, J AM COLL CARDIOL, V65, P1065, DOI 10.1016/j.jacc.2015.01.017
   Bots ML, 2014, HYPERTENSION, V63, P1173, DOI 10.1161/HYPERTENSIONAHA.113.02683
   Howard G, 1998, JAMA-J AM MED ASSOC, V279, P119, DOI 10.1001/jama.279.2.119
   Huang LC, 2016, J ATHEROSCLER THROMB, V23, P940, DOI 10.5551/jat.32177
   Ikeda N, 2015, ULTRASOUND MED BIOL, V41, P1247, DOI 10.1016/j.ultrasmedbio.2014.12.024
   James PA, 2014, JAMA-J AM MED ASSOC, V311, P1809, DOI 10.1001/jama.2013.284427
   Li W, 2016, J HYPERTENS, V34, P39, DOI 10.1097/HJH.0000000000000745
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liu AY, 2015, INT J CLIN EXP MED, V8, P21932
   Liu F, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0145325
   Lu M, 2004, J HYPERTENS, V22, P1699, DOI 10.1097/00004872-200409000-00013
   Manios E, 2015, BLOOD PRESS MONIT, V20, P64, DOI 10.1097/MBP.0000000000000093
   Manolio TA, 2008, ATHEROSCLEROSIS, V197, P132, DOI 10.1016/j.atherosclerosis.2007.02.030
   Nambi V, 2010, J AM COLL CARDIOL, V55, P1600, DOI 10.1016/j.jacc.2009.11.075
   O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103
   Piepoli MF, 2016, EUR HEART J, V37, P2315, DOI [10.1093/eurheartj/ehw106, 10.1016/j.rec.2016.09.009]
   Polak JF, 2015, J AM HEART ASSOC, V4, DOI 10.1161/JAHA.114.001492
   Usman A, 2015, J ATHEROSCLER THROMB, V22, P739, DOI 10.5551/jat.30460
   Wang MY, 2015, HYPERTENSION, V65, P698, DOI 10.1161/HYPERTENSIONAHA.114.03618
   Xie W, 2014, HYPERTENS RES, V37, P960, DOI 10.1038/hr.2014.93
   Xie WX, 2011, J AM SOC ECHOCARDIOG, V24, P729, DOI 10.1016/j.echo.2011.02.011
   Xie X, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015181
   Xie X, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013997
   Zielinski T, 2007, AM J HYPERTENS, V20, P1058, DOI 10.1016/j.amjhyper.2007.05.011
NR 25
TC 3
Z9 3
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 15
PY 2017
VL 12
IS 2
AR e0171791
DI 10.1371/journal.pone.0171791
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EL2BF
UT WOS:000394424400049
PM 28199358
OA DOAJ Gold, Green Published
DA 2019-06-18
ER

PT J
AU Vallet-Courbin, A
   Lariviere, M
   Hocquellet, A
   Hemadou, A
   Parimala, SN
   Laroche-Traineau, J
   Santarelli, X
   Clofent-Sanchez, G
   Jacobin-Valat, MJ
   Noubhani, A
AF Vallet-Courbin, Amelie
   Lariviere, Melusine
   Hocquellet, Agnes
   Hemadou, Audrey
   Parimala, Sarjapura-Nagaraja
   Laroche-Traineau, Jeanny
   Santarelli, Xavier
   Clofent-Sanchez, Gisele
   Jacobin-Valat, Marie-Josee
   Noubhani, Abdelmajid
TI A Recombinant Human Anti-Platelet scFv Antibody Produced in Pichia
   pastoris for Atheroma Targeting
SO PLOS ONE
LA English
DT Article
ID CHAIN FV ANTIBODY; IIB-IIIA COMPLEX; MONOCLONAL-ANTIBODY; PHAGE DISPLAY;
   FAB FRAGMENT; HIGH-YIELD; ATHEROSCLEROSIS; PLATELETS; INFLAMMATION;
   EXPRESSION
AB Cells of the innate and adaptive immune system are key factors in the progression of atherosclerotic plaque, leading to plaque instability and rupture, potentially resulting in acute atherothrombotic events such as coronary artery disease, cerebrovascular disease and peripheral arterial disease. Here, we describe the cloning, expression, purification, and immunoreactivity assessment of a recombinant single-chain variable fragment (scFv) derived from a human anti-alpha IIb beta 3 antibody (HuAb) selected to target atheromatous lesions for the presence of platelets. Indeed, platelets within atheroma plaques have been shown to play a role in inflammation, in platelet-leucocyte aggregates and in thrombi formation and might thus be considered relevant biomarkers of atherosclerotic progression. The DNA sequence that encodes the anti-alpha IIb beta 3 TEG4 scFv previously obtained from a phage-display selection on activated platelets, was inserted into the eukaryote vector (pPICZaA) in fusion with a tag sequence encoding 2 cysteines useable for specific probes grafting experiments. The recombinant protein was expressed at high yields in Pichia pastoris (30 mg/L culture). The advantage of P.pastoris as an expression system is the production and secretion of recombinant proteins in the supernatant, ruling out the difficulties encountered when scFv are produced in the cytoplasm of bacteria (low yield, low solubility and reduced affinity). The improved conditions allowed for the recovery of highly purified and biologically active scFv fragments ready to be grafted in a site-directed way to nanoparticles for the imaging of atherosclerotic plaques involving inflammatory processes and thus at high risk of instability.
C1 [Vallet-Courbin, Amelie; Hocquellet, Agnes; Parimala, Sarjapura-Nagaraja; Santarelli, Xavier; Noubhani, Abdelmajid] Bordeaux INP, UMR5248, CBMN, Pessac, France.
   [Lariviere, Melusine; Hemadou, Audrey; Laroche-Traineau, Jeanny; Clofent-Sanchez, Gisele; Jacobin-Valat, Marie-Josee] CNRS, Ctr Resonance Magnet Syst Biol, Bordeaux, France.
   [Lariviere, Melusine; Hemadou, Audrey; Laroche-Traineau, Jeanny; Clofent-Sanchez, Gisele; Jacobin-Valat, Marie-Josee] Univ Bordeaux, Bordeaux, France.
RP Noubhani, A (reprint author), Bordeaux INP, UMR5248, CBMN, Pessac, France.
EM noubhani@bordeaux-inp.fr
OI SANTARELLI, Xavier/0000-0003-1530-4632
FU French National Research Agency Program [ANR-07-PCVI-0023 IMATHABIO];
   SFR TecSan (Technology for Health) of University of Bordeaux; French
   National Research Agency [ANR-10-LABX-57, ANR-13-BSV5-0018]
FX This study was funded by (1) the French National Research Agency Program
   ANR-07-PCVI-0023 IMATHABIO, (2) the SFR TecSan (Technology for Health)
   of University of Bordeaux and (3) a public grant from the French
   National Research Agency within the context of the Investments for the
   Future Program, referenced ANR-10-LABX-57 and named TRAIL, Grant
   ANR-13-BSV5-0018 French National Research Agency Program.
CR Ahmad ZA, 2012, CLIN DEV IMMUNOL, DOI 10.1155/2012/980250
   Aloui C, 2014, INT J MOL SCI, V15, P22342, DOI 10.3390/ijms151222342
   Badrnya S, 2014, ARTERIOSCL THROM VAS, V34, P571, DOI 10.1161/ATVBAHA.113.302919
   Burioni R, 2009, J IMMUNOL, V183, P2537, DOI 10.4049/jimmunol.0901076
   Cupit PM, 1999, LETT APPL MICROBIOL, V29, P273, DOI 10.1046/j.1472-765X.1999.00600.x
   Dabadie M, 2001, PLATELETS, V12, P395, DOI 10.1080/09537100120071031
   Daub K, 2010, SEMIN THROMB HEMOST, V36, P146, DOI 10.1055/s-0030-1251498
   Eldin P, 1997, J IMMUNOL METHODS, V201, P67, DOI 10.1016/S0022-1759(96)00213-X
   Falk E, 2006, J AM COLL CARDIOL, V47, pC7, DOI 10.1016/j.jacc.2005.09.068
   Fenyo IM, 2013, IMMUNOBIOLOGY, V218, P1376, DOI 10.1016/j.imbio.2013.06.005
   Ferdous F, 2015, IMMUNOL LETT, V163, P32, DOI 10.1016/j.imlet.2014.11.010
   Frenzel A, 2016, MABS-AUSTIN, V8, P1177, DOI 10.1080/19420862.2016.1212149
   Frenzel A, 2013, FRONT IMMUNOL, V4, DOI 10.3389/fimmu.2013.00217
   Freyre FM, 2000, J BIOTECHNOL, V76, P157, DOI 10.1016/S0168-1656(99)00183-2
   Groves MAT, 2014, MABS-AUSTIN, V6, P236, DOI 10.4161/mabs.27261
   Hagemeyer CE, 2009, THROMB HAEMOSTASIS, V101, P1012, DOI 10.1160/TH08-12-0816
   Herter JM, 2014, J THROMB HAEMOST, V12, P1764, DOI 10.1111/jth.12730
   Hohmann JD, 2013, BLOOD, V121, P3067, DOI 10.1182/blood-2012-08-449694
   Jacobin MJ, 2002, J IMMUNOL, V168, P2035, DOI 10.4049/jimmunol.168.4.2035
   Jacobin-Valat MJ, 2015, NANOMED-NANOTECHNOL, V11, P927, DOI 10.1016/j.nano.2014.12.006
   Janakiraman VN, 2016, BIOTECHNOL J, V11, P117, DOI 10.1002/biot.201500245
   Joosten V, 2003, MICROB CELL FACT, V2, DOI 10.1186/1475-2859-2-1
   Joshi FR, 2012, EUR HEART J-CARD IMG, V13, P205, DOI [10.1093/ejechocard/jer319, 10.1093/ehjci/jer319]
   Kyaw T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0060430
   Kyaw T, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0029371
   Kyaw T, 2010, J IMMUNOL, V185, P4410, DOI 10.4049/jimmunol.1000033
   Lange S, 2001, J IMMUNOL METHODS, V255, P103, DOI 10.1016/S0022-1759(01)00351-9
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lievens D, 2010, BLOOD, V116, P4317, DOI 10.1182/blood-2010-01-261206
   Morrell CN, 2014, BLOOD, V123, P2759, DOI 10.1182/blood-2013-11-462432
   PIDARD D, 1983, J BIOL CHEM, V258, P2582
   Reichert JM, 2016, MABS-AUSTIN, V8, P197, DOI 10.1080/19420862.2015.1125583
   Robert R, 2006, INT J BIOL MACROMOL, V39, P51, DOI 10.1016/j.ijbiomac.2006.01.014
   Robert R, 2005, J CHROMATOGR B, V818, P43, DOI 10.1016/j.jchromb.2004.10.038
   SHATTIL SJ, 1985, J BIOL CHEM, V260, P1107
   Takahashi K, 2000, BIOSCI BIOTECH BIOCH, V64, P2138, DOI 10.1271/bbb.64.2138
   Weber C, 2008, NAT REV IMMUNOL, V8, P802, DOI 10.1038/nri2415
   Wildgruber M, 2013, THERANOSTICS, V3, P865, DOI 10.7150/thno.5771
NR 38
TC 1
Z9 1
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JAN 26
PY 2017
VL 12
IS 1
AR e0170305
DI 10.1371/journal.pone.0170305
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EN7IT
UT WOS:000396176100120
PM 28125612
OA DOAJ Gold, Green Published
DA 2019-06-18
ER

PT J
AU Wu, RD
   Tang, S
   Wang, M
   Xu, XD
   Yao, C
   Wang, SM
AF Wu, Ridong
   Tang, Shi
   Wang, Mian
   Xu, Xiangdong
   Yao, Chen
   Wang, Shenming
TI MicroRNA-497 Induces Apoptosis and Suppresses Proliferation via the
   Bcl-2/Bax-Caspase9-Caspase3 Pathway and Cyclin D2 Protein in HUVECs
SO PLOS ONE
LA English
DT Article
ID ENDOTHELIAL-CELLS; BREAST-CANCER; OX-LDL; ATHEROSCLEROSIS; EXPRESSION;
   CASPASE-3
AB Introduction MicroRNAs play crucial roles in various types of diseases. However, to date, no information about the role of miR-497 in the development of atherosclerosis has been reported. This study investigated the possible role of miR-497 in vascular endothelial cell injury during the early stage of atherosclerosis.
   Materials and Methods The expression level of miR-497 in human umbilical vein endothelial cells (HUVECs) exposed to ox-LDL was detected using qRT-PCR. To perform gain of function and loss of function analyses, miR-497 mimics were transfected into HUVECs, and miR-497 inhibitors were transfected into HUVECs stimulated with ox-LDL. Flow cytometry was used to analyze cell cycle progression and apoptosis. EdU and CCK-8 assays were employed to detect DNA synthesis and cell proliferation, respectively. After bioinformatics prediction, a dual Luciferase Reporter assay was used to analyze the direct target genes of miR-497. The mRNA and protein levels of the target genes were detected using qRT-PCR and western blot analyses, respectively. Caspase-9/3 activity was analyzed to determine the mechanism of endothelial dysfunction.
   Results We showed that miR-497 was significantly upregulated in HUVECs stimulated with ox-LDL. Ectopic expression of miR-497 suppressed cell proliferation, induced apoptosis and increased the activity of caspase-9/3. After verification, Bcl2 and CCND2 were shown to be direct target genes of miR-497 in HUVECs. MiR-497 significantly suppressed cell proliferation by arresting the cell cycle through the CCND2 protein and induced apoptosis through the Bcl2/Bax-caspase9-caspase3 pathway.
   Conclusion Overall, our study shows that miR-497 might play a role in the development of atherosclerosis by inducing apoptosis and suppressing the proliferation of vascular endothelial cells. Therefore, miR-497 could be a potential therapeutic target for the treatment of atherosclerosis.
C1 [Wu, Ridong; Wang, Mian; Xu, Xiangdong; Yao, Chen; Wang, Shenming] Sun Yat Sen Univ, Affiliated Hosp 1, Dept Vasc Surg, Guangzhou, Guangdong, Peoples R China.
   [Tang, Shi] Dongguan Maternal & Children Hlth Hosp, Dept Breast Surg, Dongguan, Peoples R China.
RP Yao, C; Wang, SM (reprint author), Sun Yat Sen Univ, Affiliated Hosp 1, Dept Vasc Surg, Guangzhou, Guangdong, Peoples R China.
EM skywalker_chenyao@yahoo.com.cn; shenmingwang@hotmail.com
CR Cain K, 2002, BIOCHIMIE, V84, P203, DOI 10.1016/S0300-9084(02)01376-7
   Caporali A, 2011, CIRCULATION, V123, P282, DOI 10.1161/CIRCULATIONAHA.110.952325
   Chehrehasa F, 2009, J NEUROSCI METH, V177, P122, DOI 10.1016/j.jneumeth.2008.10.006
   Chen K, 2012, BIOCHEM BIOPH RES CO, V427, P138, DOI 10.1016/j.bbrc.2012.09.026
   Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7
   Dong Q, 2013, BRAZ J MED BIOL RES, V46, P765, DOI 10.1590/1414-431X20132733
   Dong QC, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010147
   Fu XY, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043204
   Gui DK, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039824
   Guo ST, 2012, ONCOGENE, DOI DOI 10.3892/ETM.2011.428
   Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882
   Kaufmann SH, 2008, METHODS, V44, P262, DOI 10.1016/j.ymeth.2007.11.005
   Li HY, 2013, CELL PHYSIOL BIOCHEM, V32, P1354, DOI 10.1159/000356574
   Li L, 2012, LAB INVEST, V92, P571, DOI 10.1038/labinvest.2012.10
   Lia D, 2010, J HYPERTENS, V28, P1646, DOI 10.1097/HJH.0b013e32833a4922
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liuzzo G, 2001, Rays, V26, P221
   Luo QF, 2013, CANCER CELL INT, V13, DOI 10.1186/1475-2867-13-95
   Maiolino G, 2013, MEDIAT INFLAMM, DOI 10.1155/2013/714653
   Marsden VS, 2002, NATURE, V419, P634, DOI 10.1038/nature01101
   McNutt MC, 2007, J BIOL CHEM, V282, P20799, DOI 10.1074/jbc.C700095200
   Menghini R, 2009, CIRCULATION, V120, P1524, DOI 10.1161/CIRCULATIONAHA.109.864629
   Mermelshtein A, 2005, BRIT J CANCER, V93, P338, DOI 10.1038/sj.bjc.6602709
   Mudau M, 2012, CARDIOVASC J AFR, V23, DOI 10.5830/CVJA-2011-068
   Olejarz W, 2013, EUR J CLIN INVEST
   Porter AG, 1999, CELL DEATH DIFFER, V6, P99, DOI 10.1038/sj.cdd.4400476
   Puissant C, 2013, J MAL VASC
   Qin B, 2012, MOL BIOL REP, V39, P4509, DOI 10.1007/s11033-011-1241-0
   Rahman M, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026390
   Rodriguez J, 1999, GENE DEV, V13, P3179, DOI 10.1101/gad.13.24.3179
   Samson S, 2012, CHOLESTEROL, DOI 10.1155/2012/571846
   Shan Z, 2013, CHINESE MED J-PEKING, V126, P515, DOI 10.3760/cma.j.issn.0366-6999.20122289
   Shen L, 2012, EXP THER MED, V3, P475, DOI 10.3892/etm.2011.428
   Sun XH, 2013, CURR ATHEROSCLER REP, V15, DOI 10.1007/s11883-013-0372-2
   Tu YF, 2015, SCI REP-UK, V5, DOI 10.1038/srep13827
   Vasa-Nicotera M, 2011, ATHEROSCLEROSIS, V217, P326, DOI 10.1016/j.atherosclerosis.2011.03.034
   Vegran F, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0029058
   Wang M, 2011, ARTERIOSCL THROM VAS, V31, P2046, DOI 10.1161/ATVBAHA.111.229559
   Westhorpe CLV, 2012, EXP MOL PATHOL, V93, P220, DOI 10.1016/j.yexmp.2012.03.014
   Zhang YF, 2013, INT J MOL SCI, V14, P22708, DOI 10.3390/ijms141122708
   Zhou J, 2011, P NATL ACAD SCI USA, V108, P10355, DOI 10.1073/pnas.1107052108
NR 41
TC 23
Z9 27
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 5
PY 2016
VL 11
IS 12
AR e0167052
DI 10.1371/journal.pone.0167052
PG 15
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE4MR
UT WOS:000389577100007
PM 27918592
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Jeurissen, MLJ
   Walenbergh, SMA
   Houben, T
   Hendrikx, T
   Li, JY
   Oligschlaeger, Y
   van Gorp, PJ
   Gijbels, MJJ
   Bitorina, A
   Nessel, I
   Radtke, F
   Vooijs, M
   Theys, J
   Shiri-Sverdlov, R
AF Jeurissen, Mike L. J.
   Walenbergh, Sofie M. A.
   Houben, Tom
   Hendrikx, Tim
   Li, Jieyi
   Oligschlaeger, Yvonne
   van Gorp, Patrick J.
   Gijbels, Marion J. J.
   Bitorina, Albert
   Nessel, Isabell
   Radtke, Freddy
   Vooijs, Marc
   Theys, Jan
   Shiri-Sverdlov, Ronit
TI Myeloid DLL4 Does Not Contribute to the Pathogenesis of Non-Alcoholic
   Steatohepatitis in LdIr(-/-) Mice
SO PLOS ONE
LA English
DT Article
ID FATTY LIVER-DISEASE; DELTA-LIKE 4; NOTCH LIGAND; MACROPHAGE ACTIVATION;
   INSULIN-RESISTANCE; ADAPTIVE IMMUNITY; QUANTITATIVE PCR;
   ATHEROSCLEROSIS; EXPRESSION; EFFICIENCY
AB Non-alcoholic steatohepatitis (NASH) is characterized by liver steatosis and inflammation. Currently, the underlying mechanisms leading to hepatic inflammation are not fully understood and consequently, therapeutic options are poor. Non-alcoholic steatohepatitis (NASH) and atherosclerosis share the same etiology whereby macrophages play a key role in disease progression. Macrophage function can be modulated via activation of receptor-ligand binding of Notch signaling. Relevantly, global inhibition of Notch ligand Delta-Like Ligand-4 (DLL4) attenuates atherosclerosis by altering the macrophage-mediated inflammatory response. However, the specific contribution of macrophage DLL4 to hepatic inflammation is currently unknown. We hypothesized that myeloid DLL4 deficiency in low-density lipoprotein receptor knock-out (LdIr(-/-) mice reduces hepatic inflammation. Irradiated LdIr(-/-) mice were transplanted (tp) with bone marrow from wild type (Wt) or DLL4(f/f)LysMCre(+0) (DLL4(del)) mice and fed either chow or high fat, high cholesterol (HFC) diet for 11 weeks. Additionally, gene expression was assessed in bone marrow-derived macrophages (BMDM) of DLL4(f/f)LysM-Cre(WT) and DLL(f/f)LysMCre(+/0) mice. In contrast to our hypothesis, inflammation was not decreased in HFC-fed DLL4(del)-transplanted mice. In line, in vitro, there was no difference in the expression of inflammatory genes between DLL4-deficient and wildtype bone marrow derived macrophages. These results suggest that myeloid DLL4 deficiency does not contribute to hepatic inflammation in vivo. Since, macrophage-DLL4 expression in our model was not completely suppressed, it can't be totally excluded that complete DLL4 deletion in macrophages might lead to different results. Nevertheless, the contribution of non-myeloid Kupffer cells to notch signaling with regard to the pathogenesis of steatohepatitis is unknown and as such it is possible that, DLL4 on Kupffer cells promote the pathogenesis of steatohepatitis.
C1 [Jeurissen, Mike L. J.; Walenbergh, Sofie M. A.; Houben, Tom; Hendrikx, Tim; Li, Jieyi; Oligschlaeger, Yvonne; van Gorp, Patrick J.; Gijbels, Marion J. J.; Bitorina, Albert; Nessel, Isabell; Vooijs, Marc; Theys, Jan; Shiri-Sverdlov, Ronit] Maastricht Univ, Med Ctr, Sch Nutr & Translat Res Metab NUTRIM, Sch Cardiovasc Dis CARIM,Dept Mol Genet, Maastricht, Netherlands.
   [Jeurissen, Mike L. J.; Walenbergh, Sofie M. A.; Houben, Tom; Hendrikx, Tim; Li, Jieyi; Oligschlaeger, Yvonne; van Gorp, Patrick J.; Gijbels, Marion J. J.; Bitorina, Albert; Nessel, Isabell; Vooijs, Marc; Theys, Jan; Shiri-Sverdlov, Ronit] Maastricht Univ, Med Ctr, Sch Nutr & Translat Res Metab NUTRIM, Sch Cardiovasc Dis CARIM,Dept Pathol, Maastricht, Netherlands.
   [Jeurissen, Mike L. J.; Walenbergh, Sofie M. A.; Houben, Tom; Hendrikx, Tim; Li, Jieyi; Oligschlaeger, Yvonne; van Gorp, Patrick J.; Gijbels, Marion J. J.; Bitorina, Albert; Nessel, Isabell; Vooijs, Marc; Theys, Jan; Shiri-Sverdlov, Ronit] Maastricht Univ, Med Ctr, Sch Nutr & Translat Res Metab NUTRIM, Sch Cardiovasc Dis CARIM,Dept Radiotherapy, Maastricht, Netherlands.
   [Jeurissen, Mike L. J.; Walenbergh, Sofie M. A.; Houben, Tom; Hendrikx, Tim; Li, Jieyi; Oligschlaeger, Yvonne; van Gorp, Patrick J.; Gijbels, Marion J. J.; Bitorina, Albert; Nessel, Isabell; Vooijs, Marc; Theys, Jan; Shiri-Sverdlov, Ronit] Maastricht Univ, Med Ctr, MAASTRO Sch Dev Biol & Oncol GROW, Maastricht, Netherlands.
   [Gijbels, Marion J. J.] Univ Amsterdam, Acad Med Ctr, Dept Med Biochem, Expt Vasc Biol, Amsterdam, Netherlands.
   [Radtke, Freddy] Ecole Polytech Fed Lausanne, Sch Life Sci, Swiss Expt Canc Res Inst, Lausanne, Switzerland.
RP Shiri-Sverdlov, R (reprint author), Maastricht Univ, Med Ctr, Sch Nutr & Translat Res Metab NUTRIM, Sch Cardiovasc Dis CARIM,Dept Mol Genet, Maastricht, Netherlands.; Shiri-Sverdlov, R (reprint author), Maastricht Univ, Med Ctr, Sch Nutr & Translat Res Metab NUTRIM, Sch Cardiovasc Dis CARIM,Dept Pathol, Maastricht, Netherlands.; Shiri-Sverdlov, R (reprint author), Maastricht Univ, Med Ctr, Sch Nutr & Translat Res Metab NUTRIM, Sch Cardiovasc Dis CARIM,Dept Radiotherapy, Maastricht, Netherlands.; Shiri-Sverdlov, R (reprint author), Maastricht Univ, Med Ctr, MAASTRO Sch Dev Biol & Oncol GROW, Maastricht, Netherlands.
EM r.sverdlov@maastrichtuniversity.nl
RI Houben, Tom/T-1083-2017; van Gorp, Patrick/S-3892-2019; Vooijs,
   Marc/K-3522-2019; Shiri-Sverdlov, Ronit/E-5571-2017; Theys,
   Jan/K-6685-2015; van Gorp, Patrick/L-9580-2018; Radtke,
   Freddy/Q-3198-2017
OI Houben, Tom/0000-0002-0441-3166; van Gorp, Patrick/0000-0002-0355-5349;
   Shiri-Sverdlov, Ronit/0000-0002-6736-7814; van Gorp,
   Patrick/0000-0002-0355-5349; Radtke, Freddy/0000-0003-4315-4045; Nessel,
   Isabell/0000-0001-6621-4149
FU Maag Lever Darm Stichting (MLDS) [WO 08-16, WO 11-35]; Netherlands
   Organisation for Scientific Research (NWO) [016.126.327, 015.008.043];
   Cardiovascular Research Netherlands (CVON) IN-CONTROL grant [CVON
   2012-03]
FX This research was supported by the Maag Lever Darm Stichting (MLDS) (WO
   08-16 and WO 11-35), the Netherlands Organisation for Scientific
   Research (NWO) (Vidi grant number: 016.126.327) and (ASPASIA grant
   number:015.008.043), and by the Cardiovascular Research Netherlands
   (CVON) IN-CONTROL grant (CVON 2012-03). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Aoyama T, 2009, BIOCHEM BIOPH RES CO, V383, P216, DOI 10.1016/j.bbrc.2009.03.154
   Bi PP, 2015, TRENDS ENDOCRIN MET, V26, P248, DOI 10.1016/j.tem.2015.02.006
   Bieghs V, 2013, GASTROENTEROLOGY, V144, P167, DOI 10.1053/j.gastro.2012.09.062
   Bieghs V, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034378
   Bieghs V, 2012, ATHEROSCLEROSIS, V220, P287, DOI 10.1016/j.atherosclerosis.2011.08.041
   Bieghs V, 2010, GASTROENTEROLOGY, V138, P2477, DOI 10.1053/j.gastro.2010.02.051
   Clark JM, 2006, J CLIN GASTROENTEROL, V40, pS5
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Fukuda D, 2012, P NATL ACAD SCI USA, V109, pE1868, DOI 10.1073/pnas.1116889109
   Fung E, 2007, CIRCULATION, V115, P2948, DOI 10.1161/CIRCULATIONAHA.107.675462
   Groot AJ, 2014, MOL CELL BIOL, V34, P2822, DOI 10.1128/MCB.00206-14
   Hansson GK, 2006, NAT REV IMMUNOL, V6, P508, DOI 10.1038/nri1882
   Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001
   Hoebe KHN, 2001, AM J PHYSIOL-GASTR L, V280, pG720
   Jin CC, 2013, CELL METAB, V17, P873, DOI 10.1016/j.cmet.2013.05.011
   Koch U, 2008, J EXP MED, V205, P2515, DOI 10.1084/jem.20080829
   Koga JI, 2013, CIRCULATION, V128
   Kopec KL, 2011, NUTR CLIN PRACT, V26, P565, DOI 10.1177/0884533611419668
   Kume T, 2009, VASC CELL, V1, DOI 10.1186/2040-2384-1-8
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Libby P, 2009, J AM COLL CARDIOL, V54, P2129, DOI 10.1016/j.jacc.2009.09.009
   Lin LP, 2010, CANCER RES, V70, P632, DOI 10.1158/0008-5472.CAN-09-3293
   Lu RC, 2013, ONCOL LETT, V5, P845, DOI 10.3892/ol.2013.1113
   Martinez JC, 2009, HISTOPATHOLOGY, V54, P598, DOI 10.1111/j.1365-2559.2009.03279.x
   Monsalve E, 2006, J IMMUNOL, V176, P5362, DOI 10.4049/jimmunol.176.9.5362
   Monsalve E, 2009, EUR J IMMUNOL, V39, P2556, DOI 10.1002/eji.200838722
   Niida T, 2013, CIRCULATION, V128
   Ohishi K, 2000, BLOOD, V95, P2847
   Pajvani UB, 2013, NAT MED, V19, P1055, DOI 10.1038/nm.3259
   Palaga T, 2008, EUR J IMMUNOL, V38, P174, DOI 10.1002/eji.200636999
   Portincasa Piero, 2005, Rom J Gastroenterol, V14, P43
   Purow BW, 2005, CANCER RES, V65, P2353, DOI 10.1158/0008-5472.CAN-04-1890
   Quillard T, 2013, INT J MOL SCI, V14, P6863, DOI 10.3390/ijms14046863
   Radtke F, 2013, NAT REV IMMUNOL, V13, P427, DOI 10.1038/nri3445
   Ruijter JM, 2009, NUCLEIC ACIDS RES, V37, DOI 10.1093/nar/gkp045
   Ruijter JM, 2014, MICROCHIM ACTA, V181, P1689, DOI 10.1007/s00604-013-1155-8
   Sell H, 2012, NAT REV ENDOCRINOL, V8, P709, DOI 10.1038/nrendo.2012.114
   Shiri-Sverdlov R, 2006, J HEPATOL, V44, P732, DOI 10.1016/j.jhep.2005.10.033
   Shutter JR, 2000, GENE DEV, V14, P1313
   Tuomi JM, 2010, METHODS, V50, P313, DOI 10.1016/j.ymeth.2010.02.003
   Valenti L, 2013, DIABETES, V62, P4052, DOI 10.2337/db13-0769
   Zhou DX, 2014, CELL SIGNAL, V26, P192, DOI 10.1016/j.cellsig.2013.11.004
NR 42
TC 1
Z9 1
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 29
PY 2016
VL 11
IS 11
AR e0167199
DI 10.1371/journal.pone.0167199
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE3FU
UT WOS:000389474000037
PM 27898698
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Gammelmark, A
   Nielsen, MS
   Lundbye-Christensen, S
   Tjonneland, A
   Schmidt, EB
   Overvad, K
AF Gammelmark, Anders
   Nielsen, Michael S.
   Lundbye-Christensen, Soren
   Tjonneland, Anne
   Schmidt, Erik B.
   Overvad, Kim
TI Common Polymorphisms in the 5-Lipoxygenase Pathway and Risk of Incident
   Myocardial Infarction: A Danish Case-Cohort Study
SO PLOS ONE
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; LEUKOTRIENE BIOSYNTHESIS PATHWAY;
   CENTRAL-EUROPEAN POPULATION; ISCHEMIC-STROKE; REPEAT POLYMORPHISM;
   PLAQUE INSTABILITY; PROMOTER GENOTYPE; GENETIC-VARIATION; CONFERS RISK;
   C-4 SYNTHASE
AB Background
   The 5-lipoxygenase pathway (5-LOX) has been implicated in the development of cardiovascular disease and studies have suggested that genetic polymorphisms related to key enzymes in this pathway may confer risk of myocardial infarction (MI). This study investigated the association of pre-selected genetic polymorphisms in four candidate genes of 5-LOX (arachidonate 5-lipoxygenase and its activating protein (ALOX-5 and FLAP), leukotriene A4 hydroxylase (LTA4-H) and leukotriene C4 synthase (LTC4-S)) with incident MI.
   Methods
   In a Danish cohort including 57,053 participants, aged 50-64 at enrolment and recruited from 1993-97, we conducted a case-cohort study including cases with incident MI and a randomly selected sub cohort of 3,000 participants. Cases were identified from national registries through July 2013. A total of 22 SNPs were selected and genotyped using the commercially available KASP (TM) assay. A tandem-repeat polymorphism, located in the ALOX-5 gene, was genotyped by multi-titre plate sequencing. Haplotypes were inferred using PHASE 2.1.
   Results
   During a median follow-up of 17.0 years we identified 3,089 cases of incident MI. In FLAP, two SNPs were negatively associated with incident MI (rs9551963 & rs17222842) while one SNP (rs2247570) located in LTA4-H, was associated with higher risk of MI when comparing subjects with two copies of the variant allele to homozygotes for the wild type. However, only rs17222842 remained significantly associated with MI after correcting for multiple testing. Furthermore, the promoter polymorphism rs59439148 was associated with risk of MI in men. For male carriers of two variant alleles we found a hazard ratio of 1.63 (95% CI: 1.06;2.52) compared to homozygotes for the wild type. Previously described haplotypes (Hap-A-B, -E and -K) were not associated with MI in our population.
   Conclusion
   In conclusion, some common polymorphisms in the 5-lipoxygenase pathway were modestly associated with incident MI, suggesting a potential role for this pathway in the development of cardiovascular disease.
C1 [Gammelmark, Anders; Nielsen, Michael S.; Schmidt, Erik B.; Overvad, Kim] Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark.
   [Gammelmark, Anders; Schmidt, Erik B.] Aalborg Univ, Dept Clin Med, Aalborg, Denmark.
   [Lundbye-Christensen, Soren] Aalborg Univ Hosp, Unit Clin Biostat & Bioinformat, Aalborg, Denmark.
   [Tjonneland, Anne] Danish Canc Soc, Res Ctr, Copenhagen, Denmark.
   [Overvad, Kim] Aarhus Univ, Epidemiol Sect, Dept Publ Hlth, Aarhus, Denmark.
RP Gammelmark, A (reprint author), Aalborg Univ Hosp, Dept Cardiol, Aalborg, Denmark.; Gammelmark, A (reprint author), Aalborg Univ, Dept Clin Med, Aalborg, Denmark.
EM anders.gammelmark@rn.dk
OI Tjonneland, Anne/0000-0003-4385-2097
FU Danish Heart Association, Copenhagen, Denmark; Hertha Christensens
   Foundation, Aalborg, Denmark; Medical Specialist Heinrich Kopp's Grant;
   Danish Cancer Society
FX The study was supported by a research grant from The Danish Heart
   Association (https://www.hjerteforeningen.dk), Copenhagen, Denmark,
   Hertha Christensens Foundation, Aalborg, Denmark and Medical Specialist
   Heinrich Kopp's Grant. The Diet, Cancer and Health study was funded by
   the Danish Cancer Society (https://www.cancer.dk). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Aiello RJ, 2002, ARTERIOSCL THROM VAS, V22, P443, DOI 10.1161/hq0302.105593
   Allayee H, 2008, AM J CLIN NUTR, V88, P934
   Assimes TL, 2008, HUM GENET, V123, P399, DOI 10.1007/s00439-008-0489-5
   Bevan S, 2008, STROKE, V39, P1109, DOI 10.1161/STROKEAHA.107.491969
   Cipollone F, 2005, ARTERIOSCL THROM VAS, V25, P1665, DOI 10.1161/01.ATV.0000172632.96987.2d
   Crosslin DR, 2009, HUM GENET, V125, P217, DOI 10.1007/s00439-008-0619-0
   Deloukas P, 2013, NAT GENET, V45, P25, DOI 10.1038/ng.2480
   Domingues-Montanari S, 2010, CEREBROVASC DIS, V29, P528, DOI 10.1159/000302738
   Dwyer JH, 2004, NEW ENGL J MED, V350, P29, DOI 10.1056/NEJMoa025079
   Freiberg JJ, 2008, ARTERIOSCL THROM VAS, V28, P990, DOI 10.1161/ATVBAHA.107.158873
   French B, 2012, STAT APPL GENET MOL, V11, DOI 10.1515/1544-6115.1764
   Gao XY, 2008, GENET EPIDEMIOL, V32, P361, DOI 10.1002/gepi.20310
   Gonzalez P, 2007, INT J IMMUNOGENET, V34, P127, DOI 10.1111/j.1744-313X.2007.00671.x
   Haeggstrom JZ, 2011, CHEM REV, V111, P5866, DOI 10.1021/cr200246d
   Hansson GK, 2015, J INTERN MED, V278, P483, DOI 10.1111/joim.12406
   Hartiala J, 2011, HUM GENET, V129, P617, DOI 10.1007/s00439-011-0963-3
   He CL, 2014, METHODS MOL BIOL, V1145, P75, DOI 10.1007/978-1-4939-0446-4_7
   Helgadottir A, 2006, NAT GENET, V38, P68, DOI 10.1038/ng1692
   Helgadottir A, 2005, AM J HUM GENET, V76, P505, DOI 10.1086/428066
   Helgadottir A, 2004, NAT GENET, V36, P233, DOI 10.1038/ng1311
   Iovannisci DM, 2007, ARTERIOSCL THROM VAS, V27, P394, DOI 10.1161/01.ATV.0000252680.72734.10
   Jawien J, 2006, EUR J CLIN INVEST, V36, P141, DOI 10.1111/j.1365-2362.2006.01606.x
   Joensen AM, 2009, J CLIN EPIDEMIOL, V62, P188, DOI 10.1016/j.jclinepi.2008.03.005
   KALBFLEISCH JD, 1988, STAT MED, V7, P149, DOI 10.1002/sim.4780070116
   Koch W, 2007, GENET MED, V9, P123, DOI 10.1097/GIM.0b013e318030c9c5
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lin DY, 2004, GENET EPIDEMIOL, V26, P255, DOI 10.1002/gepi.10317
   Lohmussaar E, 2005, STROKE, V36, P731, DOI 10.1161/01.STR.0000157587.59821.87
   Maznyczka A, 2008, ATHEROSCLEROSIS, V199, P328, DOI 10.1016/j.atherosclerosis.2007.11.027
   Mehrabian M, 2003, CURR OPIN LIPIDOL, V14, P447, DOI 10.1097/01.mol.0000092617.86399.95
   Mehrabian M, 2002, CIRC RES, V91, P120, DOI 10.1161/01.RES.0000028008.99774.7F
   Nikpay M, 2015, NAT GENET, V47, P1121, DOI 10.1038/ng.3396
   Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236
   Poeckel D, 2010, CARDIOVASC RES, V86, P243, DOI 10.1093/cvr/cvq016
   Qiu H, 2006, P NATL ACAD SCI USA, V103, P8161, DOI 10.1073/pnas.0602414103
   Radmark O, 2007, PROSTAG OTH LIPID M, V83, P162, DOI 10.1016/j.prostaglandins.2007.01.003
   Riccioni G, 2012, THESCIENTIFICWORLDJO, V2012, DOI [10.1100/2012/490968, DOI 10.1100/2012/490968]
   Sharma V, 2013, J NEUROL SCI, V331, P108, DOI 10.1016/j.jns.2013.05.024
   SIDAK Z, 1967, J AM STAT ASSOC, V62, P626, DOI 10.2307/2283989
   Spanbroek R, 2003, P NATL ACAD SCI USA, V100, P1238, DOI 10.1073/pnas.242716099
   Stephens M, 2005, AM J HUM GENET, V76, P449, DOI 10.1086/428594
   Stephens M, 2001, AM J HUM GENET, V68, P978, DOI 10.1086/319501
   Subbarao K, 2004, ARTERIOSCL THROM VAS, V24, P369, DOI 10.1161/01.ATV.0000110503.16605.15
   Tjonneland A, 2007, SCAND J PUBLIC HEALT, V35, P432, DOI 10.1080/14034940601047986
   Todur SP, 2012, CTS-CLIN TRANSL SCI, V5, P408, DOI 10.1111/j.1752-8062.2011.00396.x
   Tsai AK, 2009, ATHEROSCLEROSIS, V207, P487, DOI 10.1016/j.atherosclerosis.2009.06.018
   Wang GN, 2012, PROSTAG LEUKOTR ESS, V87, P169, DOI 10.1016/j.plefa.2012.09.005
   Zhao JY, 2014, ATHEROSCLEROSIS, V233, P165, DOI 10.1016/j.atherosclerosis.2013.12.007
   Zhao JY, 2013, ATHEROSCLEROSIS, V226, P238, DOI 10.1016/j.atherosclerosis.2012.10.048
NR 49
TC 6
Z9 7
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 28
PY 2016
VL 11
IS 11
AR e0167217
DI 10.1371/journal.pone.0167217
PG 19
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA EE3FE
UT WOS:000389472400102
PM 27893808
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Ziganshina, EE
   Sharifullina, DM
   Lozhkin, AP
   Khayrullin, RN
   Ignatyev, IM
   Ziganshin, AM
AF Ziganshina, Elvira E.
   Sharifullina, Dilyara M.
   Lozhkin, Andrey P.
   Khayrullin, Rustem N.
   Ignatyev, Igor M.
   Ziganshin, Ayrat M.
TI Bacterial Communities Associated with Atherosclerotic Plaques from
   Russian Individuals with Atherosclerosis
SO PLOS ONE
LA English
DT Article
ID PROPIONIBACTERIUM-ACNES; RALSTONIA-PICKETTII; VASCULAR-DISEASE;
   INFECTION; WATER; NOV.; ENDOCARDITIS; INFLAMMATION; MECHANISMS;
   CHALLENGES
AB Atherosclerosis is considered a chronic disease of the arterial wall and is the major cause of severe disease and death among individuals all over the world. Some recent studies have established the presence of bacteria in atherosclerotic plaque samples and suggested their possible contribution to the development of cardiovascular disease. The main objective of this preliminary pilot study was to better understand the bacterial diversity and abundance in human atherosclerotic plaques derived from common carotid arteries of individuals with atherosclerosis (Russian nationwide group) and contribute towards the further identification of a main group of atherosclerotic plaque bacteria by 454 pyrosequencing their 16S ribosomal RNA (16S rRNA) genes. The applied approach enabled the detection of bacterial DNA in all atherosclerotic plaques. We found that distinct members of the order Burkholderiales were present at high levels in all atherosclerotic plaques obtained from patients with atherosclerosis with the genus Curvibacter being predominant in all plaque samples. Moreover, unclassified Burkholderiales as well as members of the genera Propionibacterium and Ralstonia were typically the most significant taxa for all atherosclerotic plaques. Other genera such as Burkholderia, Corynebacterium and Sediminibacterium as well as unclassified Comamonadaceae, Oxalobacteraceae, Rhodospirillaceae, Bradyrhizobiaceae and Burkholderiaceae were always found but at low relative abundances of the total 16S rRNA gene population derived from all samples. Also, we found that some bacteria found in plaque samples correlated with some clinical parameters, including total cholesterol, alanine aminotransferase and fibrinogen levels. Finally, our study indicates that some bacterial agents at least partially may be involved in affecting the development of cardiovascular disease through different mechanisms.
C1 [Ziganshina, Elvira E.; Ziganshin, Ayrat M.] Kazan Volga Reg Fed Univ, Inst Fundamental Med & Biol, Kazan 420008, The Republic Of, Russia.
   [Sharifullina, Dilyara M.; Lozhkin, Andrey P.; Khayrullin, Rustem N.; Ignatyev, Igor M.] Interreg Clin & Diagnost Ctr, Kazan 420101, The Republic Of, Russia.
RP Ziganshin, AM (reprint author), Kazan Volga Reg Fed Univ, Inst Fundamental Med & Biol, Kazan 420008, The Republic Of, Russia.
EM a.ziganshin06@fulbrightmail.org
RI Ziganshin, Ayrat/A-7013-2014; Ziganshina, Elvira/G-3068-2016
OI Ziganshin, Ayrat/0000-0001-6296-8955; Ziganshina,
   Elvira/0000-0003-2777-843X
FU Investment and Venture Fund of the Republic of Tatarstan, Russia
FX Partial financial support was provided by the Investment and Venture
   Fund of the Republic of Tatarstan, Russia (DMS).
CR Alviar CL, 2011, MED HYPOTHESES, V76, P517, DOI 10.1016/j.mehy.2010.12.006
   Andraws R, 2005, JAMA-J AM MED ASSOC, V293, P2641, DOI 10.1001/jama.293.21.2641
   Armingohar Z, 2014, J ORAL MICROBIOL, V6, DOI 10.3402/jom.v6.23408
   BROOK I, 1991, REV INFECT DIS, V13, P819
   Bryers JD, 2008, BIOTECHNOL BIOENG, V100, P1, DOI 10.1002/bit.21838
   Budzynski J, 2016, INT J ANGIOL, V25, P3, DOI 10.1055/s-0035-1547385
   Budzynski J, 2014, CLIN RES CARDIOL, V103, P855, DOI 10.1007/s00392-014-0720-4
   Calandrini CA, 2014, ORAL DIS, V20, pe128, DOI 10.1111/odi.12205
   Caporaso JG, 2010, NAT METHODS, V7, P335, DOI 10.1038/nmeth.f.303
   Cargill JS, 2012, J MED MICROBIOL, V61, P755, DOI 10.1099/jmm.0.039693-0
   Coenye T, 2003, INT J SYST EVOL MICR, V53, P1075, DOI 10.1099/ijs.0.02555-0
   Ding LX, 2010, J GEN APPL MICROBIOL, V56, P267, DOI 10.2323/jgam.56.267
   Ding LX, 2004, INT J SYST EVOL MICR, V54, P2223, DOI 10.1099/ijs.0.02975-0
   Edgar RC, 2010, BIOINFORMATICS, V26, P2460, DOI 10.1093/bioinformatics/btq461
   Falcone-Dias MF, 2012, WATER RES, V46, P3612, DOI 10.1016/j.watres.2012.04.007
   Gaspar JM, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0532-1
   GUNTHARD H, 1994, J CLIN MICROBIOL, V32, P3043
   Haidar R, 2010, SCAND J INFECT DIS, V42, P405, DOI 10.3109/00365540903582459
   Hansen GM, 2016, AM J CARDIOL, V118, P489, DOI 10.1016/j.amjcard.2016.05.036
   Hansson GK, 2015, J INTERN MED, V278, P483, DOI 10.1111/joim.12406
   Hansson GK, 2009, J THROMB HAEMOST, V7, P328, DOI 10.1111/j.1538-7836.2009.03416.x
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Koren O, 2011, P NATL ACAD SCI USA, V108, P4592, DOI 10.1073/pnas.1011383107
   Lee J, 2010, WATER RES, V44, P5050, DOI 10.1016/j.watres.2010.07.027
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lockhart PB, 2012, CIRCULATION, V125, P2520, DOI 10.1161/CIR.0b013e31825719f3
   Lundberg AM, 2010, CLIN IMMUNOL, V134, P5, DOI 10.1016/j.clim.2009.07.016
   Matthaioua DK, 2011, RESP MED CME, V4, P144
   McDonald D, 2012, ISME J, V6, P610, DOI 10.1038/ismej.2011.139
   Mitra S, 2015, MICROBIOME, V3, DOI 10.1186/s40168-015-0100-y
   Neuwirth C, 2006, EMERG INFECT DIS, V12, P1737, DOI 10.3201/eid1211.060143
   Ott SJ, 2006, CIRCULATION, V113, P929, DOI 10.1161/CIRCULATIONAHA.105.579979
   Peplinski K, 2010, MICROBIOL-SGM, V156, P2136, DOI 10.1099/mic.0.038380-0
   Pierce D, 2012, AM FAM PHYSICIAN, V85, P981
   Quillard T, 2015, EUR HEART J, V36, P1394, DOI 10.1093/eurheartj/ehv044
   Rafferty B, 2011, J ATHEROSCLER THROMB, V18, P72, DOI 10.5551/jat.5207
   Rasmussen RV, 2011, FUTURE MICROBIOL, V6, P43, DOI 10.2217/FMB.10.155
   Rosenfeld ME, 2011, THROMB HAEMOSTASIS, V106, P858, DOI 10.1160/TH11-06-0392
   Rune I, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0146439
   Ryan MP, 2013, J MED MICROBIOL, V62, P1025, DOI 10.1099/jmm.0.054759-0
   Ryan MP, 2006, J HOSP INFECT, V62, P278, DOI 10.1016/j.jhin.2005.08.015
   Safni I, 2014, INT J SYST EVOL MICR, V64, P3087, DOI 10.1099/ijs.0.066712-0
   Scannapieco Frank A, 2004, Compend Contin Educ Dent, V25, P16
   Silva WSE, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0109761
   Sgrelli A, 2012, NEW MICROBIOL, V35, P245
   Sharifullina D. M., 2015, Kazanskii Meditsinskii Zhurnal, V96, P979
   Shindo A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0100045
   VAFIDIS G, 1991, BRIT J OPHTHALMOL, V75, P706, DOI 10.1136/bjo.75.12.706
   Vankov PY, 2016, BIONANOSCIENCE, V6, P490, DOI 10.1007/s12668-016-0270-5
   Velsko IM, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0097811
   Voronina OL, 2015, BIOMED RES INT, DOI 10.1155/2015/680210
   Wolcott R. D., 2012, J BACTERIOL PARASITO, V3, P127
   Zakharkina T, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068302
   Zhang M, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141310
   Ziganshin AM, 2012, ACTA NATURAE, V4, P91
   Ziganshina EE, 2016, BIOLOGIA, V71, P70, DOI 10.1515/biolog-2016-0014
   Ziganshina EE, 2015, MICROB ECOL, V70, P948, DOI 10.1007/s00248-015-0635-2
   Ziganshina EE, 2014, J MICROBIOL BIOTECHN, V24, P1464, DOI 10.4014/jmb.1404.04043
   Zong ZY, 2011, EUR RESPIR J, V38, P1482, DOI 10.1183/09031936.00046011
NR 59
TC 9
Z9 9
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 13
PY 2016
VL 11
IS 10
AR e0164836
DI 10.1371/journal.pone.0164836
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DZ0CV
UT WOS:000385505800135
PM 27736997
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Christophersen, DV
   Jacobsen, NR
   Jensen, DM
   Kermanizadeh, A
   Sheykhzade, M
   Loft, S
   Vogel, U
   Wallin, H
   Moller, P
AF Christophersen, Daniel Vest
   Jacobsen, Nicklas Raun
   Jensen, Ditte Marie
   Kermanizadeh, Ali
   Sheykhzade, Majid
   Loft, Steffen
   Vogel, Ulla
   Wallin, Hakan
   Moller, Peter
TI Inflammation and Vascular Effects after Repeated Intratracheal
   Instillations of Carbon Black and Lipopolysaccharide
SO PLOS ONE
LA English
DT Article
ID LUNG EPITHELIAL-CELLS; ACUTE-PHASE RESPONSE; AMERICAN-HEART-ASSOCIATION;
   KILLER T-CELLS; PARTICULATE MATTER; ENDOTHELIAL DYSFUNCTION; OXIDATIVE
   STRESS; DIESEL EXHAUST; AIR-POLLUTION; CARDIOVASCULAR-DISEASE
AB Inflammation and oxidative stress are considered the main drivers of vasomotor dysfunction and progression of atherosclerosis after inhalation of particulate matter. In addition, new studies have shown that particle exposure can induce the level of bioactive mediators in serum, driving vascular-and systemic toxicity. We aimed to investigate if pulmonary inflammation would accelerate nanoparticle-induced atherosclerotic plaque progression in Apolipoprotein E knockout (ApoE(-/-)) mice. ApoE(-/-) mice were exposed to vehicle, 8.53 or 25.6 mu g nanosized carbon black (CB) alone or spiked with LPS (0.2 mu g/mouse/exposure; once a week for 10 weeks). Inflammation was determined by counting cells in bronchoalveolar lavage fluid. Serum Amyloid A3 (Saa3) expression and glutathione status were determined in lung tissue. Plaque progression was assessed in the aorta and the brachiocephalic artery. The effect of vasoactive mediators in plasma of exposed ApoE(-/-) mice was assessed in aorta rings isolated from naive C57BL/6 mice. Pulmonary exposure to CB and/or LPS resulted in pulmonary inflammation with a robust influx of neutrophils. The CB exposure did not promote plaque progression in aorta or BCA. Incubation with 0.5% plasma extracted from CB-exposed ApoE(-/-) mice caused vasoconstriction in aorta rings isolated from naive mice; this effect was abolished by the treatment with the serotonin receptor antagonist Ketanserin. In conclusion, repeated pulmonary exposure to nanosized CB and LPS caused lung inflammation without progression of atherosclerosis in ApoE(-/-) mice. Nevertheless, plasma extracted from mice exposed to nanosized CB induced vasoconstriction in aortas of naive wild-type mice, an effect possibly related to increased plasma serotonin.
C1 [Christophersen, Daniel Vest; Jensen, Ditte Marie; Kermanizadeh, Ali; Loft, Steffen; Wallin, Hakan; Moller, Peter] Univ Copenhagen, Environm Hlth Sect, Dept Publ Hlth, Copenhagen K, Denmark.
   [Jacobsen, Nicklas Raun; Vogel, Ulla; Wallin, Hakan] Natl Res Ctr Working Environm, Copenhagen, Denmark.
   [Sheykhzade, Majid] Univ Copenhagen, Fac Hlth Sci, Sect Mol & Cellular Pharmacol, Dept Drug Design & Pharmacol, Copenhagen, Denmark.
   [Vogel, Ulla] Tech Univ Denmark, Dept Micro & Nanotechnol, Lyngby, Denmark.
RP Moller, P (reprint author), Univ Copenhagen, Environm Hlth Sect, Dept Publ Hlth, Copenhagen K, Denmark.
EM Pemo@sund.ku.dk
RI Wallin, Hakan/I-6459-2012; Kermanizadeh, Ali/L-9691-2017
OI Wallin, Hakan/0000-0001-7716-0166; Loft, Steffen/0000-0001-9552-8518;
   Sheykhzade, Majid/0000-0002-4561-0326; Kermanizadeh,
   Ali/0000-0002-2989-9078; Jensen, Ditte Marie/0000-0003-2623-6882
FU Danish Nanosafety Centre from the Danish Working Environment Research
   Foundation [20110092173-3]
FX The work was supported by the Danish Nanosafety Centre (grant no.
   20110092173-3) from the Danish Working Environment Research Foundation.
   The funder had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andoh Y, 2013, IMMUNOBIOLOGY, V218, P561, DOI 10.1016/j.imbio.2012.07.022
   Aragon MJ, 2016, CARDIOVASC TOXICOL, V16, P163, DOI 10.1007/s12012-015-9325-z
   Araujo JA, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-24
   Bakker ENTP, 2000, AM J PHYSIOL-HEART C, V278, pH1233
   Bourdon JA, 2012, ENVIRON MOL MUTAGEN, V53, P462, DOI 10.1002/em.21706
   Bourdon JA, 2012, TOXICOL SCI, V127, P474, DOI 10.1093/toxsci/kfs119
   Bourdon JA, 2012, PART FIBRE TOXICOL, V9, DOI 10.1186/1743-8977-9-5
   Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1
   Brown DM, 2001, TOXICOL APPL PHARM, V175, P191, DOI 10.1006/taap.2001.9240
   Cai XN, 2013, NANOMED-NANOTECHNOL, V9, P583, DOI 10.1016/j.nano.2012.09.004
   Corbel M, 2001, INFLAMM RES, V50, P129, DOI 10.1007/s000110050736
   Courtois A, 2008, ENVIRON HEALTH PERSP, V116, P1294, DOI 10.1289/ehp.11021
   DEMEY JGR, 1989, CIRC RES, V65, P1125, DOI 10.1161/01.RES.65.4.1125
   Folkmann JK, 2012, TOXICOL SCI, V129, P98, DOI 10.1093/toxsci/kfs180
   Fuks KB, 2014, ENVIRON HEALTH PERSP, V122, P896, DOI 10.1289/ehp.1307725
   Gilmour PS, 2004, TOXICOL APPL PHARM, V195, P35, DOI 10.1016/j.taap.2003.10.003
   Gitlin JM, 2009, CARDIOVASC RES, V81, P400, DOI 10.1093/cvr/cvn286
   Hansen CS, 2007, TOXICOL APPL PHARM, V219, P24, DOI 10.1016/j.taap.2006.10.032
   Harder V, 2005, INHAL TOXICOL, V17, P29, DOI 10.1080/08958370590885681
   Hogsberg T, 2013, EXP DERMATOL, V22, P464, DOI 10.1111/exd.12178
   Holzer M, 2014, J APPL TOXICOL, V34, P1167, DOI 10.1002/jat.2996
   Jackson P, 2012, NANOTOXICOLOGY, V6, P486, DOI 10.3109/17435390.2011.587902
   Jacobsen NR, 2008, ENVIRON MOL MUTAGEN, V49, P476, DOI 10.1002/em.20406
   Jacobsen NR, 2007, ENVIRON MOL MUTAGEN, V48, P451, DOI 10.1002/em.20300
   Jacobsen NR, 2015, FOOD CHEM TOXICOL, V85, P84, DOI 10.1016/j.fct.2015.08.008
   Jacobsen NR, 2011, ENVIRON MOL MUTAGEN, V52, P331, DOI 10.1002/em.20629
   Jacobsen NR, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-2
   Kennedy AJ, 2010, DIS MODEL MECH, V3, P156, DOI 10.1242/dmm.003467
   Kermanizadeh A, 2015, CRIT REV TOXICOL, V45, P837, DOI 10.3109/10408444.2015.1058747
   Kido T, 2011, AM J RESP CELL MOL, V44, P197, DOI 10.1165/rcmb.2009-0427OC
   Kim H, 2012, J TOXICOL ENV HEAL A, V75, P1471, DOI 10.1080/15287394.2012.722519
   Kim JK, 2011, SAF HEALTH WORK, V2, P282, DOI 10.5491/SHAW.2011.2.3.282
   KOCH DD, 1980, ANAL CHEM, V52, P27, DOI 10.1021/ac50051a008
   Kyjovska ZO, 2015, MUTAGENESIS, V30, P499, DOI 10.1093/mutage/gev009
   Laurent S, 2001, HYPERTENSION, V37, P1236, DOI 10.1161/01.HYP.37.5.1236
   Lee GS, 2014, J BONE MINER RES, V29, P976, DOI 10.1002/jbmr.2086
   Lee KS, 2007, EXP MOL MED, V39, P756, DOI 10.1038/emm.2007.82
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Mikkelsen L, 2011, PART FIBRE TOXICOL, V8, DOI 10.1186/1743-8977-8-32
   Moller P, 2016, CRIT REV TOXICOL, V46, P437, DOI 10.3109/10408444.2016.1149451
   Moller P, 2014, ARCH TOXICOL, V88, P1939, DOI 10.1007/s00204-014-1356-x
   Moller P, 2011, CRIT REV TOXICOL, V41, P339, DOI 10.3109/10408444.2010.533152
   Moller P, 2010, FREE RADICAL RES, V44, P1, DOI 10.3109/10715760903300691
   Niwa Y, 2007, CIRC J, V71, P1157, DOI 10.1253/circj.71.1157
   Nurkiewicz TR, 2006, ENVIRON HEALTH PERSP, V114, P412, DOI 10.1289/ehp.8413
   Ostos MA, 2002, FEBS LETT, V519, P23, DOI 10.1016/S0014-5793(02)02692-3
   Paffett ML, 2015, TOXICOL SCI, V146, P244, DOI 10.1093/toxsci/kfv093
   Provost EB, 2016, ENVIRON INT, V88, P228, DOI 10.1016/j.envint.2015.12.023
   Robertson S, 2013, TOXICOL SCI, V134, P304, DOI 10.1093/toxsci/kft107
   Saber AT, 2014, WIRES NANOMED NANOBI, V6, P517, DOI 10.1002/wnan.1279
   Saber AT, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-12
   Saber AT, 2012, NANOTOXICOLOGY, V6, P453, DOI 10.3109/17435390.2011.587900
   Saber AT, 2012, NANOTOXICOLOGY, V6, P776, DOI 10.3109/17435390.2011.620745
   Saber AT, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0069020
   Senft AP, 2000, ANAL BIOCHEM, V280, P80, DOI 10.1006/abio.2000.4498
   STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355
   Sun QH, 2005, JAMA-J AM MED ASSOC, V294, P3003, DOI 10.1001/jama.294.23.3003
   Tin-Tin-Win-Shwe, 2005, TOXICOL APPL PHARM, V209, P51, DOI 10.1016/j.taap.2005.03.014
   Tong HY, 2009, TOXICOL APPL PHARM, V239, P224, DOI 10.1016/j.taap.2009.05.019
   VANHOUTTE P, 1988, HYPERTENSION, V11, P111, DOI 10.1161/01.HYP.11.2.111
   Vesterdal LK, 2014, NANOTOXICOLOGY, V8, P61, DOI 10.3109/17435390.2012.750385
   Vesterdal LK, 2012, TOXICOL LETT, V214, P19, DOI 10.1016/j.toxlet.2012.07.022
   Vesterdal LK, 2010, PART FIBRE TOXICOL, V7, DOI 10.1186/1743-8977-7-33
   Vesterdal LK, 2009, PART FIBRE TOXICOL, V6, DOI 10.1186/1743-8977-6-5
NR 66
TC 6
Z9 6
U1 0
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD AUG 29
PY 2016
VL 11
IS 8
AR e0160731
DI 10.1371/journal.pone.0160731
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DV4DZ
UT WOS:000382876700006
PM 27571356
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Marzullo, A
   Ambrosi, F
   Inchingolo, M
   Manca, F
   Devito, F
   Angiletta, D
   Zito, A
   Scicchitano, P
   Ciccone, MM
AF Marzullo, Andrea
   Ambrosi, Francesca
   Inchingolo, Mirjam
   Manca, Fabio
   Devito, Fiorella
   Angiletta, Domenico
   Zito, Annapaola
   Scicchitano, Pietro
   Ciccone, Marco Matteo
TI ST2L Transmembrane Receptor Expression: An Immunochemical Study on
   Endarterectomy Samples
SO PLOS ONE
LA English
DT Article
ID SOLUBLE ST2; HISTOLOGICAL CLASSIFICATION; ATHEROSCLEROTIC LESIONS;
   VULNERABLE PLAQUE; ENDOTHELIAL-CELLS; VASCULAR-SURGERY; ARTERY-DISEASE;
   IL-33; INTERLEUKIN-33; ACTIVATION
AB Background
   ST2 (suppression of tumorigenity) has been described as a receptor for the interleukin-33, a member of the IL-1 family of cytokines. It is associated to coronary artery disease, all-causes mortality and cardiovascular mortality.
   Aims
   The present study was designed to assess the immunohistochemical expression of the ST2 receptor (ST2L/II-1R) in atherosclerotic plaques of formalin fixed paraffin-embedded internal carotid arteries of patients with and without cerebro-vascular symptoms.
   Methods and Results
   The study involved 41 cases (23 asymptomatic and 18 symptomatic). All the clinical and morphological parameters examined were uniformly distributed between the two groups, with a mild predominance of degree of calcification in asymptomatic cases (p = 0.01). ST2L expression was found to be more evident as a membrane pattern in macrophages when observing carotid atherosclerotic plaques of symptomatic patients, rather than in asymptomatic patients' plaques (77.7% vs 39.1%; p = 0.015), and its expression was particularly remarkable in VI type plaque (AHA). Significantly, ST2L was marked by the endothelium of neoangiogenetic vessels on the shoulder region of the plaque, but not (apart from a few cases) in the endothelium covering the residual lumen of the vessel.
   Conclusions
   The ST2L immunohistochemical expression was for the first time investigated in a large number of human carotid atherosclerotic plaques, as for its pattern of distribution in the different plaque cell populations. Furthermore, ST2L was particularly remarkable on macrophages, as a membrane pattern, of symptomatic patients' plaque. Considering our data, we hypothesize that ST2L/IL33 axis could drive the mechanism of plaque development and eventually rupture.
C1 [Marzullo, Andrea; Ambrosi, Francesca] Univ Bari, Sch Med, Pathol Sect, Dept Emergency & Organ Transplantat DETO, Bari, Italy.
   [Inchingolo, Mirjam; Angiletta, Domenico] Univ Bari, Sch Med, Vasc Surg Sect, Dept Emergency & Organ Transplantat DETO, Bari, Italy.
   [Manca, Fabio] Univ Bari, Dept Sci Educ Psychol & Commun, Bari, Italy.
   [Devito, Fiorella; Zito, Annapaola; Scicchitano, Pietro; Ciccone, Marco Matteo] Univ Bari, Dept Emergency & Organ Transplantat DETO, Cardiovasc Dis Sect, Bari, Italy.
RP Ciccone, MM (reprint author), Univ Bari, Dept Emergency & Organ Transplantat DETO, Cardiovasc Dis Sect, Bari, Italy.
EM marcomatteo.ciccone@uniba.it
RI Scicchitano, Pietro/K-8870-2016; Ciccone, Marco/C-5271-2013
OI Scicchitano, Pietro/0000-0003-0471-0053; Ciccone,
   Marco/0000-0002-5710-4228; Marzullo, Andrea/0000-0003-1265-3685
FU University of Bari; Assut Europe S.p.A. [12 - 00173]
FX This work was partly supported by a grant of University of Bari (2010)
   which came from the financial fund of the Pathology Section of the
   Department of Emergency and Organ Transplantation (DETO), Medical
   School, University of Bari, Bari, Italy. This work was also partially
   supported by Assut Europe S.p.A. (Via G. Gregoraci, 12 - 00173 Rome -
   Italy). The funds from Assut Europe S.p.A were used to cover the costs
   of publication. No other additional external funding was received for
   this study. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Aoki S, 2010, MOL CELL BIOCHEM, V335, P75, DOI 10.1007/s11010-009-0244-9
   Chen LQ, 2013, CLIN CHEM, V59, P536, DOI 10.1373/clinchem.2012.191106
   Choi YS, 2009, BLOOD, V114, P3117, DOI 10.1182/blood-2009-02-203372
   Ciccone MM, 2013, MOLECULES, V18, P15314, DOI 10.3390/molecules181215314
   Demyanets S, 2011, ARTERIOSCL THROM VAS, V31, P2080, DOI 10.1161/ATVBAHA.111.231431
   Hobson RW, 2008, J VASC SURG, V48, P480, DOI 10.1016/j.jvs.2008.05.036
   Kakkar R, 2008, NAT REV DRUG DISCOV, V7, P827, DOI 10.1038/nrd2660
   Kuchler AM, 2008, AM J PATHOL, V173, P1229, DOI 10.2353/ajpath.2008.080014
   Kunes Pavel, 2010, Acta Medica (Hradec Kralove), V53, P125
   Kurowska-Stolarska M, 2009, J IMMUNOL, V183, P6469, DOI 10.4049/jimmunol.0901575
   Lee RT, 1997, ARTERIOSCL THROM VAS, V17, P1859, DOI 10.1161/01.ATV.17.10.1859
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liew FY, 2010, NAT REV IMMUNOL, V10, P103, DOI 10.1038/nri2692
   Lusis MJ, 2004, ANNU REV GENOM HUM G, V5, P189, DOI 10.1146/annurev.genom.5.061903.175930
   Mahmood SS, 2014, LANCET, V383, P999, DOI 10.1016/S0140-6736(13)61752-3
   McLaren JE, 2010, J IMMUNOL, V185, P1222, DOI 10.4049/jimmunol.1000520
   Miller AM, 2008, J EXP MED, V205, P339, DOI 10.1084/jem.20071868
   Nighoghossian N, 2005, STROKE, V36, P2764, DOI 10.1161/01.STR.0000190895.51934.43
   Oboki Keisuke, 2010, Allergology International, V59, P143, DOI 10.2332/allergolint.10-RAI-0186
   Pollheimer J, 2013, ARTERIOSCL THROM VAS, V33, pE47, DOI 10.1161/ATVBAHA.112.253427
   Prefontaine D, 2009, J IMMUNOL, V183, P5094, DOI 10.4049/jimmunol.0802387
   Rao DS, 2005, CARDIOVASC PATHOL, V14, P285, DOI 10.1016/j.carpath.2005.07.003
   Ribatti D, 2008, ANN MED, V40, P606, DOI 10.1080/07853890802186913
   Ricotta JJ, 2011, J VASC SURG, V54, pE1, DOI 10.1016/j.jvs.2011.07.031
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Schmitz J, 2005, IMMUNITY, V23, P479, DOI 10.1016/j.immuni.2005.09.015
   Shah PK, 2003, J AM COLL CARDIOL, V41, p15S, DOI 10.1016/S0735-1097(02)02834-6
   Shen JY, 2015, SEMIN ARTHRITIS RHEU, V45, P18, DOI 10.1016/j.semarthrit.2015.02.001
   STARY HC, 1995, CIRCULATION, V92, P1355, DOI 10.1161/01.CIR.92.5.1355
   Stary HC, 2000, ARTERIOSCL THROM VAS, V20, P1177, DOI 10.1161/01.ATV.20.5.1177
   Tu X, 2013, AM J HUM GENET, V93, P652, DOI 10.1016/j.ajhg.2013.08.009
   van der Wal AC, 1999, CARDIOVASC RES, V41, P334, DOI 10.1016/S0008-6363(98)00276-4
   Virmani R, 2006, J AM COLL CARDIOL, V47, pC13, DOI 10.1016/j.jacc.2005.10.065
   Wasserman A, 2012, ISR MED ASSOC J, V14, P620
   Weinberg EO, 2009, BIOMARK MED, V3, P495, DOI 10.2217/BMM.09.56
   Willems S, 2013, ATHEROSCLEROSIS, V231, P48, DOI 10.1016/j.atherosclerosis.2013.08.024
NR 36
TC 6
Z9 6
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 25
PY 2016
VL 11
IS 5
AR e0156315
DI 10.1371/journal.pone.0156315
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DN2GI
UT WOS:000376881700085
PM 27223112
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Chen, WM
   Sheu, WHH
   Tseng, PC
   Lee, TS
   Lee, WJ
   Chang, PJ
   Chiang, AN
AF Chen, Wei-Ming
   Sheu, Wayne H-H
   Tseng, Pei-Chi
   Lee, Tzong-Shyuan
   Lee, Wen-Jane
   Chang, Pey-Jium
   Chiang, An-Na
TI Modulation of microRNA Expression in Subjects with Metabolic Syndrome
   and Decrease of Cholesterol Efflux from Macrophages via
   microRNA-33-Mediated Attenuation of ATP-Binding Cassette Transporter A1
   Expression by Statins
SO PLOS ONE
LA English
DT Article
ID DENSITY-LIPOPROTEIN CHOLESTEROL; ONSET DIABETES-MELLITUS;
   GLUCOSE-METABOLISM; ATORVASTATIN; ABCA1; HDL; ATHEROSCLEROSIS;
   METAANALYSIS; DISEASE; LIVER
AB Metabolic syndrome (MetS) is a complicated health problem that encompasses a variety of metabolic disorders. In this study, we analyzed the relationship between the major biochemical parameters associated with MetS and circulating levels of microRNA (miR)-33, miR-103, and miR-155. We found that miRNA-33 levels were positively correlated with levels of fasting blood glucose, glycosylated hemoglobin A1c, total cholesterol, LDL-cholesterol, and triacylglycerol, but negatively correlated with HDL-cholesterol levels. In the cellular study, miR-33 levels were increased in macrophages treated with high glucose and cholesterol-lowering drugs atorvastatin and pitavastatin. miR-33 has been reported to play an essential role in cholesterol homeostasis through ATP-binding cassette transporter A1 (ABCA1) regulation and reverse cholesterol transport. However, the molecular mechanism underlying the linkage between miR-33 and statin treatment remains unclear. In the present study, we investigated whether atorvastatin and pitavastatin exert their functions through the modulation of miR-33 and ABCA1-mediated cholesterol efflux from macrophages. The results showed that treatment of the statins up-regulated miR-33 expression, but down-regulated ABCA1 mRNA levels in RAW264.7 cells and bone marrow-derived macrophages. Statin-mediated ABCA1 regulation occurs at the post-transcriptional level through targeting of the 3'-UTR of the ABCA1 transcript by miR-33. Additionally, we found significant down-regulation of ABCA1 protein expression in macrophages treated with statins. Finally, we showed that high glucose and statin treatment significantly suppressed cholesterol efflux from macrophages. These findings have highlighted the complexity of statins, which may exert detrimental effects on metabolic abnormalities through regulation of miR-33 target genes.
C1 [Chen, Wei-Ming; Tseng, Pei-Chi; Chiang, An-Na] Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.
   [Chen, Wei-Ming; Chang, Pey-Jium] Chang Gung Mem Hosp, Dept Internal Med, Div Gastroenterol & Hepatol, Chiayi, Taiwan.
   [Chen, Wei-Ming; Chang, Pey-Jium] Chang Gung Univ, Grad Inst Clin Med Sci, Coll Med, Taoyuan, Taiwan.
   [Sheu, Wayne H-H; Lee, Wen-Jane] Taichung Vet Gen Hosp, Div Endocrinol & Metab, Dept Internal Med, Taichung, Taiwan.
   [Sheu, Wayne H-H] Natl Yang Ming Univ, Sch Med, Taipei 112, Taiwan.
   [Sheu, Wayne H-H] Natl Def Med Ctr, Sch Med, Taipei, Taiwan.
   [Sheu, Wayne H-H] Natl Chung Hsing Univ, Inst Med Technol, Taichung 40227, Taiwan.
   [Lee, Tzong-Shyuan] Natl Yang Ming Univ, Inst Physiol, Taipei 112, Taiwan.
RP Chiang, AN (reprint author), Natl Yang Ming Univ, Inst Biochem & Mol Biol, Taipei 112, Taiwan.
EM anchia@ym.edu.tw
OI LEE, TZONG-SHYUAN/0000-0002-9593-4062; Chang,
   Pey-Jium/0000-0002-6492-0346
FU Ministry of Education, Aim for the Top University Plan, Taiwan, R.O.C.
   [103AC-P504]; TCVGH-NYMU Joint Research Program [TCVGH-YM1030202];
   Ministry of Science and Technology, R.O.C. [MOST
   104-3011-B-010-001-1-4-2]; Ministry of Education; Ministry of Science
   and Technology, Taiwan
FX This study was supported by grants from the Ministry of Education, Aim
   for the Top University Plan (103AC-P504), Taiwan, R.O.C., the TCVGH-NYMU
   Joint Research Program (TCVGH-YM1030202), and the Ministry of Science
   and Technology (MOST 104-3011-B-010-001-1-4-2), R.O.C. The funders had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.; We wish to particularly
   acknowledge the subjects enrolled in this study for their participation
   and the financial support from the Ministry of Education and the
   Ministry of Science and Technology, Taiwan.
CR Abel ED, 2001, NATURE, V409, P729, DOI 10.1038/35055575
   Alberti KGMM, 2005, LANCET, V366, P1059, DOI 10.1016/S0140-6736(05)67402-8
   Baigent C, 2010, LANCET, V376, P1670, DOI 10.1016/S0140-6736(10)61350-5
   Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5
   Brault M, 2014, METABOLISM, V63, P735, DOI 10.1016/j.metabol.2014.02.014
   Brown AS, 1998, J AM COLL CARDIOL, V32, P665, DOI 10.1016/S0735-1097(98)00300-3
   Brunham LR, 2008, J CLIN INVEST, V118, P403, DOI 10.1172/JCI33296
   Buechler C, 2012, CURR PHARM BIOTECHNO, V13, P319, DOI 10.2174/138920112799095365
   Canfran-Duque A, 2014, CARDIOVASC RES, V103, P414, DOI 10.1093/cvr/cvu140
   Cederberg H, 2015, DIABETOLOGIA, V58, P1109, DOI 10.1007/s00125-015-3528-5
   Chang YC, 2013, J CELL BIOCHEM, V114, P1364, DOI 10.1002/jcb.24478
   Chang YC, 2012, J LIPID RES, V53, P1840, DOI 10.1194/jlr.M024471
   Corral-Fernandez NE, 2013, EXP CLIN ENDOCR DIAB, V121, P347, DOI 10.1055/s-0033-1341516
   Costet P, 2000, J BIOL CHEM, V275, P28240
   Guay C, 2013, NAT REV ENDOCRINOL, V9, P513, DOI 10.1038/nrendo.2013.86
   Heinecke JW, 2015, CIRC RES, V116, P1101, DOI 10.1161/CIRCRESAHA.115.306052
   Ho PC, 2011, FASEB J, V25, P1758, DOI 10.1096/fj.10-179267
   Horie T, 2010, P NATL ACAD SCI USA, V107, P17321, DOI 10.1073/pnas.1008499107
   Kardassis D, 2014, CURR MED CHEM, V21, P2864, DOI 10.2174/0929867321666140303153430
   Kim HS, 2010, CELL METAB, V12, P224, DOI 10.1016/j.cmet.2010.06.009
   Kim VN, 2005, MOL CELLS, V19, P1
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lujambio A, 2012, NATURE, V482, P347, DOI 10.1038/nature10888
   Marim FM, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0015263
   Masana L, 2013, CARDIOVASC DIABETOL, V12, DOI [10.1186/1475-2840-12-S1-SX, 10.1186/1475-2840-12-S1-S2]
   Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005
   Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123
   Navarese EP, 2013, AM J CARDIOL, V111, P1123, DOI 10.1016/j.amjcard.2012.12.037
   O'Connell RM, 2010, NAT REV IMMUNOL, V10, P111, DOI 10.1038/nri2708
   Oikonomou E, 2015, ATHEROSCLEROSIS, V238, P159, DOI 10.1016/j.atherosclerosis.2014.12.014
   Park JY, 2015, INT J CARDIOL, V184, P502, DOI 10.1016/j.ijcard.2015.03.047
   Patel DC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022142
   Petersen CP, 2006, MOL CELL, V21, P533, DOI 10.1016/j.molcel.2006.01.031
   Pincus J, 1998, AM J CARDIOL, V82, P406
   Preiss D, 2011, JAMA-J AM MED ASSOC, V305, P2556, DOI 10.1001/jama.2011.860
   Raitoharju E, 2013, CLIN CHEM, V59, P1708, DOI 10.1373/clinchem.2013.204917
   Rajpathak SN, 2009, DIABETES CARE, V32, P1924, DOI 10.2337/dc09-0738
   Ramirez CM, 2013, MOL CELL BIOL, V33, P2891, DOI 10.1128/MCB.00016-13
   Rayner KJ, 2011, NATURE, V478, P404, DOI 10.1038/nature10486
   Rayner KJ, 2011, J CLIN INVEST, V121, P2921, DOI 10.1172/JCI57275
   Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862
   Rottiers V, 2011, Cold Spring Harb Symp Quant Biol, V76, P225, DOI 10.1101/sqb.2011.76.011049
   Sasaki J, 2008, CLIN THER, V30, P1089, DOI 10.1016/j.clinthera.2008.05.017
   Satoh M, 2015, CLIN SCI, V129, P93, DOI 10.1042/CS20150027
   Sattar N, 2010, LANCET, V375, P735, DOI 10.1016/S0140-6736(09)61965-6
   Takaguri A, 2008, J PHARMACOL SCI, V107, P80, DOI 10.1254/jphs.FP0072403
   Tang CR, 2009, BBA-MOL CELL BIOL L, V1791, P563, DOI 10.1016/j.bbalip.2009.03.011
   Thum T, 2012, EMBO MOL MED, V4, P3, DOI 10.1002/emmm.201100191
   Vickers Kasey C, 2010, Curr Opin Endocrinol Diabetes Obes, V17, P150, DOI 10.1097/MED.0b013e32833727a1
   Wong J, 2006, BIOCHEM J, V400, P485, DOI 10.1042/BJ200609014
   Xu Q, 2015, WORLD J GASTROENTERO, V21, P511, DOI 10.3748/wjg.v21.i2.511
   Yildirir Aylin, 2004, Current Vascular Pharmacology, V2, P309, DOI 10.2174/1570161043385475
   Yin K, 2010, MOL MED, V16, P438, DOI 10.2119/molmed.2010.00004
NR 53
TC 9
Z9 9
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 3
PY 2016
VL 11
IS 5
AR e0154672
DI 10.1371/journal.pone.0154672
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DL5KK
UT WOS:000375675700053
PM 27139226
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Tsaousi, A
   Hayes, EM
   Di Gregoli, K
   Bond, AR
   Bevan, L
   Thomas, AC
   Newby, AC
AF Tsaousi, Aikaterini
   Hayes, Elaine M.
   Di Gregoli, Karina
   Bond, Andrew R.
   Bevan, Laura
   Thomas, Anita C.
   Newby, Andrew C.
TI Plaque Size Is Decreased but M1 Macrophage Polarization and Rupture
   Related Metalloproteinase Expression Are Maintained after Deleting T-Bet
   in ApoE Null Mice
SO PLOS ONE
LA English
DT Article
ID HUMAN ATHEROSCLEROTIC PLAQUES; E-KNOCKOUT MICE; LOW-DENSITY-LIPOPROTEIN;
   FOAM-CELL MACROPHAGES; APOLIPOPROTEIN-E; IFN-GAMMA; TRANSCRIPTION
   FACTOR; INTERFERON-GAMMA; IMMUNE-RESPONSE; DEFICIENT MICE
AB Background
   Thelper1 (Th1) lymphocytes have been previously implicated in atherosclerotic plaque growth but their role in plaque vulnerability to rupture is less clear. We investigated whether T-bet knockout that prevents Th1 lymphocyte differentiation modulates classical (M1) macrophage activation or production of matrix degrading metalloproteinases (MMPs) and their tissue inhibitors, TIMPs.
   Methods & Results
   We studied the effect of T-bet deletion in apolipoproteinE (ApoE) knockout mice fed a high fat diet (HFD) or normal chow diet (ND). Transcript levels of M1/M2 macrophage polarization markers, selected MMPs and TIMPs were measured by RT-qPCR in macrophages isolated from subcutaneous granulomas or in whole aortae. Immunohistochemistry of aortic sinus (AS) and brachiocephalic artery (BCA) plaques was conducted to quantify protein expression of the same factors.
   Deletion of T-bet decreased mRNA for the M1 marker NOS-2 in granuloma macrophages but levels of M2 markers (CD206, arginase-1 and Ym-1), MMPs-2, -9, -12, -13, -14 and -19 or TIMPs-1 to -3 were unchanged. No mRNA differences were observed in aortic extracts from mice fed a HFD for 12 weeks. Moreover, AS and BCA plaques were similarly sized between genotypes, and had similar areas stained for NOS-2, COX-2, MMP-12 and MMP-14 proteins. T-bet deletion increased MMP-13, MMP-14 and arginase-1 in AS plaques. After 35 weeks of ND, T-bet deletion reduced the size of AS and BCA plaques but there were no differences in the percentage areas stained for M1 or M2 markers, MMPs-12, -13, -14, or TIMP-3.
   Conclusions
   Absence of Th1 lymphocytes is associated with reduced plaque size in ApoE knockout mice fed a normal but not high fat diet. In either case, M1 macrophage polarization and expression of several MMPs related to plaque instability are either maintained or increased.
C1 [Tsaousi, Aikaterini; Hayes, Elaine M.; Di Gregoli, Karina; Bond, Andrew R.; Bevan, Laura; Thomas, Anita C.; Newby, Andrew C.] Univ Bristol, Sch Clin Sci, Bristol, Avon, England.
RP Tsaousi, A (reprint author), Univ Bristol, Sch Clin Sci, Bristol, Avon, England.
EM a.tsaousi@bristol.ac.uk
RI Thomas, Anita C/E-1743-2011
OI Thomas, Anita C/0000-0002-3792-2653
FU British Heart Foundation Programme [RG/09/006/27918]; British Heart
   Foundation [RG/09/006/27918]
FX Funding was provided by British Heart Foundation Programme Grant No.
   RG/09/006/27918. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0
   Buono C, 2005, P NATL ACAD SCI USA, V102, P1596, DOI 10.1073/pnas.0409015102
   Buono C, 2003, ARTERIOSCL THROM VAS, V23, P454, DOI 10.1161/01.ATV.0000059419.11002.6E
   Cardilo-Reis L, 2012, EMBO MOL MED, V4, P1072, DOI 10.1002/emmm.201201374
   Casagrande V, 2012, ARTERIOSCL THROM VAS, V32, P74, DOI 10.1161/ATVBAHA.111.238402
   Castrillo A, 2003, J BIOL CHEM, V278, P10443, DOI 10.1074/jbc.M213071200
   Chase AJ, 2002, ARTERIOSCL THROM VAS, V22, P765, DOI 10.1161/01.ATV.0000015078.09208.92
   Dansky HM, 1997, P NATL ACAD SCI USA, V94, P4642, DOI 10.1073/pnas.94.9.4642
   Daugherty A, 1997, J CLIN INVEST, V100, P1575, DOI 10.1172/JCI119681
   Di Gregoli K, 2014, ARTERIOSCL THROM VAS, V34, P1990, DOI 10.1161/ATVBAHA.114.304088
   Frostegard J, 1999, ATHEROSCLEROSIS, V145, P33, DOI 10.1016/S0021-9150(99)00011-8
   Gupta S, 1997, J CLIN INVEST, V99, P2752, DOI 10.1172/JCI119465
   HANSSON GK, 1991, ARTERIOSCLER THROMB, V11, P745, DOI 10.1161/01.ATV.11.3.745
   Hansson GK, 2002, CIRC RES, V91, P281, DOI 10.1161/01.RES.0000029784.15893.10
   HANSSON GK, 1988, CIRC RES, V63, P712, DOI 10.1161/01.RES.63.4.712
   HANSSON GK, 1989, AM J PATHOL, V135, P169
   Hartley CJ, 2000, AM J PHYSIOL-HEART C, V279, pH2326
   Hayes EM, 2014, FRONT IMMUNOL, V5, DOI 10.3389/fimmu.2014.00537
   Huang WC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0042507
   Johnson J, 2005, CIRCULATION, V111, P1422, DOI 10.1161/01.CIR.0000158435.98035.8D
   Johnson J. L., 2014, MEDIAT INFLAMM, V2014, DOI DOI 10.1155/2014/276457
   Johnson JL, 2008, ARTERIOSCL THROM VAS, V28, P1647, DOI 10.1161/ATVBAHA.108.170548
   Johnson JL, 2011, ARTERIOSCL THROM VAS, V31, P528, DOI 10.1161/ATVBAHA.110.219147
   Johnson JL, 2005, P NATL ACAD SCI USA, V102, P15575, DOI 10.1073/pnas.0506201102
   Joven J, 2007, ATHEROSCLEROSIS, V195, pE85, DOI 10.1016/j.atherosclerosis.2007.06.012
   Kadl A, 2010, CIRC RES, V107, P737, DOI 10.1161/CIRCRESAHA.109.215715
   Klingenberg R, 2013, J CLIN INVEST, V123, P1323, DOI 10.1172/JCI63891
   Koltsova EK, 2013, CURR OPIN LIPIDOL, V24, P371, DOI 10.1097/MOL.0b013e328363d298
   Libby P, 2013, J CLIN INVEST, V123, P3201, DOI 10.1172/JCI67526
   Libby P, 2013, IMMUNITY, V38, P1092, DOI 10.1016/j.immuni.2013.06.009
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lugo-Villarino G, 2003, P NATL ACAD SCI USA, V100, P7749, DOI 10.1073/pnas.1332767100
   Lumeng CN, 2007, J CLIN INVEST, V117, P175, DOI 10.1172/JCI29881
   Lundberg AM, 2011, CURR OPIN LIPIDOL, V22, P343, DOI 10.1097/MOL.0b013e32834ada80
   Lutgens E, 2010, J EXP MED, V207, P391, DOI 10.1084/jem.20091293
   Martinez FO, 2006, J IMMUNOL, V177, P7303, DOI 10.4049/jimmunol.177.10.7303
   Mosser DM, 2008, NAT REV IMMUNOL, V8, P958, DOI 10.1038/nri2448
   Murphy KM, 2002, NAT REV IMMUNOL, V2, P933, DOI 10.1038/nri954
   NAKASHIMA Y, 1994, ARTERIOSCLER THROMB, V14, P133, DOI 10.1161/01.ATV.14.1.133
   Naura AS, 2009, LAB INVEST, V89, P1243, DOI 10.1038/labinvest.2009.98
   Newby AC, 2008, ARTERIOSCL THROM VAS, V28, P2108, DOI 10.1161/ATVBAHA.108.173898
   Newby AC, 2014, CURR OPIN LIPIDOL, V25, P358, DOI 10.1097/MOL.0000000000000111
   Osborn O, 2012, NAT MED, V18, P363, DOI 10.1038/nm.2627
   PAIGEN B, 1990, ARTERIOSCLEROSIS, V10, P316, DOI 10.1161/01.ATV.10.2.316
   Paulson KE, 2010, CIRC RES, V106, P383, DOI 10.1161/CIRCRESAHA.109.210781
   Pearce EL, 2003, SCIENCE, V302, P1041, DOI 10.1126/science.1090148
   Quillard T, 2014, ARTERIOSCL THROM VAS, V34, P1179, DOI 10.1161/ATVBAHA.114.303326
   Quillard T, 2011, ARTERIOSCL THROM VAS, V31, P2464, DOI 10.1161/ATVBAHA.111.231563
   Robbins CS, 2012, CIRCULATION, V125, P364, DOI 10.1161/CIRCULATIONAHA.111.061986
   Romagnani S, 2000, ANN ALLERG ASTHMA IM, V85, P9, DOI 10.1016/S1081-1206(10)62426-X
   Rong JX, 2003, P NATL ACAD SCI USA, V100, P13531, DOI 10.1073/pnas.1735526100
   Rossmann A, 2008, EXP GERONTOL, V43, P229, DOI 10.1016/j.exger.2007.11.009
   Schneider F, 2008, CIRCULATION, V117, P931, DOI 10.1161/CIRCULATIONAHA.107.707448
   SMITH JD, 1995, P NATL ACAD SCI USA, V92, P8264, DOI 10.1073/pnas.92.18.8264
   Spann NJ, 2012, CELL, V151, P138, DOI 10.1016/j.cell.2012.06.054
   STEMME S, 1992, ARTERIOSCLER THROMB, V12, P206, DOI 10.1161/01.ATV.12.2.206
   STEMME S, 1995, P NATL ACAD SCI USA, V92, P3893, DOI 10.1073/pnas.92.9.3893
   Stohr R, 2014, ATHEROSCLEROSIS, V235, P438, DOI 10.1016/j.atherosclerosis.2014.05.946
   Stolarczyk E, 2013, CELL METAB, V17, P520, DOI 10.1016/j.cmet.2013.02.019
   Szabo SJ, 2000, CELL, V100, P655, DOI 10.1016/S0092-8674(00)80702-3
   Szabo SJ, 2002, SCIENCE, V295, P338, DOI 10.1126/science.1065543
   Tedgui A, 2006, PHYSIOL REV, V86, P515, DOI 10.1152/physrev.00024.2005
   Thale C, 2005, IMMUNOBIOLOGY, V210, P673, DOI 10.1016/j.imbio.2005.07.003
   Thomas AC, 2007, ARTERIOSCL THROM VAS, V27, P571, DOI 10.1161/01.ATV.0000256470.23842.94
   Virmani R, 2006, J AM COLL CARDIOL, V47, pC13, DOI 10.1016/j.jacc.2005.10.065
   Wang YN, 2007, CIRC RES, V101, P560, DOI 10.1161/CIRCRESAHA.107.151068
   Whitman SC, 2002, J INTERF CYTOK RES, V22, P661, DOI 10.1089/10799900260100141
   Wick G, 2004, ANNU REV IMMUNOL, V22, P361, DOI 10.1146/annurev.immunol.22.012703.014644
   Xu W, 2007, EUR J IMMUNOL, V37, P1594, DOI 10.1002/eji.200737042
   Zhou XH, 2000, CIRCULATION, V102, P2919
   Zhou XH, 2003, BIOMED PHARMACOTHER, V57, P287, DOI 10.1016/S0753-3322(03)00082-9
   Zhou XH, 1998, J CLIN INVEST, V101, P1717, DOI 10.1172/JCI1216
   Zhou XH, 1996, AM J PATHOL, V149, P359
NR 73
TC 4
Z9 4
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 17
PY 2016
VL 11
IS 2
AR e0148873
DI 10.1371/journal.pone.0148873
PG 28
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA DF3BJ
UT WOS:000371218400056
PM 26886778
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Ren, LJ
   Cai, JJ
   Liang, J
   Li, WP
   Sun, ZH
AF Ren, Lijie
   Cai, Jingjing
   Liang, Jie
   Li, Weiping
   Sun, Zhonghua
TI Impact of Cardiovascular Risk Factors on Carotid Intima-Media Thickness
   and Degree of Severity: A Cross-Sectional Study
SO PLOS ONE
LA English
DT Article
ID BASE-LINE DATA; YOUNG-ADULTS; DEPRESSIVE SYMPTOMS; ARTERIAL STIFFNESS;
   HEART-DISEASE; ATHEROSCLEROSIS; STROKE; PROGRESSION; HYPERTENSION;
   PLAQUE
AB Objective
   Age, hypertension, dyslipidemia and diabetes are common cardiovascular risk factors (CVRFs) that contribute to the development of atherosclerosis in cardiovascular system including carotid artery disease. However, the impact of these risk factors on the increased carotid intima-media thickness (cIMT) and degree of carotid severity remains to be further clarified. This study aims to evaluate the relationship between CVRFs and degree of carotid severity and cIMT in high-risk subjects.
   Methods
   Four thousand and three hundred ninety-four subjects with one or more risk factors were retrospectively reviewed in this study. Patients were divided into different groups based on age, the type and quantity of CVRFs. cIMT and degree of carotid artery stenosis were measured and analyzed based on carotid ultrasound imaging with findings compared to the CVRFs to determine the correlation between these variables.
   Results
   Aging was significantly associated with degree of severity (P < 0.05) and cIMT was significantly increased with age (P < 0.05). Individual CVRF analysis shows that hypertension was more related to the degree of severity than dyslipidemia and diabetes with corresponding abnormal cIMT rates being 79.39%, 72.98% and 32.37%, respectively. The prevalence of carotid atherosclerosis were 20.06%, 22.88% and 28.63%, respectively corresponding to patients with zero, one and more than one chronic diseases. The percentage of abnormal cIMT in hypertensive patient group with dyslipidemia is significantly higher than the other groups (P< 0.05).
   Conclusions
   This study shows a direct correlation between the degree of carotid severity and cIMT and cardiovascular risk factors, especially with age and hypertension. Carotid atherosclerosis is closely related to the number of cardiovascular risk factors.
C1 [Ren, Lijie; Cai, Jingjing] Anhui Med Univ, Clin Med Coll, Peoples Hosp 2, Dept Shenzhen, Shenzhen, Guangdong, Peoples R China.
   [Ren, Lijie; Cai, Jingjing; Liang, Jie] Shenzhen Second Peoples Hosp, Dept Neurol, Shenzhen, Guangdong, Peoples R China.
   [Liang, Jie] Guangzhou Med Univ, Clin Med Coll, Peoples Hosp 2, Dept Shenzhen, Shenzhen, Guangdong, Peoples R China.
   [Li, Weiping] Shenzhen Second Peoples Hosp, Dept Neurosurg, Shenzhen, Guangdong, Peoples R China.
   [Sun, Zhonghua] Curtin Univ, Dept Med Radiat Sci, Perth, WA 6845, Australia.
RP Li, WP (reprint author), Shenzhen Second Peoples Hosp, Dept Neurosurg, Shenzhen, Guangdong, Peoples R China.
EM liweiping60@yahoo.com.cn
RI Sun, Zhonghua/N-1648-2019; Sun, Zhonghua/B-3125-2010
OI Sun, Zhonghua/0000-0002-7538-4761; Sun, Zhonghua/0000-0002-7538-4761
FU Shenzhen Development and Reform Commission [2012110]; Shenzhen-based
   chronic disease tracking and monitoring and control of public service
   platform cloud platform [20120830145119425]; Guangdong Province Science
   and Technology Project [2013B021800102]; Shenzhen Knowledge Innovation
   Program [20130322131035]; Shenzhen-based research project
   [JCYJ20140414170821262]
FX This work was supported in part by Shenzhen Development and Reform
   Commission project "Shenzhen stroke screening and prevention public
   service platform" (2012110), the Shenzhen-based chronic disease tracking
   and monitoring and control of public service platform cloud platform
   (20120830145119425), Guangdong Province Science and Technology Project
   (2013B021800102), Shenzhen Knowledge Innovation Program (20130322131035)
   and Shenzhen-based research project (JCYJ20140414170821262).; This work
   was supported in part by Shenzhen Development and Reform Commission
   project "Shenzhen stroke screening and prevention public service
   platform" (2012110), the Shenzhen-based chronic disease tracking and
   monitoring and control of public service platform cloud platform
   (20120830145119425), Guangdong Province Science and Technology Project
   (2013B021800102), Shenzhen Knowledge Innovation Program (20130322131035)
   and Shenzhen-based research project (JCYJ20140414170821262).
CR Alberti KGMM, 2009, CIRCULATION, V120, P1640, DOI 10.1161/CIRCULATIONAHA.109.192644
   Beckman JA, 2002, JAMA-J AM MED ASSOC, V287, P2570, DOI 10.1001/jama.287.19.2570
   Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302
   Bots ML, 2012, J AM COLL CARDIOL, V60, P1599, DOI 10.1016/j.jacc.2011.12.061
   CHEN ZM, 1991, BRIT MED J, V303, P276, DOI 10.1136/bmj.303.6797.276
   Chirinos DA, 2015, J BEHAV MED, V38, P284, DOI 10.1007/s10865-014-9599-9
   Conner W T, 1998, Evid Based Cardiovasc Med, V2, P71, DOI 10.1016/S1361-2611(98)80064-X
   Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults, 2001, JAMA, V285, P2486
   Herder M, 2012, STROKE, V43, P1818, DOI 10.1161/STROKEAHA.111.646596
   Kabir AA, 2009, AM J MED, V122, DOI 10.1016/j.amjmed.2009.07.016
   KANNEL WB, 1988, AM J CARDIOL, V62, P1109, DOI 10.1016/0002-9149(88)90558-9
   Koskinen J, 2009, CIRCULATION, V120, P229, DOI 10.1161/CIRCULATIONAHA.108.845065
   Lee HY, 2010, CIRC J, V74, P2257, DOI 10.1253/circj.CJ-10-0910
   Liang YJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0085927
   Liapis CD, 2001, STROKE, V32, P2782, DOI 10.1161/hs1201.099797
   Libby P, 2002, NATURE, V420, P868, DOI 10.1038/nature01323
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lorenz MW, 2007, CIRCULATION, V115, P459, DOI 10.1161/CIRCULATIONAHA.106.628875
   Lorenz MW, 2006, STROKE, V37, P87, DOI 10.1161/01.STR.0000196964.24024.ea
   Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
   Mancia G, 2001, J HYPERTENS, V19, P1981, DOI 10.1097/00004872-200111000-00008
   Meschia JF, 2014, STROKE, V45, P3754, DOI 10.1161/STR.0000000000000046
   Mostaza JM, 2015, ATHEROSCLEROSIS, V242, P377, DOI 10.1016/j.atherosclerosis.2015.07.028
   Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI 10.1161/CIR.0000000000000152
   Naqvi TZ, 2014, JACC-CARDIOVASC IMAG, V7, P1025, DOI 10.1016/j.jcmg.2013.11.014
   Niu LL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067809
   O'Donnell MJ, 2010, LANCET, V376, P112, DOI 10.1016/S0140-6736(10)60834-3
   Pall D, 2003, CEREBROVASC DIS, V15, P167, DOI 10.1159/000068834
   Pan A, 2011, JAMA-J AM MED ASSOC, V306, P1241, DOI 10.1001/jama.2011.1282
   Paul TK, 2005, AM J CARDIOL, V95, P469, DOI 10.1016/j.amjcard.2004.10.013
   Polak JF, 2011, STROKE, V42, P3017, DOI 10.1161/STROKEAHA.111.625186
   Rothwell PM, 2000, LANCET, V355, P19, DOI 10.1016/S0140-6736(99)04470-0
   Rundek T, 2013, STROKE, V44, P2101, DOI 10.1161/STROKEAHA.111.000745
   Santos IS, 2015, ATHEROSCLEROSIS, V240, P529, DOI 10.1016/j.atherosclerosis.2015.04.800
   Sun ZJ, 2015, HYPERTENSION, V65, P252, DOI 10.1161/HYPERTENSIONAHA.114.03617
   Sztajzel R, 2005, SWISS MED WKLY, V135, P635
   Talelli P, 2007, J CLIN NEUROSCI, V14, P1067, DOI 10.1016/j.jocn.2006.06.019
   Tattersall MC, 2014, STROKE, V45, P3257, DOI 10.1161/STROKEAHA.114.005669
   Touboul PJ, 2012, CEREBROVASC DIS, V34, P290, DOI 10.1159/000343145
   Tsivgoulis G, 2006, STROKE, V37, P1913, DOI 10.1161/01.STR.0000226399.13528.0a
   Urbina EM, 2009, CIRCULATION, V119, P2913, DOI 10.1161/CIRCULATIONAHA.108.830380
   Urbina EM, 2002, AM J CARDIOL, V90, P953, DOI 10.1016/S0002-9149(02)02660-7
   van der Meer IM, 2003, STROKE, V34, P2374, DOI 10.1161/01.STR.0000088643.07108.19
   van Rooy MJ, 2014, CURR MED CHEM, V21, P2121
   WALDSTEIN SR, 1991, PSYCHOL BULL, V110, P451, DOI 10.1037/0033-2909.110.3.451
   Weingartner O, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013467
   Yang YP, 2015, MED SCI MONITOR, V21, P2467, DOI 10.12659/MSM.894693
   Yuan C, 2014, J DIABETES RES, DOI 10.1155/2014/179686
   Yusuf S, 2004, LANCET, V364, P937, DOI 10.1016/S0140-6736(04)17018-9
   Yusuf S, 2001, CIRCULATION, V104, P2855, DOI 10.1161/hc4701.099488
   Zhang FL, 2014, INT J CLIN EXP MED, V7, P5412
NR 51
TC 12
Z9 13
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD DEC 4
PY 2015
VL 10
IS 12
AR e0144182
DI 10.1371/journal.pone.0144182
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CY1CH
UT WOS:000366143800054
PM 26636669
OA DOAJ Gold, Green Published
DA 2019-06-18
ER

PT J
AU Pagano, S
   Gaertner, H
   Cerini, F
   Mannic, T
   Satta, N
   Teixeira, PC
   Cutler, P
   Mach, F
   Vuilleumier, N
   Hartley, O
AF Pagano, Sabrina
   Gaertner, Hubert
   Cerini, Fabrice
   Mannic, Tiphaine
   Satta, Nathalie
   Teixeira, Priscila Camillo
   Cutler, Paul
   Mach, Francois
   Vuilleumier, Nicolas
   Hartley, Oliver
TI The Human Autoantibody Response to Apolipoprotein A-I Is Focused on the
   C-Terminal Helix: A New Rationale for Diagnosis and Treatment of
   Cardiovascular Disease?
SO PLOS ONE
LA English
DT Article
ID SYSTEMIC-LUPUS-ERYTHEMATOSUS; HIGH-DENSITY-LIPOPROTEINS; SOLID-PHASE
   SYNTHESIS; MYOCARDIAL-INFARCTION; RHEUMATOID-ARTHRITIS; A-1
   AUTOANTIBODIES; IGG; ANTIBODIES; PEPTIDES; RISK
AB Background
   Cardiovascular disease (CVD) is the leading cause of death worldwide and new approaches for both diagnosis and treatment are required. Autoantibodies directed against apolipoprotein A-I (ApoA-I) represent promising biomarkers for use in risk stratification of CVD and may also play a direct role in pathogenesis.
   Methodology
   To characterize the anti-ApoA-I autoantibody response, we measured the immunoreactivity to engineered peptides corresponding to the different alpha-helical regions of ApoA-I, using plasma from acute chest pain cohort patients known to be positive for anti-ApoA-I autoantibodies.
   Principal Findings
   Our results indicate that the anti-ApoA-I autoantibody response is strongly biased towards the C-terminal alpha-helix of the protein, with an optimized mimetic peptide corresponding to this part of the protein recapitulating the diagnostic accuracy for an acute ischemic coronary etiology (non-ST segment elevation myocardial infarction and unstable angina) obtainable using intact endogenous ApoA-I in immunoassay. Furthermore, the optimized mimetic peptide strongly inhibits the pathology-associated capacity of anti-ApoA-I antibodies to elicit proinflammatory cytokine release from cultured human macrophages.
   Conclusions
   In addition to providing a rationale for the development of new approaches for the diagnosis and therapy of CVD, our observations may contribute to the elucidation of how anti-ApoA-I autoantibodies are elicited in individuals without autoimmune disease.
C1 [Pagano, Sabrina; Mannic, Tiphaine; Satta, Nathalie; Vuilleumier, Nicolas] Univ Geneva, Dept Human Prot Sci, Fac Med, Geneva, Switzerland.
   [Pagano, Sabrina; Mannic, Tiphaine; Satta, Nathalie; Vuilleumier, Nicolas] Univ Hosp Geneva, Dept Genet & Lab Med, Div Lab Med, Geneva, Switzerland.
   [Gaertner, Hubert; Cerini, Fabrice; Hartley, Oliver] Univ Geneva, Dept Pathol & Immunol, Fac Med, Geneva, Switzerland.
   [Teixeira, Priscila Camillo; Cutler, Paul] F Hoffmann La Roche, Pharmaceut Sci Pharma Res & Early Dev, Basel, Switzerland.
   [Mach, Francois] Univ Geneva, Div Cardiol, Fdn Med Res, Geneva, Switzerland.
RP Vuilleumier, N (reprint author), Univ Geneva, Dept Human Prot Sci, Fac Med, Geneva, Switzerland.
EM Nicolas.Vuilleumier@hcuge.ch; Oliver.Hartley@unige.ch
FU Swiss National Science Foundation [310030_140736]; Leenaards Foundation
   [3698]; deReuters foundation [566]
FX This work was supported by Swiss National Science Foundation Grants
   #310030_140736 to NV, by grants from the Leenaards Foundation no. 3698
   to NV and OH, and from the deReuters foundation no. 566 to NV. These
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript. F. Hoffmann-La
   Roche played an indirect role in the form of salaries for authors PC and
   PT, but did not have any additional role in the study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript. The specific roles of these authors are articulated in the
   'author contributions' section.
CR Ajees AA, 2006, P NATL ACAD SCI USA, V103, P2126, DOI 10.1073/pnas.0506877103
   Ames PRJ, 2010, LUPUS, V19, P711, DOI 10.1177/0961203309357765
   Antman EM, 2000, JAMA-J AM MED ASSOC, V284, P835, DOI 10.1001/jama.284.7.835
   Batuca JR, 2007, ANN NY ACAD SCI, V1108, P137, DOI 10.1196/annals.1422.016
   Bloedon LT, 2008, J LIPID RES, V49, P1344, DOI 10.1194/jlr.P800003-JLR200
   Cunningham MW, 2012, CURR OPIN RHEUMATOL, V24, P408, DOI 10.1097/BOR.0b013e32835461d3
   Davidson WS, 2007, J BIOL CHEM, V282, P22249, DOI 10.1074/jbc.R700014200
   DELONG ER, 1988, BIOMETRICS, V44, P837, DOI 10.2307/2531595
   Dinu AR, 1998, LUPUS, V7, P355, DOI 10.1191/096120398678920262
   Eyre H, 2004, CIRCULATION, V109, P3244, DOI 10.1161/01.CIR.0000133321.00456.00
   Finckh A, 2012, ARTHRIT CARE RES, V64, P817, DOI 10.1002/acr.21631
   Hafiane A, 2014, CURR OPIN ENDOCRINOL, V21, P134, DOI 10.1097/MED.0000000000000049
   Henchey LK, 2008, CURR OPIN CHEM BIOL, V12, P692, DOI 10.1016/j.cbpa.2008.08.019
   KATES SA, 1993, TETRAHEDRON LETT, V34, P1549, DOI 10.1016/0040-4039(93)85003-F
   Keller PF, 2012, J INTERN MED, V271, P451, DOI 10.1111/j.1365-2796.2011.02479.x
   Krauel K, 2011, BLOOD, V117, P1370, DOI 10.1182/blood-2010-08-301424
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   McManus DD, 2011, AM J MED, V124, P40, DOI 10.1016/j.amjmed.2010.07.023
   Montecucco F, 2011, EUR HEART J, V32, P412, DOI 10.1093/eurheartj/ehq521
   Naghavi M, 2006, AM J CARDIOL, V98, p2H, DOI 10.1016/j.amjcard.2006.03.002
   Navab M, 2011, NAT REV CARDIOL, V8, P222, DOI 10.1038/nrcardio.2010.222
   Pagano S, 2012, J INTERN MED, V272, P344, DOI 10.1111/j.1365-2796.2012.02530.x
   Patgiri A, 2010, NAT PROTOC, V5, P1857, DOI 10.1038/nprot.2010.146
   Rossier MF, 2012, ENDOCRINOLOGY, V153, P1269, DOI 10.1210/en.2011-1835
   Roux-Lombard P, 2013, CLIN REV ALLERG IMMU, V44, P84, DOI 10.1007/s12016-010-8233-z
   Srivastava R, 2011, ARTHRITIS RHEUM-US, V63, P201, DOI 10.1002/art.27764
   Taylor JW, 2002, BIOPOLYMERS, V66, P49, DOI 10.1002/bip.10203
   Teixeira PC, 2014, J BIOL CHEM, V289, P28249, DOI 10.1074/jbc.M114.589002
   Thygesen K, 2012, EUR HEART J, V33, P2551, DOI 10.1093/eurheartj/ehs184
   Vuilleumier N, 2010, SCAND J RHEUMATOL, V39, P447, DOI 10.3109/03009741003742755
   Vuilleumier N, 2013, SWISS MED WKLY, V143, DOI 10.4414/smw.2013.13781
   Vuilleumier N, 2013, THROMB HAEMOSTASIS, V109, P706, DOI 10.1160/TH12-10-0714
   Vuilleumier N, 2010, ARTHRITIS RHEUM-US, V62, P2640, DOI 10.1002/art.27546
   Vuilleumier N, 2010, EUR HEART J, V31, P815, DOI 10.1093/eurheartj/ehq055
   Watson CE, 2011, J LIPID RES, V52, P361, DOI 10.1194/jlr.M011098
   Wick PA, 2013, J PERIODONTAL RES, V48, P350, DOI 10.1111/jre.12014
   Yuki N, 2001, Lancet Infect Dis, V1, P29
NR 37
TC 8
Z9 8
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 15
PY 2015
VL 10
IS 7
AR e0132780
DI 10.1371/journal.pone.0132780
PG 18
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1RL
UT WOS:000358197600154
PM 26177543
OA DOAJ Gold, Green Published
DA 2019-06-18
ER

PT J
AU Gao, CX
   Li, TT
   Liu, J
   Guo, Q
   Tian, LM
AF Gao, Cuixia
   Li, Tingting
   Liu, Jing
   Guo, Qian
   Tian, Limin
TI Endothelial Functioning and Hemodynamic Parameters in Rats with
   Subclinical Hypothyroid and the Effects of Thyroxine Replacement
SO PLOS ONE
LA English
DT Article
ID LEFT-VENTRICULAR FUNCTION; CORONARY-HEART-DISEASE; THYROID-HORMONE
   ACTION; CARDIOVASCULAR RISK-FACTORS; VASCULAR SMOOTH-MUSCLE;
   CARDIAC-FUNCTION; STIMULATING HORMONE; OXIDATIVE STRESS; DYSFUNCTION;
   ATHEROSCLEROSIS
AB Objective
   Subclinical hypothyroidism (SCH) and its associations with atherosclerosis (AS) and cardiovascular disease remain controversial. The purpose of our study was to observe changes in endothelial functioning and hemodynamics in rats with SCH and to determine whether L-thyroxine (L-T4) administration affects these changes.
   Methods
   In total, sixty male Wistar rats were randomly divided into the following three groups with 20 rats each: control euthyroid rats, SCH rats and SCH rats that had been treated with thyroxine (SCH+T4). The SCH rats were induced by administration of 10 mg.kg(-1). d(-1) methimazole (MMI) once daily by gavage for 3 months. The SCH+T4 rats were administered the same dose of MMI for three months in addition to 2 mu g.kg(-1). d(-1) L-T4 once daily by gavage after 45 days of MMI administration. The control rats received physiological saline via gavage.
   Results
   The SCH group had significantly higher thyroid-stimulating hormone (TSH), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and endothelin (ET) levels and a lower nitric oxide (NO) level than the control and SCH+T4 groups. The tail and carotid artery blood pressures, left ventricular systolic pressure, heart rate and aorta ventralis blood flow were significantly lower in the SCH group than in the control and SCH+T4 groups. ACH treatment caused concentration-dependent relaxation, which was reduced in the SCH arteries compared with the control and SCH+T4 arteries. Histopathological examination revealed the absence of pathological changes in the SCH rat arteries.
   Conclusions
   These findings demonstrate that L-T4 treatment ameliorates endothelial dysfunction and hemodynamic changes in SCH rats.
C1 [Gao, Cuixia] Gansu Prov Hosp, Dept Ultrason Diag, Lanzhou, Gansu, Peoples R China.
   [Li, Tingting] Gansu Univ Chinese Med, Dept Clin Med, Lanzhou, Gansu, Peoples R China.
   [Liu, Jing; Guo, Qian; Tian, Limin] Gansu Prov Hosp, Dept Endocrinol, Lanzhou, Gansu, Peoples R China.
RP Tian, LM (reprint author), Gansu Prov Hosp, Dept Endocrinol, Lanzhou, Gansu, Peoples R China.
EM tlm7066@sina.com
RI Tian, Limin/K-4855-2019
FU National Natural Science Foundation of China [81160100, 81360125]
FX This research was funded by grants from the National Natural Science
   Foundation of China (81160100, 81360125). The funders had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ahmed OM, 2012, J DIABETES COMPLICAT, V26, P491, DOI 10.1016/j.jdiacomp.2012.05.021
   BELL GM, 1983, CLIN ENDOCRINOL, V18, P511, DOI 10.1111/j.1365-2265.1983.tb02881.x
   Billic-Komarica Edina, 2012, Mater Sociomed, V24, P212, DOI 10.5455/msm.2012.24.212-219
   Biondi B, 2002, ANN INTERN MED, V137, P904, DOI 10.7326/0003-4819-137-11-200212030-00011
   Biondi B, 1999, J CLIN ENDOCR METAB, V84, P2064, DOI 10.1210/jc.84.6.2064
   Biondi B, 2008, ENDOCR REV, V29, P76, DOI 10.1210/er.2006-0043
   Biondi B, 2007, THYROID, V17, P625, DOI 10.1089/thy.2007.0158
   Biondi B, 2009, EUR J ENDOCRINOL, V161, P323, DOI 10.1530/EJE-09-0196
   Bonetti PO, 2003, ARTERIOSCL THROM VAS, V23, P168, DOI 10.1161/01.ATV.0000051384.43104.FC
   Cabral MD, 2011, CLINICS, V66, P1321, DOI 10.1590/S1807-59322011000800003
   Cai YF, 2011, HYPERTENS RES, V34, P1098, DOI 10.1038/hr.2011.91
   Cappola AR, 2006, JAMA-J AM MED ASSOC, V295, P1033, DOI 10.1001/jama.295.9.1033
   Cappola AR, 2003, J CLIN ENDOCR METAB, V88, P2438, DOI 10.1210/jc.2003-030398
   Chen X, 2013, J CARDIOL, V61, P8, DOI 10.1016/j.jjcc.2012.08.017
   Chopra S, 2011, INDIAN J ENDOCRINOL, V15, P354
   DILLMANN WH, 1990, AM J MED, V88, P626, DOI 10.1016/0002-9343(90)90530-Q
   Dorr M, 2005, J CLIN ENDOCR METAB, V90, P673, DOI 10.1210/jc.2004-1554
   Drexler H, 1997, PROG CARDIOVASC DIS, V39, P287, DOI 10.1016/S0033-0620(97)80030-8
   Fazio S, 2004, RECENT PROG HORM RES, V59, P31, DOI 10.1210/rp.59.1.31
   FOLDES J, 1987, ACTA MED HUNG, V44, P337
   Fraczek Magdalena Maria, 2014, Pol Merkur Lekarski, V37, P170
   Gerdes AM, 2015, AM J PHYSIOL-HEART C, V308, pH1, DOI 10.1152/ajpheart.00704.2014
   GRAETTINGER JS, 1958, J CLIN INVEST, V37, P502, DOI 10.1172/JCI103631
   Gunaldi M, 2016, J ONCOL PHARM PRACT, V22, P242, DOI 10.1177/1078155214567162
   Gussekloo J, 2004, JAMA-J AM MED ASSOC, V292, P2591, DOI 10.1001/jama.292.21.2591
   HEALY B, 1990, J AM COLL CARDIOL, V16, P357, DOI 10.1016/0735-1097(90)90585-D
   Heitzer T, 2001, CIRCULATION, V104, P2673, DOI 10.1161/hc4601.099485
   Herwig A, 2014, THYROID, V24, P1575, DOI 10.1089/thy.2014.0169
   Imaizumi M, 2004, J CLIN ENDOCR METAB, V89, P3365, DOI 10.1210/jc.2003-031089
   Iqbal A, 2007, J CLIN ENDOCR METAB, V92, P3504, DOI 10.1210/jc.2007-0727
   Kahaly GJ, 2005, ENDOCR REV, V26, P704, DOI 10.1210/er.2003-0033
   Karthick N, 2013, J CLIN DIAGN RES, V7, P2122, DOI 10.7860/JCDR/2013/5777.3448
   KLEIN I, 1994, J CLIN ENDOCR METAB, V78, P1026, DOI 10.1210/jc.78.5.1026
   Klein I, 2007, CIRCULATION, V116, P1725, DOI 10.1161/CIRCULATIONAHA.106.678326
   Leal ALRC, 2007, ENDOCRINE, V31, P174, DOI 10.1007/s12020-007-0029-4
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lombardi A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0116498
   Mariotti S, 2008, INT J CARDIOL, V126, P190, DOI 10.1016/j.ijcard.2007.03.130
   Martins RM, 2011, ARQ BRAS ENDOCRINOL, V55, P460, DOI 10.1590/S0004-27302011000700005
   Meena C L, 2012, Acta Inform Med, V20, P218, DOI 10.5455/aim.2012.20.21-218-220
   Monzani F, 2001, J CLIN ENDOCR METAB, V86, P1110, DOI 10.1210/jc.86.3.1110
   Nam SM, 2013, NEURAL REGEN RES, V8, P2458, DOI 10.3969/j.issn.1673-5374.2013.26.007
   Ochs N, 2008, ANN INTERN MED, V148, P832, DOI 10.7326/0003-4819-148-11-200806030-00225
   Ojamaa K, 1996, THYROID, V6, P505, DOI 10.1089/thy.1996.6.505
   OJAMAA K, 1993, ENDOCRINOLOGY, V132, P1002, DOI 10.1210/en.132.3.1002
   Osman Faizel, 2001, Current Opinion in Pharmacology, V1, P626, DOI 10.1016/S1471-4892(01)00107-2
   Owen PJD, 2006, J CLIN ENDOCR METAB, V91, P2126, DOI 10.1210/jc.2005-2108
   Razvi S, 2007, J CLIN ENDOCR METAB, V92, P1715, DOI 10.1210/jc.2006-1869
   Roos A, 2007, J CLIN ENDOCR METAB, V92, P491, DOI 10.1210/jc.2006-1718
   Santi A, 2014, EXP CLIN ENDOCR DIAB, V122, P533, DOI 10.1055/s-0034-1376968
   Schachinger V, 2000, CIRCULATION, V101, P1899, DOI 10.1161/01.CIR.101.16.1899
   Schultz M, 2011, HORM METAB RES, V43, P653, DOI 10.1055/s-0031-1283162
   Sigal GA, 2011, THYROID, V21, P347, DOI 10.1089/thy.2010.0313
   Silva JF, 2014, J OVARIAN RES, V7, DOI 10.1186/1757-2215-7-75
   Sunbul M, 2013, EUR REV MED PHARMACO, V17, P3323
   Tian LM, 2014, ENDOCRINE, V46, P651, DOI 10.1007/s12020-013-0135-4
   Tian LM, 2014, J MOL ENDOCRINOL, V52, P215, DOI 10.1530/JME-13-0119
   Torrens C, 2006, HYPERTENSION, V47, P982, DOI 10.1161/01.HYP.0000215580.43711.d1
   Torrens C, 2009, HYPERTENSION, V53, P661, DOI 10.1161/HYPERTENSIONAHA.108.122820
   Treskatsch S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087531
   Tsujio M, 2008, VET PATHOL, V45, P505, DOI 10.1354/vp.45-4-505
   Valentina VN, 2011, ARQ BRAS ENDOCRINOL, V55, P475, DOI 10.1590/S0004-27302011000700007
   Vanhoutte PM, 2009, CIRC J, V73, P595, DOI 10.1253/circj.CJ-08-1169
   Walsh JP, 2005, ARCH INTERN MED, V165, P2467, DOI 10.1001/archinte.165.21.2467
   Wang JQ, 2013, EXP CLIN CARDIOL, V18, pE16
   Wu S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0055599
   Xu C, 2012, NUTR METAB, V9, DOI 10.1186/1743-7075-9-44
   Yang SS, 2014, NEUROENDOCRINOL LETT, V35, P80
   Yazici M, 2004, INT J CARDIOL, V95, P135, DOI 10.1016/j.ijcard.2003.05.015
   Yen PM, 2001, PHYSIOL REV, V81, P1097
   Yonetci N, 2002, EXP TOXICOL PATHOL, V54, P197, DOI 10.1078/0940-2993-00248
   Yotani K, 2014, J PHYSIOL ANTHROPOL, V33, DOI 10.1186/1880-6805-33-23
   Zaki SM, 2013, FOLIA MORPHOL, V72, P333, DOI 10.5603/FM.2013.0056
NR 73
TC 2
Z9 3
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUL 9
PY 2015
VL 10
IS 7
AR e0131776
DI 10.1371/journal.pone.0131776
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CN1EW
UT WOS:000358161200038
PM 26158620
OA DOAJ Gold, Green Published
DA 2019-06-18
ER

PT J
AU Ikeda, J
   Ichiki, T
   Takahara, Y
   Kojima, H
   Sankoda, C
   Kitamoto, S
   Tokunou, T
   Sunagawa, K
AF Ikeda, Jiro
   Ichiki, Toshihiro
   Takahara, Yusuke
   Kojima, Hiroshi
   Sankoda, Chikahiro
   Kitamoto, Shiro
   Tokunou, Tomotake
   Sunagawa, Kenji
TI PPAR gamma Agonists Attenuate Palmitate-Induced ER Stress through
   Up-Regulation of SCD-1 in Macrophages
SO PLOS ONE
LA English
DT Article
ID ENDOPLASMIC-RETICULUM STRESS; STEAROYL-COA DESATURASE; UNFOLDED PROTEIN
   RESPONSE; ACTIVATED RECEPTOR-GAMMA; BETA-CELLS; ATHEROSCLEROSIS; MICE;
   APOPTOSIS; EXPRESSION; PIOGLITAZONE
AB Background
   Clinical trials have shown that treatment of patients with type 2 diabetes with pioglitazone, a peroxisome proliferator-activated receptor (PPAR). agonist, reduces cardiovascular events. However, the effect of PPAR. agonists on endoplasmic reticulum (ER) stress that plays an important role in the progression of atherosclerosis has not been determined. We sought to determine the effect of PPAR. agonists on ER stress induced by palmitate, the most abundant saturated fatty acid in the serum.
   Methods and Results
   Protein expression of ER stress marker was evaluated by Western blot analysis and stearoyl- CoA desaturase1 (SCD-1) mRNA expression was evaluated by qRT-PCR. Macrophage apoptosis was detected by flowcytometry. Pioglitazone and rosiglitazone reduced palmitate- induced phosphorylation of PERK, a marker of ER stress, in RAW264.7, a murine macrophage cell line. Pioglitazone also suppressed palmitate-induced apoptosis in association with inhibition of CHOP expression, JNK phosphorylation and cleavage of caspase-3. These effects of pioglitazone were reversed by GW9662, a PPAR. antagonist, indicating that PPAR. is involved in this process. PPAR. agonists increased expression of SCD-1 that introduces a double bond on the acyl chain of long-chain fatty acid. 4-(2-Chlorophenoxy)- N-(3-(3-methylcarbamoyl)phenyl)piperidine-1-carboxamide, an inhibitor of SCD-1, abolished the anti-ER stress and anti-apoptotic effects of pioglitazone. These results suggest that PPAR. agonists attenuate palmitate-induced ER stress and apoptosis through SCD-1 induction. Up-regulation of SCD-1 may contribute to the reduction of cardiovascular events by treatment with PPAR gamma agonists.
C1 [Ikeda, Jiro; Ichiki, Toshihiro; Takahara, Yusuke; Kojima, Hiroshi; Sankoda, Chikahiro; Kitamoto, Shiro; Tokunou, Tomotake; Sunagawa, Kenji] Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Fukuoka 812, Japan.
   [Ichiki, Toshihiro; Kitamoto, Shiro] Kyushu Univ, Grad Sch Med Sci, Dept Adv Therapeut Cardiovasc Dis, Fukuoka 812, Japan.
RP Ichiki, T (reprint author), Kyushu Univ, Grad Sch Med Sci, Dept Cardiovasc Med, Fukuoka 812, Japan.
EM ichiki@cardiol.med.kyushu-u.ac.jp
FU Scientific Research for Ministry of Education, Culture, Sports and
   Technology of Japan [23659421]
FX This study is supported by a grant-in-aid for Scientific Research for
   Ministry of Education, Culture, Sports and Technology of Japan (23659421
   to T.I.). The funder had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Baranova I, 2002, INFECT IMMUN, V70, P2995, DOI 10.1128/IAI.70.6.2995-3003.2002
   Brown JM, 2008, CIRCULATION, V118, P1467, DOI 10.1161/CIRCULATIONAHA.108.793182
   Chawla A, 2001, MOL CELL, V7, P161, DOI 10.1016/S1097-2765(01)00164-2
   Erbay E, 2009, NAT MED, V15, P1383, DOI 10.1038/nm.2067
   Evans-Molina C, 2009, MOL CELL BIOL, V29, P2053, DOI 10.1128/MCB.01179-08
   Guo W, 2007, AM J PHYSIOL-ENDOC M, V293, pE576, DOI 10.1152/ajpendo.00523.2006
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Karaskov E, 2006, ENDOCRINOLOGY, V147, P3398, DOI 10.1210/en.2005-1494
   Koeberle A, 2012, J BIOL CHEM, V287, P27244, DOI 10.1074/jbc.M111.274829
   Kurebayashi S, 1997, DIABETES, V46, P2115, DOI 10.2337/diabetes.46.12.2115
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liu J, 2005, ARTERIOSCL THROM VAS, V25, P174, DOI 10.1161/01.ATV.0000148548.47755.22
   MacDonald MLE, 2009, ARTERIOSCL THROM VAS, V29, P341, DOI 10.1161/ATVBAHA.108.181099
   Mozaffarian D, 2010, PLOS MED, V7, DOI 10.1371/journal.pmed.1000252
   Myoishi M, 2007, CIRCULATION, V116, P1226, DOI 10.1161/CIRCULATIONAHA.106.682054
   Nakayama T, 2010, INT J CARDIOL, V138, P157, DOI 10.1016/j.ijcard.2008.08.031
   Park Y, 2012, INFLAMM RES, V61, P465, DOI 10.1007/s00011-011-0433-3
   Peter A, 2008, AM J PHYSIOL-ENDOC M, V295, pE339, DOI 10.1152/ajpendo.00022.2008
   Quan JX, 2014, J DIABETES, V6, P33, DOI 10.1111/1753-0407.12073
   RALPH P, 1977, J IMMUNOL, V119, P950
   Riserus U, 2005, DIABETES, V54, P1379, DOI 10.2337/diabetes.54.5.1379
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Tabas I, 2005, ARTERIOSCL THROM VAS, V25, P2255, DOI 10.1161/01.ATV.0000184783.04864.9f
   Tabas I, 2010, CIRC RES, V107, P839, DOI 10.1161/CIRCRESAHA.110.224766
   Thorn K, 2010, LIPIDS HEALTH DIS, V9, DOI 10.1186/1476-511X-9-108
   Thorp E, 2009, CELL METAB, V9, P474, DOI 10.1016/j.cmet.2009.03.003
   Toyama T, 2007, J PHARMACOL SCI, V104, P137, DOI 10.1254/jphs.FP0060997
   Weber SM, 2004, AM J PHYSIOL-ENDOC M, V287, pE1171, DOI 10.1152/ajpendo.00331.2004
   Yoshiuchi K, 2009, ENDOCR J, V56, P1103, DOI 10.1507/endocrj.K09E-140
   Zang CB, 2009, MOL CANCER THER, V8, P2296, DOI 10.1158/1535-7163.MCT-09-0347
   Zhang L, 2001, BIOCHEM J, V357, P183, DOI 10.1042/0264-6021:3570183
   Zhang YH, 2006, AM J PHYSIOL-RENAL, V290, pF1065, DOI 10.1152/ajprenal.00131.2005
   Zhou J, 2005, CIRCULATION, V111, P1814, DOI 10.1161/01.CIR.0000160864.31351.C1
NR 33
TC 15
Z9 16
U1 0
U2 7
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 10
PY 2015
VL 10
IS 6
AR e0128546
DI 10.1371/journal.pone.0128546
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK1PO
UT WOS:000355979500087
PM 26061913
OA DOAJ Gold, Green Published
DA 2019-06-18
ER

PT J
AU Lillis, AP
   Muratoglu, SC
   Au, DT
   Migliorini, M
   Lee, MJ
   Fried, SK
   Mikhailenko, I
   Strickland, DK
AF Lillis, Anna P.
   Muratoglu, Selen Catania
   Au, Dianaly T.
   Migliorini, Mary
   Lee, Mi-Jeong
   Fried, Susan K.
   Mikhailenko, Irina
   Strickland, Dudley K.
TI LDL Receptor-Related Protein-1 (LRP1) Regulates Cholesterol Accumulation
   in Macrophages
SO PLOS ONE
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; SMOOTH-MUSCLE-CELLS; ATHEROSCLEROTIC LESION
   DEVELOPMENT; CARBOXYL-TERMINAL DOMAIN; ALPHA-2-MACROGLOBULIN RECEPTOR;
   APOLIPOPROTEIN-E; MEDIATES UPTAKE; AGGREGATED LDL; KNOCKOUT MICE;
   BONE-MARROW
AB Within the circulation, cholesterol is transported by lipoprotein particles and is taken up by cells when these particles associate with cellular receptors. In macrophages, excessive lipoprotein particle uptake leads to foam cell formation, which is an early event in the development of atherosclerosis. Currently, mechanisms responsible for foam cell formation are incompletely understood. To date, several macrophage receptors have been identified that contribute to the uptake of modified forms of lipoproteins leading to foam cell formation, but the contribution of the LDL receptor-related protein 1 (LRP1) to this process is not known. To investigate the role of LRP1 in cholesterol accumulation in macrophages, we generated mice with a selective deletion of LRP1 in macrophages on an LDL receptor (LDLR)-deficient background (macLRP1-/-). After feeding mice a high fat diet for 11 weeks, peritoneal macrophages isolated from Lrp(+/+) mice contained significantly higher levels of total cholesterol than those from macLRP1-/- mice. Further analysis revealed that this was due to increased levels of cholesterol esters. Interestingly, macLRP1-/- mice displayed elevated plasma cholesterol and triglyceride levels resulting from accumulation of large, triglyceride-rich lipoprotein particles in the circulation. This increase did not result from an increase in hepatic VLDL biosynthesis, but rather results from a defect in catabolism of triglyceride-rich lipoprotein particles in macLRP1-/- mice. These studies reveal an important in vivo contribution of macrophage LRP1 to cholesterol homeostasis.
C1 [Lillis, Anna P.; Muratoglu, Selen Catania; Au, Dianaly T.; Migliorini, Mary; Mikhailenko, Irina; Strickland, Dudley K.] Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA.
   [Muratoglu, Selen Catania; Mikhailenko, Irina; Strickland, Dudley K.] Univ Maryland, Sch Med, Dept Physiol, Baltimore, MD 21201 USA.
   [Migliorini, Mary; Strickland, Dudley K.] Univ Maryland, Sch Med, Dept Surg, Baltimore, MD 21201 USA.
   [Lee, Mi-Jeong; Fried, Susan K.] Boston Univ, Sch Med, Dept Med, Sect Endocrinol Diabet & Nutr, Boston, MA 02118 USA.
   [Lillis, Anna P.] Duke Univ, Med Ctr, Dept Pathol, Durham, NC 27710 USA.
RP Strickland, DK (reprint author), Univ Maryland, Sch Med, Ctr Vasc & Inflammatory Dis, Baltimore, MD 21201 USA.
EM dstrickland@som.umaryland.edu
OI Muratoglu, Selen/0000-0002-1804-4875; Au, Dianaly/0000-0002-8797-833X;
   Lee, Mi-Jeong/0000-0002-8171-7913
FU National Heart, Lung, and Blood Institute, of the National Institutes of
   Health [R01 HL114379, R01 HL120388, T32 HL007698]; National Institute of
   Diabetes and Disgestive and Kidney Disease of the National Institutes of
   Health [P30 DK072488]
FX This research was funded by research grants R01 HL114379 (DKS), R01
   HL120388 (DKS), T32 HL007698 (DKS), from the National Heart, Lung, and
   Blood Institute, of the National Institutes of Health, and P30 DK072488
   (SKF) from the National Institute of Diabetes and Disgestive and Kidney
   Disease of the National Institutes of Health.
CR alto-Setala K, 1996, J LIPID RES, V37, P1802
   alto- Setala K, 1992, J CLIN INVEST, V90, P1889
   ASHCOM JD, 1990, J CELL BIOL, V110, P1041, DOI 10.1083/jcb.110.4.1041
   BEISIEGEL U, 1989, NATURE, V341, P162, DOI 10.1038/341162a0
   Boucher P, 2003, SCIENCE, V300, P329, DOI 10.1126/science.1082095
   BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311
   BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107
   BROWN MS, 1983, ANNU REV BIOCHEM, V52, P223, DOI 10.1146/annurev.bi.52.070183.001255
   Cao CZ, 2006, EMBO J, V25, P1860, DOI 10.1038/sj.emboj.7601082
   CHAPPELL DA, 1993, J BIOL CHEM, V268, P14168
   CHAPPELL DA, 1994, J BIOL CHEM, V269, P18001
   Clausen BE, 1999, TRANSGENIC RES, V8, P265, DOI 10.1023/A:1008942828960
   Devlin CM, 2008, ARTERIOSCL THROM VAS, V28, P1723, DOI 10.1161/ATVBAHA.108.173344
   ENDEMANN G, 1993, J BIOL CHEM, V268, P11811
   Febbraio M, 2000, J CLIN INVEST, V105, P1049, DOI 10.1172/JCI9259
   FELDMAN SR, 1985, BIOCHEM BIOPH RES CO, V128, P795, DOI 10.1016/0006-291X(85)90117-2
   GOLDSTEIN JL, 1979, P NATL ACAD SCI USA, V76, P333, DOI 10.1073/pnas.76.1.333
   HERZ J, 1988, EMBO J, V7, P4119, DOI 10.1002/j.1460-2075.1988.tb03306.x
   Hu L, 2006, ARTERIOSCL THROM VAS, V26, P2710, DOI 10.1161/01.ATV.0000249641.96896.e6
   HUSSAIN MM, 1989, J BIOL CHEM, V264, P9571
   HUSSAIN MM, 1989, J BIOL CHEM, V264, P17931
   ISHIBASHI S, 1993, J CLIN INVEST, V92, P883, DOI 10.1172/JCI116663
   Kanda T, 2009, J CLIN INVEST, V119, P110, DOI 10.1172/JCI36233
   Kennedy DW, 1997, BLOOD, V90, P986
   KODAMA T, 1990, NATURE, V343, P531, DOI 10.1038/343531a0
   KOWAL RC, 1989, P NATL ACAD SCI USA, V86, P5810, DOI 10.1073/pnas.86.15.5810
   KOWAL RC, 1990, J BIOL CHEM, V265, P10771
   Kruth HS, 2005, J BIOL CHEM, V280, P2352, DOI 10.1074/jbc.M407167200
   Kruth HS, 2002, CURR OPIN LIPIDOL, V13, P483, DOI 10.1097/00041433-200210000-00003
   Kunjathoor VV, 2002, J BIOL CHEM, V277, P49982, DOI 10.1074/jbc.M209649200
   Leroux A, 2012, J HEPATOL, V57, P141, DOI 10.1016/j.jhep.2012.02.028
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lillis AP, 2008, J IMMUNOL, V181, P364, DOI 10.4049/jimmunol.181.1.364
   Linton MF, 1998, J CLIN INVEST, V101, P1726, DOI 10.1172/JCI2181
   Llorente-Cortes V, 2007, J LIPID RES, V48, P2133, DOI 10.1194/jlr.M700039-JLR200
   Llorente-Cortes V, 2006, ARTERIOSCL THROM VAS, V26, P117, DOI 10.1161/01.ATV.0000193618.32611.8b
   Llorente-Cortes V, 2000, ARTERIOSCL THROM VAS, V20, P1572, DOI 10.1161/01.ATV.20.6.1572
   Loukinova E, 2002, J BIOL CHEM, V277, P15499, DOI 10.1074/jbc.M200427200
   Low H, 2012, JOVE-J VIS EXP, DOI 10.3791/3810
   Mahley RW, 2007, J CLIN INVEST, V117, P94, DOI 10.1172/JCI30889
   Manning-Tobin JJ, 2009, ARTERIOSCL THROM VAS, V29, P19, DOI 10.1161/ATVBAHA.108.176644
   Mehta JL, 2007, CIRC RES, V100, P1634, DOI 10.1161/CIRCRESAHA.107.149724
   Migliorini MM, 2003, J BIOL CHEM, V278, P17986, DOI 10.1074/jbc.M212592200
   Millar JS, 2005, J LIPID RES, V46, P2023, DOI 10.1194/jlr.D500019-JLR200
   MOESTRUP SK, 1989, J BIOL CHEM, V264, P15574
   Moore KJ, 2005, J CLIN INVEST, V115, P2192, DOI 10.1172/JCI24061
   Muratoglu SC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0028846
   Muratoglu SC, 2010, J BIOL CHEM, V285, P14308, DOI 10.1074/jbc.M109.046672
   Musso G, 2013, PROG LIPID RES, V52, P175, DOI 10.1016/j.plipres.2012.11.002
   Newton CS, 2005, J BIOL CHEM, V280, P27872, DOI 10.1074/jbc.M505410200
   NILSSONEHLE P, 1976, J LIPID RES, V17, P536
   OTTNAD E, 1995, P NATL ACAD SCI USA, V92, P1391, DOI 10.1073/pnas.92.5.1391
   Overton CD, 2007, CIRC RES, V100, P670, DOI 10.1161/01.RES.0000260204.40510.aa
   Rohlmann A, 1998, J CLIN INVEST, V101, P689, DOI 10.1172/JCI1240
   Santamarina-Fojo S, 2001, J LIPID RES, V42, P1339
   Sawamura T, 1997, NATURE, V386, P73, DOI 10.1038/386073a0
   Schissel SL, 1998, J BIOL CHEM, V273, P2738, DOI 10.1074/jbc.273.5.2738
   SCHUMAKER VN, 1986, METHOD ENZYMOL, V128, P155
   Stanford KI, 2009, J CLIN INVEST, V119, P3236, DOI 10.1172/JCI38251
   STRICKLAND DK, 1990, J BIOL CHEM, V265, P17401
   Suzuki H, 1997, NATURE, V386, P292, DOI 10.1038/386292a0
   TABAS I, 1993, J BIOL CHEM, V268, P20419
   Terrand J, 2009, J BIOL CHEM, V284, P381, DOI 10.1074/jbc.M806538200
   TRABER MG, 1980, P NATL ACAD SCI-BIOL, V77, P5466, DOI 10.1073/pnas.77.9.5466
   Van EM, 2000, ARTERIOSCLER THROMB, V20, pE53
   Williams KJ, 2008, J CLIN INVEST, V118, P3247, DOI 10.1172/JCI35206
   WILLIAMS KJ, 1995, ARTERIOSCL THROM VAS, V15, P551, DOI 10.1161/01.ATV.15.5.551
   WILLIAMS SE, 1994, J BIOL CHEM, V269, P8653
   Yancey PG, 2011, CIRCULATION, V124, P454, DOI 10.1161/CIRCULATIONAHA.111.032268
   Yancey PG, 2010, ARTERIOSCL THROM VAS, V30, P787, DOI 10.1161/ATVBAHA.109.202051
   Zhou L, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006853
   Zurhove K, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.1164263
NR 72
TC 18
Z9 18
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 10
PY 2015
VL 10
IS 6
AR e0128903
DI 10.1371/journal.pone.0128903
PG 20
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CK1PO
UT WOS:000355979500107
PM 26061292
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Dmitrieva, NI
   Burg, MB
AF Dmitrieva, Natalia I.
   Burg, Maurice B.
TI Elevated Sodium and Dehydration Stimulate Inflammatory Signaling in
   Endothelial Cells and Promote Atherosclerosis
SO PLOS ONE
LA English
DT Article
ID CORONARY-HEART-DISEASE; PLASMA SODIUM; CARDIOVASCULAR-DISEASE; VASCULAR
   ENDOTHELIUM; MULTIVARIABLE ANALYSIS; LEUKOCYTE RECRUITMENT;
   BLOOD-PRESSURE; SHEAR-STRESS; SALT INTAKE; RISK-FACTOR
AB Cardiovascular diseases (CVDs) are a leading health problem worldwide. Epidemiologic studies link high salt intake and conditions predisposing to dehydration such as low water intake, diabetes and old age to increased risk of CVD. Previously, we demonstrated that elevation of extracellular sodium, which is a common consequence of these conditions, stimulates production by endothelial cells of clotting initiator, von Willebrand Factor, increases its level in blood and promotes thrombogenesis. In present study, by PCR array, using human umbilical vein endothelial cells (HUVECs), we analyzed the effect of high NaCl on 84 genes related to endothelial cell biology. The analysis showed that the affected genes regulate many aspects of endothelial cell biology including cell adhesion, proliferation, leukocyte and lymphocyte activation, coagulation, angiogenesis and inflammatory response. The genes whose expression increased the most were adhesion molecules VCAM1 and E-selectin and the chemoattractant MCP-1. These are key participants in the leukocyte adhesion and transmigration that play a major role in the inflammation and pathophysiology of CVD, including atherosclerosis. Indeed, high NaCl increased adhesion of mononuclear cells and their transmigration through HUVECs monolayers. In mice, mild water restriction that elevates serum sodium by 5 mmol/l, increased VCAM1, E-selectin and MCP-1 expression in mouse tissues, accelerated atherosclerotic plaque formation in aortic root and caused thickening or walls of coronary arteries. Multivariable linear regression analysis of clinical data from the Atherosclerosis Risk in Communities Study (n = 12779) demonstrated that serum sodium is a significant predictor of 10 Years Risk of coronary heart disease. These findings indicate that elevation of extracellular sodium within the physiological range is accompanied by vascular changes that facilitate development of CVD. The findings bring attention to serum sodium as a risk factor for CVDs and give additional support to recommendations for dietary salt restriction and adequate water intake as preventives of CVD.
C1 [Dmitrieva, Natalia I.; Burg, Maurice B.] NHLBI, NIH, Bethesda, MD 20892 USA.
RP Dmitrieva, NI (reprint author), NHLBI, NIH, Bldg 10, Bethesda, MD 20892 USA.
EM dmitrien@nhlbi.nih.gov
RI Dmitrieva, Natalia/Q-9175-2019; Dmitrieva, Natalia/A-2924-2013
OI Dmitrieva, Natalia/0000-0001-8074-6950; Dmitrieva,
   Natalia/0000-0001-8074-6950
FU Intramural Program of National Lung Heart and Blood Institute
FX The study was supported by the Intramural Program of National Lung Heart
   and Blood Institute.
CR Adrogue HJ, 2000, NEW ENGL J MED, V342, P1493, DOI 10.1056/NEJM200005183422006
   [Anonymous], 2005, STANDING COMMITTEE O, P558
   Blankenberg S, 2003, ATHEROSCLEROSIS, V170, P191, DOI 10.1016/S0021-9150(03)00097-2
   Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788
   Chambless LE, 2003, J CLIN EPIDEMIOL, V56, P880, DOI 10.1016/S0895-4356(03)00055-6
   Chan J, 2002, AM J EPIDEMIOL, V155, P827, DOI 10.1093/aje/155.9.827
   Chien S, 2003, PROG BIOPHYS MOL BIO, V83, P131, DOI [10.1016/S0079-6107(03)00053-1, 10.1016/s0079-6107(03)00053-1]
   Chiu JJ, 2011, PHYSIOL REV, V91, P327, DOI 10.1152/physrev.00047.2009
   Cowen LE, 2013, ENDOCRIN METAB CLIN, V42, P349, DOI 10.1016/j.ecl.2013.02.005
   Croce K, 2007, CURR OPIN HEMATOL, V14, P55, DOI 10.1097/00062752-200701000-00011
   Cunningham KS, 2005, LAB INVEST, V85, P9, DOI 10.1038/labinvest.3700215
   DAHL LK, 1958, NEW ENGL J MED, V258, P1205, DOI 10.1056/NEJM195806122582406
   Daugherty Alan, 2003, Methods Mol Biol, V209, P293
   Deshmane SL, 2009, J INTERF CYTOK RES, V29, P313, DOI 10.1089/jir.2008.0027
   Dmitrieva NI, 2014, P NATL ACAD SCI USA, V111, P6485, DOI 10.1073/pnas.1404809111
   Dmitrieva NI, 2007, CELL CYCLE, V6
   Folsom AR, 2003, DIABETES CARE, V26, P2777, DOI 10.2337/diacare.26.10.2777
   Fox CS, 2010, TRENDS CARDIOVAS MED, V20, P90, DOI 10.1016/j.tcm.2010.08.001
   Go AS, 2013, CIRCULATION, V127, P143, DOI 10.1161/CIR.0b013e318282ab8f
   Go WY, 2004, P NATL ACAD SCI USA, V101, P10673, DOI 10.1073/pnas.0403139101
   He FJ, 2012, ANN MED, V44, pS127, DOI 10.3109/07853890.2012.660495
   He FJ, 2005, HYPERTENSION, V45, P98, DOI 10.1161/01.HYP.0000149431.79450.a2
   Hickey MJ, 2013, IMMUNOL CELL BIOL, V91, P281, DOI 10.1038/icb.2012.83
   Huang DW, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-9-r183
   Hui X, 2013, AM J KIDNEY DIS, V62, P691, DOI 10.1053/j.ajkd.2013.04.010
   Katz M. H., 2011, MULTIVARIABLE ANAL P
   Katz MH, 2003, ANN INTERN MED, V138, P644, DOI 10.7326/0003-4819-138-8-200304150-00012
   Komiya I, 1997, J HYPERTENS, V15, P65, DOI 10.1097/00004872-199715010-00006
   Kovesdy CP, 2012, NEPHROL DIAL TRANSPL, V27, P891, DOI 10.1093/ndt/gfs038
   Krychtiuk KA, 2013, HAMOSTASEOLOGIE, V33, P269, DOI 10.5482/HAMO-13-07-0039
   Lakatta EG, 2003, CIRCULATION, V107, P139, DOI 10.1161/01.CIR.0000048892.83521.58
   Ley K, 2007, NAT REV IMMUNOL, V7, P678, DOI 10.1038/nri2156
   Libby P, 2002, NATURE, V420, P868, DOI 10.1038/nature01323
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lim Gregory B, 2013, Nat Rev Cardiol, V10, P59, DOI 10.1038/nrcardio.2012.194
   Liu LX, 2003, THROMB HAEMOSTASIS, V89, P213
   Machnik A, 2009, NAT MED, V15, P545, DOI 10.1038/nm.1960
   Maganto-Garcia E, 2012, Curr Protoc Immunol, VChapter 15, DOI 10.1002/0471142735.im1524s96
   Maletkovic J, 2013, ENDOCRIN METAB CLIN, V42, P677, DOI 10.1016/j.ecl.2013.07.001
   Manz F, 2005, NUTR REV, V63, pS2, DOI 10.1301/nr.2005.jun.S2-S5
   Michiels C, 2003, J CELL PHYSIOL, V196, P430, DOI 10.1002/jcp.10333
   Muller WA, ANGIOGENESIS IN VITR, P155
   Nieswandt B, 2011, J PHYSIOL-LONDON, V589, P4115, DOI 10.1113/jphysiol.2011.212886
   North BJ, 2012, CIRC RES, V110, P1097, DOI 10.1161/CIRCRESAHA.111.246876
   O'Leary DH, 1999, NEW ENGL J MED, V340, P14, DOI 10.1056/NEJM199901073400103
   Oberleithner H, 2007, P NATL ACAD SCI USA, V104, P16281, DOI 10.1073/pnas.0707791104
   Oberleithner H, 2012, ANN MED, V44, pS143, DOI 10.3109/07853890.2011.653397
   Oberleithner H, 2011, PFLUG ARCH EUR J PHY, V462, P519, DOI 10.1007/s00424-011-0999-1
   Oh SW, 2013, J KOREAN MED SCI, V28, P1034, DOI 10.3346/jkms.2013.28.7.1034
   Osada J, 2000, CURR OPIN LIPIDOL, V11, P25, DOI 10.1097/00041433-200002000-00004
   Pham NA, 2007, DIAGN PATHOL, V2, DOI 10.1186/1746-1596-2-8
   Pober JS, 2007, NAT REV IMMUNOL, V7, P803, DOI 10.1038/nri2171
   Ramcharan KS, 2011, THROMB RES, V128, P1, DOI 10.1016/j.thromres.2010.11.019
   Reitsma S, 2007, PFLUG ARCH EUR J PHY, V454, P345, DOI 10.1007/s00424-007-0212-8
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Royston P, 2008, MULTIVARIABLE MODEL, P23
   SAGNELLA GA, 1989, AM J PHYSIOL, V256, pR1171
   Schindelin J, 2012, NAT METHODS, V9, P676, DOI [10.1038/NMETH.2019, 10.1038/nmeth.2019]
   Schnermann JB, 1998, REGULATION OF EXTRAC, P79
   SENAY LC, 1965, J APPL PHYSIOL, V20, P1136
   Suckling RJ, 2012, KIDNEY INT, V81, P407, DOI 10.1038/ki.2011.369
   Titze J, 2003, AM J PHYSIOL-RENAL, V285, pF1108, DOI 10.1152/ajprenal.00200.2003
   Titze J, 2014, CAN J CARDIOL, V30, P473, DOI 10.1016/j.cjca.2014.02.006
   Wakkee M, 2014, J INVEST DERMATOL, V134, DOI 10.1038/jid.2014.132
   White AD, 1996, J CLIN EPIDEMIOL, V49, P223, DOI 10.1016/0895-4356(95)00041-0
   Wild J, 2014, THROMB HAEMOSTASIS, V112, P183, DOI 10.1160/TH13-11-0908
   WILLIAMS OD, 1989, AM J EPIDEMIOL, V129, P687
   Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837
   Zhang Z, 2014, AM J PHYSIOL-RENAL, V306, pF1534, DOI 10.1152/ajprenal.00585.2013
NR 69
TC 16
Z9 17
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 4
PY 2015
VL 10
IS 6
AR UNSP e0128870
DI 10.1371/journal.pone.0128870
PG 22
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ7TC
UT WOS:000355701600069
PM 26042828
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Qiu, MK
   Wang, SC
   Dai, YX
   Wang, SQ
   Ou, JM
   Quan, ZW
AF Qiu, Ming-Ke
   Wang, Song-Cun
   Dai, Yu-Xin
   Wang, Shu-Qing
   Ou, Jing-Min
   Quan, Zhi-Wei
TI PD-1 and Tim-3 Pathways Regulate CD8(+) T Cells Function in
   Atherosclerosis
SO PLOS ONE
LA English
DT Article
ID E-DEFICIENT MICE; IMMUNE-RESPONSE; LYMPHOCYTES; EXPRESSION; EXHAUSTION;
   INFECTION; CD4(+); DIFFERENTIATION; IMMUNOGLOBULIN; RECEPTOR
AB T cell-mediated immunity plays a significant role in the development of atherosclerosis (AS). There is increasing evidence that CD8(+) T cells are also involved in AS but their exact roles remain unclear. The inhibitory receptors programmed cell death-1 (PD-1) and T cell immunoglobulin and mucin domain 3 (Tim-3) are well known inhibitory molecules that play a crucial role in regulating CD8(+) T cell activation or tolerance. Here, we demonstrate that the co-expression of PD-1 and Tim-3 on CD8(+) T cells is up-regulated in AS patients. PD-1(+) Tim-3(+) CD8(+) T cells are enriched for within the central T (T-CM) cell subset, with high proliferative activity and CD127 expression. Co-expression of PD-1 and Tim-3 on CD8(+) T cells is associated with increased anti-atherogenic cytokine production as well as decreased proatherogenic cytokine production. Blockade of PD-1 and Tim-3 results in a decrease of anti-atherogenic cytokine production by PD-1(+) Tim-3(+) CD8(+) T cells and in an augmentation of TNF-alpha and IFN-gamma production. These findings highlight the important role of the PD-1 and Tim-3 pathways in regulating CD8(+) T cells function in human AS.
C1 [Qiu, Ming-Ke; Dai, Yu-Xin; Wang, Shu-Qing; Ou, Jing-Min; Quan, Zhi-Wei] Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Gen Surg, Shanghai 200030, Peoples R China.
   [Wang, Song-Cun] Fudan Univ, Shanghai Med Coll, Hosp & Inst Obstet & Gynecol, Lab Reprod Immunol, Shanghai 200433, Peoples R China.
RP Ou, JM (reprint author), Shanghai Jiao Tong Univ, Sch Med, Xinhua Hosp, Dept Gen Surg, Shanghai 200030, Peoples R China.
EM jingminoy@163.com; zhiwqu@163.com
FU National Natural Science Foundation of China [81272747]; Science and
   Technology Commission foundation of Shanghai, China [13140903802];
   Medicine and Engineering Cross foundation of Shanghai Jiaotong
   University [YG2012MS33]
FX This work was supported by National Natural Science Foundation of China
   (grant no. 81272747), the Science and Technology Commission foundation
   of Shanghai, China (no. 13140903802), and the Medicine and Engineering
   Cross foundation of Shanghai Jiaotong University (no. YG2012MS33). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Andersson J, 2010, CLIN IMMUNOL, V134, P33, DOI 10.1016/j.clim.2009.07.002
   Barber DL, 2006, NATURE, V439, P682, DOI 10.1038/nature04444
   Bu DX, 2011, ARTERIOSCL THROM VAS, V31, P1100, DOI 10.1161/ATVBAHA.111.224709
   Dimayuga PC, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000155
   Dimayuga PC, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0020214
   Elhage R, 2004, AM J PATHOL, V165, P2013, DOI 10.1016/S0002-9440(10)63252-X
   Foks AC, 2013, ARTERIOSCL THROM VAS, V33, P2558, DOI 10.1161/ATVBAHA.113.301879
   Fourcade J, 2014, CANCER RES, V74, P1045, DOI 10.1158/0008-5472.CAN-13-2908
   FYFE AI, 1994, J CLIN INVEST, V94, P2516, DOI 10.1172/JCI117622
   GERDES J, 1984, J IMMUNOL, V133, P1710
   Gewaltig J, 2008, HUM PATHOL, V39, P1756, DOI 10.1016/j.humpath.2008.04.018
   Golden-Mason L, 2009, J VIROL, V83, P9122, DOI 10.1128/JVI.00639-09
   Gotsman I, 2007, J CLIN INVEST, V117, P2974, DOI 10.1172/JCI31344
   Grivel JC, 2011, ARTERIOSCL THROM VAS, V31, P2929, DOI 10.1161/ATVBAHA.111.237081
   Hou N, 2012, ATHEROSCLEROSIS, V222, P67, DOI 10.1016/j.atherosclerosis.2012.02.009
   Jones RB, 2008, J EXP MED, V205, P2763, DOI 10.1084/jem.20081398
   Kaech SM, 2003, NAT IMMUNOL, V4, P1191, DOI 10.1038/ni1009
   KLEINDIENST R, 1993, AM J PATHOL, V142, P1927
   Kolbus D, 2013, J INTERN MED, V274, P41, DOI 10.1111/joim.12038
   Kolbus D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033932
   Kyaw T, 2013, CIRCULATION, V127, P1028, DOI 10.1161/CIRCULATIONAHA.112.001347
   Lanzavecchia A, 2002, NAT REV IMMUNOL, V2, P982, DOI 10.1038/nri959
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Oh SJ, 2011, J IMMUNOL, V186, P6815, DOI 10.4049/jimmunol.1003916
   Packard RRS, 2009, SEMIN IMMUNOPATHOL, V31, P5, DOI 10.1007/s00281-009-0153-8
   Sakuishi K, 2010, J EXP MED, V207, P2187, DOI 10.1084/jem.20100643
   Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385
   Sharpe AH, 2002, NAT REV IMMUNOL, V2, P116, DOI 10.1038/nri727
   Tedgui A, 2006, PHYSIOL REV, V86, P515, DOI 10.1152/physrev.00024.2005
   Trautmann L, 2006, NAT MED, V12, P1198, DOI 10.1038/nm1482
   Tse K, 2013, INT IMMUNOL, V25, P615, DOI 10.1093/intimm/dxt043
   Wherry EJ, 2011, NAT IMMUNOL, V12, P492, DOI 10.1038/ni.2035
   Yang ZZ, 2014, LEUKEMIA, V28, P1872, DOI 10.1038/leu.2014.84
   Zarling S, 2013, J IMMUNOL, V190, P5128, DOI 10.4049/jimmunol.1203396
   Zhou JC, 2014, BIOCHEM BIOPH RES CO, V443, P864, DOI 10.1016/j.bbrc.2013.12.057
   Zhou Q, 2011, BLOOD, V117, P4501, DOI 10.1182/blood-2010-10-310425
   Zhou XH, 1996, AM J PATHOL, V149, P359
   Zhu JF, 2010, ANNU REV IMMUNOL, V28, P445, DOI 10.1146/annurev-immunol-030409-101212
NR 38
TC 18
Z9 21
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 2
PY 2015
VL 10
IS 6
AR UNSP e0128523
DI 10.1371/journal.pone.0128523
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ7SJ
UT WOS:000355699100036
PM 26035207
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Li, CL
   Wang, ZJ
   Wang, CX
   Ma, Q
   Zhao, YX
AF Li, Changlong
   Wang, Zhijian
   Wang, Chunxiao
   Ma, Qian
   Zhao, Yingxin
TI Perivascular Adipose Tissue-Derived Adiponectin Inhibits Collar-Induced
   Carotid Atherosclerosis by Promoting Macrophage Autophagy
SO PLOS ONE
LA English
DT Article
ID APOLIPOPROTEIN-E-DEFICIENT; OXIDATIVE STRESS; CANCER CELLS; PATHWAY;
   MICE; ATHEROGENESIS; ACTIVATION; MECHANISMS; DISEASE; PLAQUES
AB Objectives
   Adiponectin (APN) secreted from perivascular adipose tissue (PVAT) is one of the important anti-inflammatory adipokines to inhibit the development of atherosclerosis, but the underlying mechanism has not been clarified. In this study, we aimed to elucidate how APN regulates plaque formation in atherosclerosis.
   Methods and Results
   To assess the role of APN secreted by PVAT in atherosclerosis progression, we performed PVAT transplantation experiments on carotid artery atherosclerosis model: ApoE knockout (ApoE(-/-)) mice with a perivascular collar placement around the left carotid artery in combination with a high-fat diet feeding. Our results show that the ApoE(-/-) mice with PVAT derived from APN knockout (APN(-/-)) mice exhibited accelerated plaque volume formation compared to ApoE(-/-) mice transplanted with wild-type littermate tissue. Conversely, autophagy in macrophages was significantly attenuated in ApoE(-/-) mice transplanted with APN(-/-) mouse-derived PVAT compared to controls. Furthermore, in vitro studies indicate that APN treatment increased autophagy in primary macrophages, as evidenced by increased LC3-I processing and Beclin1 expression, which was accompanied by down-regulation of p62. Moreover, our results demonstrate that APN promotes macrophage autophagy via suppressing the Akt/FOXO3a signaling pathway.
   Conclusions
   Our results indicate that PVAT-secreted APN suppresses plaque formation by inducing macrophage autophagy.
C1 [Li, Changlong; Wang, Zhijian; Ma, Qian; Zhao, Yingxin] Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China.
   [Wang, Chunxiao; Zhao, Yingxin] Capital Med Univ, Anzhen Hosp, Dept Cardiol, Beijing, Peoples R China.
RP Zhao, YX (reprint author), Beijing Inst Heart Lung & Blood Vessel Dis, Beijing, Peoples R China.
EM zyingxinmi@126.com
FU National Natural Science Foundation of China [81170265]
FX The present study was supported by grants from a National Natural
   Science Foundation of China (Grant No. 81170265). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR Barb D, 2007, ENDOCR-RELAT CANCER, V14, P995, DOI 10.1677/ERC-06-0091
   Chen S, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.380
   De Meyer I, 2012, BASIC RES CARDIOL, V107, DOI 10.1007/s00395-012-0269-1
   Errafiy R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083318
   Essick EE, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068697
   Essick EE, 2011, AM J PHYSIOL-HEART C, V301, pH984, DOI 10.1152/ajpheart.00428.2011
   Farini D, 2007, DEV BIOL, V306, P572, DOI 10.1016/j.ydbio.2007.03.031
   Galkina E, 2009, ANNU REV IMMUNOL, V27, P165, DOI 10.1146/annurev.immunol.021908.132620
   Guo R, 2013, BBA-MOL BASIS DIS, V1832, P1136, DOI 10.1016/j.bbadis.2013.03.013
   Huypens PR, 2007, MED HYPOTHESES, V68, P1134, DOI 10.1016/j.mehy.2006.09.046
   Iacobellis G, 2008, CURR DIABETES REP, V8, P20, DOI 10.1007/s11892-008-0005-2
   Inoki K, 2002, NAT CELL BIOL, V4, P648, DOI 10.1038/ncb839
   Kawahito H, 2013, AM J PHYSIOL-HEART C, V305, pH667, DOI 10.1152/ajpheart.00053.2013
   Kroemer G, 2010, MOL CELL, V40, P280, DOI 10.1016/j.molcel.2010.09.023
   Levine B, 2009, CELL DEATH DIFFER, V16, P1, DOI 10.1038/cdd.2008.139
   Li BH, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.146
   Li L, 2010, CIRC J, V74, P552, DOI 10.1253/circj.CJ-09-0304
   Liao XH, 2012, CELL METAB, V15, P545, DOI 10.1016/j.cmet.2012.01.022
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Maiuri M. C., 2013, MEDIAT INFLAMM, V2013, DOI [10.1155/2013/584715, DOI 10.1155/2013/584715]
   Miao CY, 2012, BRIT J PHARMACOL, V165, P643, DOI 10.1111/j.1476-5381.2011.01404.x
   Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005
   Muller C, 2011, AUTOPHAGY, V7, P541, DOI 10.4161/auto.7.5.15003
   Nawrocki AR, 2010, ARTERIOSCL THROM VAS, V30, P1159, DOI 10.1161/ATVBAHA.109.195826
   Ni HM, 2013, AM J PATHOL, V183, P1815, DOI 10.1016/j.ajpath.2013.08.011
   Ohman MK, 2011, ATHEROSCLEROSIS, V219, P33, DOI 10.1016/j.atherosclerosis.2011.07.012
   Okamoto Y, 2002, CIRCULATION, V106, P2767, DOI 10.1161/01.CIR.0000042707.50032.19
   Okamoto Y, 2006, CLIN SCI, V110, P267, DOI 10.1042/CS20050182
   Okamoto Y, 2008, CIRC RES, V102, P218, DOI 10.1161/CIRCRESAHA.107.164988
   Ouwens DM, 2010, J CELL MOL MED, V14, P2223, DOI 10.1111/j.1582-4934.2010.01141.x
   Peng N, 2014, SCI REP-UK, V4, DOI 10.1038/srep05519
   Razani B, 2012, CELL METAB, V15, P534, DOI 10.1016/j.cmet.2012.02.011
   Sarbassov DD, 2005, CURR OPIN CELL BIOL, V17, P596, DOI 10.1016/j.ceb.2005.09.009
   Scherz-Shouval R, 2011, TRENDS BIOCHEM SCI, V36, P30, DOI 10.1016/j.tibs.2010.07.007
   Shi GD, 2011, BIOCHEM BIOPH RES CO, V404, P941, DOI 10.1016/j.bbrc.2010.12.085
   Shibata R, 2005, NAT MED, V11, P1096, DOI 10.1038/nm1295
   Sobiesiak M, 2009, J IMMUNOL, V183, P4395, DOI 10.4049/jimmunol.0803017
   Strozyk E, 2013, INT J MOL SCI, V14, P15260, DOI 10.3390/ijms140815260
   Tian Z, 2013, J MOL CELL CARDIOL, V57, P1, DOI 10.1016/j.yjmcc.2013.01.004
   Tsubakio-Yamamoto K, 2008, BIOCHEM BIOPH RES CO, V375, P390, DOI 10.1016/j.bbrc.2008.08.009
   Verheye S, 2007, J AM COLL CARDIOL, V49, P706, DOI 10.1016/j.jacc.2006.09.047
   von der Thusen JH, 2001, CIRCULATION, V103, P1164, DOI 10.1161/01.CIR.103.8.1164
   Wang XM, 2014, MED SCI MONITOR, V20, P1792, DOI 10.12659/MSM.892299
   Yang K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0095935
NR 44
TC 25
Z9 27
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 28
PY 2015
VL 10
IS 5
AR e0124031
DI 10.1371/journal.pone.0124031
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CJ0SC
UT WOS:000355187300005
PM 26020520
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Motawae, TM
   Ismail, MF
   Shabayek, MI
   Seleem, MM
AF Motawae, Tarek M.
   Ismail, Manal F.
   Shabayek, Marwa I.
   Seleem, Mae M.
TI MicroRNAs 9 and 370 Association with Biochemical Markers in T2D and CAD
   Complication of T2D
SO PLOS ONE
LA English
DT Article
ID CARDIAC-HYPERTROPHY; EXPRESSION; DISEASE; CELLS; GENE
AB Background
   MicroRNAs (miRNAs) are small non coding RNAs with essential roles, of which any alteration leads to several conditions. Their roles in diabetes (DM) and its vascular complications have not been completely assessed.
   Aim
   to study the association of two miRNAs; 9 and 370, with biochemical parameters of type 2 diabetic (T2D), dyslipidemia and coronary artery disease (CAD).
   Subjects and Methods
   Blood samples were taken from 200 subjects of both genders, in the Outpatient clinic of Al Qasr El-Einy teaching hospitals, in which levels of both miRNAs (using real time PCR) and routine parameters were measured. Subjects were divided over four groups, 50 in each group as follows; patients with T2D, patients with CAD, patients with T2D and CAD, and healthy control subjects.
   Main Outcome
   miRNA 9 levels were expected to be over expressed in diabetic patients, while miRNA 370 levels were expected to be over expressed in those suffering from CAD and their association with CAD complication of T2D.
   Results
   miRNA 9 levels were significantly higher in T2D patients and T2D patients with CAD, (1.18 +/- 0.07, and 1.31 +/- 0.08 respectively), while miRNA 370 levels were significantly higher in T2D patients, CAD patients, and T2D patients with CAD (0.59 +/- 0.05, 1.00 +/- 0.05, and 1.20 +/- 0.06 respectively), compared to control group at p = 0.000. In addition both miRNAs were still significantly associated with each other even after conducting multiple regression analysis.
   Conclusion
   This study associates the possible role of miRNAs in the diagnosis/prognosis of CAD complication of T2D.
C1 [Motawae, Tarek M.; Ismail, Manal F.] Cairo Univ, Fac Pharm, Dept Biochem, Cairo, Egypt.
   [Shabayek, Marwa I.; Seleem, Mae M.] Future Univ, Fac Pharmaceut Sci & Pharmaceut Ind, Dept Biochem, Cairo, Egypt.
RP Seleem, MM (reprint author), Future Univ, Fac Pharmaceut Sci & Pharmaceut Ind, Dept Biochem, Cairo, Egypt.
EM Biochemistry.fue@gmail.com
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Bonauer A, 2009, SCIENCE, V324, P1710, DOI 10.1126/science.1174381
   Bonow RO, 1996, AM J MED, V101, pA17S
   da Costa Martins PA, 2010, NAT CELL BIOL, V12, P1220, DOI [10.1038/ncb2126., DOI 10.1038/NCB2126]
   Ersin A, 2012, BIOCHEM J, V442, P539, DOI [10.1042/BJ20111678, DOI 10.1042/BJ20111678]
   Herder C, 2011, CLIN PHARMACOL THER, V90, P52, DOI 10.1038/clpt.2011.93
   Hoekstra M, 2010, BIOCHEM BIOPH RES CO, V394, P792, DOI 10.1016/j.bbrc.2010.03.075
   Iliopoulos D, 2012, J LIPID RES, V51, P1513
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liu Y, 2012, INT J PATHOLOGY CLIN, V5, P012
   Lovis P, 2008, BIOL CHEM, V389, P305, DOI 10.1515/BC.2008.026
   Lynn FC, 2007, DIABETES, V56, P2938, DOI 10.2337/db07-0175
   Olszanecka-Glinianowicz Magdalena, 2005, Pol Merkur Lekarski, V18, P101
   Plaisance V, 2006, J BIOL CHEM, V281, P26932, DOI 10.1074/jbc.M601225200
   Poitout V, 2006, J NUTR, V136, P873
   Puri R, 2011, NAT REV CARDIOL, V8, P131, DOI 10.1038/nrcardio.2010.210
   Qin B, 2012, MOL BIOL REP, V39, P4509, DOI 10.1007/s11033-011-1241-0
   Rosenson RS, 2005, CURR PROB CARDIOLOGY, V30, P241, DOI 10.1016/j.cpcardiol.2004.10.001
   Sacco J, 2012, CURR OPIN LIPIDOL, V23, P220, DOI 10.1097/MOL.0b013e3283534c9f
   Sayed D, 2007, CIRC RES, V100, P416, DOI 10.1161/01.RES.0000257913.42552.23
   Singh V, 2009, VASC HEALTH RISK MAN, V5, P495
   Thum T, 2007, CIRCULATION, V116, P258, DOI 10.1161/CIRCULATIONAHA.107.687947
   Wang K, 2010, J BIOL CHEM, V285, P11903, DOI 10.1074/jbc.M109.098004
   Williams MD, 2012, MICRORNAS INSULIN RE
NR 24
TC 10
Z9 10
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 15
PY 2015
VL 10
IS 5
AR e0126957
DI 10.1371/journal.pone.0126957
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI7AU
UT WOS:000354916100116
PM 25978320
OA DOAJ Gold, Green Published
DA 2019-06-18
ER

PT J
AU AlBacha, JD
   Khoury, M
   Mouawad, C
   Haddad, K
   Hamoui, S
   Azar, A
   Fajloun, Z
   Makdissy, N
AF AlBacha, Jeanne d'Arc
   Khoury, Mira
   Mouawad, Charbel
   Haddad, Katia
   Hamoui, Samar
   Azar, Albert
   Fajloun, Ziad
   Makdissy, Nehman
TI High Incidence of ACE/PAI-1 in Association to a Spectrum of Other
   Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory
   Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility
   with a Combination of ACE Inhibitor and Statin
SO PLOS ONE
LA English
DT Article
ID ANGIOTENSIN-CONVERTING-ENZYME; PLASMINOGEN-ACTIVATOR INHIBITOR-1;
   CORONARY-ARTERY-DISEASE; FACTOR-V-LEIDEN; R506Q MUTATION-LEIDEN;
   OF-THE-LITERATURE; FACTOR-XIII GENE; LEBANESE POPULATION;
   INSERTION/DELETION POLYMORPHISM; MYOCARDIAL-INFARCTION
AB Cardiovascular diseases (CVDs) are significantly high in the Lebanese population with the two most predominant forms being atherosclerosis and venous thrombosis. The purpose of our study was to assess the association of a spectrum of CVD related genes and combined state of hypertension hypercholesterolemia (HH) in unrelated Lebanese. Twelve polymorphisms were studied by multiplex PCR and reverse hybridization of DNA from 171 healthy individuals and 144 HH subjects. Two genes were significantly associated with HH: ACE (OR: 9.20, P<0.0001) and PAI-1 (OR: 2.29, P = 0.007), respectively with the occurrence of the risky alleles "Del" and "4G". The frequencies of the Del and 4G alleles were found to be 0.98 and 0.90 in the HH group versus 0.84 and 0.79 in the healthy group, respectively. Serum ACE activity and PAI-I increased significantly with Del/Del and 4G/5G genotypes. The co-expression of Del/4G(+/+) was detected in 113 out of 171 (66.0%) controls and 125 out of 144 (86.8%) HH subjects. Del/4G(-/-) was detected in only 6 (3.5%) controls and undetected in the HH group. Three venous thrombosis related genes [FV(Leiden), MTHFR (A1298C) and FXIII(V34L)] were significantly related to the prominence of the co-expression of Del/4G(+/+). A range of 2 to 8 combined polymorphisms co-expressed per subject where 5 mutations were the most detected. In Del/4G(+/+) subjects, peripheral blood mononuclear cells (PBMCs) produced significant elevated levels of IFN-gamma and TNF-alpha contrary to IL-10, and no variations occurred for IL-4. ACE inhibitor (ramipril) in combination with statin (atorvastatin) and not alone reversed significantly the situation. This first report from Lebanon sheds light on an additional genetic predisposition of a complex spectrum of genes involved in CVD and suggests that the most requested gene FVL by physicians may not be sufficient to diagnose eventual future problems that can occur in the cardiovascular system. Subjects expressing the double mutations (Del/4G) are at high risk for the onset of CVDs.
C1 [AlBacha, Jeanne d'Arc; Khoury, Mira; Azar, Albert; Fajloun, Ziad; Makdissy, Nehman] Middle East Inst Hlth Hosp, Ctr Human Genet, Reviva Regenerat Med Ctr, Bsalim, Lebanon.
   [AlBacha, Jeanne d'Arc; Fajloun, Ziad] Lebanese Univ, Doctoral Sch Sci & Technol, Azm Ctr Res Biotechnol & Applicat, Lab Appl Biotechnol, Tripoli, Lebanon.
   [Mouawad, Charbel; Haddad, Katia; Hamoui, Samar; Makdissy, Nehman] Lebanese Univ, Sect 3, Fac Sci, Dept Biol, El Kobeh, Lebanon.
RP Makdissy, N (reprint author), Middle East Inst Hlth Hosp, Ctr Human Genet, Reviva Regenerat Med Ctr, Bsalim, Lebanon.
EM n.makdissy@revivamedical.com
FU National Council for Scientific Research (CNRS-Lebanon); Francophone
   University Agency (AUF)
FX The authors are deeply appreciative to the National Council for
   Scientific Research (CNRS-Lebanon) and Francophone University Agency
   (AUF) for the financial support and the funding of their work.
CR Abd El-Aziz TA, 2012, GENE, V498, P270, DOI 10.1016/j.gene.2012.02.033
   Agachan B, 2003, EXP MOL MED, V35, P545, DOI 10.1038/emm.2003.71
   Ait-Oufella H, 2011, ARTERIOSCL THROM VAS, V31, P969, DOI 10.1161/ATVBAHA.110.207415
   Alghasham A, 2012, INT J HEALTH SCI-IJH, V6, P3, DOI 10.12816/0005968
   Alharbi KK, 2013, LIPIDS HEALTH DIS, V12, DOI 10.1186/1476-511X-12-177
   Andersson B, 1996, J AM COLL CARDIOL, V28, P162, DOI 10.1016/0735-1097(96)00098-8
   Antonopoulos AS, 2012, CURR PHARM DESIGN, V18, P1519
   Ariens RAS, 2000, BLOOD, V96, P988
   Ascer E, 2004, ATHEROSCLEROSIS, V177, P161, DOI 10.1016/j.atherosclerosis.2004.07.003
   Aydenian H, 1999, ANN BIOL CLIN-PARIS, V57, P697
   Bae Y, 2007, J HUM HYPERTENS, V21, P159, DOI 10.1002/sj.jhh.1002110
   Barley J, 1996, J HUM HYPERTENS, V10, P31
   BERTINA RM, 1994, NATURE, V369, P64, DOI 10.1038/369064a0
   Biller H, 2006, EUR RESPIR J, V28, P1085, DOI 10.1183/09031936.00050106
   Blaschke S, 2009, SCAND J RHEUMATOL, V38, P235, DOI 10.1080/03009740802572475
   Boncoraglio GB, 2006, CEREBROVASC DIS, V22, P191, DOI 10.1159/000093604
   Bornfeldt KE, 2011, CELL METAB, V14, P575, DOI 10.1016/j.cmet.2011.07.015
   Chen F, 2013, CLIN APPL THROMB HEM
   Corsetti JP, 2008, ARTERIOSCL THROM VAS, V28, P548, DOI 10.1161/ATVBAHA.107.155556
   Daniels PR, 2004, AM J MED, V116, P676, DOI 10.1016/j.amjmed.2003.12.032
   DAWSON SJ, 1993, J BIOL CHEM, V268, P10739
   Declerck PJ, 2013, SEMIN THROMB HEMOST, V39, P356, DOI 10.1055/s-0033-1334487
   Di Pasquale P, 2004, EUR J HEART FAIL, V6, P11, DOI 10.1016/j.ejheart.2003.07.009
   Egan BM, 2013, CIRCULATION, V128, P29, DOI 10.1161/CIRCULATIONAHA.112.000500
   ERIKSSON P, 1995, P NATL ACAD SCI USA, V92, P1851, DOI 10.1073/pnas.92.6.1851
   Fahed AC, 2011, MOL GENET METAB, V102, P181, DOI 10.1016/j.ymgme.2010.11.006
   FALK E, 1995, CIRCULATION, V92, P657, DOI 10.1161/01.CIR.92.3.657
   Franchini M, 2012, BLOOD TRANSFUS-ITALY, V10, P257, DOI 10.2450/2012.0095-12
   Francis CW, 2002, ARCH PATHOL LAB MED, V126, P1391
   Franzosi MG, 1998, CIRCULATION, V97, P2202
   Gesang L, 2002, HYPERTENS RES, V25, P481, DOI 10.1291/hypres.25.481
   Gohil R, 2009, THROMB HAEMOSTASIS, V102, P360, DOI 10.1160/TH09-01-0013
   Goodman CS, 2006, AM J REPROD IMMUNOL, V56, P230, DOI 10.1111/j.1600-0897.2006.00419.x
   Guney AI, 2013, GENET MOL RES, V12, P6895, DOI 10.4238/2013.December.19.8
   Haber M, 2012, ANN HUM GENET, V76, P1, DOI 10.1111/j.1469-1809.2011.00682.x
   Ilhan N, 2008, ARCH MED RES, V39, P125, DOI 10.1016/j.arcmed.2007.07.009
   Ince FDA, 2010, ANADOLU KARDIYOL DER, V10, P202, DOI 10.5152/akd.2010.058
   Irani-Hakime N, 2001, J THROMB THROMBOLYS, V11, P111, DOI 10.1023/A:1011268531377
   Irani-Hakime N, 2000, AM J HEMATOL, V65, P45, DOI 10.1002/1096-8652(200009)65:1<45::AID-AJH8>3.0.CO;2-V
   Ismail M, 2004, J BIOCHEM MOL BIOL, V37, P552
   JEUNEMAITRE X, 1992, CELL, V71, P169, DOI 10.1016/0092-8674(92)90275-H
   Kawashiri M, 2000, AM J CARDIOL, V86, P840, DOI 10.1016/S0002-9149(00)01103-6
   Keavney B, 2000, LANCET, V355, P434
   Kim DK, 1997, ARTERIOSCL THROM VAS, V17, P3242, DOI 10.1161/01.ATV.17.11.3242
   Klingenberg R, 2009, EUR HEART J, V30, P2838, DOI 10.1093/eurheartj/ehp477
   Kohler HP, 1998, THROMB HAEMOSTASIS, V79, P8
   Koupepidou P, 2005, INT ANGIOL, V24, P287
   Kwak B, 2001, SWISS MED WKLY, V131, P41
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lin PT, 2008, INT J VITAM NUTR RES, V78, P33, DOI 10.1024/0300-9831.78.1.33
   Loew M, 2006, EUR J CARDIOV PREV R, V13, P449
   Mahfouz RAR, 2008, MOL BIOL REP, V35, P375, DOI 10.1007/s11033-007-9096-0
   Mahfouz RAR, 2006, MOL BIOL REP, V33, P145, DOI 10.1007/s11033-006-6260-x
   Margaglione M, 1997, ARTERIOSCL THROM VAS, V17, P2082, DOI 10.1161/01.ATV.17.10.2082
   Margaglione M, 1998, ARTERIOSCL THROM VAS, V18, P152, DOI 10.1161/01.ATV.18.2.152
   Markan S, 2007, MOL CELL BIOCHEM, V302, P125, DOI 10.1007/s11010-007-9434-5
   Mein CA, 2004, HUM MOL GENET, V13, pR169, DOI 10.1093/hmg/ddh078
   Minihane AM, 2007, P NUTR SOC, V66, P183, DOI 10.1017/S0029665107005435
   Niemiec P, 2007, GENET TEST, V11, P353, DOI 10.1089/gte.2007.0005
   O'Malley JP, 1998, CIRCULATION, V97, P1780, DOI 10.1161/01.CIR.97.18.1780
   REES DC, 1995, LANCET, V346, P1133, DOI 10.1016/S0140-6736(95)91803-5
   Ridker PM, 1997, JAMA-J AM MED ASSOC, V277, P1305, DOI 10.1001/jama.277.16.1305
   Roger VL, 2011, CIRCULATION, V123, pE18, DOI 10.1161/CIR.0b013e3182009701
   Saab YB, 2011, J RENIN-ANGIO-ALDO S, V12, P588, DOI 10.1177/1470320311408465
   Sabbagh AS, 2007, TRANSFUSION MED, V17, P473, DOI 10.1111/j.1365-3148.2007.00792.x
   Sabbagh AS, 2008, GENET TEST, V12, P75, DOI 10.1089/gte.2007.0064
   Sabbagh AS, 2007, MOL BIOL REP, V34, P267, DOI 10.1007/s11033-006-9041-7
   Sabbagh AS, 2007, MOL BIOL REP, V34, P47, DOI 10.1007/s11033-006-9013-y
   Samani NJ, 1996, CIRCULATION, V94, P708, DOI 10.1161/01.CIR.94.4.708
   SAWA H, 1993, CIRC RES, V73, P671, DOI 10.1161/01.RES.73.4.671
   Schmidt-Ott KM, 2000, REGUL PEPTIDES, V93, P65, DOI 10.1016/S0167-0115(00)00178-6
   Shammaa DMR, 2008, MOL BIOL REP, V35, P453, DOI 10.1007/s11033-007-9106-2
   Shammaa DMR, 2008, MOL BIOL REP, V35, P307, DOI 10.1007/s11033-007-9087-1
   SMITH GD, 1992, JAMA-J AM MED ASSOC, V267, P70, DOI 10.1001/jama.267.1.70
   Smith SC, 2004, CIRCULATION, V109, P2613, DOI 10.1161/01.CIR.0000128519.60762.84
   Snieder H, 2003, HYPERTENSION, V41, P1196, DOI 10.1161/01.HYP.0000072269.19820.0D
   Strey RF, 2005, PATHOPHYSIOL HAEMO T, V34, P279, DOI 10.1159/000093108
   Szmitko PE, 2003, CIRCULATION, V108, P1917, DOI 10.1161/01.CIR.0000089190.95415.9F
   Thomas DP, 1996, BLOOD COAGUL FIBRIN, V7, P583, DOI 10.1097/00001721-199609000-00001
   Thomas GN, 2001, DIABETES CARE, V24, P356, DOI 10.2337/diacare.24.2.356
   Todoroki M, 2003, J HUM HYPERTENS, V17, P713, DOI 10.1038/sj.jhh.1001601
   Tohme RA, 2005, J HUM HYPERTENS, V19, P861, DOI 10.1038/sj.jhh.1001909
   Tripathi Gaurav, 2006, BMC Nephrol, V7, P15, DOI 10.1186/1471-2369-7-15
   Tsantes AE, 2007, THROMB HAEMOSTASIS, V97, P907, DOI 10.1160/TH06-12-0745
   Vargas-Alarcon G, 2003, HUM BIOL, V75, P889, DOI 10.1353/hub.2004.0012
   Wang Y, 2011, BIOMED PHARMACOTHER, V65, P118, DOI 10.1016/j.biopha.2010.12.005
   Weiss D, 2001, AM J CARDIOL, V87, p25C
   Yang BY, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0087497
   Ye S, 2003, HEART, V89, P1195, DOI 10.1136/heart.89.10.1195
   Zaatari GS, 2006, PATHOLOGY, V38, P442, DOI 10.1080/00313020600922934
   Zhang AY, 2010, CARDIOL RES, V1, P8, DOI 10.4021/cr108e
   Zhang Yu-ling, 2007, Nan Fang Yi Ke Da Xue Xue Bao, V27, P1681
   Zhu XF, 2003, HYPERTENSION, V41, P1027, DOI 10.1161/01.HYP.0000068681.69874.CB
NR 93
TC 4
Z9 4
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 14
PY 2015
VL 10
IS 5
AR UNSP e0127266
DI 10.1371/journal.pone.0127266
PG 24
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CI2AC
UT WOS:000354545600107
PM 25973747
OA DOAJ Gold, Green Published
DA 2019-06-18
ER

PT J
AU Erdembileg, A
   Mirsoian, A
   Enkhmaa, B
   Zhang, W
   Beckett, LA
   Murphy, WJ
   Berglund, LF
AF Erdembileg, Anuurad
   Mirsoian, Annie
   Enkhmaa, Byambaa
   Zhang, Wei
   Beckett, Laurel A.
   Murphy, William J.
   Berglund, Lars F.
TI Attenuated Age-Impact on Systemic Inflammatory Markers in the Presence
   of a Metabolic Burden
SO PLOS ONE
LA English
DT Article
ID CORONARY-ARTERY-DISEASE; DENSITY-LIPOPROTEIN CHOLESTEROL; CARDIOVASCULAR
   RISK-FACTORS; C-REACTIVE PROTEIN; COMPUTED-TOMOGRAPHY; BODY-COMPOSITION;
   HEART-DISEASE; ATHEROSCLEROSIS; DIAGNOSIS; MEN
AB Background
   The overall burden of chronic disease, inflammation and cardiovascular risk increases with age. Whether the relationship between age and inflammation is impacted by presence of an adverse metabolic burden is not known.
   Methods
   We determined inflammatory markers in humans (336 Caucasians and 224 African Americans) and in mice, representing a spectrum of age, weight and metabolic burden.
   Results
   In humans, levels of inflammatory markers increased significantly with age in subjects without the metabolic syndrome, (P=0.009 and P=0.037 for C-reactive protein, P<0.001 and P=0.001 for fibrinogen, P<0.001 and P=0.005 for serum amyloid-A, for Caucasians and African Americans, respectively). In contrast, trend patterns of inflammatory markers did not change significantly with age in subjects with metabolic syndrome in either ethnic group, except for fibrinogen in Caucasians. A composite z-score for systemic inflammation increased significantly with age in subjects without metabolic syndrome (P=0.004 and P<0.006 for Caucasians and African Americans, respectively) but not in subjects with metabolic syndrome (P=0.009 for difference in age trend between metabolic syndrome and non-metabolic syndrome). In contrast, no similar age trend was found in vascular inflammation. The findings in humans were paralleled by results in mice as serum amyloid-A levels increased across age (range 2-15 months, P<0.01) and were higher in ob/ob mice compared to control mice (P<0.001).
   Conclusions
   Presence of a metabolic challenge in mice and humans influences levels of inflammatory markers over a wide age range. Our results underscore that already at a young age, presence of a metabolic burden enhances inflammation to a level that appears to be similar to that of decades older people without metabolic syndrome.
C1 [Erdembileg, Anuurad; Enkhmaa, Byambaa; Zhang, Wei; Murphy, William J.; Berglund, Lars F.] Univ Calif Davis, Dept Med, Davis, CA 95616 USA.
   [Mirsoian, Annie; Murphy, William J.] Univ Calif Davis, Dept Dermatol, Davis, CA 95616 USA.
   [Beckett, Laurel A.] Univ Calif Davis, Dept Publ Hlth Sci, Davis, CA 95616 USA.
   [Berglund, Lars F.] VA Northern Calif Hlth Care Syst, Sacramento, CA USA.
RP Berglund, LF (reprint author), Univ Calif Davis, Dept Med, Davis, CA 95616 USA.
EM lars.berglund@ucdmc.ucdavis.edu
OI Berglund, Lars/0000-0001-6705-1791
FU National Institutes of Health [HL62705, TR000002, CA095572, RR024144,
   2K12HD051958]; American Heart Association [14CRP17930014]
FX This work was supported by National Institutes of Health HL62705,
   TR000002, CA095572, RR024144, 2K12HD051958; and American Heart
   Association 14CRP17930014. The sponsors provided funding in response to
   grant applications but had no role in design of the study, data
   collection or manuscript preparation.
CR Adler AI, 2005, DIABETIC MED, V22, P306, DOI 10.1111/j.1464-5491.2004.01418.x
   ALLAIN CC, 1974, CLIN CHEM, V20, P470
   Anuurad E, 2006, J LIPID RES, V47, P2475, DOI 10.1194/jlr.M600288-JLR200
   Anuurad E, 2011, ARTERIOSCL THROM VAS, V31, P2151, DOI 10.1161/ATVBAHA.111.232348
   Anuurad E, 2010, J CLIN ENDOCR METAB, V95, P2376, DOI 10.1210/jc.2009-2498
   Anuurad E, 2009, ATHEROSCLEROSIS, V205, P290, DOI 10.1016/j.atherosclerosis.2008.11.028
   Beckett N, 2000, CARDIOVASC DRUG THER, V14, P397, DOI 10.1023/A:1007812232328
   BORKAN GA, 1985, AM J PHYS ANTHROPOL, V66, P289, DOI 10.1002/ajpa.1330660306
   Cleeman JI, 2001, JAMA-J AM MED ASSOC, V285, P2486, DOI 10.1001/jama.285.19.2486
   Dada Nisha, 2002, Expert Rev Mol Diagn, V2, P17
   Enkhmaa B, 2011, TRANSL RES, V158, P92, DOI 10.1016/j.trsl.2011.01.004
   Ervin R. B., 2009, NATL HLTH STAT REPOR, P1
   Ferrucci L, 2005, BLOOD, V105, P2294, DOI 10.1182/blood-2004-07-2599
   Flegal KM, 2010, JAMA-J AM MED ASSOC, V303, P235, DOI 10.1001/jama.2009.2014
   Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356
   Franceschi C, 2007, NUTR REV, V65, pS173, DOI 10.1301/nr.2007.dec.S173-S176
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Gallagher D, 2000, AM J PHYSIOL-ENDOC M, V279, pE366
   Giunta Sergio, 2006, Immun Ageing, V3, P12, DOI 10.1186/1742-4933-3-12
   Goodpaster BH, 1985, J APPL PHYSIOL, V89, P104
   Grundy SM, 2006, AM J CLIN NUTR, V83, P1248
   Grundy SM, 2005, CIRCULATION, V112, P2735, DOI 10.1161/CIRCULATIONAHA.105.169404
   Guo SS, 1999, AM J CLIN NUTR, V70, P405
   Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001
   Koenig W, 2006, ARTERIOSCL THROM VAS, V26, P1586, DOI 10.1161/01.ATV.0000222983.73369.c8
   Kosaka T, 2000, CLIN CHIM ACTA, V296, P151, DOI 10.1016/S0009-8981(00)00216-3
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Libby P, 2010, CIRC J, V74, P213, DOI 10.1253/circj.CJ-09-0706
   Macy EM, 1997, CLIN CHEM, V43, P52
   MCGOWAN MW, 1983, CLIN CHEM, V29, P538
   Mendall MA, 1997, HEART, V78, P273, DOI 10.1136/hrt.78.3.273
   Miller AM, 2011, CURR PHARM DESIGN, V17, P1
   MILLER M, 1990, AM J CARDIOL, V65, P1, DOI 10.1016/0002-9149(90)90017-U
   Paultre F, 2000, ARTERIOSCL THROM VAS, V20, P2619, DOI 10.1161/01.ATV.20.12.2619
   Reaven GM, 2006, AM J CLIN NUTR, V83, P1237
   REAVEN GM, 1988, DIABETES, V37, P1595, DOI 10.2337/diabetes.37.12.1595
   Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121
   WARNICK GR, 1982, CLIN CHEM, V28, P1379
NR 40
TC 2
Z9 2
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 27
PY 2015
VL 10
IS 3
AR e0121947
DI 10.1371/journal.pone.0121947
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CE8ZT
UT WOS:000352133600130
PM 25815855
OA DOAJ Gold, Green Published
DA 2019-06-18
ER

PT J
AU Mao, M
   Lei, H
   Liu, Q
   Chen, YX
   Zhao, L
   Li, Q
   Luo, SX
   Zuo, Z
   He, Q
   Huang, W
   Zhang, N
   Zhou, C
   Ruan, XZ
AF Mao, Min
   Lei, Han
   Liu, Qing
   Chen, Yaxi
   Zhao, Lei
   Li, Qing
   Luo, Suxin
   Zuo, Zhong
   He, Quan
   Huang, Wei
   Zhang, Nan
   Zhou, Chao
   Ruan, Xiong Z.
TI Effects of miR-33a-5P on ABCA1/G1-Mediated Cholesterol Efflux under
   Inflammatory Stress in THP-1 Macrophages
SO PLOS ONE
LA English
DT Article
ID FOAM CELL-FORMATION; LIPID-METABOLISM; HEPATIC CELLS; ATHEROSCLEROSIS;
   MICRORNAS; ACCUMULATION; BINDING; HDL; TRANSPORTERS; HOMEOSTASIS
AB The present study is to investigate whether inflammatory cytokines inhibit ABCA1/ABCG1-mediated cholesterol efflux by regulating miR-33a-5P in THP-1 macrophages. We used interleukin-6 and tumor necrosis factor-alpha in the presence or absence of native low density lipoprotein (LDL) to stimulate THP-1 macrophages. THP-1 macrophages were infected by either control lentivirus vectors or lentivirus encoding miR-33a-5P or antisense miR-33a-5P. The effects of inflammatory cytokines, miR-33a-5P and antisense miR-33a-5P on intracellular lipids accumulation and intracellular cholesterol contents were assessed by oil red O staining and quantitative intracellular cholesterol assay. ApoA-I-mediated cholesterol efflux was examined using the fluorescent sterol (BODIPY-cholesterol). The gene and protein expressions of the molecules involved in cholesterol trafficking were examined using quantitative real-time polymerase chain reaction and Western blotting. Inflammatory cytokines or miR-33a-5P increased intracellular lipid accumulation and decreased apoA-I-mediated cholesterol efflux via decreasing the expression of ABCA1 and ABCG1 in the absence or presence of LDL in THP-1 macrophages. However, antisense miR-33a-5P reversed the effects of inflammatory cytokines on intracellular lipid accumulation, cholesterol efflux, and the expression of miR-33a-5P, ABCA1 and ABCG1 in the absence or presence of LDL in THP-1 macrophages. This study indicated that inflammatory cytokines inhibited ABCA1/ABCG1-mediated cholesterol efflux by upregulating miR-33a-5P in THP-1 macrophages.
C1 [Mao, Min; Lei, Han; Luo, Suxin; Zuo, Zhong; He, Quan; Huang, Wei; Zhang, Nan; Zhou, Chao] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing, Peoples R China.
   [Mao, Min; Lei, Han; Chen, Yaxi; Zhao, Lei; Li, Qing; Zhou, Chao; Ruan, Xiong Z.] Chongqing Med Univ, Ctr Lipid Res, Key Lab Metab Lipid & Glucose, Chongqing, Peoples R China.
   [Mao, Min; Liu, Qing] Chongqing Med Univ, Affiliated Hosp 1, Clin Res Ctr, Chongqing, Peoples R China.
   [Ruan, Xiong Z.] UCL, Sch Med, Ctr Nephrol, John Moorhead Res Lab, London W1N 8AA, England.
RP Lei, H (reprint author), Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing, Peoples R China.
EM maominmaomin123@163.com
FU Major State Basic Research Development Program of China (973 Program)
   [2012CB517700, 2012CB517500]; National Natural Science Foundation of
   China [81070631, 81070317, 81030008, 81270493, 81270789, 81200567];
   National Key Clinical Specialties Construction Program of China
FX This study was supported by Major State Basic Research Development
   Program of China (973 Program, Nos. 2012CB517700 and 2012CB517500),
   National Natural Science Foundation of China (81070631, 81070317, and
   Key Program Nos. 81030008, 81270493, 81270789 and 81200567), and
   National Key Clinical Specialties Construction Program of China. The
   funders did not participate in study design, data collection and
   analysis, decision for publication, or the preparation of the
   manuscript.
CR Bartel DP, 2009, CELL, V136, P215, DOI 10.1016/j.cell.2009.01.002
   Brown MS, 2010, SCIENCE, V328, P1495, DOI 10.1126/science.1192409
   Chen WJ, 2013, ATHEROSCLEROSIS, V227, P201, DOI 10.1016/j.atherosclerosis.2012.11.025
   Chen Y, 2007, AM J PHYSIOL-RENAL, V293, pF680, DOI 10.1152/aj.prenal.00209.2007
   Chen YY, 2012, J GASTROEN HEPATOL, V27, P974, DOI 10.1111/j.1440-1746.2011.06986.x
   Fernandez-Hernando C, 2013, HEPATOLOGY, V57, P432, DOI 10.1002/hep.25960
   Fernandez-Hernando C, 2011, ARTERIOSCL THROM VAS, V31, P2378, DOI 10.1161/ATVBAHA.111.226688
   Fernandez-Hernando C, 2011, CURR OPIN LIPIDOL, V22, P86, DOI 10.1097/MOL.0b013e3283428d9d
   Horie T, 2010, P NATL ACAD SCI USA, V107, P17321, DOI 10.1073/pnas.1008499107
   Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
   Kennedy MA, 2005, CELL METAB, V1, P121, DOI 10.1016/j.cmet.2005.01.002
   Klucken J, 2000, P NATL ACAD SCI USA, V97, P817, DOI 10.1073/pnas.97.2.817
   Lawn RM, 1999, J CLIN INVEST, V104, pR25, DOI 10.1172/JCI8119
   Li LC, 2013, AM J PHYSIOL-HEART C, V304, pH874, DOI 10.1152/ajpheart.00096.2012
   Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Ma KL, 2008, HEPATOLOGY, V48, P770, DOI 10.1002/hep.22423
   Marquart TJ, 2010, P NATL ACAD SCI USA, V107, P12228, DOI 10.1073/pnas.1005191107
   Mikita T, 2001, J BIOL CHEM, V276, P45729, DOI 10.1074/jbc.M106114200
   Moore KJ, 2013, NAT REV IMMUNOL, V13, P709, DOI 10.1038/nri3520
   Moore KJ, 2013, J LIPID RES, V54, P1159, DOI 10.1194/jlr.E036954
   Moore KJ, 2011, ANNU REV NUTR, V31, P49, DOI 10.1146/annurev-nutr-081810-160756
   Moore KJ, 2011, CELL, V145, P341, DOI 10.1016/j.cell.2011.04.005
   Najafi-Shoushtari SH, 2010, SCIENCE, V328, P1566, DOI 10.1126/science.1189123
   [National Institutes of Health National Heart Lung and Blood Institute], 2012, NHLBI MORB MOR CHART
   Rayner KJ, 2012, THROMB HAEMOSTASIS, V107, P642, DOI 10.1160/TH11-10-0694
   Rayner KJ, 2010, SCIENCE, V328, P1570, DOI 10.1126/science.1189862
   Ruan XZ, 2006, ARTERIOSCL THROM VAS, V26, P1150, DOI 10.1161/01.ATV.0000217957.93135.c2
   Sankaranarayanan S, 2011, J LIPID RES, V52, P2332, DOI 10.1194/jlr.D018051
   STOSCHECK CM, 1990, METHOD ENZYMOL, V182, P50
   von Hundelshausen P, 2013, DEUT MED WOCHENSCHR, V138, P1839, DOI 10.1055/s-0033-1349426
   Wang N, 2000, J BIOL CHEM, V275, P33053, DOI 10.1074/jbc.M005438200
   Wang N, 2004, P NATL ACAD SCI USA, V101, P9774, DOI 10.1073/pnas.0403506101
   Yang L, 2004, CELL RES, V14, P315, DOI 10.1038/sj.cr.7290231
   Ye Q, 2009, INFLAMM RES, V58, P809, DOI 10.1007/s00011-009-0052-4
   Yin K, 2010, MOL MED, V16, P438, DOI 10.2119/molmed.2010.00004
   Yuan Y, 2011, AM J PHYSIOL-RENAL, V301, pF236, DOI 10.1152/ajprenal.00646.2010
   Yvan-Charvet L, 2010, ARTERIOSCL THROM VAS, V30, P139, DOI 10.1161/ATVBAHA.108.179283
   Zhang J, 2011, ASSAY DRUG DEV TECHN, V9, P136, DOI 10.1089/adt.2010.0288
   Zhao L, 2011, J GASTROEN HEPATOL, V26, P875, DOI 10.1111/j.1440-1746.2010.06560.x
   Zhou C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075650
NR 41
TC 15
Z9 16
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 17
PY 2014
VL 9
IS 10
AR e109722
DI 10.1371/journal.pone.0109722
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AT8TF
UT WOS:000345204100021
PM 25329888
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Krasner, NM
   Ido, Y
   Ruderman, NB
   Cacicedo, JM
AF Krasner, Nadia M.
   Ido, Yasuo
   Ruderman, Neil B.
   Cacicedo, Jose M.
TI Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial
   Cell Inflammation through a Calcium and AMPK Dependent Mechanism
SO PLOS ONE
LA English
DT Article
ID ACTIVATED PROTEIN-KINASE; ANTIDIABETIC DRUG; OXIDATIVE STRESS; BINDING
   PROTEIN; TNF-ALPHA; DYSFUNCTION; EXENATIDE; THERAPIES; INCRETIN;
   ADHESION
AB Liraglutide is a glucagon-like peptide-1 (GLP-1) mimetic used for the treatment of Type 2 diabetes. Similar to the actions of endogenous GLP-1, liraglutide potentiates the post-prandial release of insulin, inhibits glucagon release and increases satiety. Recent epidemiological studies and clinical trials have suggested that treatment with GLP-1 mimetics may also diminish the risk of cardiovascular disease in diabetic patients. The mechanism responsible for this effect has yet to be determined; however, one possibility is that they might do so by a direct effect on vascular endothelium. Since low grade inflammation of the endothelium is an early event in the pathogenesis of atherosclerotic cardiovascular disease (ASCVD), we determined the effects of liraglutide on inflammation in cultured human aortic endothelial cells (HAECs). Liraglutide reduced the inflammatory responses to TNF alpha and LPS stimulation, as evidenced by both reduced protein expression of the adhesion molecules VCAM-1 and E-Selectin, and THP-1 monocyte adhesion. This was found to result from increased cell Ca2+ and several molecules sensitive to Ca2+ with known anti inflammatory actions in endothelial cells, including CaMKK beta, CaMKI, AMPK, eNOS and CREB. Treatment of the cells with STO-609, a CaMKK inhibitor, diminished both the activation of AMPK, CaMKI and the inhibition of TNF alpha and LPS-induced monocyte adhesion by liraglutide. Likewise, expression of an shRNA against AMPK nullified the anti-inflammatory effects of liraglutide. The results indicate that liraglutide exerts a strong anti-inflammatory effect on HAECs. They also demonstrate that this is due to its ability to increase intracellular Ca2+ and activate CAMKK beta, which in turn activates AMPK.
C1 [Krasner, Nadia M.; Ido, Yasuo; Ruderman, Neil B.; Cacicedo, Jose M.] Boston Univ, Sch Med, Dept Med, Diabet & Metab Res Unit, Boston, MA 02118 USA.
   [Krasner, Nadia M.; Ido, Yasuo; Ruderman, Neil B.; Cacicedo, Jose M.] Boston Univ, Sch Med, Endocrinol Sect, Boston, MA 02118 USA.
   [Krasner, Nadia M.] Boston Univ, Sch Med, Dept Med, Program Nutr & Metab, Boston, MA 02118 USA.
RP Krasner, NM (reprint author), Boston Univ, Sch Med, Dept Med, Diabet & Metab Res Unit, Boston, MA 02118 USA.
EM nadiakrasner@gmail.com; cacicedo@bu.edu
FU NIH/NHLBI [PO1 HL068758]; NIH/NIDDK [R24 DK094749]; Takeda
   Pharmaceuticals; NHLBI [HL07969]
FX This work was supported by NIH/NHLBI Program Project Grant PO1 HL068758
   and NIH/NIDDK R24 Seed Grant R24 DK094749 and funding from Takeda
   Pharmaceuticals. NMK was supported by NHLBI T32 training grant HL07969.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Aoki C, 2012, J PHARMACOL SCI, V120, P121, DOI 10.1254/jphs.12108FP
   Best JH, 2011, DIABETES CARE, V34, P90, DOI 10.2337/dc10-1393
   Bullock BP, 1996, ENDOCRINOLOGY, V137, P2968, DOI 10.1210/en.137.7.2968
   Cacicedo JM, 2004, BIOCHEM BIOPH RES CO, V324, P1204, DOI 10.1016/j.bbrc.2004.09.177
   Ceriello A, 2011, DIABETES CARE, V34, P697, DOI 10.2337/dc10-1949
   Chen C, 2013, INFLAMMATION, V36, P309, DOI 10.1007/s10753-012-9548-0
   Creely SJ, 2007, AM J PHYSIOL-ENDOC M, V292, pE740, DOI 10.1152/ajpendo.00302.2006
   CULLINAN CA, 1994, CELL CALCIUM, V15, P391, DOI 10.1016/0143-4160(94)90014-0
   Cuthbertson DJ, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0050117
   Damdindorj B, 2012, FEBS LETT, V586, P2555, DOI 10.1016/j.febslet.2012.06.034
   Drucker DJ, 2006, CELL METAB, V3, P153, DOI 10.1016/j.cmet.2006.01.004
   DRUCKER DJ, 1987, P NATL ACAD SCI USA, V84, P3434, DOI 10.1073/pnas.84.10.3434
   Flint A, 2011, ADV THER, V28, P213, DOI 10.1007/s12325-010-0110-x
   Forst T, 2012, DIABETIC MED, V29, P1115, DOI 10.1111/j.1464-5491.2012.03589.x
   Francis H, 2008, AM J PHYSIOL-CELL PH, V295, pC499, DOI 10.1152/ajpcell.00369.2007
   Galkina E, 2007, ARTERIOSCL THROM VAS, V27, P2292, DOI 10.1161/ATVBAHA.107.149179
   Gaspari T, 2011, DIABETES VASC DIS RE, V8, P117, DOI 10.1177/1479164111404257
   HAWLEY SA, 1995, J BIOL CHEM, V270, P27186, DOI 10.1074/jbc.270.45.27186
   Hawley Simon A, 2003, J Biol, V2, P28, DOI 10.1186/1475-4924-2-28
   Holz GG, 2004, DIABETES, V53, P5, DOI 10.2337/diabetes.53.1.5
   Horowitz M, 2012, DIABETES RES CLIN PR, V97, P258, DOI 10.1016/j.diabres.2012.02.016
   Horton ES, 2010, DIABETES CARE, V33, P1759, DOI 10.2337/dc09-2062
   Hurley RL, 2005, J BIOL CHEM, V280, P29060, DOI 10.1074/jbc.M503824200
   Kelly CJ, 2012, NUTR CLIN PRACT, V27, P215, DOI 10.1177/0884533611434934
   Koska J, 2010, DIABETES CARE, V33, P1028, DOI 10.2337/dc09-1961
   Krasner N, 2011, GLUCAGON LIKE PEPTID
   KREYMANN B, 1987, LANCET, V2, P1300
   Kwan HY, 2009, CLIN EXP PHARMACOL P, V36, P857, DOI 10.1111/j.1440-1681.2009.05199.x
   Lee W, 2013, INFLAMMATION, V36, P94, DOI 10.1007/s10753-012-9523-9
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liu HB, 2008, J ENDOCRINOL, V196, P57, DOI 10.1677/JOE-07-0387
   Marso SP, 2011, DIABETES VASC DIS RE, V8, P237, DOI 10.1177/1479164111408937
   Moretto TJ, 2008, CLIN THER, V30, P1448, DOI 10.1016/j.clinthera.2008.08.006
   Morrow VA, 2003, J BIOL CHEM, V278, P31629, DOI 10.1074/jbc.M212831200
   Nakamura K, 2012, ARTERIOSCL THROM VAS, V32, P2670, DOI 10.1161/ATVBAHA.112.254946
   Nauck M, 2003, DIABETES, V52, pA128
   Nikolaidis LA, 2004, CIRCULATION, V109, P962, DOI 10.1161/01.CIR.0000120505.91348.58
   Niswender K, 2013, DIABETES OBES METAB, V15, P42, DOI 10.1111/j.1463-1326.2012.01673.x
   Nordisk N, 2014, PRODUCT MONOGRAPH
   Nystrom T, 2004, AM J PHYSIOL-ENDOC M, V287, pE1209, DOI 10.1152/ajpendo.00237.2004
   Ou HC, 2012, J VASC SURG, V55, P1104, DOI 10.1016/j.jvs.2011.10.011
   Pussinen PJ, 2007, ARTERIOSCL THROM VAS, V27, P1433, DOI 10.1161/ATABAHA.106.138743
   Qin ZY, 2012, ATHEROSCLEROSIS, V221, P2, DOI 10.1016/j.atherosclerosis.2011.09.003
   Read PA, 2012, HEART, V98, P408, DOI 10.1136/hrt.2010.219345
   Russell-Jones D, 2009, MOL CELL ENDOCRINOL, V297, P137, DOI 10.1016/j.mce.2008.11.018
   Schisano B, 2012, REGUL PEPTIDES, V174, P46, DOI 10.1016/j.regpep.2011.11.008
   Shiraki A, 2012, ATHEROSCLEROSIS, V221, P375, DOI 10.1016/j.atherosclerosis.2011.12.039
   Sokos GG, 2006, J CARD FAIL, V12, P694, DOI 10.1016/j.cardfail.2006.08.211
   Stahmann N, 2006, MOL CELL BIOL, V26, P5933, DOI 10.1128/MCB.00383-06
   Tran QK, 2000, CARDIOVASC RES, V48, P13, DOI 10.1016/S0008-6363(00)00172-3
   Tuttolomondo A, 2012, CURR PHARM DESIGN, V18, P4266, DOI 10.2174/138161212802481237
   van Can J, 2013, INT J OBESE
   Westhorpe CLV, 2012, EXP MOL PATHOL, V93, P220, DOI 10.1016/j.yexmp.2012.03.014
   Woods A, 2005, CELL METAB, V2, P21, DOI 10.1016/j.cmet.2005.06.005
   Woollard KJ, 2013, CLIN SCI, V125, P221, DOI 10.1042/CS20120576
   Wu Y, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0035508
   Xing JJ, 2013, AM J PATHOL, V182, P1021, DOI 10.1016/j.ajpath.2012.11.022
   Yamamizu K, 2011, CIRC J, V75, P253, DOI 10.1253/circj.CJ-10-0915
NR 58
TC 66
Z9 72
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 16
PY 2014
VL 9
IS 5
AR e97554
DI 10.1371/journal.pone.0097554
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM1NZ
UT WOS:000339614800050
PM 24835252
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Leblond, F
   Poirier, S
   Yu, C
   Duquette, N
   Mayer, G
   Thorin, E
AF Leblond, Francois
   Poirier, Steve
   Yu, Carol
   Duquette, Natacha
   Mayer, Gaetan
   Thorin, Eric
TI The Anti-Hypercholesterolemic Effect of Low p53 Expression Protects
   Vascular Endothelial Function in Mice
SO PLOS ONE
LA English
DT Article
ID SMALL HETERODIMER PARTNER; BILE-ACID HOMEOSTASIS; TUMOR-SUPPRESSOR;
   OXIDATIVE STRESS; DEPENDENT CONTRACTIONS; ATHEROSCLEROTIC PATIENTS;
   CARDIOVASCULAR-DISEASE; CELLULAR SENESCENCE; POSSIBLE MECHANISM; NUCLEAR
   RECEPTOR
AB Aims: To demonstrate that p53 modulates endothelial function and the stress response to a high-fat western diet (WD).
   Methods and Results: Three-month old p53(+/+) wild type (WT) and p53(+/-) male mice were fed a regular or WD for 3 months. Plasma levels of total cholesterol (TC) and LDL-cholesterol were significantly elevated (p < 0.05) in WD-fed WT (from 2.1 +/- 0.2 mmol/L to 3.1 +/- 0.2, and from 0.64 +/- 0.09 mmol/L to 1.25 +/- 0.11, respectively) but not in p53(+/-) mice. The lack of cholesterol accumulation in WD-fed p53(+/-) mice was ass-ociated with high bile acid plasma concentrations (p53(+/-) = 4.7 +/- 0.9 vs. WT = 3.3 +/- 0.2 mu mol/L, p < 0.05) concomitant with an increased hepatic 7-alpha-hydroxylase mRNA expression. While the WD did not affect aortic endothelial relaxant function in p53(+/-) mice (WD = 8365 and RD = 82 +/- 4% relaxation), it increased the maximal response to acetylcholine in WT mice (WD = 8762 vs. RD = 62 +/- 5% relaxation, p < 0.05) to levels of p53(+/-). In WT mice, the rise in TC associated with higher (p < 0.05) plasma levels of pro-inflammatory keratinocyte-derived chemokine, and an over-activation (p < 0.05) of the relaxant non-nitric oxide/non-prostacyclin endothelial pathway. It is likely that in WT mice, activations of these pathways are adaptive and contributed to maintain endothelial function, while the WD neither promoted inflammation nor affected endothelial function in p53(+/-) mice.
   Conclusions: Our data demonstrate that low endogenous p53 expression prevents the rise in circulating levels of cholesterol when fed a WD. Consequently, the endothelial stress of hypercholesterolemia is absent in young p53(+/-) mice as evidenced by the absence of endothelial adaptive pathway over-activation to minimize stress-related damage.
C1 [Leblond, Francois; Poirier, Steve; Yu, Carol; Mayer, Gaetan; Thorin, Eric] Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada.
   [Thorin, Eric] Univ Montreal, Dept Surg, Montreal, PQ H3C 3J7, Canada.
   [Leblond, Francois; Poirier, Steve; Yu, Carol; Mayer, Gaetan; Thorin, Eric] Univ Montreal, Fac Med, Montreal, PQ H3C 3J7, Canada.
   [Leblond, Francois; Poirier, Steve; Yu, Carol; Duquette, Natacha; Mayer, Gaetan; Thorin, Eric] Montreal Heart Inst, Res Ctr, Montreal, PQ H1T 1C8, Canada.
RP Thorin, E (reprint author), Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada.
EM eric.thorin@umontreal.ca
RI Thorin, Eric/K-3978-2013
OI Thorin, Eric/0000-0001-5827-8935
FU Canadian Institutes of Health Research [MOP 14496]
FX This work was supported by the Canadian Institutes of Health Research
   (MOP 14496 to E. T.). F. Leblond is supported by a Banting and Best PhD
   scholarship from the Canadian Institutes of Health Research. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Apostolakis S, 2009, CARDIOVASC RES, V84, P353, DOI 10.1093/cvr/cvp241
   Bailey-Downs LC, 2013, J GERONTOL A-BIOL, V68, P780, DOI 10.1093/gerona/gls238
   Benkhoff S, 2012, ARTERIOSCL THROM VAS, V32, P1605, DOI 10.1161/ATVBAHA.112.251140
   Bensaad K, 2005, NAT MED, V11, P1278, DOI 10.1038/nm1205-1278
   Cheng HM, 2007, EUR J CLIN INVEST, V37, P197, DOI 10.1111/j.1365-2362.2007.01772.x
   Chiang JYL, 2009, J LIPID RES, V50, P1955, DOI 10.1194/jlr.R900010-JLR200
   Chumakov PM, 2007, BIOCHEMISTRY-MOSCOW+, V72, P1399, DOI 10.1134/S0006297907130019
   Collins AR, 2009, CIRC RES, V104, pe42, DOI 10.1161/CIRCRESAHA.108.188771
   DONEHOWER LA, 1992, NATURE, V356, P215, DOI 10.1038/356215a0
   Drouin A, 2011, PFLUG ARCH EUR J PHY, V462, P371, DOI 10.1007/s00424-011-0973-y
   Drouin A, 2011, AM J PHYSIOL-HEART C, V300, pH1032, DOI 10.1152/ajpheart.00410.2010
   Durrant JR, 2009, J PHYSIOL-LONDON, V587, P3271, DOI 10.1113/jphysiol.2009.169771
   Farhat N, 2008, CAN J PHYSIOL PHARM, V86, P761, DOI 10.1139/Y08-082
   Feletou M, 2011, BRIT J PHARMACOL, V164, P894, DOI 10.1111/j.1476-5381.2011.01276.x
   Feng ZH, 2007, P NATL ACAD SCI USA, V104, P16633, DOI 10.1073/pnas.0708043104
   Gendron ME, 2007, AM J PHYSIOL-HEART C, V293, pH2508, DOI 10.1152/ajpheart.00352.2007
   Gerszten RE, 1999, NATURE, V398, P718
   Grigore L, 2013, EUR J CLIN PHARMACOL, V69, P341, DOI 10.1007/s00228-012-1345-z
   Guevara NV, 1999, NAT MED, V5, P335, DOI 10.1038/6585
   HARVEY M, 1993, NAT GENET, V5, P225, DOI 10.1038/ng1193-225
   Higashi Y, 2009, CIRC J, V73, P411, DOI 10.1253/circj.CJ-08-1102
   Huo YQ, 2001, J CLIN INVEST, V108, P1307, DOI 10.1172/JCI200112877
   Insull W, 2006, SOUTH MED J, V99, P257, DOI 10.1097/01.smj.0000208120.73327.db
   JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6
   Janowski BA, 1996, NATURE, V383, P728, DOI 10.1038/383728a0
   Kim CS, 2008, CIRC RES, V103, P1441, DOI 10.1161/CIRCRESAHA.108.181644
   Kim DH, 2011, MOL ENDOCRINOL, V25, P2076, DOI 10.1210/me.2011-1198
   Kim DH, 2011, P NATL ACAD SCI USA, V108, P12266, DOI 10.1073/pnas.1019678108
   Krummen S, 2005, BRIT J PHARMACOL, V145, P264, DOI 10.1038/sj.bjp.0706194
   Kumar A, 2011, ARTERIOSCL THROM VAS, V31, P133, DOI 10.1161/ATVBAHA.110.215061
   Levine AJ, 1997, CELL, V88, P323, DOI 10.1016/S0092-8674(00)81871-1
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Liu B, 2008, FREE RADICAL BIO MED, V44, P1529, DOI 10.1016/j.freeradbiomed.2008.01.011
   Maeda Y, 2006, BIOCHEM J, V400, P303, DOI 10.1042/BJ0060614
   Makishima M, 1999, SCIENCE, V284, P1362, DOI 10.1126/science.284.5418.1362
   Matoba S, 2006, SCIENCE, V312, P1650, DOI 10.1126/science.1126863
   Mercer J, 2005, CIRC RES, V96, P667, DOI 10.1161/01.RES.0000161069.15577.ca
   Mercer J, 2006, CELL CYCLE, V5, P1907, DOI 10.4161/cc.5.17.3166
   Merched AJ, 2003, ARTERIOSCL THROM VAS, V23, P1608, DOI 10.1161/01.ATV.0000084825.88022.53
   MINOR RL, 1990, J CLIN INVEST, V86, P2109, DOI 10.1172/JCI114949
   NISHINA PM, 1993, J LIPID RES, V34, P1413
   Perez MJ, 2009, WORLD J GASTROENTERO, V15, P1677, DOI 10.3748/wjg.15.1677
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Polyak K, 1997, NATURE, V389, P300, DOI 10.1038/38525
   Rippe C, 2010, AGING CELL, V9, P304, DOI 10.1111/j.1474-9726.2010.00557.x
   Sablina AA, 2005, NAT MED, V11, P1306, DOI 10.1038/nm1320
   Sansbury BE, 2012, CIRC RES, V111, P1176, DOI [10.1161/CIRCRESAHA.112.266395, 10.1161/circresaha.112.266395]
   Schwartzenberg-Bar-Yoseph F, 2004, CANCER RES, V64, P2627, DOI 10.1158/0008-5472.CAN-03-0846
   Shi Y, 2008, ACTA PHARMACOL SIN, V29, P185, DOI 10.1111/j.1745-7254.2008.00749.x
   Thorin E, 2000, CIRCULATION, V101, P1430, DOI 10.1161/01.CIR.101.12.1430
   Tyner SD, 2002, NATURE, V415, P45, DOI 10.1038/415045a
   Versari D, 2009, DIABETES CARE, V32, pS314, DOI 10.2337/dc09-S330
   Voghel G, 2008, MECH AGEING DEV, V129, P261, DOI 10.1016/j.mad.2008.01.004
   Voghel G, 2007, MECH AGEING DEV, V128, P662, DOI 10.1016/j.mad.2007.09.006
   Vousden KH, 2009, CELL, V137, P413, DOI 10.1016/j.cell.2009.04.037
   Webster NJG, 1996, CANCER RES, V56, P2781
   Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837
   Wong SL, 2009, CIRC RES, V104, P228, DOI 10.1161/CIRCRESAHA.108.179770
   Yang D, 2002, BRIT J PHARMACOL, V136, P104, DOI 10.1038/sj.bjp.0704669
NR 59
TC 1
Z9 1
U1 0
U2 1
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 19
PY 2014
VL 9
IS 3
AR e92394
DI 10.1371/journal.pone.0092394
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AD6ER
UT WOS:000333348500126
PM 24647794
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Manichaikul, A
   Rich, SS
   Perry, H
   Yeboah, J
   Law, M
   Davis, M
   Parker, M
   Ragosta, M
   Connelly, JJ
   McNamara, CA
   Taylor, AM
AF Manichaikul, Ani
   Rich, Stephen S.
   Perry, Heather
   Yeboah, Joseph
   Law, Michelle
   Davis, Molly
   Parker, Matthew
   Ragosta, Michael
   Connelly, Jessica J.
   McNamara, Coleen A.
   Taylor, Angela M.
TI A Functionally Significant Polymorphism in ID3 Is Associated with Human
   Coronary Pathology
SO PLOS ONE
LA English
DT Article
ID BINDING INHIBITOR ID3; T-CELLS; INTRAVASCULAR ULTRASOUND;
   SJOGRENS-SYNDROME; ARTERY-DISEASE; MOUSE MODEL; ATHEROSCLEROSIS; MICE;
   12/15-LIPOXYGENASE; DIFFERENTIATION
AB Aims: We previously identified association between the ID3 SNP rs11574 and carotid intima-media thickness in the Diabetes Heart Study, a predominantly White diabetic population. The nonsynonymous SNP rs11574 results in an amino acid substitution in the C-terminal region of ID3, attenuating the dominant negative function of ID3 as an inhibitor of basic HLH factor E12-mediated transcription. In the current investigation, we characterize the association between the functionally significant polymorphism in ID3, rs11574, with human coronary pathology.
   Methods and Results: The Multi-Ethnic Study of Atherosclerosis (MESA) is a longitudinal study of subclinical cardiovascular disease, including non-Hispanic White (n = 2,588), African American (n = 2,560) and Hispanic (n = 2,130) participants with data on coronary artery calcium (CAC). The Coronary Assessment in Virginia cohort (CAVA) included 71 patients aged 30-80 years, undergoing a medically necessary cardiac catheterization and intravascular ultrasound (IVUS) at the University of Virginia. ID3 SNP rs11574 risk allele was associated with the presence of CAC in MESA Whites (P = 0.017). In addition, the risk allele was associated with greater atheroma burden and stenosis in the CAVA cohort (P = 0.003, P = 0.04 respectively). The risk allele remained predictive of atheroma burden in multivariate analysis (Model 1: covariates age, gender, and LDL, regression coefficient = 9.578, SE = 3.657, p = 0.0110; Model 2: covariates Model 1, presence of hypertension, presence of diabetes, regression coefficient = 8.389, SE = 4.788, p = 0.0163).
   Conclusions: We present additional cohorts that demonstrate association of ID3 SNP rs11574 directly with human coronary artery pathology as measured by CAC and IVUS: one a multiethnic, relatively healthy population with low levels of diabetes and the second a predominantly White population with a higher incidence of T2DM referred for cardiac catheterization.
C1 [Manichaikul, Ani; Rich, Stephen S.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA.
   [Manichaikul, Ani] Univ Virginia, Dept Publ Hlth Sci, Div Biostat & Epidemiol, Charlottesville, VA USA.
   [Perry, Heather; Law, Michelle; Davis, Molly; Parker, Matthew; Connelly, Jessica J.; McNamara, Coleen A.; Taylor, Angela M.] Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22903 USA.
   [Yeboah, Joseph] Wake Forest Univ Hlth Sci, Dept Internal Med Cardiol, Winston Salem, NC USA.
   [Law, Michelle; Ragosta, Michael; Connelly, Jessica J.; McNamara, Coleen A.; Taylor, Angela M.] Univ Virginia, Dept Med, Div Cardiovasc Med, Charlottesville, VA USA.
RP Taylor, AM (reprint author), Univ Virginia, Cardiovasc Res Ctr, Charlottesville, VA 22903 USA.
EM amt6b@virginia.edu
OI Manichaikul, Ani/0000-0002-5998-795X
FU NIH [P01 HL55798, R01 HL096447, R01 HL107490, K23HL093118-04]; Pfizer
   Preventive Cardiology Award; National Heart, Lung, and Blood Institute
   (NHLBI) [N01-HC-95159, N01-HC-95169, RR-024156]; NHLBI [N02-HL-6-4278]; 
   [R01HL071051];  [R01HL071205];  [R01HL071250];  [R01HL071251]; 
   [R01HL071252];  [R01HL071258];  [R01HL071259]
FX The CAVA study was supported by NIH P01 HL55798 (CAM), NIH R01 HL096447
   (CAM), NIH R01 HL107490 (CAM), K23HL093118-04 (AMT), Pfizer Preventive
   Cardiology Award (AMT). The funders of the CAVA study had no role in
   study design, data collection and analysis, decision to publish, or
   preparation of the manuscript. MESA and the MESA SHARe project are
   conducted and supported by contracts N01-HC-95159 through N01-HC-95169
   and RR-024156 from the National Heart, Lung, and Blood Institute
   (NHLBI). Funding for MESA SHARe genotyping was provided by NHLBI
   Contract N02-HL-6-4278. MESA Family is conducted and supported in
   collaboration with MESA investigators; support is provided by grants and
   contracts R01HL071051, R01HL071205, R01HL071250, R01HL071251,
   R01HL071252, R01HL071258, R01HL071259. The funders (NHLBI) had a
   significant role in design and data collection for the MESA study. The
   funders had no role in analysis, decision to publish, or preparation of
   the manuscript.
CR Bild DE, 2002, AM J EPIDEMIOL, V156, P871, DOI 10.1093/aje/kwf113
   Calvert PA, 2011, JACC-CARDIOVASC IMAG, V4, P894, DOI 10.1016/j.jcmg.2011.05.005
   Campbell KA, 2012, CIRC RES, V110, P889, DOI 10.1161/CIRCRESAHA.111.263186
   Chan L, 1994, CARDIOL REV, V2, P130, DOI DOI 10.1097/00045415-199405000-00003
   Chou MY, 2009, J CLIN INVEST, V119, P1335, DOI 10.1172/JCI36800
   Deliri H, 2011, ARTERIOSCL THROM VAS, V31, P110, DOI 10.1161/ATVBAHA.110.212068
   Doran AC, 2012, CIRC RES, V110, pE1, DOI 10.1161/CIRCRESAHA.111.256438
   Doran AC, 2010, CIRC RES, V106, P1303, DOI 10.1161/CIRCRESAHA.109.210294
   Guo ZL, 2011, IMMUNOL LETT, V135, P34, DOI 10.1016/j.imlet.2010.09.009
   Hansson GK, 2011, NAT IMMUNOL, V12, P204, DOI 10.1038/ni.2001
   Ji Y, 2011, NAT IMMUNOL, V12, P1230, DOI 10.1038/ni.2153
   Jones-Mason ME, 2012, IMMUNITY, V36, P348, DOI 10.1016/j.immuni.2012.02.010
   KEYS A, 1986, AM J EPIDEMIOL, V124, P903, DOI 10.1093/oxfordjournals.aje.a114480
   Lahoute C, 2011, NAT REV CARDIOL, V8, P348, DOI 10.1038/nrcardio.2011.62
   Li HM, 2004, IMMUNITY, V21, P551, DOI 10.1016/j.immuni.2004.08.013
   Libby P, 2002, NATURE, V420, P868, DOI 10.1038/nature01323
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lipinski MJ, 2012, ARTERIOSCL THROM VAS, V32, P2855, DOI 10.1161/ATVBAHA.112.300352
   Lusis MJ, 2004, ANNU REV GENOM HUM G, V5, P189, DOI 10.1146/annurev.genom.5.061903.175930
   Mahlios J, 2011, MOL IMMUNOL, V49, P227, DOI 10.1016/j.molimm.2011.08.012
   Maruyama T, 2011, NAT IMMUNOL, V12, P86, DOI 10.1038/ni.1965
   Mintz GS, 2001, J AM COLL CARDIOL, V37, P1478, DOI 10.1016/S0735-1097(01)01175-5
   Miyazaki M, 2011, NAT IMMUNOL, V12, P992, DOI 10.1038/ni.2086
   Morris-Rosenfeld S, 2013, EXPERT REV CLIN IMMU
   NICHAMAN MZ, 1975, AM J EPIDEMIOL, V102, P491, DOI 10.1093/oxfordjournals.aje.a112187
   Nicholls SJ, 2010, J AM COLL CARDIOL, V55, P2399, DOI 10.1016/j.jacc.2010.02.026
   Perry HM, 2013, ARTERIOSCL THROM VAS, V33, P2771, DOI 10.1161/ATVBAHA.113.302571
   Ragosta M, 2011, J CARDIOVASC TRANSL, V4, P385, DOI 10.1007/s12265-011-9274-2
   Taylor AM, 2005, ARTERIOSCL THROM VAS, V25, P2069, DOI 10.1161/01.ATV.0000178992.40088.f2
   Tsimikas S, 2007, J LIPID RES, V48, P425, DOI 10.1194/jlr.M600361-JLR200
   Wang Q, 2004, AM J HUM GENET, V74, P262, DOI 10.1086/381560
   Welch CL, 2001, P NATL ACAD SCI USA, V98, P7946, DOI 10.1073/pnas.141239098
   Yang CY, 2011, NAT IMMUNOL, V12, P1221, DOI 10.1038/ni.2158
   Yeboah J, 2012, JAMA-J AM MED ASSOC, V308, P788, DOI 10.1001/jama.2012.9624
NR 34
TC 11
Z9 11
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAR 6
PY 2014
VL 9
IS 3
AR e90222
DI 10.1371/journal.pone.0090222
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AC4ID
UT WOS:000332483600030
PM 24603695
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Vijil, C
   Hermansson, C
   Jeppsson, A
   Bergstrom, G
   Hulten, LM
AF Vijil, Carolina
   Hermansson, Cecilia
   Jeppsson, Anders
   Bergstrom, Goran
   Hulten, Lillemor Mattsson
TI Arachidonate 15-Lipoxygenase Enzyme Products Increase Platelet
   Aggregation and Thrombin Generation
SO PLOS ONE
LA English
DT Article
ID HUMAN MACROPHAGES; ISCHEMIC-STROKE; ATHEROSCLEROSIS; ATHEROTHROMBOSIS;
   EXPRESSION; DISEASE; INFLAMMATION; ACTIVATION; MECHANISMS; PLAQUES
AB Atherosclerotic cardiovascular diseases are the leading causes of morbidity and mortality worldwide. We have previously shown that arachidonate 15-lipoxygenase B (ALOX15B) is highly expressed in atherosclerotic carotid plaques, and elucidation of mechanisms downstream of activated lipoxygenases may be relevant to our understanding of the genesis of atherosclerotic diseases. We examined 120 carotid plaques from patients with symptomatic carotid artery stenosis and showed that the extent of ALOX15B staining was significantly increased in carotid plaques with thrombosis. Impedance aggregometry analyses showed that the ALOX15B enzyme products 15-HETE and 15-HPETE increased platelet aggregation. By using a calibrated automatic thrombin assay, we showed that the ALOX15B products also increased both peak levels of thrombin and the total endogenous thrombin potential. Moreover, platelet aggregation was increased by addition of cell lysates from ischemic human macrophages, whereas platelet aggregation was reduced after knockdown of ALOX15B in human macrophages. Our data show that ALOX15B expression in human carotid plaques is associated with thrombus formation and that enzyme products of ALOX15B increase platelet aggregation and thrombin generation. We therefore propose that activated ALOX15B in macrophages may play a role in the induction of atherothrombotic events by increasing platelet aggregation and thrombin generation.
C1 [Vijil, Carolina; Hulten, Lillemor Mattsson] Sahlgrens Univ Hosp, Dept Clin Chem, Gothenburg, Sweden.
   [Hermansson, Cecilia; Jeppsson, Anders; Bergstrom, Goran; Hulten, Lillemor Mattsson] Univ Gothenburg, Sahlgrenska Acad, Dept Mol & Clin Med, Inst Med, Gothenburg, Sweden.
   [Jeppsson, Anders] Sahlgrens Univ Hosp, Dept Cardiothorac Surg, Gothenburg, Sweden.
RP Hulten, LM (reprint author), Sahlgrens Univ Hosp, Dept Clin Chem, Gothenburg, Sweden.
EM Lillemor.Mattsson@wlab.gu.se
OI Bergstrom, Goran/0000-0003-4289-5722
FU Swedish Research Council; Swedish Heart Lung Foundation; Laboratory
   Medicine Sahlgrenska University Hospital Sweden
FX This study was supported by the Swedish Research Council, Swedish Heart
   Lung Foundation, and Laboratory Medicine Sahlgrenska University Hospital
   Sweden. The funders had no role in study design, data collection and
   analysis, decision to publish, or preparation of the manuscript.
CR Al Dieri R, 2012, BLOOD REV, V26, P197, DOI 10.1016/j.blre.2012.06.001
   Carcaillon L, 2011, ARTERIOSCL THROM VAS, V31, P1445, DOI 10.1161/ATVBAHA.111.223453
   Danielsson KN, 2008, ATHEROSCLEROSIS, V199, P34, DOI 10.1016/j.atherosclerosis.2007.10.027
   Davi G, 2007, NEW ENGL J MED, V357, P2482, DOI 10.1056/NEJMra071014
   GALIS ZS, 1994, J CLIN INVEST, V94, P2493, DOI 10.1172/JCI117619
   Gertow K, 2011, ATHEROSCLEROSIS, V215, P411, DOI 10.1016/j.atherosclerosis.2011.01.015
   HAMBERG M, 1975, P NATL ACAD SCI USA, V72, P2994, DOI 10.1073/pnas.72.8.2994
   Hemker HC, 2002, PATHOPHYSIOL HAEMO T, V32, P249, DOI 10.1159/000073575
   Hemker HC, 2003, PATHOPHYSIOL HAEMO T, V33, P4, DOI 10.1159/000071636
   HEMKER HC, 1993, THROMB HAEMOSTASIS, V70, P617
   Hulten LM, 2010, EUR J CLIN INVEST, V40, P11, DOI 10.1111/j.1365-2362.2009.02223.x
   Jennings LK, 2009, THROMB HAEMOSTASIS, V102, P248, DOI 10.1160/TH09-03-0192
   Jisaka M, 2000, J BIOL CHEM, V275, P1287, DOI 10.1074/jbc.275.2.1287
   Krasopoulos G, 2008, BMJ-BRIT MED J, V336, P195, DOI 10.1136/bmj.39430.529549.BE
   Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
   Magnusson LU, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043142
   McLaren JE, 2011, PROG LIPID RES, V50, P331, DOI 10.1016/j.plipres.2011.04.002
   Owens AP, 2012, CURR ATHEROSCLER REP, V14, P394, DOI 10.1007/s11883-012-0269-5
   Rydberg EK, 2004, ARTERIOSCL THROM VAS, V24, P2040, DOI 10.1161/01.ATV.0000144951.08072.0b
   Seet RCS, 2011, STROKE, V42, P2326, DOI 10.1161/STROKEAHA.111.618835
   SETTY BNY, 1992, BLOOD, V80, P2765
   Sibbing D, 2010, THROMB HAEMOSTASIS, V103, P151, DOI 10.1160/TH09-05-0284
   STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512
   Toth O, 2006, THROMB HAEMOSTASIS, V96, P781, DOI 10.1160/TH06-05-0242
   Wagner DD, 2003, ARTERIOSCL THROM VAS, V23, P2131, DOI 10.1161/01.ATV.0000095974.95122.EC
   WARLOW C, 1991, LANCET, V337, P1235, DOI 10.1016/0140-6736(91)92916-P
   Yigitkanli K, 2013, ANN NEUROL, V73, P129, DOI 10.1002/ana.23734
NR 29
TC 15
Z9 15
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 12
PY 2014
VL 9
IS 2
AR e88546
DI 10.1371/journal.pone.0088546
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AA7FJ
UT WOS:000331262600062
PM 24533104
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Wang, YI
   Bettaieb, A
   Sun, CX
   DeVerse, JS
   Radecke, CE
   Mathew, S
   Edwards, CM
   Haj, FG
   Passerini, AG
   Simon, SI
AF Wang, Ying I.
   Bettaieb, Ahmed
   Sun, Chongxiu
   DeVerse, J. Sherrod
   Radecke, Christopher E.
   Mathew, Steven
   Edwards, Christina M.
   Haj, Fawaz G.
   Passerini, Anthony G.
   Simon, Scott I.
TI Triglyceride-Rich Lipoprotein Modulates Endothelial Vascular Cell
   Adhesion Molecule (VCAM)-1 Expression via Differential Regulation of
   Endoplasmic Reticulum Stress
SO PLOS ONE
LA English
DT Article
ID UNFOLDED PROTEIN RESPONSE; NECROSIS-FACTOR-ALPHA; INDUCED ER STRESS;
   HOMOLOGOUS PROTEIN; FATTY-ACIDS; ATHEROSCLEROSIS; DISEASE; OBESITY;
   INFLAMMATION; HOMEOSTASIS
AB Circulating triglyceride-rich lipoproteins (TGRL) from hypertriglyceridemic subjects exacerbate endothelial inflammation and promote monocyte infiltration into the arterial wall. We have recently reported that TGRL isolated from human blood after a high-fat meal can elicit a pro- or anti-atherogenic state in human aortic endothelial cells (HAEC), defined as up- or down-regulation of VCAM-1 expression in response to tumor necrosis factor alpha (TNF alpha) stimulation, respectively. A direct correlation was found between subjects categorized at higher risk for cardiovascular disease based upon serum triglycerides and postprandial production of TGRL particles that increased VCAM-1-dependent monocyte adhesion to inflamed endothelium. To establish how TGRL metabolism is linked to VCAM-1 regulation, we examined endoplasmic reticulum (ER) stress and the unfolded protein response (UPR) pathways. Regardless of its atherogenicity, the rate and extent of TGRL internalization and lipid droplet formation by HAEC were uniform. However, pro-atherogenic TGRL exacerbated ER membrane expansion and stress following TNF alpha stimulation, whereas anti-atherogenic TGRL ameliorated such effects. Inhibition of ER stress with a chemical chaperone 4-phenylbutyric acid decreased TNF alpha-induced VCAM-1 expression and abrogated TGRL's atherogenic effect. Activation of ER stress sensors PKR-like ER-regulated kinase (PERK) and inositol requiring protein 1 alpha (IRE1 alpha), and downstream effectors including eukaryotic initiation factor-2 alpha (eIF2 alpha), spliced X-box-binding protein 1 (sXBP1) and C/EBP homologous protein (CHOP), directly correlated with the atherogenic activity of an individual's TGRL. Modulation of ER stress sensors also correlated with changes in expression of interferon regulatory factor 1 (IRF-1), a transcription factor of Vcam-1 responsible for regulation of its expression. Moreover, knockdown studies using siRNA defined a causal relationship between the PERK/eIF2 alpha/CHOP pathway and IRF-1-mediated VCAM-1 expression. We conclude that ER stress and the UPR contribute to the regulation of Vcam-1 transcription as a function of the atherogenic nature of TGRL.
C1 [Wang, Ying I.; Sun, Chongxiu; DeVerse, J. Sherrod; Radecke, Christopher E.; Mathew, Steven; Edwards, Christina M.; Passerini, Anthony G.; Simon, Scott I.] Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
   [Bettaieb, Ahmed; Haj, Fawaz G.] Univ Calif Davis, Dept Nutr, Davis, CA 95616 USA.
   [Haj, Fawaz G.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA.
RP Simon, SI (reprint author), Univ Calif Davis, Dept Biomed Engn, Davis, CA 95616 USA.
EM sisimon@ucdavis.edu
OI Passerini, Anthony/0000-0001-8007-4672
FU National Institutes of Health [HL082689, R01DK090492]
FX This work was supported by National Institutes of Health grants HL082689
   to SIS and AGP, and R01DK090492 to FGH. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Boden G, 2008, DIABETES, V57, P2438, DOI 10.2337/db08-0604
   Boden G, 2009, DIABETES, V58, P518, DOI 10.2337/db08-1746
   Civelek M, 2009, CIRC RES, V105, P453, DOI 10.1161/CIRCRESAHA.109.203711
   Deguil J, 2011, TRAFFIC, V12, P349, DOI 10.1111/j.1600-0854.2010.01150.x
   Diakogiannaki E, 2008, J ENDOCRINOL, V197, P553, DOI 10.1677/JOE-08-0041
   Erbay E, 2009, NAT MED, V15, P1383, DOI 10.1038/nm.2067
   FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
   Fu SN, 2011, NATURE, V473, P528, DOI 10.1038/nature09968
   Gao JH, 2011, CIRCULATION, V124, P830, DOI 10.1161/CIRCULATIONAHA.110.014050
   Gargalovic PS, 2006, ARTERIOSCL THROM VAS, V26, P2490, DOI 10.1161/01.ATV.0000242903.41158.a1
   Gower RM, 2011, ARTERIOSCL THROM VAS, V31, P160, DOI 10.1161/ATVBAHA.110.215434
   Guo Y, 2009, J CELL SCI, V122, P749, DOI 10.1242/jcs.037630
   Hotamisligil GS, 2010, CELL, V140, P900, DOI 10.1016/j.cell.2010.02.034
   Hummasti S, 2010, ENDOPLASMIC RETICULU
   Kannel WB, 2009, CURR OPIN CARDIOL, V24, P345, DOI 10.1097/HCO.0b013e32832c1284
   Karaskov E, 2006, ENDOCRINOLOGY, V147, P3398, DOI 10.1210/en.2005-1494
   Libby P, 2002, NATURE, V420, P868, DOI 10.1038/nature01323
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Marciniak SJ, 2006, PHYSIOL REV, V86, P1133, DOI 10.1152/physrev.00015.2006
   Michalak M, 1999, BIOCHEM J, V344, P281, DOI 10.1042/0264-6021:3440281
   Miller M, 2011, CIRCULATION, V123, P2292, DOI 10.1161/CIR.0b013e3182160726
   Namba T, 2009, AM J PATHOL, V174, P1786, DOI 10.2353/ajpath.2009.080864
   Norata GD, 2007, ATHEROSCLEROSIS, V193, P321, DOI 10.1016/j.atherosclerosis.2006.09.015
   Ozcan U, 2006, SCIENCE, V313, P1137, DOI 10.1126/science.1128294
   Oyadomari S, 2004, CELL DEATH DIFFER, V11, P381, DOI 10.1038/sj.cdd.4401373
   Ozcan U, 2004, SCIENCE, V306, P457, DOI 10.1126/science.1103160
   Peng G, 2011, ENDOCRINOLOGY, V152, P2206, DOI 10.1210/en.2010-1369
   Pineau L, 2009, TRAFFIC, V10, P673, DOI 10.1111/j.1600-0854.2009.00903.x
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   RUS HG, 1991, ATHEROSCLEROSIS, V89, P247
   Schuck S, 2009, J CELL BIOL, V187, P525, DOI 10.1083/jcb.200907074
   Sha HB, 2009, CELL METAB, V9, P556, DOI 10.1016/j.cmet.2009.04.009
   SUN CT, 2012, FRACTURE MECHANICS, P1, DOI DOI 10.1161/CIRCRESAHA.112.270314
   Tabas I, 2010, CIRC RES, V107, P839, DOI 10.1161/CIRCRESAHA.110.224766
   Thorp E, 2009, CELL METAB, V9, P474, DOI 10.1016/j.cmet.2009.03.003
   Ting HJ, 2007, CIRC RES, V100, P381, DOI 10.1161/01.RES.00002580223.76515.a3
   Wang YI, 2011, AM J PHYSIOL-HEART C, V300, pH784, DOI 10.1152/ajpheart.01036.2010
   Xu GS, 2012, BLOOD, V119, P4205, DOI 10.1182/blood-2011-05-353300
   Zhou J, 2005, CIRCULATION, V111, P1814, DOI 10.1161/01.CIR.0000160864.31351.C1
NR 39
TC 9
Z9 11
U1 0
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 21
PY 2013
VL 8
IS 10
AR UNSP e78322
DI 10.1371/journal.pone.0078322
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 239NN
UT WOS:000326032600093
PM 24205197
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Zhou, C
   Lei, H
   Chen, YX
   Liu, Q
   Li, LC
   Moorhead, JF
   Varghese, Z
   Ruan, XZ
AF Zhou, Chao
   Lei, Han
   Chen, Yaxi
   Liu, Qing
   Li, Lung-Chih
   Moorhead, John F.
   Varghese, Zac
   Ruan, Xiong Z.
TI Enhanced SCAP Glycosylation by Inflammation Induces Macrophage Foam Cell
   Formation
SO PLOS ONE
LA English
DT Article
ID ACCELERATED ATHEROSCLEROSIS; CHOLESTEROL; MECHANISMS; RECEPTOR;
   INFECTION; PROLIFERATION; DYSREGULATION; EXPRESSION; RESISTANCE;
   SIROLIMUS
AB Inflammatory stress promotes foam cell formation by disrupting LDL receptor feedback regulation in macrophages. Sterol Regulatory Element Binding Proteins (SREBPs) Cleavage-Activating Protein (SCAP) glycosylation plays crucial roles in regulating LDL receptor and 3-hydroxy-3-methyl-glutaryl-CoA reductase (HMGCoAR) feedback regulation. The present study was to investigate if inflammatory stress disrupts LDL receptor and HMGCoAR feedback regulation by affecting SCAP glycosylation in THP-1 macrophages. Intracellular cholesterol content was assessed by Oil Red O staining and quantitative assay. The expression of molecules controlling cholesterol homeostasis was examined using real-time quantitative RT-PCR and Western blotting. The translocation of SCAP from the endoplasmic reticulum (ER) to the Golgi was detected by confocal microscopy. We demonstrated that exposure to inflammatory cytokines increased lipid accumulation in THP-1 macrophages, accompanying with an increased SCAP expression even in the presence of a high concentration of LDL. These inflammatory cytokines also prolonged the half-life of SCAP by enhancing glycosylation of SCAP due to the elevated expression of the Golgi mannosidase II. This may enhance translocation and recycling of SCAP between the ER and the Golgi, escorting more SREBP2 from the ER to the Golgi for activation by proteolytic cleavages as evidenced by an increased N-terminal of SREBP2 (active form). As a consequence, the LDL receptor and HMGCoAR expression were up-regulated. Interestingly, these effects could be blocked by inhibitors of Golgi mannosidases. Our results indicated that inflammation increased native LDL uptake and endogenous cholesterol de novo synthesis, thereby causing foam cell formation via increasing transcription and protein glycosylation of SCAP in macrophages. These data imply that inhibitors of Golgi processing enzymes might have a potential vascular-protective role in prevention of atherosclerotic foam cell formation.
C1 [Zhou, Chao; Lei, Han; Chen, Yaxi; Ruan, Xiong Z.] Chongqing Med Univ, Ctr Lipid Res, Key Lab Metab Lipid & Glucose, Chongqing, Peoples R China.
   [Zhou, Chao; Lei, Han] Chongqing Med Univ, Affiliated Hosp 1, Dept Cardiol, Chongqing, Peoples R China.
   [Liu, Qing] Chongqing Med Univ, Affiliated Hosp 1, Clin Res Ctr, Chongqing, Peoples R China.
   [Zhou, Chao; Li, Lung-Chih; Moorhead, John F.; Varghese, Zac; Ruan, Xiong Z.] UCL, Sch Med, Ctr Nephrol, John Moorhead Res Lab, London W1N 8AA, England.
   [Li, Lung-Chih] Kaohsiung Chang Gung Mem Hosp, Kaohsiung, Taiwan.
   [Li, Lung-Chih] Chang Gung Univ, Coll Med, Kaohsiung, Taiwan.
RP Lei, H (reprint author), Chongqing Med Univ, Ctr Lipid Res, Key Lab Metab Lipid & Glucose, Chongqing, Peoples R China.
EM xiaoban@cqmu.edu.cn; x.ruan@ucl.ac.uk
RI Moorhead, John/M-7404-2014
FU Major State Basic Research Development Program of China (973 Program)
   [2012CB517700, 2012CB517500]; National Natural Science Foundation of
   China [81070631, 81070317, 81030008, 81270493, 81270789, 81200567];
   Moorhead Trust; Royal Free Hospital Special Trustees Grant [115]; Kidney
   Research UK [RP37/2008]
FX This study was supported by Major State Basic Research Development
   Program of China (973 Program, NO. 2012CB517700 & 2012CB517500), the
   National Natural Science Foundation of China (81070631, 81070317, and
   Key Program, No. 81030008,81270493, 81270789, 81200567), the Moorhead
   Trust, the Royal Free Hospital Special Trustees Grant-115 through Dr.
   Zac Varghese, and Kidney Research UK (RP37/2008). The funders had no
   role in study design, data collection and analysis, decision to publish,
   or preparation of the manuscript.
CR [Anonymous], 2012, NHLBI MORB MORT CHAR, DOI Bethesda, MD
   Brown MS, 2000, CELL, V100, P391, DOI 10.1016/S0092-8674(00)80675-3
   BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311
   Chang TY, 2009, AM J PHYSIOL-ENDOC M, V297, pE1, DOI 10.1152/ajpendo.90926.2008
   Cooke CL, 2009, GASTROENTEROLOGY, V137, P1061, DOI 10.1053/j.gastro.2009.04.014
   DUNPHY WG, 1985, CELL, V40, P463, DOI 10.1016/0092-8674(85)90161-8
   Hart GW, 2010, CELL, V143, P672, DOI 10.1016/j.cell.2010.11.008
   Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
   Hua XX, 1996, CELL, V87, P415, DOI 10.1016/S0092-8674(00)81362-8
   KLAG MJ, 1993, NEW ENGL J MED, V328, P313, DOI 10.1056/NEJM199302043280504
   Kreisman LSC, 2012, GLYCOBIOLOGY, V22, P1019, DOI 10.1093/glycob/cws070
   Kzhyshkowska J, 2012, IMMUNOBIOLOGY, V217, P492, DOI 10.1016/j.imbio.2012.02.015
   Li LC, 2013, AM J PHYSIOL-HEART C, V304, pH874, DOI 10.1152/ajpheart.00096.2012
   Libby P, 2012, ARTERIOSCL THROM VAS, V32, P2045, DOI 10.1161/ATVBAHA.108.179705
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Linden S, 2010, HELICOBACTER, V15, P251, DOI 10.1111/j.1523-5378.2010.00765.x
   Liuzzo G, 1999, J AM COLL CARDIOL, V34, P1696, DOI 10.1016/S0735-1097(99)00432-5
   Ma KL, 2007, AM J PHYSIOL-HEART C, V292, pH2721, DOI 10.1152/ajpheart.01174.2006
   Ma KL, 2010, AM J PHYSIOL-HEART C, V298, pH1646, DOI 10.1152/ajpheart.00492.2009
   Moore KJ, 2005, J CLIN INVEST, V115, P2192, DOI 10.1172/JCI24061
   MOSMANN T, 1983, J IMMUNOL METHODS, V65, P55, DOI 10.1016/0022-1759(83)90303-4
   Murray PJ, 2011, NAT REV IMMUNOL, V11, P723, DOI 10.1038/nri3073
   Nohturfft A, 1999, P NATL ACAD SCI USA, V96, P11235, DOI 10.1073/pnas.96.20.11235
   Ohtsubo K, 2006, CELL, V126, P855, DOI 10.1016/j.cell.2006.08.019
   ROSENFELD ME, 1990, ARTERIOSCLEROSIS, V10, P680, DOI 10.1161/01.ATV.10.5.680
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Ruan XZ, 2006, ARTERIOSCL THROM VAS, V26, P1150, DOI 10.1161/01.ATV.0000217957.93135.c2
   Ruan XZ, 2003, NEPHROL DIAL TRANSPL, V18, P27, DOI 10.1093/ndt/18.1.27
   Ruan XZ, 2001, KIDNEY INT, V60, P1716, DOI 10.1046/j.1523-1755.2001.00025.x
   Skaggs BJ, 2012, NAT REV RHEUMATOL, V8, P214, DOI 10.1038/nrrheum.2012.14
   Swaminathan S, 2011, KIDNEY INT, V80, P453, DOI 10.1038/ki.2011.178
   VELASCO A, 1993, J CELL BIOL, V122, P39, DOI 10.1083/jcb.122.1.39
   Ye Q, 2009, INFLAMM RES, V58, P809, DOI 10.1007/s00011-009-0052-4
   Yuan Y, 2011, AM J PHYSIOL-RENAL, V301, pF236, DOI 10.1152/ajprenal.00646.2010
NR 34
TC 11
Z9 15
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD OCT 16
PY 2013
VL 8
IS 10
AR e75650
DI 10.1371/journal.pone.0075650
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 239JR
UT WOS:000326019400013
PM 24146768
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Li, Y
   Xu, SQ
   Jiang, BB
   Cohen, RA
   Zang, MW
AF Li, Yu
   Xu, Shanqin
   Jiang, Bingbing
   Cohen, Richard A.
   Zang, Mengwei
TI Activation of Sterol Regulatory Element Binding Protein and NLRP3
   Inflammasome in Atherosclerotic Lesion Development in Diabetic Pigs
SO PLOS ONE
LA English
DT Article
ID LIPID-METABOLISM; ACCELERATED ATHEROSCLEROSIS; INSULIN-RESISTANCE;
   DEFICIENT MICE; LIFE-SPAN; SIRT1; KINASE; STRESS; P53; ATHEROGENESIS
AB Background: Aberrantly elevated sterol regulatory element binding protein (SREBP), the lipogenic transcription factor, contributes to the development of fatty liver and insulin resistance in animals. Our recent studies have discovered that AMP-activated protein kinase (AMPK) phosphorylates SREBP at Ser-327 and inhibits its activity, represses SREBP-dependent lipogenesis, and thereby ameliorates hepatic steatosis and atherosclerosis in insulin-resistant LDLR-/- mice. Chronic inflammation and activation of NLRP3 inflammasome have been implicated in atherosclerosis and fatty liver disease. However, whether SREBP is involved in vascular lipid accumulation and inflammation in atherosclerosis remains largely unknown.
   Principal Findings: The preclinical study with aortic pouch biopsy specimens from humans with atherosclerosis and diabetes shows intense immunostaining for SREBP-1 and the inflammatory marker VCAM-1 in atherosclerotic plaques. The cleavage processing of SREBP-1 and -2 and expression of their target genes are increased in the well-established porcine model of diabetes and atherosclerosis, which develops human-like, complex atherosclerotic plaques. Immunostaining analysis indicates an elevation in SREBP-1 that is primarily localized in endothelial cells and in infiltrated macrophages within fatty streaks, fibrous caps with necrotic cores, and cholesterol crystals in advanced lesions. Moreover, concomitant suppression of NAD-dependent deacetylase SIRT1 and AMPK is observed in atherosclerotic pigs, which leads to the proteolytic activation of SREBP-1 by diminishing the deacetylation and Ser-372 phosphorylation of SREBP-1. Aberrantly elevated NLRP3 inflammasome markers are evidenced by increased expression of inflammasome components including NLPR3, ASC, and IL-1 beta. The increase in SREBP-1 activity and IL-1b production in lesions is associated with vascular inflammation and endothelial dysfunction in atherosclerotic pig aorta, as demonstrated by the induction of NF-kappa B, VCAM-1, iNOS, and COX-2, as well as by the repression of eNOS.
   Conclusions: These translational studies provide in vivo evidence that the dysregulation of SIRT1-AMPK-SREBP and stimulation of NLRP3 inflammasome may contribute to vascular lipid deposition and inflammation in atherosclerosis.
C1 [Li, Yu; Xu, Shanqin; Jiang, Bingbing; Cohen, Richard A.; Zang, Mengwei] Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Vasc Biol Sect,Dept Med, Boston, MA 02118 USA.
RP Zang, MW (reprint author), Boston Univ, Sch Med, Whitaker Cardiovasc Inst, Vasc Biol Sect,Dept Med, Boston, MA 02118 USA.
EM mwzang1@bu.edu
OI Cohen, Richard/0000-0002-1070-6408; Zang, Mengwei/0000-0002-2502-2586
FU National Institutes of Health [DK 076942, HL068758]; Wing Tat Lee Award
   at Boston University School of Medicine; National Natural Science
   Foundation of China [81270930]
FX This study is supported by the National Institutes of Health grants DK
   076942 (MZ) and HL068758 (RAC) and by the Wing Tat Lee Award at Boston
   University School of Medicine (MZ). YL is currently supported by a
   National Natural Science Foundation of China grant (81270930). The
   funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Bornfeldt KE, 2011, CELL METAB, V14, P575, DOI 10.1016/j.cmet.2011.07.015
   Cheng HL, 2003, P NATL ACAD SCI USA, V100, P10794, DOI 10.1073/pnas.1934713100
   Chua KF, 2005, CELL METAB, V2, P67, DOI 10.1016/j.cmet.2005.06.007
   Dong YZ, 2010, CIRCULATION, V121, P792, DOI 10.1161/CIRCULATIONAHA.109.900928
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Foretz M, 1999, MOL CELL BIOL, V19, P3760
   GERRITY RG, 1979, AM J PATHOL, V95, P775
   Gerrity RG, 2001, DIABETES, V50, P1654, DOI 10.2337/diabetes.50.7.1654
   Goldin A, 2006, CIRCULATION, V114, P597, DOI 10.1161/CIRCULATIONAHA.106.621854
   Goldstein JL, 2008, J CLIN INVEST, V118, P1220, DOI 10.1172/JCI34973
   Hansson GK, 2005, NEW ENGL J MED, V353, P429
   Horton JD, 2002, J CLIN INVEST, V109, P1125, DOI 10.1172/JCI200215593
   Hou XY, 2008, J BIOL CHEM, V283, P20015, DOI 10.1074/jbc.M802187200
   Howitz KT, 2003, NATURE, V425, P191, DOI 10.1038/nature01960
   Im SS, 2011, CELL METAB, V13, P540, DOI 10.1016/j.cmet.2011.04.001
   Iyer SS, 2009, P NATL ACAD SCI USA, V106, P20388, DOI 10.1073/pnas.0908698106
   Jawien J, 2004, J PHYSIOL PHARMACOL, V55, P503
   Lan F, 2008, J BIOL CHEM, V283, P27628, DOI 10.1074/jbc.M805711200
   Li Y, 2011, CELL METAB, V13, P376, DOI 10.1016/j.cmet.2011.03.009
   Li Y, 2011, FASEB J, V25, P1664, DOI 10.1096/fj.10-173492
   Libby P, 2005, CIRCULATION, V111, P3481, DOI 10.1161/CIRCULATIONAHA.105.537878
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lin T, 2003, CIRC RES, V92, P1296, DOI 10.1161/01.RES.0000078780.65824.8B
   Luo JY, 2000, NATURE, V408, P377, DOI 10.1038/35042612
   Luo JY, 2001, CELL, V107, P137, DOI 10.1016/S0092-8674(01)00524-4
   Ponugoti B, 2010, J BIOL CHEM, V285, P33959, DOI 10.1074/jbc.M110.122978
   Price NL, 2012, CELL METAB, V15, P675, DOI 10.1016/j.cmet.2012.04.003
   Raghow R, 2008, TRENDS ENDOCRIN MET, V19, P65, DOI 10.1016/j.tem.2007.10.009
   Schroder K, 2010, CELL, V140, P821, DOI 10.1016/j.cell.2010.01.040
   Stein S, 2011, CELL CYCLE, V10, P640, DOI 10.4161/cc.10.4.14863
   Towler MC, 2007, CIRC RES, V100, P328, DOI 10.1161/01.RES.0000256090.42690.05
   Vandanmagsar B, 2011, NAT MED, V17, P179, DOI 10.1038/nm.2279
   Vaziri H, 2001, CELL, V107, P149, DOI 10.1016/S0092-8674(01)00527-X
   Walker AK, 2010, GENE DEV, V24, P1403, DOI 10.1101/gad.1901210
   Xu SQ, 2006, AM J PHYSIOL-HEART C, V290, pH2220, DOI 10.1152/ajpheart.01293.2005
   Xu SQ, 2011, J CARDIOVASC PHARM, V58, P263, DOI 10.1097/FJC.0b013e3182239eb7
   Yeh M, 2004, CIRC RES, V95, P780, DOI 10.1161/01.RES.0000146030.53089.18
   Yin HQ, 2012, HEPATOLOGY, V56, p1119A
   Ying J, 2008, FREE RADICAL BIO MED, V45, P756, DOI 10.1016/j.freeradbiomed.2008.05.029
   You M, 2008, AM J PHYSIOL-GASTR L, V294, pG892, DOI 10.1152/ajpgi.00575.2007
   Zang MW, 2006, DIABETES, V55, P2180, DOI 10.2337/db05-1188
   Zang MW, 2004, J BIOL CHEM, V279, P47898, DOI 10.1074/jbc.M408149200
   Zhang QJ, 2008, CARDIOVASC RES, V80, P191, DOI 10.1093/cvr/cvn224
   Zuccollo A, 2005, CIRCULATION, V112, P3001, DOI 10.1161/CIRCULATIONHA.105.581892
NR 44
TC 22
Z9 27
U1 0
U2 32
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 25
PY 2013
VL 8
IS 6
AR e67532
DI 10.1371/journal.pone.0067532
PG 13
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 175IB
UT WOS:000321223000107
PM 23825667
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Yoon, Y
   Yoon, J
   Jang, MY
   Na, Y
   Ko, Y
   Choi, JH
   Seok, SH
AF Yoon, Yina
   Yoon, Jihye
   Jang, Man-Young
   Na, Yirang
   Ko, Youngho
   Choi, Jae-Hoon
   Seok, Seung Hyeok
TI High Cholesterol Diet Induces IL-1 beta Expression in Adult but Not
   Larval Zebrafish
SO PLOS ONE
LA English
DT Article
ID TARGETED GENE DISRUPTION; ZINC-FINGER NUCLEASES; MOUSE MODELS;
   HYPERCHOLESTEROLEMIC ZEBRAFISH; LIPID-ACCUMULATION; TNF-ALPHA;
   ATHEROSCLEROSIS; DISEASE; INTERLEUKIN-1-BETA; TALENS
AB Recently, it has been demonstrated that high cholesterol diet induced hypercholesterolemia and vascular lipid oxidation and accumulation in zebrafish larvae, suggesting that zebrafish is a new promising atherosclerosis model in addition to mouse models. However, up to date, there was no report regarding inflammatory cytokine expression during the lipid accumulation in zebrafish larva and adult fish. In this study, we first demonstrated the expression levels of IL-1 beta and TNF-alpha in high cholesterol diet (HCD)-fed zebrafish larvae, and found that although HCD induced vascular lipid accumulation, the cytokine expressions in the larvae were not changed by HCD. Furthermore, there was no significant difference in leukocyte accumulation in vessels between control and HCD fed group. But prolonged HCD induced IL-1 beta expression in spleen and liver compared to those of control zebrafish, and produced very early stage of fatty streak lesion in dorsal aorta of 19 week HCD-fed zebrafish. These results indicate that HCD induced hypercholesterolemia and atherosclerotic changes in zebrafish are very early stage, and suggest the necessity of the generation of mutant zebrafish having a disruption in a lipid metabolism-related gene leading to severe hypercholesterolemia and advanced atherosclerosis.
C1 [Yoon, Yina; Na, Yirang; Ko, Youngho; Seok, Seung Hyeok] Seoul Natl Univ, Coll Med, Dept Microbiol & Immunol, Seoul, South Korea.
   [Yoon, Yina; Na, Yirang; Ko, Youngho; Seok, Seung Hyeok] Seoul Natl Univ, Coll Med, Inst Endem Dis, Seoul, South Korea.
   [Yoon, Jihye; Jang, Man-Young; Choi, Jae-Hoon] Hanyang Univ, Coll Nat Sci, Dept Life Sci, Seoul 133791, South Korea.
   [Yoon, Jihye; Jang, Man-Young; Choi, Jae-Hoon] Hanyang Univ, Res Inst Nat Sci, Seoul 133791, South Korea.
RP Choi, JH (reprint author), Hanyang Univ, Coll Nat Sci, Dept Life Sci, Seoul 133791, South Korea.
EM jchoi75@hanyang.ac.kr; lamseok@snu.ac.kr
RI Choi, Jae-Hoon/R-6224-2016; Seok, Seung Hyeok/J-3279-2012
OI Choi, Jae-Hoon/0000-0002-5265-3463; Seok, Seung
   Hyeok/0000-0002-4315-0688
FU Ministry of Education, Science and Technology, Korea [2011-0005843];
   National Research Foundation of Korea (NRF); Ministry of Education,
   Science and Technology, South Korea [2011-0013669]
FX This work was funded by the Ministry of Education, Science and
   Technology, Korea (2011-0005843) and Basic Science Research Program
   through the National Research Foundation of Korea (NRF) funded by the
   Ministry of Education, Science and Technology, South Korea
   (2011-0013669). The funders had no role in study design, data collection
   and analysis, decision to publish, or preparation of the manuscript.
CR Alestrom P, 2006, TRENDS BIOTECHNOL, V24, P15, DOI 10.1016/j.tibtech.2005.11.004
   Dooley K, 2000, CURR OPIN GENET DEV, V10, P252, DOI 10.1016/S0959-437X(00)00074-5
   Doyon Y, 2008, NAT BIOTECHNOL, V26, P702, DOI 10.1038/nbt1409
   Duewell P, 2010, NATURE, V464, P1357, DOI 10.1038/nature08938
   Fang LH, 2011, J CLIN INVEST, V121, P4861, DOI 10.1172/JCI57755
   Galea J, 1996, ARTERIOSCL THROM VAS, V16, P1000, DOI 10.1161/01.ATV.16.8.1000
   Getz GS, 2012, ARTERIOSCL THROM VAS, V32, P1104, DOI 10.1161/ATVBAHA.111.237693
   Holtta-Vuori M, 2010, BIOCHEM J, V429, P235, DOI 10.1042/BJ20100293
   Huang P, 2011, NAT BIOTECHNOL, V29, P699, DOI 10.1038/nbt.1939
   Jing LL, 2011, DIS MODEL MECH, V4, P433, DOI 10.1242/dmm.006791
   Jovinge S, 1996, ARTERIOSCL THROM VAS, V16, P1573, DOI 10.1161/01.ATV.16.12.1573
   Kirii H, 2003, ARTERIOSCL THROM VAS, V23, P656, DOI 10.1161/01.ATV.0000064374.15232.C3
   Lei L, 2009, J LIPID RES, V50, P1057, DOI 10.1194/jlr.M800484-JLR200
   Lewis JD, 2005, CANCER RES, V65, P2938, DOI 10.1158/0008-5472.CAN-04-2874
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Meng XD, 2008, NAT BIOTECHNOL, V26, P695, DOI 10.1038/nbt1398
   Ozeren A, 2003, MEDIAT INFLAMM, V12, P361, DOI 10.1080/09629350310001633360
   PALINSKI W, 1989, P NATL ACAD SCI USA, V86, P1372, DOI 10.1073/pnas.86.4.1372
   Rajamaki K, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011765
   Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207
   Sander JD, 2011, NAT BIOTECHNOL, V29, P697, DOI 10.1038/nbt.1934
   Schonbeck U, 2002, CIRCULATION, V106, P2888, DOI 10.1161/01.CIR.0000043029.52803.7B
   Stoletov K, 2009, CIRC RES, V104, P952, DOI 10.1161/CIRCRESAHA.108.189803
   STREISINGER G, 1981, NATURE, V291, P293, DOI 10.1038/291293a0
   Weber C, 2008, NAT REV IMMUNOL, V8, P802, DOI 10.1038/nri2415
   Wouters K, 2008, HEPATOLOGY, V48, P474, DOI 10.1002/hep.22363
   Xu XH, 2001, CIRCULATION, V104, P3103, DOI 10.1161/hc5001.100631
   Zadelaar S, 2007, ARTERIOSCL THROM VAS, V27, P1706, DOI 10.1161/ATVBAHA.107.142570
NR 28
TC 9
Z9 9
U1 0
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 25
PY 2013
VL 8
IS 6
AR e66970
DI 10.1371/journal.pone.0066970
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 175IB
UT WOS:000321223000054
PM 23825600
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Berisha, SZ
   Hsu, J
   Robinet, P
   Smith, JD
AF Berisha, Stela Z.
   Hsu, Jeffrey
   Robinet, Peggy
   Smith, Jonathan D.
TI Transcriptome Analysis of Genes Regulated by Cholesterol Loading in Two
   Strains of Mouse Macrophages Associates Lysosome Pathway and ER Stress
   Response with Atherosclerosis Susceptibility
SO PLOS ONE
LA English
DT Article
ID LIVER X RECEPTOR; E-DEFICIENT MICE; FOAM CELLS; HEMATOPOIETIC STEM;
   PROGENITOR CELLS; TRANSPORT; APOPTOSIS; METABOLISM; EXPRESSION; EFFLUX
AB Cholesterol loaded macrophages in the arterial intima are the earliest histological evidence of atherosclerosis. Studies of mouse models of atherosclerosis have shown that the strain background can have a significant effect on lesion development. We have previously shown that DBA/2 ApoE(-/-) mice have aortic root lesions 10-fold larger than AKR ApoE(-/-) mice. The current study analyzes the response to cholesterol loading of macrophages from these two strains. Macrophages from the atherosclerosis susceptible DBA/2 strain had significantly higher levels of total and esterified cholesterol compared to atherosclerosis resistant AKR macrophages, while free cholesterol levels were higher in AKR cells. Gene expression profiles were obtained and data were analyzed for strain, cholesterol loading, and strain-cholesterol loading interaction effects by a fitted linear model. Pathway and transcriptional motif enrichment were identified by gene set enrichment analysis. In addition to observed strain differences in basal gene expression, we identified many transcripts whose expression was significantly altered in response to cholesterol loading, including P2ry13 and P2ry14, Trib3, Hyal1, Vegfa, Ccr5, Ly6a, and Ifit3. Eight pathways were significantly enriched in transcripts regulated by cholesterol loading, among which the lysosome and cytokine-cytokine receptor interaction pathways had the highest number of significantly regulated transcripts. Of the differentially regulated transcripts with a strain-cholesterol loading interaction effect, we identified three genes known to participate in the endoplasmic reticulum (ER) stress response, Ddit3, Trib3 and Atf4. These three transcripts were highly up-regulated by cholesterol in AKR and either down-regulated or unchanged in loaded DBA/2 macrophages, thus associating a robust ER stress response with atherosclerosis resistance. We identified significant transcripts with strain, loading, or strain-loading interaction effect that reside within previously described quantitative trait loci as atherosclerosis modifier candidate genes. In conclusion, we characterized several strain and cholesterol induced differences that may lead to new insights into cellular cholesterol metabolism and atherosclerosis.
C1 [Berisha, Stela Z.; Hsu, Jeffrey; Robinet, Peggy; Smith, Jonathan D.] Cleveland Clin, Lerner Res Inst, Dept Cellular & Mol Med, Cleveland, OH 44106 USA.
   [Hsu, Jeffrey; Smith, Jonathan D.] Case Western Reserve Univ, Lerner Coll Med, Cleveland Clin, Dept Mol Med, Cleveland, OH 44106 USA.
RP Smith, JD (reprint author), Cleveland Clin, Lerner Res Inst, Dept Cellular & Mol Med, Cleveland, OH 44106 USA.
EM smithj4@ccf.org
RI Smith, Jonathan D./H-9723-2013
OI Smith, Jonathan D./0000-0002-0415-386X
FU National Institutes of Health grant [HL098193]
FX This work was supported by National Institutes of Health grant HL098193
   to JDS (http://www.nih.gov/). The funders had no role in study design,
   data collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Alwaili K, 2010, EXPERT REV CARDIOVAS, V8, P413, DOI [10.1586/erc.10.4, 10.1586/ERC.10.4]
   Blom D, 2010, BBA-MOL CELL BIOL L, V1801, P1349, DOI 10.1016/j.bbalip.2010.08.013
   Cazanave SC, 2010, AM J PHYSIOL-GASTR L, V299, pG236, DOI 10.1152/ajpgi.00091.2010
   Curcio-Morelli C, 2010, NEUROBIOL DIS, V40, P370, DOI 10.1016/j.nbd.2010.06.010
   DeBose-Boyd RA, 2011, COLD SPRING HARB PER, V3, P10
   DeVries-Seimon T, 2005, J CELL BIOL, V171, P61, DOI 10.1083/jcb.200502078
   Dorum G, 2009, STAT APPL GENET MOL, V8, DOI 10.2202/1544-6115.1418
   Du P, 2008, BIOINFORMATICS, V24, P1547, DOI 10.1093/bioinformatics/btn224
   Fabre AC, 2010, HEPATOLOGY, V52, P1477, DOI 10.1002/hep.23897
   GENTLEMAN R, 2005, BIOINFORMATICS COMPU, V746718470
   Ghazalpour A, 2011, PLOS GENET, V7, DOI 10.1371/journal.pgen.1001393
   Glass CK, 2001, CELL, V104, P503, DOI 10.1016/S0092-8674(01)00238-0
   Greaves DR, 2009, J LIPID RES, V50, pS282, DOI 10.1194/jlr.R800066-JLR200
   Hsu J, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.112.005421
   Ide T, 2004, NAT CELL BIOL, V6, P351, DOI 10.1038/ncb1111
   Im SS, 2011, CELL METAB, V13, P540, DOI 10.1016/j.cmet.2011.04.001
   Jones KL, 2011, BRIT J PHARMACOL, V162, P1453, DOI 10.1111/j.1476-5381.2010.01147.x
   Lee BC, 2003, GENE DEV, V17, P1592, DOI 10.1101/gad.1071503
   Li CM, 2002, GENOMICS, V79, P218, DOI 10.1006/geno.2002.6686
   Liao XH, 2012, CELL METAB, V15, P545, DOI 10.1016/j.cmet.2012.01.022
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262
   Lusis AJ, 2000, NATURE, V407, P233, DOI 10.1038/35025203
   Lusis MJ, 2004, ANNU REV GENOM HUM G, V5, P189, DOI 10.1146/annurev.genom.5.061903.175930
   Maier T, 2009, FEBS LETT, V583, P3966, DOI 10.1016/j.febslet.2009.10.036
   Majewski IJ, 2010, BLOOD, V116, P731, DOI 10.1182/blood-2009-12-260760
   Marcel YL, 2008, CURR OPIN LIPIDOL, V19, P455, DOI 10.1097/MOL.0b013e32830f4a1d
   Moore KJ, 2006, ARTERIOSCL THROM VAS, V26, P1702, DOI 10.1161/01.ATV.0000229218.97976.43
   Moreno PR, 2009, J AM COLL CARDIOL, V53, P2315, DOI 10.1016/j.jacc.2009.02.057
   Ouimet M, 2011, CELL METAB, V13, P655, DOI 10.1016/j.cmet.2011.03.023
   Pehkonen P, 2012, BMC GENOMICS, V13, DOI 10.1186/1471-2164-13-50
   Pennings M, 2006, FEBS LETT, V580, P5588, DOI 10.1016/j.febslet.2006.08.022
   Prudente S, 2012, ENDOCR REV, V33, P526, DOI 10.1210/er.2011-1042
   Robinet P, 2013, ARTERIOSCLE IN PRESS
   Robinet P, 2010, J LIPID RES, V51, P3364, DOI 10.1194/jlr.D007336
   Ron D, 2007, NAT REV MOL CELL BIO, V8, P519, DOI 10.1038/nrm2199
   Shang YY, 2010, CLIN EXP PHARMACOL P, V37, P51, DOI 10.1111/j.1440-1681.2009.05229.x
   Shang YY, 2009, FEBS J, V276, P2752, DOI 10.1111/j.1742-4658.2009.06998.x
   Shashkin P, 2005, CURR PHARM DESIGN, V11, P3061, DOI 10.2174/1381612054865064
   Smith JD, 2006, ARTERIOSCL THROM VAS, V26, P597, DOI 10.1161/01.ATV.0000201044.33220.5c
   Smith JD, 2003, ARTERIOSCL THROM VAS, V23, P117, DOI 10.1161/01.ATV.0000047461.18902.80
   Smyth G. K., 2004, STAT APPL GENET MOL, V3, DOI DOI 10.2202/1544-6115.1027
   Soccio RE, 2004, ARTERIOSCL THROM VAS, V24, P1150, DOI 10.1161/01.ATV.0000131264.66417.d5
   Strong A, 2012, J CLIN INVEST, V122, P2807, DOI 10.1172/JCI63563
   Subramanian A, 2005, P NATL ACAD SCI USA, V102, P15545, DOI 10.1073/pnas.0506580102
   Tabas I, 2005, ARTERIOSCL THROM VAS, V25, P2255, DOI 10.1161/01.ATV.0000184783.04864.9f
   Thompson EG, 2007, BMC CELL BIOL, V8, DOI 10.1186/1471-2121-8-54
   Thorp E, 2009, CELL METAB, V9, P474, DOI 10.1016/j.cmet.2009.03.003
   Tiwari RL, 2008, MED RES REV, V28, P483, DOI 10.1002/med.20118
   Vainio S, 2003, ANN MED, V35, P146, DOI 10.1080/07853890310008198
   Wang X, 2007, CURR OPIN CARDIOL, V22, P368, DOI 10.1097/HCO.0b013e3281ec5113
   Wang ZH, 2012, DIABETES, V61, P463, DOI 10.2337/db11-0518
   Yvan-Charvet L, 2010, ARTERIOSCL THROM VAS, V30, P139, DOI 10.1161/ATVBAHA.108.179283
   Zhao CY, 2010, J ENDOCRINOL, V204, P233, DOI 10.1677/JOE-09-0271
NR 54
TC 14
Z9 14
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2013
VL 8
IS 5
AR e65003
DI 10.1371/journal.pone.0065003
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149OK
UT WOS:000319330200180
PM 23705026
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Eberhard, J
   Grote, K
   Luchtefeld, M
   Heuer, W
   Schuett, H
   Divchev, D
   Scherer, R
   Schmitz-Streit, R
   Langfeldt, D
   Stumpp, N
   Staufenbiel, I
   Schieffer, B
   Stiesch, M
AF Eberhard, Joerg
   Grote, Karsten
   Luchtefeld, Maren
   Heuer, Wieland
   Schuett, Harald
   Divchev, Dimitar
   Scherer, Ralph
   Schmitz-Streit, Ruth
   Langfeldt, Daniela
   Stumpp, Nico
   Staufenbiel, Ingmar
   Schieffer, Bernhard
   Stiesch, Meike
TI Experimental Gingivitis Induces Systemic Inflammatory Markers in Young
   Healthy Individuals: A Single-Subject Interventional Study
SO PLOS ONE
LA English
DT Article
ID POLYMERASE-CHAIN-REACTION; C-REACTIVE PROTEIN; ATHEROSCLEROTIC PLAQUES;
   PERIODONTAL PATHOGENS; SUPRAGINGIVAL PLAQUE; MICROBIAL COMPLEXES;
   SUBGINGIVAL PLAQUE; RISK-FACTORS; DISEASE; IDENTIFICATION
AB Objectives: We here investigated whether experimental gingivitis enhances systemic markers of inflammation which are also known as surrogate markers of atherosclerotic plaque development.
   Background: Gingivitis is a low-level oral infection induced by bacterial deposits with a high prevalence within Western populations. A potential link between the more severe oral disease periodontitis and cardiovascular disease has already been shown.
   Methods: 37 non-smoking young volunteers with no inflammatory disease or any cardiovascular risk factors participated in this single-subject interventional study with an intra-individual control. Intentionally experimental oral inflammation was induced by the interruption of oral hygiene for 21 days, followed by a 21-days resolving phase after reinitiation of oral hygiene. Primary outcome measures at baseline, day 21 and 42 were concentrations of hsCRP, IL-6, and MCP-1, as well as adhesion capacity and oxLDL uptake of isolated blood monocytes.
   Results: The partial cessation of oral hygiene procedures was followed by the significant increase of gingival bleeding (34.0%, P<0.0001). This local inflammation was associated with a systemic increase in hsCRP (0.24 mg/L, P = 0.038), IL-6 (12.52 ng/L, P = 0.0002) and MCP-1 (9.10 ng/l, P = 0.124) in peripheral blood samples between baseline and day 21, which decreased at day 42. Monocytes showed an enhanced adherence to endothelial cells and increased foam cell formation after oxLDL uptake (P<0.050) at day 21 of gingivitis.
   Conclusions: Bacterial-induced gingival low-level inflammation induced a systemic increase in inflammatory markers. Dental hygiene almost completely reversed this experimental inflammatory process, suggesting that appropriate dental prophylaxis may also limit systemic markers of inflammation in subjects with natural gingivitis. International Clinical Trials Register Platform of the World Health Organization, registry number: DRKS00003366, URL: http://apps.who.int/trialsearch/Default.aspx.
C1 [Eberhard, Joerg; Heuer, Wieland; Stumpp, Nico; Stiesch, Meike] Hannover Med Sch, Dept Prosthet Dent & Biomat Sci, Hannover, Germany.
   [Grote, Karsten; Luchtefeld, Maren; Schuett, Harald; Divchev, Dimitar; Schieffer, Bernhard] Hannover Med Sch, Dept Cardiol & Angiol, Hannover, Germany.
   [Scherer, Ralph] Hannover Med Sch, Dept Med Stat, Hannover, Germany.
   [Staufenbiel, Ingmar] Hannover Med Sch, Dept Operat Dent & Periodontol, Hannover, Germany.
   [Schmitz-Streit, Ruth; Langfeldt, Daniela] Univ Kiel, Inst Microbiol, Kiel, Germany.
RP Eberhard, J (reprint author), Hannover Med Sch, Dept Prosthet Dent & Biomat Sci, Hannover, Germany.
EM eberhard.joerg@mh-hannover.de
RI Eberhard, Jorg/G-1103-2012; Staufenbiel, Ingmar/K-7675-2018
OI Schmitz-Streit, Ruth Anne/0000-0002-6788-0829; Divchev,
   Dimitar/0000-0002-3062-3271; Eberhard, Joerg/0000-0001-8060-2893
FU Deutsche Forschungsgemeinschaft DFG, Bonn, Germany [Eb 223/5-1];
   Deutsche Forschungsgemeinschaft
FX This study was in part supported by the Deutsche Forschungsgemeinschaft
   DFG, Bonn, Germany (Eb 223/5-1). The authors acknowledge funding of the
   publication costs by the Deutsche Forschungsgemeinschaft. The funders
   had no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Andriankaja OM, 2009, J PERIODONTOL, V80, P307, DOI [10.1902/jop.2009.080385, 10.1902/jop.2009.080385 ]
   Ashimoto A, 1996, ORAL MICROBIOL IMMUN, V11, P266, DOI 10.1111/j.1399-302X.1996.tb00180.x
   Baumgartner JC, 1999, J ENDODONT, V25, P413, DOI 10.1016/S0099-2399(99)80268-4
   Boucelma M, 2011, INT ANGIOL, V30, P18
   Chiu B, 1999, AM HEART J, V138, pS534, DOI 10.1016/S0002-8703(99)70294-2
   Conrads G, 1997, J ENDODONT, V23, P433, DOI 10.1016/S0099-2399(97)80297-X
   Conrads G, 1996, J PERIODONTOL, V67, P994, DOI 10.1902/jop.1996.67.10.994
   De Groot L, 2010, EUR J CLIN INVEST, V40, P835, DOI 10.1111/j.1365-2362.2010.02333.x
   Demmer RT, 2010, PERIODONTOL 2000, V53, P28, DOI 10.1111/j.1600-0757.2009.00326.x
   Drakopoulou M, 2009, ATHEROSCLEROSIS, V206, P335, DOI 10.1016/j.atherosclerosis.2009.01.041
   Eberhard J, 2005, BIOMATERIALS, V26, P1545, DOI 10.1016/j.biomaterials.2004.05.005
   Eberhard J, 2000, ANAL BIOCHEM, V280, P258, DOI 10.1006/abio.2000.4540
   Elkaim R, 2008, J PERIODONTAL RES, V43, P224, DOI 10.1111/j.1600-0765.2007.01018.x
   Elter JR, 2006, AM HEART J, V151, DOI 10.1016/j.ahj.2005.10.002
   Ericsson JS, 2009, SWED DENT J, V33, P131
   Forner L, 2006, J CLIN PERIODONTOL, V33, P401, DOI 10.1111/j.1600-051X.2006.00924.x
   Gaetti-Jardim E, 2009, J MED MICROBIOL, V58, P1568, DOI 10.1099/jmm.0.013383-0
   Haffajee AD, 2008, ORAL MICROBIOL IMMUN, V23, P196, DOI 10.1111/j.1399-302X.2007.00411.x
   Haffajee AD, 2009, J PERIODONTAL RES, V44, P511, DOI 10.1111/j.1600-0765.2008.01154.x
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   Honda T, 2006, CLIN EXP IMMUNOL, V144, P35, DOI 10.1111/j.1365-2249.2006.03028.x
   Hoshino T, 2004, DIAGN MICR INFEC DIS, V48, P195, DOI 10.1016/j.diagmicrobio.2003.10.002
   Igarashi E, 2009, ORAL MICROBIOL IMMUN, V24, P310, DOI 10.1111/j.1399-302X.2009.00513.x
   Kebschull M, 2010, J DENT RES, V89, P879, DOI 10.1177/0022034510375281
   Kim SG, 2005, J MICROBIOL, V43, P209
   Koren O, 2011, P NATL ACAD SCI USA, V108, P4592, DOI 10.1073/pnas.1011383107
   Li YM, 2010, AM J DENT, V23, P9
   Libby P, 1997, CIRCULATION, V96, P4095
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lockhart PB, 2012, CIRCULATION, V125, P2520, DOI 10.1161/CIR.0b013e31825719f3
   LOE H, 1965, J PERIODONTOL, V36, P177, DOI 10.1902/jop.1965.36.3.177
   LOE HARALD, 1963, ACTA ODONTOL SCAND, V21, P533, DOI 10.3109/00016356309011240
   Lu QA, 2010, J CLIN PERIODONTOL, V37, P789, DOI 10.1111/j.1600-051X.2010.01600.x
   Pihlstrom BL, 2005, LANCET, V366, P1809, DOI 10.1016/S0140-6736(05)67728-8
   Ridker PM, 2000, CIRCULATION, V101, P1767, DOI 10.1161/01.CIR.101.15.1767
   Ridker PM, 2000, NEW ENGL J MED, V342, P836, DOI 10.1056/NEJM200003233421202
   SAGLIE FR, 1987, J PERIODONTOL, V58, P837, DOI 10.1902/jop.1987.58.12.837
   SILNESS J, 1964, Acta Odontol Scand, V22, P121, DOI 10.3109/00016356408993968
   Slawik S, 2011, EUR J CLIN NUTR, V65, P857, DOI 10.1038/ejcn.2011.45
   Socransky SS, 1998, J CLIN PERIODONTOL, V25, P134, DOI 10.1111/j.1600-051X.1998.tb02419.x
   Tonetti MS, 2007, NEW ENGL J MED, V356, P911, DOI 10.1056/NEJMoa063186
   Uno K, 2010, BIOMARK MED, V4, P361, DOI 10.2217/BMM.10.57
   Wahaidi VY, 2011, J CLIN PERIODONTOL, V38, P412, DOI 10.1111/j.1600-051X.2011.01710.x
   Wohifeil M, 2009, CLIN CHIM ACTA, V401, P105, DOI 10.1016/j.cca.2008.11.017
   Ylostalo PV, 2006, J CLIN PERIODONTOL, V33, P92, DOI 10.1111/j.1600.051X2005.00875.x
   Zee KY, 1996, J CLIN PERIODONTOL, V23, P1025, DOI 10.1111/j.1600-051X.1996.tb00532.x
NR 46
TC 19
Z9 19
U1 1
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 7
PY 2013
VL 8
IS 2
AR e55265
DI 10.1371/journal.pone.0055265
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 092XV
UT WOS:000315157200021
PM 23408963
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Conway, RG
   Chernet, E
   De Rosa, DC
   Benschop, RJ
   Need, AB
   Collins, EC
   Bean, JS
   Kalbfleisch, JM
   Rekhter, MD
AF Conway, Richard G.
   Chernet, Eyassu
   De Rosa, David C.
   Benschop, Robert J.
   Need, Anne B.
   Collins, Emily C.
   Bean, James S.
   Kalbfleisch, J. Michael
   Rekhter, Mark D.
TI Glucose Metabolic Trapping in Mouse Arteries: Nonradioactive Assay of
   Atherosclerotic Plaque Inflammation Applicable to Drug Discovery
SO PLOS ONE
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; VASCULAR INFLAMMATION; NOFDG ACCUMULATION;
   TC-99M-ANNEXIN A5; FDG-MICROPET; RISK-FACTORS; F-18-FDG;
   FLUORODEOXYGLUCOSE; PET; MICE
AB Background: F-18-Fluorodeoxyglucose (FDG)-positron emission tomography (PET) imaging of atherosclerosis in the clinic is based on preferential accumulation of radioactive glucose analog in atherosclerotic plaques. FDG-PET is challenging in mouse models due to limited resolution and high cost. We aimed to quantify accumulation of nonradioactive glucose metabolite, FDG-6-phosphate, in the mouse atherosclerotic plaques as a simple alternative to PET imaging.
   Methodology/Principal Findings: Nonradioactive FDG was injected 30 minutes before euthanasia. Arteries were dissected, and lipids were extracted. The arteries were re-extracted with 50% acetonitrile-50% methanol-0.1% formic acid. A daughter ion of FDG-6-phosphate was quantified using liquid chromatography and mass spectrometry (LC/MS/MS). Thus, both traditional (cholesterol) and novel (FDG-6-phosphate) markers were assayed in the same tissue. FDG-6-phosphate was accumulated in atherosclerotic lesions associated with carotid ligation of the Western diet fed ApoE knockout mice (5.9 times increase compare to unligated carotids, p<0.001). Treatment with the liver X receptor agonist T0901317 significantly (2.1 times, p<0.01) reduced FDG-6-phosphate accumulation 2 weeks after surgery. Anti-atherosclerotic effects were independently confirmed by reduction in lesion size, macrophage number, cholesterol ester accumulation, and macrophage proteolytic activity.
   Conclusions/Significance: Mass spectrometry of FDG-6-phosphate in experimental atherosclerosis is consistent with plaque inflammation and provides potential translational link to the clinical studies utilizing FDG-PET imaging.
C1 [Conway, Richard G.; Bean, James S.; Rekhter, Mark D.] Eli Lilly & Co, Lilly Res Labs, Cardiometab Dis & Diabet Complicat, Indianapolis, IN 46285 USA.
   [Chernet, Eyassu] Eli Lilly & Co, Lilly Res Labs, Psychiat Disorders, Indianapolis, IN 46285 USA.
   [De Rosa, David C.; Benschop, Robert J.] Eli Lilly & Co, Lilly Res Labs, ImmunoModulat, Indianapolis, IN 46285 USA.
   [Need, Anne B.; Collins, Emily C.; Kalbfleisch, J. Michael] Eli Lilly & Co, Lilly Res Labs, Translat Sci, Indianapolis, IN 46285 USA.
RP Rekhter, MD (reprint author), Eli Lilly & Co, Lilly Res Labs, Cardiometab Dis & Diabet Complicat, Indianapolis, IN 46285 USA.
EM rekhter_mark@lilly.com
FU Lilly Research Laboratories
FX The work is funded by Lilly Research Laboratories that employs all the
   authors. Lilly Research Laboratories supported preparation of the
   manuscript and its submission. The funder had no role in study design,
   data collection and analysis.
CR Calcagno C, 2008, ARTERIOSCL THROM VAS, V28, P1311, DOI 10.1161/ATVBAHA.108.166173
   Charo IF, 2011, NAT REV DRUG DISCOV, V10, P365, DOI 10.1038/nrd3444
   Chen JQ, 2002, CIRCULATION, V105, P2766, DOI 10.1161/01.CIR.0000017860.20619.23
   Davies JR, 2010, INT J CARDIOVAS IMAG, V26, P41, DOI 10.1007/s10554-009-9506-6
   Figueroa AL, 2011, IMAGING
   Folco EJ, 2011, J AM COLL CARDIOL, V58, P603, DOI 10.1016/j.jacc.2011.03.044
   Fryburg DA, 2011, SCI TRANSL MED, V3, p72cm76
   Ishii H, 2010, CLIN THER, V32, P2337, DOI 10.1016/j.clinthera.2010.12.001
   Kim TN, 2010, CIRC-CARDIOVASC IMAG, V3, P142, DOI 10.1161/CIRCIMAGING.109.888909
   Kuo MS, 2008, J LIPID RES, V49, P1353, DOI 10.1194/jlr.D700037-JLR200
   Laurberg JM, 2007, ATHEROSCLEROSIS, V192, P275, DOI 10.1016/j.atherosclerosis.2006.07.019
   Libby P, 2011, CIRC RES, V109, P1100, DOI 10.1161/RES.0b013e31823bdb84
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lindsay AC, 2008, NAT REV DRUG DISCOV, V7, P517, DOI 10.1038/nrd2588
   Masteling MG, 2011, J NUCL CARDIOL, V18, P1066, DOI 10.1007/s12350-011-9460-2
   Menezes LJ, 2011, J NUCL MED, V52, P1698, DOI 10.2967/jnumed.111.093724
   Ogawa M, 2004, J NUCL MED, V45, P1245
   Pedersen SF, 2010, NUCL MED COMMUN, V31, P423, DOI 10.1097/MNM.0b013e32833767e0
   Rudd JHF, 2007, ATHEROSCLEROSIS, V192, P453, DOI 10.1016/j.atherosclerosis.2006.10.027
   Rudd JHF, 2010, J AM COLL CARDIOL, V55, P2527, DOI 10.1016/j.jacc.2009.12.061
   Rudd JHF, 2009, CIRC-CARDIOVASC IMAG, V2, P107, DOI 10.1161/CIRCIMAGING.108.811752
   Tahara N, 2006, J AM COLL CARDIOL, V48, P1825, DOI 10.1016/j.jacc.2006.03.069
   Terasaka N, 2003, FEBS LETT, V536, P6, DOI 10.1016/S0014-5793(02)03578-0
   Wasselius J, 2009, INT J CARDIOVAS IMAG, V25, P133, DOI 10.1007/s10554-008-9366-5
   Wenning C, 2011, CURR CARDIOVASC IMAG, V4, P190, DOI 10.1007/s12410-011-9083-7
   Yoo HJ, 2011, J NUCL MED, V52, P10, DOI 10.2967/jnumed.110.080838
   Zhang Zhuangyu, 2006, BMC Nucl Med, V6, P3, DOI 10.1186/1471-2385-6-3
   Zhao Y, 2008, J NUCL MED, V49, P1707, DOI 10.2967/jnumed.108.051847
   Zhao Y, 2007, EUR J NUCL MED MOL I, V34, P1747, DOI 10.1007/s00259-007-0433-2
   Zhao Y, 2011, MOL IMAGING BIOL, V13, P712, DOI 10.1007/s11307-010-0389-7
NR 30
TC 6
Z9 6
U1 0
U2 15
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 28
PY 2012
VL 7
IS 11
AR e50349
DI 10.1371/journal.pone.0050349
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 057YW
UT WOS:000312601700062
PM 23209718
OA DOAJ Gold, Green Published
DA 2019-06-18
ER

PT J
AU Kiliszek, M
   Burzynska, B
   Michalak, M
   Gora, M
   Winkler, A
   Maciejak, A
   Leszczynska, A
   Gajda, E
   Kochanowski, J
   Opolski, G
AF Kiliszek, Marek
   Burzynska, Beata
   Michalak, Marcin
   Gora, Monika
   Winkler, Aleksandra
   Maciejak, Agata
   Leszczynska, Agata
   Gajda, Ewa
   Kochanowski, Janusz
   Opolski, Grzegorz
TI Altered Gene Expression Pattern in Peripheral Blood Mononuclear Cells in
   Patients with Acute Myocardial Infarction
SO PLOS ONE
LA English
DT Article
ID EARLY GROWTH RESPONSE-1; ACUTE CORONARY SYNDROME; ST-SEGMENT ELEVATION;
   FC-GAMMA-RI; SOCS PROTEINS; KNOCKOUT MICE; ATHEROSCLEROSIS; RECEPTOR;
   INTERLEUKIN-6; MORTALITY
AB Background: Despite a substantial progress in diagnosis and therapy, acute myocardial infarction (MI) is a major cause of mortality in the general population. A novel insight into the pathophysiology of myocardial infarction obtained by studying gene expression should help to discover novel biomarkers of MI and to suggest novel strategies of therapy. The aim of our study was to establish gene expression patterns in leukocytes from acute myocardial infarction patients.
   Methods and Results: Twenty-eight patients with ST-segment elevation myocardial infarction (STEMI) were included. The blood was collected on the 1st day of myocardial infarction, after 4-6 days, and after 6 months. Control group comprised 14 patients with stable coronary artery disease, without history of myocardial infarction. Gene expression analysis was performed with Affymetrix Human Gene 1.0 ST microarrays and GCS3000 TG system. Lists of genes showing altered expression levels (fold change >1.5, p<0.05) were submitted to Ingenuity Pathway Analysis. Gene lists from each group were examined for canonical pathways and molecular and cellular functions. Comparing acute phase of MI with the same patients after 6 months (stable phase) and with control group we found 24 genes with changed expression. In canonical analysis three pathways were highlighted: signaling of PPAR (peroxisome proliferator-activated receptor), IL-10 and IL-6 (interleukin 10 and 6).
   Conclusions: In the acute phase of STEMI, dozens of genes from several pathways linked with lipid/glucose metabolism, platelet function and atherosclerotic plaque stability show altered expression. Up-regulation of SOCS3 and FAM20 genes in the first days of myocardial infarction is observed in the vast majority of patients.
C1 [Kiliszek, Marek; Michalak, Marcin; Winkler, Aleksandra; Gajda, Ewa; Kochanowski, Janusz; Opolski, Grzegorz] Med Univ Warsaw, Chair 1, Warsaw, Poland.
   [Kiliszek, Marek; Michalak, Marcin; Winkler, Aleksandra; Gajda, Ewa; Kochanowski, Janusz; Opolski, Grzegorz] Med Univ Warsaw, Dept Cardiol, Warsaw, Poland.
   [Burzynska, Beata; Gora, Monika; Maciejak, Agata; Leszczynska, Agata] Polish Acad Sci, Inst Biochem & Biophys, Warsaw, Poland.
RP Kiliszek, M (reprint author), Med Univ Warsaw, Chair 1, Warsaw, Poland.
EM kiliszek@mp.pl; atka@ibb.waw.pl
RI Burzynska, Beata/A-4691-2013; Maciejak, Agata/O-7427-2018
OI Maciejak, Agata/0000-0002-7654-8414; Kochanowski,
   Janusz/0000-0003-2727-5701; Gora, Monika/0000-0002-8554-663X; Burzynska,
   Beata/0000-0003-1595-0036
FU National Centre for Research and Development (NCBiR) [R13 0001 06]
FX This work was supported by grant R13 0001 06 from The National Centre
   for Research and Development (NCBiR). The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR Ait-Oufella H, 2011, ARTERIOSCL THROM VAS, V31, P969, DOI 10.1161/ATVBAHA.110.207415
   Asnani S, 2003, METAB SYNDR RELAT D, V1, P23, DOI 10.1089/154041903321648234
   Barron HV, 2001, J AM COLL CARDIOL, V38, P1654, DOI 10.1016/S0735-1097(01)01613-8
   Calkin AC, 2010, ARTERIOSCL THROM VAS, V30, P1513, DOI 10.1161/ATVBAHA.109.191197
   Carbrey JM, 2003, P NATL ACAD SCI USA, V100, P2945, DOI 10.1073/pnas.0437994100
   Cavusoglu E, 2011, AM J MED, V124, P724, DOI 10.1016/j.amjmed.2011.02.040
   Darragh MR, 2008, FRONT BIOSCI-LANDMRK, V13, P528, DOI 10.2741/2698
   Gupta GK, 2011, EXP MOL PATHOL, V91, P346, DOI 10.1016/j.yexmp.2011.04.004
   Harja E, 2004, CIRC RES, V94, P333, DOI 10.1161/01.RES.0000112405.61577.95
   Holley CL, 2011, CARDIOVASC DRUG THER, V25, P151, DOI 10.1007/s10557-011-6290-z
   Huber SA, 1999, ARTERIOSCL THROM VAS, V19, P2364, DOI 10.1161/01.ATV.19.10.2364
   Jandeleit-Dahm KAM, 2009, CURR OPIN LIPIDOL, V20, P24, DOI 10.1097/MOL.0b013e32831f1b18
   Kaminski KA, 2009, ATHEROSCLEROSIS, V206, P581, DOI 10.1016/j.atherosclerosis.2009.03.033
   Khachigian LM, 2006, CIRC RES, V98, P186, DOI 10.1161/01.RES.0000200177.538882.c3
   Khachigian LM, 1996, SCIENCE, V271, P1427, DOI 10.1126/science.271.5254.1427
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Magni F, 2006, PROTEOMICS, V6, P5637, DOI 10.1002/pmic.200600212
   Millonig G, 2002, ATHEROSCLEROSIS, V160, P441, DOI 10.1016/S0021-9150(01)00596-2
   Mueller C, 2003, HEART, V89, P389, DOI 10.1136/heart.89.4.389
   Nalbant D, 2005, BMC GENOMICS, V27, P6
   Ndrepepa G, 2009, CLIN SCI, V116, P651, DOI 10.1042/CS20080298
   Oba T, 2012, J AM COLL CARDIOL, V59, P838, DOI 10.1016/j.jacc.2011.10.887
   OHTA Y, 1991, CELL, V67, P275, DOI 10.1016/0092-8674(91)90179-3
   Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36
   Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45
   Potteaux S, 2004, ARTERIOSCL THROM VAS, V24, P1474, DOI 10.1161/01.ATV.0000134378.86443.cd
   Rojek AM, 2007, P NATL ACAD SCI USA, V104, P3609, DOI 10.1073/pnas.0610894104
   ROSENBERG HF, 1989, P NATL ACAD SCI USA, V86, P4460, DOI 10.1073/pnas.86.12.4460
   Seitz I, 2007, ARTERIOSCL THROM VAS, V27, P769, DOI 10.1161/01.ATV.0000258862.61067.14
   Sorensen AL, 2009, BLOOD, V114, P1645, DOI 10.1182/blood-2009-01-199414
   Tamiya T, 2011, ARTERIOSCL THROM VAS, V31, P980, DOI 10.1161/ATVBAHA.110.207464
   Tan J, 2009, HEART VESSELS, V24, P329, DOI 10.1007/s00380-008-1128-8
   Van de Werf F, 2008, EUR HEART J, V29, P2909, DOI 10.1093/eurheartj/ehn416
   van der Poel CE, 2011, J IMMUNOL, V186, P2699, DOI 10.4049/jimmunol.1003526
   VanderLaan PA, 2005, J LIPID RES, V46, P829, DOI 10.1194/jlr.R500003-JLR200
   WEIGEL PH, 1994, BIOESSAYS, V16, P519, DOI 10.1002/bies.950160713
   Yoshimura A, 2007, NAT REV IMMUNOL, V7, P454, DOI 10.1038/nri2093
   Zhang L, 2004, TRENDS ENDOCRIN MET, V15, P500, DOI 10.1016/j.tem.2004.10.006
NR 38
TC 22
Z9 23
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD NOV 21
PY 2012
VL 7
IS 11
AR e50054
DI 10.1371/journal.pone.0050054
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 047ER
UT WOS:000311821000172
PM 23185530
OA DOAJ Gold, Green Published
DA 2019-06-18
ER

PT J
AU Kamath, AV
   Williams, SP
   Bullens, S
   Cowan, KJ
   Stenberg, Y
   Cherry, SR
   Rendig, S
   Kukis, DL
   Griesemer, C
   Damico-Beyer, LA
   Bunting, S
AF Kamath, Amrita V.
   Williams, Simon P.
   Bullens, Sherry
   Cowan, Kyra J.
   Stenberg, Yvonne
   Cherry, Simon R.
   Rendig, Stephen
   Kukis, David L.
   Griesemer, Chris
   Damico-Beyer, Lisa A.
   Bunting, Stuart
TI Pharmacokinetics and Biodistribution of a Human Monoclonal Antibody to
   Oxidized LDL in Cynomolgus Monkey Using PET Imaging
SO PLOS ONE
LA English
DT Article
ID LOW-DENSITY-LIPOPROTEIN; ATHEROSCLEROSIS; DISEASE
AB Purpose: Oxidized low-density lipoprotein (LDL) plays an essential role in the pathogenesis of atherosclerosis. The purpose of this study was to characterize the pharmacokinetics (PK) of a human recombinant IgG1 antibody to oxidized LDL (anti-oxLDL) in cynomolgus monkey. The tissue biodistribution of anti-oxLDL was also investigated using positron emission tomography (PET) imaging.
   Methods: Anti-oxLDL was conjugated with the N-hydroxysuccinimide ester of DOTA (1,4,7,10-tetraazacyclododecane 1,4,7,10-tetraacetic acid) and radiolabeled by chelation of radioactive copper-64 (Cu-64) for detection by PET. Anti-oxLDL was administered as a single intravenous (IV) dose of 10 mg/kg (as a mixture of radiolabeled and non-labeled material) to two male and two female cynomolgus monkeys. Serum samples were collected over 29 days. Two ELISA methods were used to measure serum concentrations of anti-oxLDL; Assay A was a ligand binding assay that measured free anti-oxLDL (unbound and partially bound forms) and Assay B measured total anti-oxLDL. The biodistribution was observed over a 48-hour period following dose administration using PET imaging.
   Results: Anti-oxLDL serum concentration-time profiles showed a biphasic elimination pattern that could be best described by a two-compartment elimination model. The serum concentrations obtained using the two ELISA methods were comparable. Clearance values ranged from 8 to 17 ml/day/kg, while beta half-life ranged from 8 to 12 days. The initial volume of distribution and volume of distribution at steady state were approximately 55 mL/kg and 150 mL/kg, respectively. PET imaging showed distribution predominantly to the blood pool, visible as the heart and great vessels in the trunk and limbs, plus diffuse signals in the liver, kidney, spleen, and bone marrow.
   Conclusions: The clearance of anti-oxLDL is slightly higher than typical IgG1 antibodies in cynomolgus monkeys. The biodistribution pattern appears to be consistent with an antibody that has no large, rapid antigen sink outside the blood space.
C1 [Kamath, Amrita V.; Williams, Simon P.; Bullens, Sherry; Cowan, Kyra J.; Damico-Beyer, Lisa A.; Bunting, Stuart] Genentech Inc, Genentech Res & Early Dev, San Francisco, CA 94080 USA.
   [Stenberg, Yvonne] BioInvent Int AB, Bioanalyt & Prot Chem, Lund, Sweden.
   [Cherry, Simon R.; Rendig, Stephen; Kukis, David L.; Griesemer, Chris] Univ Calif Davis, Ctr Mol & Genom Imaging, Davis, CA 95616 USA.
RP Kamath, AV (reprint author), Genentech Inc, Genentech Res & Early Dev, San Francisco, CA 94080 USA.
EM kamath.amrita@gene.com
FU Genentech, Inc.; BioInvent International AB; California National Primate
   Research Center [RR00169]; National Cancer Institute [CA86307]
FX Funding for these studies was provided by Genentech, Inc. and BioInvent
   International AB. AVK, SPW, SB, KJC, YS, LAD, SB are current or former
   employees of either Genentech, Inc. or BioInvent International AB. These
   studies were also supported by the California National Primate Research
   Center base operating grant no. RR00169. The production of 64Cu at
   Washington University at St. Louis School of Medicine was supported by
   National Cancer Institute grant CA86307. The funders of the grants had
   no role in study design, data collection and analysis, decision to
   publish, or preparation of the manuscript.
CR Cheng Z, 2007, BIOCONJUGATE CHEM, V18, P765, DOI 10.1021/bc060306g
   Deng R, 2011, MABS-AUSTIN, V3, P61, DOI 10.4161/mabs.3.1.13799
   Hansson GK, 2005, NEW ENGL J MED, V352, P1685, DOI 10.1056/NEJMra043430
   HODIS HN, 1994, J LIPID RES, V35, P669
   Holvoet P, 2003, ARTERIOSCL THROM VAS, V23, P1444, DOI 10.1161/01.ATV.0000080379.05071.22
   Hoppin J, 2011, J PHARMACOL EXP THER, V337, P350, DOI 10.1124/jpet.110.172916
   Lee JW, 2011, AAPS J, V13, P99, DOI 10.1208/s12248-011-9251-3
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Meisinger C, 2005, CIRCULATION, V112, P651, DOI 10.1161/CIRCULATIONAHA.104.529297
   Nilsson J, 2007, CURR PHARM DESIGN, V13, P1021, DOI 10.2174/138161207780487557
   Schiopu A, 2007, J AM COLL CARDIOL, V50, P2313, DOI 10.1016/j.jacc.2007.07.081
   Strickland LA, 2009, J PATHOL, V218, P380, DOI 10.1002/path.2545
   WITZTUM JL, 1991, J CLIN INVEST, V88, P1785, DOI 10.1172/JCI115499
NR 13
TC 4
Z9 4
U1 0
U2 8
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 17
PY 2012
VL 7
IS 9
AR e45116
DI 10.1371/journal.pone.0045116
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 019MC
UT WOS:000309742800036
PM 23028793
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Duprez, DA
   Neuhaus, J
   Kuller, LH
   Tracy, R
   Belloso, W
   De Wit, S
   Drummond, F
   Lane, HC
   Ledergerber, B
   Lundgren, J
   Nixon, D
   Paton, NI
   Prineas, RJ
   Neaton, JD
AF Duprez, Daniel A.
   Neuhaus, Jacqueline
   Kuller, Lewis H.
   Tracy, Russell
   Belloso, Waldo
   De Wit, Stephane
   Drummond, Fraser
   Lane, H. Clifford
   Ledergerber, Bruno
   Lundgren, Jens
   Nixon, Daniel
   Paton, Nicholas I.
   Prineas, Ronald J.
   Neaton, James D.
CA INSIGHT SMART Study Grp
TI Inflammation, Coagulation and Cardiovascular Disease in HIV-Infected
   Individuals
SO PLOS ONE
LA English
DT Article
ID CORONARY-HEART-DISEASE; ANTIRETROVIRAL THERAPY; D-DIMER;
   MYOCARDIAL-INFARCTION; OPPORTUNISTIC DISEASE; RISK; BIOMARKERS; DEATH;
   ATHEROSCLEROSIS; INTERLEUKIN-6
AB Background: The SMART study was a trial of intermittent use of antiretroviral therapy (ART) (drug conservation [DC]) versus continuous use of ART (viral suppression [VS]) as a strategy to reduce toxicities, including cardiovascular disease (CVD) risk. We studied the predictive value of high sensitivity C-reactive protein (hsCRP), interleukin-6 (IL-6) and D-dimer with CVD morbidity and mortality in HIV-infected patients who were enrolled in SMART beyond other measured CVD risk factors.
   Methods: A blood sample was available in 5098 participants who were enrolled in the SMART study for the measurement of IL-6, hsCRP and D-dimer. Hazard ratios (HR) with 95% CI for CVD events were estimated for each quartile (Q) for each biomarker vs the 1st quartile and for 1 SD higher levels. For both treatment groups combined, unadjusted and adjusted HRs were determined using Cox regression models.
   Results: There were 252 participants who had a CVD event over a median follow-up of 29 months. Adjusted HRs (95% CI) for CVD for Q4 vs Q1 were 4.65 (2.61, 8.29), 2.10 (1.40, 3.16), and 2.14 (1.38, 3.33) for IL-6, hsCRP and D-dimer, respectively. Associations were similar for the DC and VS treatment groups (interaction p-values were >0.30). The addition of the three biomarkers to a model that included baseline covariates significantly improved model fit (p<0.001). Area under the curve (AUC) estimates improved with inclusion of the three biomarkers in a model that included baseline covariates corresponding to other CVD risk factors and HIV factors (0.741 to 0.771; p<0.001 for difference).
   Conclusions: In HIV-infected individuals, IL-6, hsCRP and D-dimer are associated with an increased risk of CVD independent of other CVD risk factors. Further research is needed to determine whether these biomarkers can be used to improve CVD risk prediction among HIV positive individuals.
C1 [Duprez, Daniel A.; Neuhaus, Jacqueline; Neaton, James D.] Univ Minnesota, Minneapolis, MN 55455 USA.
   [Kuller, Lewis H.] Univ Pittsburgh, Pittsburgh, PA USA.
   [Tracy, Russell] Univ Vermont, Burlington, VT USA.
   [Belloso, Waldo] Hosp Italiano Buenos Aires, Buenos Aires, DF, Argentina.
   [De Wit, Stephane] St Pierre Hosp, Brussels, Belgium.
   [Drummond, Fraser] Univ New S Wales, Fac Med, Kirby Inst, Sydney, NSW, Australia.
   [Lane, H. Clifford] NIAID, NIH, Bethesda, MD 20892 USA.
   [Ledergerber, Bruno] Univ Zurich, Univ Zurich Hosp, Zurich, Switzerland.
   [Lundgren, Jens] Univ Copenhagen, Copenhagen, Denmark.
   [Nixon, Daniel] Virginia Commonwealth Univ, Richmond, VA USA.
   [Paton, Nicholas I.] MRC, Clin Trials Unit, London, England.
   [Prineas, Ronald J.] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA.
RP Duprez, DA (reprint author), Univ Minnesota, Minneapolis, MN 55455 USA.
EM dupre007@umn.edu
RI Emery, Sean/O-9122-2019; Infektiologie, USZ/A-6921-2011; SHCS, int.
   coll. A/G-4083-2011; Emery, Sean/J-3825-2017; Ledergerber,
   Bruno/B-5656-2009; SHCS, all/G-4072-2011
OI Emery, Sean/0000-0001-6072-8309; Emery, Sean/0000-0001-6072-8309;
   Ledergerber, Bruno/0000-0002-6881-4401; Lundgren,
   Jens/0000-0001-8901-7850
FU NIAD, United States National Institutes of Health [UO1AI068641,
   U01AI042170, U01AI046362]; Medical Research Council [MC_U122886352]
FX Support for this work was provided by NIAD, United States National
   Institutes of Health grants UO1AI068641, U01AI042170, and U01AI046362.
   The funders had no role in study design, data collection and analysis,
   decision to publish, or preparation of the manuscript.
CR Baker J, 2010, HIV MED, V11, P608, DOI 10.1111/j.1468-1293.2010.00835.x
   Baker JV, 2011, EUR HEART J, V32, P945, DOI 10.1093/eurheartj/ehq483
   Baker JV, 2011, JAIDS-J ACQ IMM DEF, V56, P36, DOI 10.1097/QAI.0b013e3181f7f61a
   Baker JV, 2010, CURR OPIN HIV AIDS, V5, P511, DOI 10.1097/COH.0b013e32833ed7ec
   Blum A, 2005, CLIN CARDIOL, V28, P149, DOI 10.1002/clc.4960280311
   Calmy A, 2009, ANTIVIR THER, V14, P165
   Chambless LE, 2006, STAT MED, V25, P3474, DOI 10.1002/sim.2299
   Croce K, 2007, CURR OPIN HEMATOL, V14, P55, DOI 10.1097/00062752-200701000-00011
   Currier JS, 2008, NY TIMES 1026, V118, pe29
   Danesh J, 2001, CIRCULATION, V103, P2323
   Danesh J, 2008, PLOS MED, V5, P600, DOI 10.1371/journal.pmed.0050078
   El-Sadr WM, 2008, ANN INTERN MED, V149, P289, DOI 10.7326/0003-4819-149-5-200809020-00003
   El-Sadr WM, 2006, NEW ENGL J MED, V355, P2283
   Folsom AR, 2009, AM J HEMATOL, V84, P349, DOI 10.1002/ajh.21429
   Ford ES, 2010, AIDS, V24, P1509, DOI 10.1097/QAD.0b013e32833ad914
   Friis-Moller N, 2003, NEW ENGL J MED, V349, P1993
   Friis-Moller N, 2007, NEW ENGL J MED, V356, P1723
   Grinspoon SK, 2008, NY TIMES        1026, V118, P198
   HARRELL FE, 1982, JAMA-J AM MED ASSOC, V247, P2543, DOI 10.1001/jama.247.18.2543
   Ho JE, 2009, HEART, V95, P1193, DOI 10.1136/hrt.2008.161463
   Hogg RS, 1998, JAMA-J AM MED ASSOC, V279, P450, DOI 10.1001/jama.279.6.450
   Hsue PY, 2009, AIDS, V23, P2021, DOI 10.1097/QAD.0b013e32832e7140
   Karpatkin S, 2002, THROMB HAEMOSTASIS, V88, P389
   Kowalska JD, 2011, EPIDEMIOLOGY, V22, P516, DOI 10.1097/EDE.0b013e31821b5332
   Kuller L. H., 2008, PLoS Medicine, V5, pe203, DOI 10.1371/journal.pmed.0050203
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lifson AR, 2010, HIV CLIN TRIALS, V11, P205, DOI 10.1310/hct1104-205
   Mocroft A, 2003, LANCET, V362, P22, DOI 10.1016/S0140-6736(03)13802-0
   Neuhaus J, 2010, J INFECT DIS, V201, P1788, DOI 10.1086/652749
   Palella FJ, 2011, CURR OPIN HIV AIDS, V6, P266, DOI 10.1097/COH.0b013e328347876c
   Phillips AN, 2008, ANTIVIR THER, V13, P177
   Rodger AJ, 2009, J INFECT DIS, V200, P973, DOI 10.1086/605447
   Sabin CA, 2008, LANCET, V371, P1417, DOI 10.1016/S0140-6736(08)60423-7
   Shen YMP, 2004, CLIN APPL THROMB-HEM, V10, P277, DOI 10.1177/107602960401000311
   Shorr AF, 2002, CHEST, V121, P1262, DOI 10.1378/chest.121.4.1262
   Soliman EZ, 2011, J ELECTROCARDIOL, V44, P779, DOI 10.1016/j.jelectrocard.2010.10.027
   The Emerging Risk Factors Collaboration, 2010, J GERONTOL B-PSYCHOL, V375, P132
   WEI LJ, 1989, J AM STAT ASSOC, V84, P1065, DOI 10.2307/2290084
NR 38
TC 274
Z9 276
U1 1
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD SEP 10
PY 2012
VL 7
IS 9
AR e44454
DI 10.1371/journal.pone.0044454
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 005KD
UT WOS:000308748400019
PM 22970224
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Nemmar, A
   Subramaniyan, D
   Ali, BH
AF Nemmar, Abderrahim
   Subramaniyan, Deepa
   Ali, Badreldin H.
TI Protective Effect of Curcumin on Pulmonary and Cardiovascular Effects
   Induced by Repeated Exposure to Diesel Exhaust Particles in Mice
SO PLOS ONE
LA English
DT Article
ID PLASMINOGEN-ACTIVATOR INHIBITOR-1; CORONARY-HEART-DISEASE;
   TUMOR-NECROSIS-FACTOR; ACUTE MYOCARDIAL-INFARCTION; AIR-POLLUTION
   EXPOSURE; PARTICULATE MATTER; INFLAMMATORY RESPONSES; THROMBOTIC EVENTS;
   HEALTHY HUMANS; BLOOD-PRESSURE
AB Particulate air pollution has been associated with increased risk of cardiopulmonary diseases. However, the underlying mechanisms are not fully understood. We have previously demonstrated that single dose exposure to diesel exhaust particle (DEP) causes lung inflammation and peripheral thrombotic events. Here, we exposed mice with repeated doses of DEP (15 mu g/animal) every 2nd day for 6 days (a total of 4 exposures), and measured several cardiopulmonary endpoints 48 h after the end of the treatments. Moreover, the potential protective effect of curcumin (the yellow pigment isolated from turmeric) on DEP-induced cardiopulmonary toxicity was assessed. DEP exposure increased macrophage and neutrophil numbers, tumor necrosis factor a (TNF alpha) in the bronchoalveolar lavage (BAL) fluid, and enhanced airway resistance to methacoline measured invasively using Flexivent. DEP also significantly increased plasma C-reactive protein (CRP) and TNF alpha concentrations, systolic blood pressure (SBP) as well as the pial arteriolar thrombosis. It also significantly enhanced the plasma D-dimer and plasminogen activator inhibitor-1 (PAI-1). Pretreatment with curcumin by oral gavage (45 mg/kg) 1h before exposure to DEP significantly prevented the influx of inflammatory cells and the increase of TNF alpha in BAL, and the increased airway resistance caused by DEP. Likewise, curcumin prevented the increase of SBP, CRP, TNF alpha, D-dimer and PAI-1. The thrombosis was partially but significantly mitigated. In conclusion, repeated exposure to DEP induced lung and systemic inflammation characterized by TNF alpha release, increased SBP, and accelerated coagulation. Our findings indicate that curcumin is a potent anti-inflammatory agent that prevents the release of TNF alpha and protects against the pulmonary and cardiovascular effects of DEP.
C1 [Nemmar, Abderrahim; Subramaniyan, Deepa] United Arab Emirates Univ, Dept Physiol, Fac Med & Hlth Sci, Al Ain, U Arab Emirates.
   [Ali, Badreldin H.] Sultan Qaboos Univ, Dept Pharmacol & Clin Pharm, Coll Med & Hlth Sci, Al Khoud, Oman.
RP Nemmar, A (reprint author), United Arab Emirates Univ, Dept Physiol, Fac Med & Hlth Sci, Al Ain, U Arab Emirates.
EM anemmar@uaeu.ac.ae
FU Emirates Foundation [2009-045]; United Arab Emirates University, Faculty
   of Medicine and Health Sciences
FX This work was supported by the Emirates Foundation grant Grant #:
   2009-045 and United Arab Emirates University, Faculty of Medicine and
   Health Sciences Grant. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Ali BH, 2006, NAT PROD COMMUN, V1, P509
   BARRY CC, 1994, ENVIRONMENT, V36, P5
   Behndig AF, 2006, EUR RESPIR J, V27, P359, DOI 10.1183/09031936.06.00136904
   Brook RD, 2004, CIRCULATION, V109, P2655, DOI 10.1161/01.CIR.0000128587.30041.C8
   Brook RD, 2010, CIRCULATION, V121, P2331, DOI 10.1161/CIR.0b013e3181dbece1
   Brook RD, 2009, J AM SOC HYPERTENS, V3, P332, DOI 10.1016/j.jash.2009.08.005
   Brook RD, 2009, HYPERTENSION, V54, P659, DOI 10.1161/HYPERTENSIONAHA.109.130237
   Budinger GRS, 2011, PLOS ONE, P6
   Cesari M, 2010, CARDIOVASC THER, V28, pe72, DOI 10.1111/j.1755-5922.2010.00171.x
   Cheng AL, 2001, ANTICANCER RES, V21, P2895
   Delfino RJ, 2008, ENVIRON HEALTH PERSP, V116, P898, DOI 10.1289/ehp.11189
   Delfino RJ, 2009, ENVIRON HEALTH PERSP, V117, P1232, DOI 10.1289/ehp.0800194
   Driscoll KE, 2000, TOXICOL SCI, V55, P24, DOI 10.1093/toxsci/55.1.24
   Egan ME, 2004, SCIENCE, V304, P600, DOI 10.1126/science.1093941
   Epstein JA, 2008, J CLIN INVEST, V118, P850, DOI 10.1172/JCI34650
   Franchini M, 2011, BLOOD, V118, P2405, DOI 10.1182/blood-2011-04-343111
   Ghosh SS, 2009, AM J PHYSIOL-RENAL, V296, pF1146, DOI 10.1152/ajprenal.90732.2008
   Gruber F, 2003, BLOOD, V101, P3042, DOI 10.1182/blood-2002-07-2331
   Hou BD, 2004, J BIOL CHEM, V279, P18127, DOI 10.1074/jbc.M310438200
   Kido T, 2010, AM J RESP CELL MOL B
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Lowe GDO, 1999, THROMB HAEMOSTASIS, V82, P667
   Maheshwari RK, 2006, LIFE SCI, V78, P2081, DOI 10.1016/j.lfs.2005.12.007
   Mills NL, 2007, NEW ENGL J MED, V357, P1075, DOI 10.1056/NEJMoa066314
   Mills NL, 2009, NAT CLIN PRACT CARD, V6, P36, DOI 10.1038/ncpcardio1399
   Morimoto T, 2008, J CLIN INVEST, V118, P868, DOI 10.1172/JCI33160
   Mutlu GM, 2007, J CLIN INVEST, V117, P2952, DOI 10.1172/JCI30639
   Nemmar A, 2004, CIRCULATION, V110, P1670, DOI 10.1161/01.CIR.0000142053.13921.21
   Nemmar A, 2003, CIRCULATION, V107, P1202, DOI 10.1161/01.CIR.0000053568.13058.67
   Nemmar A, 2008, EXP BIOL MED, V233, P610, DOI 10.3181/0706-RM-165
   Nemmar A, 2007, AM J PHYSIOL-LUNG C, V292, pL664, DOI 10.1152/ajplung.00240.2006
   Nemmar A, 2011, BRIT J PHARMACOL, V164, P1871, DOI 10.1111/j.1476-5381.2011.01442.x
   Nemmar A, 2010, TOXICOL LETT, V194, P58, DOI 10.1016/j.toxlet.2010.02.001
   Nemmar A, 2010, TOXICOL SCI, V113, P267, DOI 10.1093/toxsci/kfp222
   Nemmar A, 2009, TOXICOLOGY, V263, P84, DOI 10.1016/j.tox.2009.06.017
   Nordenhall C, 2001, EUR RESPIR J, V17, P909, DOI 10.1183/09031936.01.17509090
   Packard RRS, 2008, CLIN CHEM, V54, P24, DOI 10.1373/clinchem.2007.097360
   Pai JK, 2004, NEW ENGL J MED, V351, P2599, DOI 10.1056/NEJMoa040967
   Park NY, 2011, BRIT J NUTR, V106, P1514, DOI 10.1017/S0007114511001929
   Plomgaard P, 2005, J APPL PHYSIOL, V98, P2019, DOI 10.1152/japplphysiol.01220.2004
   Punithavathi D, 2000, BRIT J PHARMACOL, V131, P169, DOI 10.1038/sj.bjp.0703578
   RIDKER PM, 1994, CIRCULATION, V90, P2236, DOI 10.1161/01.CIR.90.5.2236
   Ruckerl R, 2006, AM J RESP CRIT CARE, V173, P432, DOI 10.1164/rccm.200507-1123OC
   Ruckerl Regina, 2007, Part Fibre Toxicol, V4, P1, DOI 10.1186/1743-8977-4-1
   Saber AT, 2005, ARCH TOXICOL, V79, P177, DOI 10.1007/s00204-004-0613-9
   Salam MT, 2008, CURR OPIN PULM MED, V14, P3, DOI 10.1097/MCP.0b013e3282f1987a
   Sallam N, 2010, MEDIAT INFLAMM, DOI 10.1155/2010/149678
   Salvi S, 1999, AM J RESP CRIT CARE, V159, P702, DOI 10.1164/ajrccm.159.3.9709083
   Shishodia S, 2003, CARCINOGENESIS, V24, P1269, DOI 10.1093/carcin/bgg078
   Su CC, 2010, PHYTOTHER RES, V24, P189, DOI 10.1002/ptr.2905
   Sun QH, 2010, CIRCULATION, V121, P2755, DOI 10.1161/CIRCULATIONAHA.109.893461
   Suresh MV, 2012, AM J RESP CELL MOL, V47, P280, DOI 10.1165/rcmb.2011-0175OC
   Suzuki M, 2009, AM J PHYSIOL-LUNG C, V296, pL614, DOI 10.1152/ajplung.90443.2008
   Thogersen AM, 1998, CIRCULATION, V98, P2241, DOI 10.1161/01.CIR.98.21.2241
   Vanoirbeek JAJ, 2004, TOXICOL SCI, V80, P310, DOI 10.1093/toxsci/kfh155
   Vermylen J, 2005, J THROMB HAEMOST, V3, P1955, DOI 10.1111/j.1538-7836.2005.01471.x
   Yamashita M, 1997, THROMB RES, V87, P165, DOI 10.1016/S0049-3848(97)00116-3
   Yeh ETH, 2004, CIRCULATION, V109, P11, DOI 10.1161/01.CIR.0000129507.12719.80
   Ying ZK, 2009, AM J PHYSIOL-HEART C, V296, pH1540, DOI 10.1152/ajpheart.01270.2008
NR 59
TC 43
Z9 45
U1 0
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD JUN 22
PY 2012
VL 7
IS 6
AR e39554
DI 10.1371/journal.pone.0039554
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 964XV
UT WOS:000305730900076
PM 22745783
OA Green Published, Other Gold
DA 2019-06-18
ER

PT J
AU Braun, TR
   Been, LF
   Singhal, A
   Worsham, J
   Ralhan, S
   Wander, GS
   Chambers, JC
   Kooner, JS
   Aston, CE
   Sanghera, DK
AF Braun, Timothy R.
   Been, Latonya F.
   Singhal, Akhil
   Worsham, Jacob
   Ralhan, Sarju
   Wander, Gurpreet S.
   Chambers, John C.
   Kooner, Jaspal S.
   Aston, Christopher E.
   Sanghera, Dharambir K.
TI A Replication Study of GWAS-Derived Lipid Genes in Asian Indians: The
   Chromosomal Region 11q23.3 Harbors Loci Contributing to Triglycerides
SO PLOS ONE
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; CORONARY-ARTERY-DISEASE; DENSITY-LIPOPROTEIN
   CHOLESTEROL; TYPE-2 DIABETES-MELLITUS; RECEPTOR SUPERFAMILY; VARIANTS;
   RISK; SUSCEPTIBILITY; POPULATION; TRAITS
AB Recent genome-wide association scans (GWAS) and meta-analysis studies on European populations have identified many genes previously implicated in lipid regulation. Validation of these loci on different global populations is important in determining their clinical relevance, particularly for development of novel drug targets for treating and preventing diabetic dyslipidemia and coronary artery disease (CAD). In an attempt to replicate GWAS findings on a non-European sample, we examined the role of six of these loci (CELSR2-PSRC1-SORT1 rs599839; CDKN2A-2B rs1333049; BUD13-ZNF259 rs964184; ZNF259 rs12286037; CETP rs3764261; APOE-C1-C4-C2 rs4420638) in our Asian Indian cohort from the Sikh Diabetes Study (SDS) comprising 3,781 individuals (2,902 from Punjab and 879 from the US). Two of the six SNPs examined showed convincing replication in these populations of Asian Indian origin. Our study confirmed a strong association of CETP rs3764261 with high-density lipoprotein cholesterol (HDL-C) (p = 2.03 x 10(-26)). Our results also showed significant associations of two GWAS SNPs (rs964184 and rs12286037) from BUD13-ZNF259 near the APOA5-A4-C3-A1 genes with triglyceride (TG) levels in this Asian Indian cohort (rs964184: p = 1.74 x 10(-17); rs12286037: p = 1.58x10(-2)). We further explored 45 SNPs in a similar to 195 kb region within the chromosomal region 11q23.3 (encompassing the BUD13-ZNF259, APOA5-A4- C3-A1, and SIK3 genes) in 8,530 Asian Indians from the London Life Sciences Population (LOLIPOP) (UK) and SDS cohorts. Five more SNPs revealed significant associations with TG in both cohorts individually as well as in a joint meta-analysis. However, the strongest signal for TG remained with BUD13-ZNF259 (rs96184: p = 1.06 x 10(-39)). Future targeted deep sequencing and functional studies should enhance our understanding of the clinical relevance of these genes in dyslipidemia and hypertriglyceridemia (HTG) and, consequently, diabetes and CAD.
C1 [Braun, Timothy R.; Been, Latonya F.; Singhal, Akhil; Worsham, Jacob; Aston, Christopher E.; Sanghera, Dharambir K.] Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Pediat, Oklahoma City, OK 73190 USA.
   [Ralhan, Sarju; Wander, Gurpreet S.] Hero Dayanand Med Coll, Cardiol Sect, Ludhiana, Punjab, India.
   [Ralhan, Sarju; Wander, Gurpreet S.] Hosp Heart Inst, Ludhiana, Punjab, India.
   [Chambers, John C.] Univ London Imperial Coll Sci Technol & Med, Dept Epidemiol & Biostat, London, England.
   [Kooner, Jaspal S.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England.
   [Aston, Christopher E.] Univ Oklahoma, Hlth Sci Ctr, Harold Hamm Diabet Ctr, Oklahoma City, OK USA.
RP Braun, TR (reprint author), Univ Oklahoma, Hlth Sci Ctr, Coll Med, Dept Pediat, Oklahoma City, OK 73190 USA.
EM Dharambir-sanghera@ouhsc.edu
FU National Institute of Health [KO1 TW006087]; Fogarty International
   Center [R01 DK082766]; National Institute of Diabetes and Digestive and
   Kidney Diseases; University of Oklahoma Health Sciences Center, Oklahoma
   City, USA; Medical Research Council [G0601966, G0801056B, G0700931]
FX This work was supported by the National Institute of Health grant
   numbers KO1 TW006087, funded by the Fogarty International Center; R01
   DK082766, funded by National Institute of Diabetes and Digestive and
   Kidney Diseases; and a seed grant from University of Oklahoma Health
   Sciences Center, Oklahoma City, USA. The funders had no role in study
   design, data collection and analysis, decision to publish, or
   preparation of the manuscript.
CR American Diabetes Association, 2004, DIABETES CARE S1, V27, pS5, DOI DOI 10.2337/DIACARE.27.2007.S5
   Bowden DW, 2008, ANN HUM GENET, V72, P598, DOI 10.1111/j.1469-1809.2008.00446.x
   Chambers JC, 2009, DIABETES, V58, P2703, DOI 10.2337/db08-1805
   Cooper RS, 2008, HUM MOL GENET, V17, pR151, DOI 10.1093/hmg/ddn263
   Corton JC, 2000, ANNU REV PHARMACOL, V40, P491, DOI 10.1146/annurev.pharmtox.40.1.491
   Dorfmeister B, 2007, BBA-MOL BASIS DIS, V1772, P355, DOI 10.1016/j.bbadis.2006.11.008
   Edmondson AC, 2008, CIRC-CARDIOVASC GENE, V1, P3, DOI 10.1161/CIRCGENETICS.108.815530
   Evans D, 2011, ATHEROSCLEROSIS, V219, P715, DOI 10.1016/j.atherosclerosis.2011.09.030
   Frayling TM, 2007, NAT REV GENET, V8, P657, DOI 10.1038/nrg2178
   GalchevaGargova Z, 1996, SCIENCE, V272, P1797, DOI 10.1126/science.272.5269.1797
   Kathiresan S, 2009, NAT GENET, V41, P56, DOI 10.1038/ng.291
   Kathiresan S, 2008, NAT GENET, V40, P189, DOI 10.1038/ng.75
   Ken-Dror G, 2010, J HUM GENET, V55, P300, DOI 10.1038/jhg.2010.27
   Kendall DM, 2005, ENDOCRIN METAB CLIN, V34, P27, DOI 10.1016/j.ecl.2004.11.004
   Klos KLE, 2006, ARTERIOSCL THROM VAS, V26, P1828, DOI 10.1161/01.ATV.0000231523.19199.45
   Kooner JS, 2008, NAT GENET, V40, P149, DOI 10.1038/ng.2007.61
   Kooner JS, 2011, NAT GENET, V43, P984, DOI 10.1038/ng.921
   Kruglyak L, 1999, P NATL ACAD SCI USA, V96, P1170, DOI 10.1073/pnas.96.4.1170
   Lehtinen AB, 2008, DIABETES, V57, P1108, DOI 10.2337/db07-1365
   Libby P, 2005, J AM COLL CARDIOL, V46, P1225, DOI 10.1016/j.jacc.2005.07.006
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   MANGELSDORF DJ, 1995, CELL, V83, P835, DOI 10.1016/0092-8674(95)90199-X
   MATTHEWS DR, 1985, DIABETOLOGIA, V28, P412, DOI 10.1007/BF00280883
   Nakayama K, 2009, J MED GENET, V46, P370, DOI 10.1136/jmg.2008.064063
   Oldroyd J, 2005, POSTGRAD MED J, V81, P486, DOI 10.1136/pgmj.2004.029124
   Price AL, 2006, NAT GENET, V38, P904, DOI 10.1038/ng1847
   Purcell S, 2003, BIOINFORMATICS, V19, P149, DOI 10.1093/bioinformatics/19.1.149
   Reich D, 2009, NATURE, V461, P489, DOI 10.1038/nature08365
   Samani NJ, 2007, NEW ENGL J MED, V357, P443, DOI 10.1056/NEMJoa072366
   Sandhu MS, 2008, LANCET, V371, P483, DOI 10.1016/S0140-6736(08)60208-1
   Sanghera DK, 2008, BMC MED GENET, V9, DOI 10.1186/1471-2350-9-59
   Sanghera DK, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0021188
   Sanghera DK, 2009, J HUM GENET, V54, P162, DOI 10.1038/jhg.2009.7
   Saxena R, 2007, SCIENCE, V316, P1331, DOI 10.1126/science.1142358
   Schierer A, 2011, PHARMACOGENET GENOM, V22, P95
   Scott LJ, 2007, SCIENCE, V316, P1341, DOI 10.1126/science.1142382
   SLADEK FM, 1990, GENE DEV, V4, P2353, DOI 10.1101/gad.4.12b.2353
   Teslovich TM, 2010, NATURE, V466, P707, DOI 10.1038/nature09270
   Waterworth DM, 2010, ARTERIOSCL THROM VAS, V30, P2264, DOI 10.1161/ATVBAHA.109.201020
   Weissglas-Volkov D, 2010, J LIPID RES, V51, P2032, DOI 10.1194/jlr.R004739
   Willer CJ, 2008, NAT GENET, V40, P161, DOI 10.1038/ng.76
   Willer CJ, 2009, NAT GENET, V41, P25, DOI 10.1038/ng.287
   Yach D, 2004, JAMA-J AM MED ASSOC, V291, P2616, DOI 10.1001/jama.291.21.2616
   Yan SK, 2005, CLIN CHEM LAB MED, V43, P607, DOI 10.1515/CCLM.2005.105
   Yasuda K, 2008, NAT GENET, V40, P1092, DOI 10.1038/ng.207
   Zabaneh D, 2009, DIABETOLOGIA, V52, P2585, DOI 10.1007/s00125-009-1504-7
NR 46
TC 37
Z9 39
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 18
PY 2012
VL 7
IS 5
AR e37056
DI 10.1371/journal.pone.0037056
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 959VG
UT WOS:000305343500055
PM 22623978
OA Other Gold, Green Published
DA 2019-06-18
ER

PT J
AU Wallstrom, P
   Sonestedt, E
   Hlebowicz, J
   Ericson, U
   Drake, I
   Persson, M
   Gullberg, B
   Hedblad, B
   Wirfalt, E
AF Wallstrom, Peter
   Sonestedt, Emily
   Hlebowicz, Joanna
   Ericson, Ulrika
   Drake, Isabel
   Persson, Margaretha
   Gullberg, Bo
   Hedblad, Bo
   Wirfalt, Elisabet
TI Dietary Fiber and Saturated Fat Intake Associations with Cardiovascular
   Disease Differ by Sex in the Malmo Diet and Cancer Cohort: A Prospective
   Study
SO PLOS ONE
LA English
DT Article
ID CORONARY-HEART-DISEASE; FOOD FREQUENCY QUESTIONNAIRE; BREAST-CANCER;
   MYOCARDIAL-INFARCTION; METABOLIC SYNDROME; POOLED ANALYSIS; HISTORY
   METHOD; HABIT CHANGE; RISK; MORTALITY
AB Background: The aim of the study was to examine associations between intake of macronutrients and dietary fiber and incident ischemic cardiovascular disease (iCVD) in men and women.
   Methods: We used data from 8,139 male and 12,535 female participants (aged 44-73 y) of the Swedish population-based Malmo Diet and Cancer cohort. The participants were without history of CVD and diabetes mellitus, and had reported stable dietary habits in the study questionnaire. Diet was assessed by a validated modified diet history method, combining a 7-d registration of cooked meals and cold beverages, a 168-item food questionnaire (covering other foods and meal patterns), and a 1-hour diet interview. Sociodemographic and lifestyle data were collected by questionnaire. iCVD cases, which included coronary events (myocardial infarctions or deaths from chronic ischemic heart disease) and ischemic strokes, were ascertained via national and local registries. Nutrient-disease associations were examined by multivariate Cox regressions.
   Results: During a mean follow-up of 13.5 years, we identified 1,089 male and 687 female iCVD cases. High fiber intakes were associated with lower incidence rates of iCVD in women and of ischemic stroke in men. In post-hoc analysis, we discovered statistically significant interactions between intake of fiber and saturated fat; these interactions also differed between men and women (p < 0.001).
   Conclusions: In this well-defined population, a high fiber intake was associated with lower risk of iCVD, but there were no robust associations between other macronutrients and iCVD risk. Judging from this study, gender-specific nutrient analysis may be preferable in epidemiology.
C1 [Wallstrom, Peter; Drake, Isabel; Gullberg, Bo; Wirfalt, Elisabet] Lund Univ, Dept Clin Sci, Nutr Epidemiol Res Grp, Malmo, Sweden.
   [Hlebowicz, Joanna] Lund Univ, Dept Clin Sci, Expt Cardiovasc Res Unit, Malmo, Sweden.
   [Persson, Margaretha] Lund Univ, Dept Clin Sci, Internal Med Res Unit, Malmo, Sweden.
RP Wallstrom, P (reprint author), Lund Univ, Dept Clin Sci, Nutr Epidemiol Res Grp, Malmo, Sweden.
EM peter.wallstrom@med.lu.se
RI Sonestedt, Emily/I-3814-2016
OI Sonestedt, Emily/0000-0002-0747-4562; Persson,
   Margaretha/0000-0001-8188-5792; /0000-0003-4629-4318
FU Swedish governmental funds for clinical research (ALF); Heart-Lung
   Foundation, Region Skane; Skane University Hospital; Ernhold Lundstrom
   Foundation
FX This paper was funded by grants from Swedish governmental funds for
   clinical research (ALF), the Heart-Lung Foundation, Region Skane, the
   research funds of the Skane University Hospital and the Ernhold
   Lundstrom Foundation. The funders had no role in study design, data
   collection and analysis, decision to publish, or preparation of the
   manuscript.
CR Andersen KK, 2009, STROKE, V40, P2068, DOI 10.1161/STROKEAHA.108.540112
   BERGLUND G, 1993, J INTERN MED, V233, P45, DOI 10.1111/j.1365-2796.1993.tb00647.x
   Bingham SA, 2006, INT J EPIDEMIOL, V35, P1022, DOI 10.1093/ije/dyl142
   Byers T, 1997, AM J CLIN NUTR S, V66, p1541S
   Cust AE, 2009, EUR J CLIN NUTR, V63, pS37, DOI 10.1038/ejcn.2009.74
   Elmadfa I, 2009, ANN NUTR METAB, V55, P56, DOI 10.1159/000228996
   Elmstahl S, 1996, EUR J CLIN NUTR, V50, P143
   Elmstahl S, 1996, EUR J CLIN NUTR, V50, P134
   Eshak ES, 2010, J NUTR, V140, P1445, DOI 10.3945/jn.110.122358
   FAO/WHO/UNU, 1985, WHO TECHN REP SER, V724
   FAO-WHO, 2010, 91 FAOWHO
   Giugliano D, 2006, J AM COLL CARDIOL, V48, P677, DOI 10.1016/j.jacc.2006.03.052
   Grundy SM, 2004, CIRCULATION, V110, P227, DOI 10.1161/01.CIR.0000133317.49796.0E
   Hlebowicz J, 2011, J INTERN MED, V270, P365, DOI 10.1111/j.1365-2796.2011.02382.x
   Holme I, 2008, J INTERN MED, V265, P275
   Jacobs DR, 2007, NUTR REV, V65, P439, DOI 10.1301/nr.2007.oct.439-450
   Jakobsen MU, 2010, AM J CLIN NUTR, V91, P1764, DOI 10.3945/ajcn.2009.29099
   Jakobsen MU, 2009, AM J CLIN NUTR, V89, P1425, DOI 10.3945/ajcn.2008.27124
   JERNTORP P, 1992, STROKE, V23, P357, DOI 10.1161/01.STR.23.3.357
   Leosdottir M, 2007, EUR J CARDIOV PREV R, V14, P701, DOI 10.1097/HJR.0b013e3282a56c45
   Libby P, 2011, NATURE, V473, P317, DOI 10.1038/nature10146
   Macintyre S, 1997, DESIGN CONCEPTS NUTR, P273
   Manjer J, 2001, EUR J CANCER PREV, V10, P489, DOI 10.1097/00008469-200112000-00003
   Manjer J, 2002, SCAND J PUBLIC HEALT, V30, P103, DOI 10.1080/14034940210133771
   Mattisson I, 2005, BRIT J NUTR, V94, P832, DOI 10.1079/BJN20051573
   Mente A, 2009, ARCH INTERN MED, V169, P659, DOI 10.1001/archinternmed.2009.38
   Mohan KM, 2011, STROKE, V42, P1489, DOI 10.1161/STROKEAHA.110.602615
   Mozaffarian D., 2010, PLOS MED, V7, P1
   Mozaffarian D, 2011, CIRCULATION, V123, P2670
   National Board of Health and Welfare, 2000, VARD DIAGN AK HJART
   National Food Administration, 2010, T FAT
   Pereira MA, 2004, ARCH INTERN MED, V164, P370, DOI 10.1001/archinte.164.4.370
   Riboli E, 1997, INT J EPIDEMIOL, V26, pS161, DOI 10.1093/ije/26.suppl_1.S161
   RICHARDSON MT, 1994, J CLIN EPIDEMIOL, V47, P271, DOI 10.1016/0895-4356(94)90008-6
   Sieri S, 2010, ARCH INTERN MED, V170, P640, DOI 10.1001/archinternmed.2010.15
   Siri-Tarino PW, 2010, AM J CLIN NUTR, V91, P535, DOI 10.3945/ajcn.2009.27725
   Skeaff CM, 2009, ANN NUTR METAB, V55, P173, DOI 10.1159/000229002
   Sonestedt E, 2005, PUBLIC HEALTH NUTR, V8, P876, DOI 10.1079/PHN2005736
   Sonestedt E, 2007, PUBLIC HEALTH NUTR, V10, P769, DOI 10.1017/S1368980007246646
   Sonestedt E, 2011, EUR J EPIDEMIOL, V26, P609, DOI 10.1007/s10654-011-9589-y
   TAYLOR HL, 1978, J CHRON DIS, V31, P741, DOI 10.1016/0021-9681(78)90058-9
   Thiebaut ACM, 2008, CANCER INVEST, V26, P68, DOI 10.1080/07357900701527918
   Warensjo E, 2010, AM J CLIN NUTR, V92, P194, DOI 10.3945/ajcn.2009.29054
   Willet W, 1998, NUTR EPIDEMIOLOGY, P101
   WILLETT W, 1998, NUTR EPIDEMIOLOGY, P273
   Wirfalt E, 2001, AM J EPIDEMIOL, V154, P1150, DOI 10.1093/aje/154.12.1150
   Wirfalt E, 2002, NUTR J, V1, DOI 10.1186/1475-2891-1-3
   World Health Organization, 2000, WHO TECHN REP SER, V894
   Zakynthinos E, 2009, J CARDIOL, V53, P317, DOI 10.1016/j.jjcc.2008.12.007
NR 49
TC 30
Z9 34
U1 0
U2 18
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD FEB 27
PY 2012
VL 7
IS 2
AR e31637
DI 10.1371/journal.pone.0031637
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 927OV
UT WOS:000302918500033
PM 22384046
OA Other Gold, Green Published
DA 2019-06-18
ER

EF